Late-stage functionalization of peptides and cyclopeptides using organozinc reagents and pyrrole protected 2-Aminoalkylzinc reagents for the enantioselective synthesis of amino derivatives by Leroux, Marcel Rainer
 Dissertation zur Erlangung des Doktorgrades 
der Fakultät für Chemie und Pharmazie 
der Ludwig-Maximilians-Universität München 
 
 
 
 
 
 
Late-Stage Functionalization of Peptides and Cyclopeptides Using 
Organozinc Reagents 
- and - 
Pyrrole Protected 2-Aminoalkylzinc Reagents for the 
Enantioselective Synthesis of Amino Derivatives 
 
 
 
 
 
 
von 
 
 
Marcel Rainer Leroux 
 
 
 
 
 
aus 
 
Saarbrücken 
 
2019  
 ERKLÄRUNG  
Diese Dissertation wurde im Sinne von § 7 der Promotionsordnung vom 28. November 2011 
von Herrn Prof. Dr. Paul Knochel betreut. 
 
 
 
 
EIDESSTATTLICHE VERSICHERUNG 
 
Diese Dissertation wurde eigenständig und ohne unerlaubte Hilfe erarbeitet. 
 
 
 
München, den 13.12.2019 
 
 
 ………….……………………………… 
 (Marcel Leroux) 
 
 
 
 
 
 
 
 
 
 
 
Dissertation eingereicht am:  13.12.2019 
1. Gutachter:    Prof. Dr. Paul Knochel 
2. Gutachter:    Prof. Dr. Konstantin Karaghiosoff 
Mündliche Prüfung am:  07.02.2020 
 This work was carried out from October 2016 to December 2019 under the guidance of Prof. Dr. Paul 
Knochel at the Department of Chemistry of the Ludwig-Maximilians-Universität, Munich. 
 
First, I would like to thank Prof. Dr. Paul Knochel for giving me the opportunity to carry out my master 
as well as my Ph.D. thesis in his group. I am grateful for his supporting guidance during my research 
and the fruitful discussions during our meetings. 
I would like to specially thank Prof. Dr. Konstantin Karaghiosoff for agreeing to be my second reviewer 
of my thesis, as well as Prof. Dr. Franz Bracher, Prof. Dr. Oliver Trapp, Prof. Dr. Manfred Heuschmann 
and Dr. Henry Dube for accepting to be members of my defense committee. 
I am very grateful to Ferdinand Lutter, Arif Music, Dr. Andreas Bellan, Lucie Grokenberger and 
Alexandre Desaintjean for proofreading my manuscript and for their careful corrections. 
Additionally, I am very thankful for the friendly and unconditional support of Prof. Dr. Konstantin 
Karaghiosoff and his time for measuring all the perfect NMR-spectra and beautiful crystal structures.  
Thanks to all present and past members of the Knochel group I had the pleasure to meet! Very special 
thanks to Dr. Andreas Bellan, Dr. Meike Simon, Dr. Michael Eisold, Arif Music, Andreas Baumann and 
Alexandre Desaintjean for being wonderful friends inside and outside the lab and for making every day 
spent together funnier and more pleasant. I also want to thank all present and former members of the 
cooking team for providing tasty and enjoyable food each day! In addition, I want to thank Dr. Moritz 
Balkenhohl, Juri Skotnitzki and Dr. Dorothée Ziegler for all the nice conversations and the funny trash 
TV evenings.  
I would also like to thank my former students Rachel Janßen, Yannick Lemke, Valentin Bockmair and 
Thaddäus Koller for their contributions during their internships and graduation works. 
Special thanks also to Sophie Hansen for friendly and reliable help in administrative questions and all 
the nice and funny conversations, as well as Dr. Vladimir Malakhov for his contributions in practical 
matters and chemicals orders. Thanks to Peter Dowling, I’m grateful for your guidance in all technical 
and chromatographical questions and for teaching me all the important HPLC-knowledge.  
Furthermore, I would like to thank my family, especially my parents and my sister, and all my friends 
for their endless and unconditional support and motivation for finishing this thesis. Each of you made a 
massive impact in my life and therefore contributed as well to this thesis more than you might expect. 
Finally, I thank you Sina for all your love, sympathy, emotional support and patient encouragement 
during this time.  
 Parts of this Ph.D. Thesis have been published 
1) “Late‐Stage Functionalization of Peptides and Cyclopeptides Using Organozinc Reagents” 
 M. Leroux, T. Vorherr, I. Lewis, M. Schaefer, G. Koch, K. Karaghiosoff, P. Knochel, Angew. 
Chem. Int. Ed. 2019, 58, 8231. 
2) “Pyrrole Protected 2-Aminoalkylzinc Reagents for the Enantioselective Synthesis of Amino-
Derivatives” M. Leroux, W.-Y. Huang, Y. Lemke, T. Koller, K. Karaghiosoff, P. 
Knochel, manuscript in preparation. 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Für meine Familie und Sina  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
„Die Wissenschaft fängt eigentlich erst 
da an interessant zu werden, wo sie aufhört.” 
Justus von Liebig   
 Abbreviations 
Ac  acetyl 
acac  acetylacetonate 
aq.  aqueous 
ATR  attenuated total reflection 
Boc  tert-butyloxycarbonyl 
Bu  butyl 
Bz  benzoyl 
calc.  calculated 
Cbz  carboxybenzyl 
dba  trans,trans-dibenzylideneacetone 
DCE  1,2-dichloroethane 
diglyme diglycoldimethylether 
DMF  N,N-dimethylformamide 
e.g.  exempli gratia, for example 
EI  electron ionization (MS) 
equiv  equivalent(s) 
Et  ethyl 
EX  electrophile 
FG  functional group 
GC  gas chromatography 
Hal  halogen 
Het  undefined heteroaryl substituent 
HRMS  high resolution mass spectrometry 
i  iso 
i.e.  id est, that is 
IR  infrared spectroscopy 
J  coupling constant (NMR) 
M  mol L-1 
MD  molecular dynamics 
MDCK  madin darby canine kidney cells assay 
Me  methyl 
Met  metal 
mol%  equiv•102 
m.p.  melting point 
MS  mass spectrometry 
NCE  new chemical entity 
 NMP  N-Metyl-2-pyrrolidone 
NMR  nuclear magnetic resonance 
PAMPA parallel artificial membrane permeability assay 
pc  precursor  
PG  protecting group 
Ph  phenyl 
Piv  pivaloyl 
PMDTA N,N,N’,N’’,N’’-pentamethyldiethylenetriamine 
ppm  parts per million 
Pr  propyl 
Py/Pyr  pyridyl 
R  undefined organic substituent 
SAPSA  solvent-accessible polar surface area 
sat.  saturated 
SFC  supercritical fluid chromatography 
t  tert 
THF  tetrahydrofuran 
tfp  tri(2-furanyl)phosphine 
TLC  thin layer chromatography 
TMEDA N,N,N’,N’-tetramethylethylenediamine 
TMP  2,2,6,6-tetramethylpiperidine 
TP  typical procedure 
vol  volume 
WHO  World Health Organization   
 
  
 TABLE OF CONTENTS 
A. INTRODUCTION ...................................................................................................................... 0 
1 GENERAL INTRODUCTION .................................................................................................. 1 
2 PREPARATION OF ORGANOZINC REAGENTS ..................................................................... 3 
2.1 Overview ....................................................................................................................................... 3 
2.2 Oxidative Insertion ........................................................................................................................ 4 
2.3 Transmetalation ............................................................................................................................. 6 
2.4 Halogen-Metal Exchange .............................................................................................................. 7 
2.5 Directed Metalation ....................................................................................................................... 9 
2.6 Zinc Pivalates ................................................................................................................................ 9 
2.7 Chiral Organozinc Reagents ........................................................................................................ 11 
3 OBJECTIVES ...................................................................................................................... 14 
B. RESULTS AND DISCUSSION .................................................................................................. 16 
1 LATE-STAGE FUNCTIONALIZATION OF PEPTIDES AND CYCLOPEPTIDES USING 
ORGANOZINC REAGENTS ........................................................................................................ 17 
1.1 Introduction ................................................................................................................................. 17 
1.2 Method Development for Iodination and Negishi Cross-Coupling Based on Tyrosine .............. 18 
1.3 Iodination of Tyrosine-based Peptides ........................................................................................ 20 
1.4 Negishi Cross-Coupling of Tyrosine based Peptides Using Organozinc Pivalates ..................... 22 
1.5 Negishi Cross-Coupling Reactions of Alkylzinc Halides with Tyrosine Derivatives ................. 27 
1.6 Negishi Cross-Couplings of Iodo-Phenylalanine-based Cyclopeptides with Pyridylzinc Pivalates
 ........................................................................................................................................................... 29 
2 PYRROLE PROTECTED 2-AMINOALKYLZINC REAGENTS FOR THE ENANTIOSELECTIVE 
SYNTHESIS OF AMINO DERIVATIVES ...................................................................................... 35 
2.1 Introduction ................................................................................................................................. 35 
2.2 Proof of Principle for β-Amino Alkylzinc Reagents Starting from Glycinol .............................. 37 
2.3 Preparation of Pyrrole-protected 2-Amino Alcohols ................................................................... 39 
 2.4 Preparation of N-Pyrrolyl Alkyl Iodides ..................................................................................... 41 
2.5 Oxidative Zinc Insertion of 1,2-substituted N-Pyrrolyl-Alkyl Iodides ........................................ 43 
2.6 Negishi Cross-Coupling and Acylation Reactions of Pyrrole-protected Organozinc Reagents .. 44 
2.7 Selective CBS-Reduction of Chiral Pyrrole-containing Acylation Products .............................. 57 
2.8 Deprotection of the Pyrrole-Group Using Ozonolysis ................................................................ 58 
3 SUMMARY ......................................................................................................................... 61 
3.1 Late-Stage Functionalization of Peptides and Cyclopeptides using Organozinc Pivalates ......... 61 
3.2 Pyrrole Protected 2-Aminoalkylzinc Reagents for the Enantioselective Synthesis of Amino 
Derivatives ........................................................................................................................................ 62 
C. EXPERIMENTAL PART ......................................................................................................... 64 
1 GENERAL CONSIDERATIONS ............................................................................................ 65 
1.1 Solvents ....................................................................................................................................... 65 
1.2 Reagents ...................................................................................................................................... 65 
1.3 Chromatography .......................................................................................................................... 66 
1.4 Preparative RP-HPLC ................................................................................................................. 66 
1.5 Analytical data ............................................................................................................................. 66 
1.6 Single Crystal X-Ray Diffraction Studies ................................................................................... 68 
2 LATE-STAGE FUNCTIONALIZATION OF PEPTIDES AND CYCLOPEPTIDES USING 
ORGANOZINC REAGENTS ........................................................................................................ 69 
2.1 Typical Procedures (TP1–8) ........................................................................................................ 69 
2.2 Characterization of the Tyrosine containing Peptides ................................................................. 72 
2.3 Preparation of Iodotyrosine containing Peptides ......................................................................... 75 
2.4 Preparation of Arylzinc Pivalates ................................................................................................ 80 
2.5 Negishi Cross-Coupling reactions of Iodotyrosine with Arylzinc Pivalates ............................... 83 
2.6 Preparation of Alkylzinc Halides ................................................................................................ 87 
2.7 Negishi Cross-Coupling reactions of Iodotyrosine with Alkylzinc Halides ............................... 88 
2.8 Negishi Cross-Coupling Reactions of Tyrosine containing Peptides with Arylzinc Pivalates ... 93 
 2.9 Negishi Cross-Coupling reactions of Iodophenylalanine containing Cyclopeptides with 
Pyridylzinc Pivalates ....................................................................................................................... 109 
3 PYRROLE PROTECTED 2-AMINOALKYLZINC REAGENTS FOR THE ENANTIOSELECTIVE 
SYNTHESIS OF AMINO DERIVATIVES .................................................................................... 121 
3.1 Typical Procedures (TP9–15) .................................................................................................... 121 
3.2 Precursor Syntheses ................................................................................................................... 125 
3.3 Preparation of β-N-Pyrrolyl-Alkyl Alcohols ............................................................................. 126 
3.4 Preparation of β-N-Pyrrolyl-Alkyl Iodides ................................................................................ 131 
3.5 Preparation of Organozinc Reagents from Chiral β-N-Pyrrolyl-Alkyl Iodides ......................... 137 
3.6 Transition-Metal-Catalyzed Reactions using β-N-Pyrrolyl-Alkylzinc Reagents ...................... 139 
3.7 Selective CBS-Reduction of Pyrrole-containing Ketones ......................................................... 184 
3.8 Deprotection of Pyrrole-Derivatives using Ozonolysis ............................................................. 187 
D. APPENDIX .......................................................................................................................... 193 
Single Crystal Structure of 1-((1R,2S)-2-iodocyclopentyl)-1H-pyrrole ((R,S)-19i) ........................ 194 
Single Crystal Structure of Methyl 2-((1S,2R)-2-(1H-pyrrol-1-yl)cyclopentyl)benzoate ((S,R)-29c)
 ......................................................................................................................................................... 195 
Mosher-Ester Analysis of (R,S)-30d using 1H-NMR spectroscopy ................................................. 196 
Single Crystal Structure of N-((1S,2R)-2-(3-(trifluoromethyl)phenyl)cyclohexyl)formamide ((S,R)-
31e) .................................................................................................................................................. 197 
Single Crystal Structure of N-((2R,4S)-4-(3-chlorophenyl)-4-hydroxy-1-phenylbutan-2-
yl)formamide ((R,S)-31g) ................................................................................................................ 198 
 
  
 
 
 
 
 
 
 
A. INTRODUCTION 
 
  
A. INTRODUCTION    1 
1 General Introduction 
In 2018, over 18 million new cancer cases and almost 10 million cancer-related deaths were recorded 
according to the world health organization (WHO).1 With a steadily rising world population (2019: 
approx. 7.7 billion)2 and the increase of life expectation3, the number of people suffering from the 
various kinds of cancer is likely to further increase. For this reason, an efficient and fast way to develop 
new pharmaceutical drugs becomes even more important in future. In general, the process of drug 
discovery from the very beginning to the drug approval, takes 12 up to 15 years and costs more than 
one billion dollar.4 In the beginning of the drug development process, the design and preparation of new 
chemical entities (NCE) is important. Usually, a lot of NCEs must be synthesized and tested to find 
only a few (2-5) suitable candidates for the clinical trial phases.5 To enhance this step, efficient and 
broadly applicable methods for the synthesis of organic molecules are necessary. Organometallic 
chemistry has found broad application in the development and production of pharmaceutical 
compounds.6 Some of the 200 top-selling drugs7 are small-molecule pharmaceuticals prepared with at 
least one step using organometallic reagents. Examples for those compounds (Figure 1) are omeprazole8 
(proton-pump inhibitor), escitalopram9 (selective serotonin reuptake inhibitor), ezetimibe10 (cholesterol 
absorption inhibitor) and sitagliptin11 (diabetes treatment). 
 
Figure 1: Examples for top-selling drugs synthesized by using organometallic reagents. 
Besides small-molecules and proteins, drugs based on bioactive peptides are gaining importance for 
pharmaceutical application.12 
 
1 F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, A. Jemal, CA-Cancer J. Clin. 2018, 68, 394. 
2 United Nations, Department of Economic and Social Affairs, Population Division (2019). World Population 
Prospects 2019, Online Edition. 
3 V. Kontis, J. E. Bennett, C. D. Mathers, G. Li, K. Foreman, M. Ezzati, Lancet 2017, 389, 1323. 
4 J. P. Hughes, S. Rees, S. B. Kalindjian, K. L. Philpott, Br. J. Pharmacol. 2011, 162, 1239. 
5 A. A. Ciociola, L. B. Cohen, P. Kulkarni, Am. J. Gastroenterol. 2014, 109, 620. 
6 M. L. Crawley, B. M. Trost, Applications of transition metal catalysis in drug discovery and development: an 
industrial perspective, John Wiley & Sons, New Jersey, USA, 2012. 
7 N. A. McGrath, M. Brichacek, J. T. Njardarson, J. Chem. Educ. 2010, 87, 1348. 
8 U. K. Junggren, S. E. Sjöstrand US-4255431, 1981. 
9 K. K. Vipin, K. M. Umar, R. B. Narsimha, K. S. Ranjith, D. Ramesh, M. Sivakumaran EP-2017271A1, 2009. 
10 C. H. V. A. Sasikala, P. Reddy Padi, V. Sunkara, P. Ramayya, P. K. Dubey, V. Bhaskar Rao Uppala, C. Praveen, 
Org. Process Res. Dev. 2009, 13, 907. 
11 D. Kim, L. Wang, M. Beconi, G. J. Eiermann, M. H. Fisher, H. He, G. J. Hickey, J. E. Kowalchick, B. Leiting, 
K. Lyons et al., J. Med. Chem. 2005, 48, 141. 
12 J. L. Lau, M. K. Dunn, Bioorg. Med. Chem. 2018, 26, 2700. 
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Two examples for peptides used for cancer therapy are carfilzomib13, a selective proteasome inhibitor 
and leuprorelin14, a gonadotropin-releasing hormone inhibitor (Figure 2). 
Furthermore, cyclopeptides have found useful application15 as peptidomimetics, since they show 
increased stability towards proteolysis16. One example is the cyclic peptide ciclosporin17, which is used 
as immunosuppressant, consisting of eleven amino acids (Figure 2). 
 
Figure 2: Selected examples for top-selling drugs based on linear and cyclic peptides. 
To accelerate the drug development process, the fast preparation of a broad range of NCEs is of 
importance. Therefore, new efficient methods for the formation of carbon-carbon bonds are needed to 
further extend the chemical space18. Organometallic chemistry and transition-metal catalysis proved to 
be powerful tools for the preparation of complex and functionalized molecules.19  
 
Figure 3: Electronegativity differences of selected metal relative to carbon, calculated with the Pauling scale.20 
Depending on the purpose, different organometallic regents must be used for organic synthesis. The 
reagents reactivities and therefore functional group tolerances are varying dependent on the metal. 
 
13 D. L. Hughes, Org. Process Res. Dev. 2016, 20, 2028. 
14 A. N. Balaev, V. N. Osipov, K. A. Okhmanovich, V. E. Fedorov, Pharm. Chem. J. 2014, 48, 217. 
15 L. Gentilucci, R. de Marco, L. Cerisoli, Curr. Pharm. Des. 2010, 16, 3185. 
16 a) K.-i. Harada, K. Fujii, T. Shimada, M. Suzuki, H. Sano, K. Adachi, W. W. Carmichael, Tetrahedron Lett. 
1995, 36, 1511; b) A. Napolitano, I. Bruno, P. Rovero, R. Lucas, M. P. Peris, L. Gomez-Paloma, R. Riccio, 
Tetrahedron 2001, 57, 6249; c) A. Aneiros, A. Garateix, J. Chromatogr. B 2004, 803, 41; d) V. Arumugam, M. 
Venkatesan, S. Ramachandran, U. Sundaresan, Int. J. Pept. Res. Ther. 2018, 24, 13. 
17 X. Wu, J. L. Stockdill, P. Wang, S. J. Danishefsky, J. Am. Chem. Soc. 2010, 132, 4098. 
18 J.-L. Reymond, M. Awale, ACS Chem. Neurosci. 2012, 3, 649. 
19 M. Schlosser, Organometallics in Synthesis Third Manual, John Wiley & Sons, New Jersey, USA, 2013. 
20 L. Pauling, J. Am. Chem. Soc. 1932, 54, 3570. 
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Origin of the diversity of reactivity is the divergent polarization of the carbon-metal bond and which 
can be ranked by the electronegativity-differences between carbon and the chosen metal (Figure 3).21 
Therefore, polar organolithium reagents show a very high reactivity and have to be handled at low 
temperatures, whereas less-polar organoboron compounds tends to be more tolerant toward functional 
groups but are in contrast less reactive. Organozinc reagents are located in the middle of this scale and 
are a reasonable compromise between reactivity and functional group tolerance. 
 
2 Preparation of Organozinc Reagents 
2.1 Overview 
The origin of organozinc chemistry can be traced back to the middle of the 19th century. Frankland 
discovered diethylzinc as the first organozinc reagent in 1848 by heating ethyl iodide with zinc metal.22 
Until Grignard discovered the convenient synthesis of organomagnesium reagents in 190023, organozinc 
compounds were the only known organometallics for the formation of new carbon-carbon bonds. 
Although magnesium reagents were more reactive towards various electrophiles and provided higher 
yields, organozinc compounds still have been used in reactions such as Simons-Smith 
cyclopropanations24 or Reformatsky reaction25. Since its discovery, organozinc chemistry evolved and 
many versatile applications have been developed.26 Organozinc compounds easily undergo a broad 
range of transmetalation reactions due to the presence of empty low-lying p-orbitals which can readily 
interact with d-orbitals of different transition metal salts. These zinc/transition-metal intermediates are 
highly reactive and can undergo various reactions with electrophiles, while retaining the high functional 
group tolerance. An important application is the transmetalation reaction to copper or palladium, which 
allows their use in very efficient cross-coupling reactions.27 The cross-coupling reaction is a very 
powerful method in organic chemistry which was awarded with the chemistry Nobel prize in 2010 to 
Negishi, Heck and Suzuki for their research on this type of C–C bond formation.28 Especially the work 
of Negishi involving organozinc reagents provides a versatile pathway to obtain highly functionalized 
 
21 A. Boudier, L. O. Bromm, M. Lotz, P. Knochel, Angew. Chem. Int. Ed. 2000, 39, 4414. 
22 E. Frankland, Liebigs Ann. Chem. 1849, 71, 171 
23 a) V. Grignard, Compt. Rend. Acad. Sci. Paris 1900, 130, 1322; b) V. Grignard, Ann. Chim. 1901, 24, 433. 
24 a) H. E. Simmons, R. D. Smith, J. Am. Chem. Soc. 1958, 80, 5323; b) H. E. Simmons, R. D. Smith, J. Am. 
Chem. Soc. 1959, 81, 4256; c) M. Nakamura, A. Hirai, E. Nakamura, J. Am. Chem. Soc. 2003, 125, 2341. 
25 a) S. Reformatsky, Ber. Dtsch. Chem. Ges. 1887, 20, 1210; b) R. Moumne, S. Lavielle, P. Karoyan, J. Org. 
Chem. 2006, 71, 3332. 
26 P. Knochel, N. Millot, A. L. Rodriguez, C. E. Tucker in Organic reactions, Wiley Online Library, Hoboken, 
N.J., 2003, pp. 417–759. 
27 a) P. Knochel, H. Leuser, L.-Z. Cong, S. Perrone, F. F. Kneisel in Handbook of Functionalized Organometallics, 
Wiley-VCH, Weinheim, Germany, 2008, pp. 251; b) F. H. Lutter, M. S. Hofmayer, J. M. Hammann, V. Malakhov, 
P. Knochel, in Organic Reactions, Vol. 100 (Ed.: S. E. Denmark), John Wiley & Sons, Hoboken,USA, 2019. 
28 X.-F. Wu, P. Anbarasan, H. Neumann, M. Beller, Angew. Chem. Int. Ed. 2010, 49, 9047. 
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organic compounds.29 In the following chapters, the preparation and application will be described in 
detail. 
 
2.2 Oxidative Insertion 
The oxidative insertion of zinc into alkyl iodides, reported by Frankland22, was the first method used to 
prepare organozinc reagents. Due to the low reactivity of this metal, the reaction scope was limited to 
a few alkyl iodides. As a base metal, the surface of elemental zinc is covered with an oxide layer, which 
reduces the reactivity for metal insertion reactions. Several methods have been developed for the 
activation of the zinc surface, including HCl washing30a, treatment with ultrasonic waves30b, or the 
addition of 1,2-dibromoethane30c or chlorotrimethylsilane30d. Another approach to obtain highly active 
zinc particles is to reduce zinc chloride with sodium or lithium in the presence of naphthalene, as 
reported by Rieke.31 With this activated zinc, functionalized alkyl bromides as well as  aryl bromides 
can be converted into the corresponding organozinc reagents and used for trapping reaction with e.g. 
acyl chlorides (Scheme 1).32 
 
Scheme 1: Insertion of Rieke zinc into alkyl and aryl bromides and subsequent transmetalation to copper for 
acylation reactions leading to functionalized ketones. 
However, the highly activated Rieke zinc is not needed for the oxidative insertion into the more reactive 
carbon-iodide bond (Scheme 2). 
 
29 a) E. Negishi, L. F. Valente, M. Kobayashi, J. Am. Chem. Soc. 1980, 102, 3298 b) E. Negishi, Acc. Chem. Res. 
1982, 15, 340; c) C. Valente, M. E. Belowich, N. Hadei, M. G. Organ, Eur. J. Org. Chem. 2010, 2010, 4343; d) 
D. Haas, J. M. Hammann, R. Greiner, P. Knochel, ACS Catal. 2016, 6, 1540. 
30 a) M. S. Newman, F. J. Evans, J. Am. Chem. Soc. 1955, 77, 946; b) B. H. Han, P. Boudjouk, J. Org. Chem. 
1982, 47, 5030. c) P. Knochel, M. C. P. Yeh, S. C. Berk, J. Talbert, J. Org. Chem. 1988, 53, 2390; d) J. K. 
Gawroński, Tetrahedron Lett. 1984, 25, 2605;  
31 a) R. D. Rieke, Science 1989, 246, 1260; b) L. Zhu, R. M. Wehmeyer, R. D. Rieke, J. Org. Chem. 1991, 56, 
1445. 
32 a) M. V. Hanson, J. D. Brown, R. D. Rieke, Q.J. Niu, Tetrahedron Lett. 1994, 35, 7205; b) A. Fürstner, R. 
Singer, P. Knochel, Tetrahedron Lett. 1994, 35, 1047. 
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Scheme 2: Direct insertion of zinc into aryl iodides at elevated temperatures providing organozinc reagents 
suitable for allylation reactions.33  
Whereas the insertion of zinc dust into alkyl iodides proceeds quite fast, the insertion into aryl iodides 
is slow and requires elevated reaction temperatures. For the examples shown in Scheme 2, zinc dust 
was activated by chlorotrimethylsilane and reacted with aryl iodides at temperatures of 70 °C up to 
130 °C in high boiling ethers to slowly form the corresponding organozinc reagents within 24 h.33  
The group of Knochel reported a more efficient protocol for the preparation of functionalized 
organozinc reagents. Thus, previously activated zinc dust and equimolar amounts lithium chloride were 
used to perform oxidative insertion into aryl- and heteroaryl iodides as well as bromides (Scheme 3). 
Using this method, corresponding organozinc reagents can be obtained in excellent yield using mild 
reaction temperatures of 25 °C up to 50 °C with significantly reduced reaction time.34 
 
Scheme 3: Preparation of functionalized organozinc reagents by oxidative insertion of zinc dust in the presence 
of LiCl and trapping reactions with various electrophiles.34a 
The role of lithium chloride during the oxidative zinc insertion has been further investigated.35  Based 
on these investigations, lithium chloride significantly increases the solubility of the formed organozinc 
compound in THF. Consequently, it promotes the solvation of the formed zinc species from the zinc-
metal surface and thus accelerates following surface reactions.  
 
33 R. Ikegami, A. Koresawa, T. Shibata, K. Takagi, J. Org. Chem. 2003, 68, 2195. 
34 a) A. Krasovskiy, V. Malakhov, A. Gavryushin, P. Knochel, Angew. Chem. Int. Ed. 2006, 45, 6040; b) N. 
Boudet, S. Sase, P. Sinha, C.-Y. Liu, A. Krasovskiy, P. Knochel, J. Am. Chem. Soc. 2007, 129, 12358; c) A. 
Metzger, M. A. Schade, P. Knochel, Org. Lett. 2008, 10, 1107.   
35 C. Feng, D. W. Cunningham, Q. T. Easter, S. A. Blum, J. Am. Chem. Soc. 2016, 138, 11156. 
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2.3 Transmetalation 
Another approach for the preparation of organozinc reagents, is the transmetalation of more polar metal-
reagents with zinc salts. The driving force of this reaction is the formation of the thermodynamically 
more stable organometallic reagent with a more covalent carbon-metal bond (Figure 4).  
 
Figure 4: General principle of a transmetalation reaction forming the thermodynamically more stable 
organometallic compound based on electronegativity.  
Many reagents suitable for the transmetalation to zinc are readily available, e.g. organolithium or 
organomagnesium compounds. This allows the preparation of organozinc reagents which might not be 
accessible via oxidative insertion. The downside of this method is the restricted functional group 
tolerance due to the increased reactivity of the more polar organometallics.36 
An elegant way to use both, the advantage of the fast magnesium insertion as well as the tolerance 
towards functional groups of zinc, was reported by the Knochel group.37 Magnesium turnings were 
inserted in the presence of lithium chloride as well as zinc chloride into aryl bromides or alkyl bromides. 
During the reaction, the in-situ generated magnesium species is directly transmetalated by the zinc salts 
to the corresponding organozinc compound. This method therefore provides an easy access to various 
reagents whose preparation would be lengthy via zinc insertion. 
 
Scheme 4: Oxidative insertion of magnesium into aryl- and alkyl-bromides in the presence of lithium chloride 
and in-situ transmetalation to the corresponding organozinc compounds.37 
An additional way for the preparation of organozinc reagents is the use of halogen-metal exchange 
reagents and subsequent transmetalation with zinc salts. In 2004, Knochel reported the lithium 
complexed exchange reagent iPrMgCl•LiCl (also known as “Turbo Grignard”), which enables the 
preparation of a broad range of aryl- and heteroarylmagnesium reagents from the corresponding aryl 
 
36 P. Knochel, Handbook of functionalized organometallics. Applications in synthesis, Wiley-VCH, Weinheim, 
Germany, 2005, 261. 
37 a) F. M. Piller, A. Metzger, M. A. Schade, B. A. Haag, A. Gavryushin, P. Knochel, Chem. Eur. J. 2009, 15, 
7192; b) T. D. Blümke, F. M. Piller, P. Knochel, Chem. Commun. 2010, 46, 4082. 
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iodides or bromides.38 Due the high reactivity of these reagents, the exchange reaction can be performed 
at low temperatures tolerating various functional groups.39  
In Scheme 5, an example for the iodine-magnesium exchange of ethyl 4-iodobenzoate is displayed, 
which was performed at –20 °C in 30 min. After subsequent transmetalation with zinc chloride, the 
resulting organozinc reagent was successfully used for palladium-catalyzed cross-coupling reaction 
with 5-bromoindole in 94% yield.40 
 
Scheme 5: Iodine-magnesium exchange using iPrMgCl•LiCl and subsequent transmetalation with zinc chloride 
providing organozinc reagents for cross-coupling chemistry.40a 
 
2.4 Halogen-Metal Exchange 
In principle, the halogen-metal exchange is driven by the formation of a more stable organometallic 
compound (Figure 5).41 In contrast to magnesium, the exchange reaction of organozinc compounds is 
more complicated, since the reactivity of mono-organozinc reagents is too low. 42 
 
Figure 5: Schematic representation of the halogen-metal exchange reaction. 
However, using dialkylzinc reagents, the zinc-iodine exchange can be performed. The solvent free 
treatment of ethyl 3-iodobutanoate with diisopropylzinc at room temperature provides the mixed 
organozinc species with can be used after transmetalation to copper, for allylation reactions (Scheme 
6).43 Since the mixed organozinc reagent is formed, both alkyl moieties react with the electrophile. For 
this reason, the electrophile must be used in excess and thus the separation of both products can be quite 
difficult.44 
 
Scheme 6: Iodine-zinc exchange using diisopropylzinc leading to a mixed zinc species, which readily reacts with 
copper(I)cyanide and allyl bromide.43 
 
38 A. Krasovskiy, P. Knochel, Angew. Chem. Int. Ed. 2004, 43, 3333. 
39 D. S. Ziegler, B. Wei, P. Knochel, Chem. Eur. J. 2019, 25, 2695. 
40 a) G. Manolikakes, M. A. Schade, C. M. Hernandez, H. Mayr, P. Knochel, Org. Lett. 2008, 10, 2765; b) P. 
Knochel, M. A. Schade, S. Bernhardt, G. Manolikakes, A. Metzger, F. M. Piller, C. J. Rohbogner, M. Mosrin, 
Beilstein J. Org. Chem. 2011, 7, 1261. 
41 D. Hauk, S. Lang, A. Murso, Org. Process Res. Dev. 2006, 10, 733.   
42 M. Balkenhohl, P. Knochel, Chem. Eur. J. 2019. 
43 L. Micouin, P. Knochel, Synlett 1997, 1997, 327. 
44 P. Knochel, Handbook of functionalized organometallics. Applications in synthesis, Wiley-VCH, Weinheim, 
Germany, 2005, 271. 
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An improved exchange reaction was described by Knochel et. al. in 2004 using diisopropylzinc in the 
presence of catalytic amounts of lithium acetylacetonate as a promoter for an intermediate ate-
complex.45 Using this procedure, the exchange of 3-iodobenzonitrile can be performed at room 
temperature within 10 h using a diethyl ether/NMP solvent mixture. The formed bis-arylzinc reagent 
can be used for a subsequent palladium-catalyzed Negishi cross-coupling with 2-iodonitrobenzene in 
84% yield (Scheme 7). 
 
Scheme 7: Preparation of a diarylzinc reagent by a Li(acac)-promoted iodine-zinc exchange using diisopropylzinc 
and subsequent palladium catalyzed cross-coupling reaction.45 
Recently, the group of Knochel reported a bimetallic halogen-zinc exchange reagent consisting of bis-
sec-butylzinc complexed with two lithium alkoxides in toluene.46 With this reagent, iodine-zinc 
exchange reactions are possible, even on electron-rich arenes, within minutes at room temperature in 
almost quantitative yields. Additionally, even bromine-zinc exchange reactions could be performed on 
aryl- as well as heteroaryl bromides with reaction times of 30 min to 5 h. The resulting bis-arylzinc 
reagents were successfully applied in transition-metal catalyzed allylation, acylation and cross-coupling 
reactions (Scheme 8). 
 
Scheme 8: Iodine-zinc exchange of 3-iodoanisole and bromine-zinc exchange of 3,5-dibromopyridine, using a 
bimetallic-alkoxide reagent in toluene.46 
 
 
45 F. F. Kneisel, M. Dochnahl, P. Knochel, Angew. Chem. Int. Ed. 2004, 43, 1017. 
46 M. Balkenhohl, D. S. Ziegler, A. Desaintjean, L. J. Bole, A. R. Kennedy, E. Hevia, P. Knochel, Angew. Chem. 
Int. Ed. 2019, 58, 12898. 
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2.5 Directed Metalation 
Besides oxidative insertion or halogen-metal exchange of halogenated substrates, another approach 
towards organozinc reagents is possible using metal bases. These reagents allow for the deprotonation 
of arenes and heteroarenes and thus converts them into the corresponding organometallic compound.47 
The group of Knochel reported the preparation of two different sterically hindered TMP bases.48  
Application of the TMPZn•LiCl49 base as well as the (TMP)2ZnCl•MgCl2•LiCl
50 base can provide mild 
chemoselective deprotonation of various aryl and heteroaryl substrates leading to functionalized 
organozinc reagents (Scheme 9). These reagents can be used for a variety of reaction with different 
electrophiles. 
 
Scheme 9: Preparation of mono49a- and bis50a-TMP-zinc bases and their application in arene metalation. 
 
2.6 Zinc Pivalates 
The main disadvantage of organozinc reagents is their sensitivity towards moisture, which leads to 
hydrolysis of the organometallic compound. To overcome this weakness, Knochel et al. investigated 
different salts for complexation. It was found, that the use of readily available zinc pivalate51 for 
transmetalation of Grignard reagents leads to solid organozinc compounds, after evaporation of the 
solvents.52 These solid organometallics exhibit an improved stability towards moisture from air. Since 
 
47 J. M. Mallan, R. L. Bebb, Chem. Rev. 1969, 69, 693. 
48 B. Haag, M. Mosrin, H. Ila, V. Malakhov, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 9794. 
49 a) S. H. Wunderlich, P. Knochel, Angew. Chem. Int. Ed. 2007, 46, 7685; b) S. H. Wunderlich, P. Knochel, Org. 
Lett. 2008, 10, 4705; c) S. H. Wunderlich, C. J. Rohbogner, A. Unsinn, P. Knochel, Org. Process Res. Dev. 2010, 
14, 339;   
50 a) M. Mosrin, P. Knochel, Org. Lett. 2009, 11, 1837; b) T. Bresser, G. Monzon, M. Mosrin, P. Knochel, Org. 
Process Res. Dev. 2010, 14, 1299.   
51 M. Ellwart, Y.-H. Chen, C. P. Tüllmann, V. Malakhov, P. Knochel, Org. Synth. 2018, 95, 127. 
52 a) S. Bernhardt, G. Manolikakes, T. Kunz, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 9205; b) C. I. Stathakis, 
S. Bernhardt, V. Quint, P. Knochel, Angew. Chem. Int. Ed. 2012, 51, 9428; c) J. R.  Colombe, S. Bernhardt, C. 
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these compounds were very stable under argon, they could be stored for future application, while losing 
only a small percentage of activity over time.  
The preparation could be performed, using magnesium for the insertion into the aryl bromides or 
iodides, while in the presence of zinc pivalate. Various functionalized, solid organozinc reagents could 
be prepared and used for subsequent reactions with a broad range of electrophiles (Scheme 10).53 
 
Scheme 10: Preparation of solid aryl- and heteroarylzinc pivalates and their application in Negishi cross-coupling 
reactions.53 [a] complexed, Mg(OPiv)X and LiCl are omitted for clarity. 
Due to the presence of different salts in the reaction mixture, the exact structure of the resulting zinc 
pivalates was hard to determine. Further structural studies performed by Mulvey and Hevia54 showed 
that the reagents have the general formula “RZnX•Mg(OPiv)2•nLiCl” (X = Br, I, Cl; n = 1–2). For 
clarity, the abbreviation RZnOPiv is used in this thesis for this sophisticated structure. It was suggested, 
that the complexed magnesium pivalate acts as a moisture scavenger which might explain the improved 
stability. 
Besides oxidative insertion, halogen-magnesium exchange via “Turbo Grignard” with a subsequent 
transmetalation by zinc pivalate can be used for the preparation. Various functionalized aryl- and 
heteroarylzinc pivalates can be obtained using this method tolerating all kinds of functional groups. 
Furthermore, the application in trapping reactions like allylation, cross-coupling or addition to 
aldehydes using trimethylaluminium can be performed (Scheme 11).55 
 
Stathakis, S. L. Buchwald, P. Knochel, Org. Lett. 2013, 15, 5754; d) C. I. Stathakis, S. M. Manolikakes, P. 
Knochel, Org. Lett. 2013, 15, 1302; e) S. M. Manolikakes, M. Ellwart, C. I. Stathakis, P. Knochel, Chem. Eur. J. 
2014, 20, 12289; f) T. J. Greshock, K. P. Moore, R. T. McClain, A. Bellomo, C. K. Chung, S. D. Dreher, P. S. 
Kutchukian, Z. Peng, I. W. Davies, P. Vachal, M. Ellwart, S. M. Manolikakes, P. Knochel, P. G. Nantermet, 
Angew. Chem. Int. Ed. 2016, 55, 13714. 
53 S. Bernhardt, G. Manolikakes, T. Kunz, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 9205. 
54 A. Hernán-Gómez, E. Herd, E. Hevia, A. R. Kennedy, P. Knochel, K. Koszinowski, S. M. Manolikakes, R. E. 
Mulvey, C. Schnegelsberg, Angew. Chem. Int. Ed. 2014, 53, 2706. 
55 a) J. R. Colombe, S. Bernhardt, C. Stathakis, S. L. Buchwald, P. Knochel, Org. Lett. 2013, 15, 5754; b) S. M. 
Manolikakes, M. Ellwart, C. I. Stathakis, P. Knochel, Chem. Eur. J. 2014, 20, 12289. 
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Scheme 11: Preparation of organozinc pivalates via halogen-metal exchange followed by transmetalation with 
Zn(OPiv)2 and reactions with various electrophiles.55 [a] complexed, Mg(OPiv)X and LiCl are omitted for clarity. 
In addition, a TMPZnOPiv•LiCl base was described starting from readily available TMPMgCl•LiCl. 
With this new sterically hindered base, sensitive heterocycles and arenes, bearing various functional 
groups could selectively be metalated, providing solid zinc pivalates in high yields. These reagents 
could then be applied in transition-metal-catalyzed reactions with various electrophiles (Scheme 12).56 
 
Scheme 12: Preparation of TMPZnOPiv•Mg(OPiv)Cl•LiCl and metalation of aryl- and heteroaryl compounds for 
subsequent acylation or cross-coupling reactions.56 [a] complexed, Mg(OPiv)X and LiCl are omitted for clarity 
 
2.7 Chiral Organozinc Reagents 
As discussed above, organozinc reagents tolerate a variety of functional groups and display a mild 
reactivity. They are therefore well suited for the preparation of functionalized alkylzinc reagents 
containing a chiral center.  Jackson has demonstrated the utility of amino acids as precursors for the 
 
56 C. I. Stathakis, S. M. Manolikakes, P. Knochel, Org. Lett. 2013, 15, 1302. 
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preparation of chiral serine-derived organozinc reagents and has shown their application for the 
synthesis of novel amino acids, using Negishi cross-couplings (Scheme 13).57 
 
Scheme 13: Preparation of a chiral serine-based alkylzinc reagent and Negishi cross-coupling reaction leading to 
a chiral lactam.57b 
The preparation of alkylzinc reagents from secondary alkyl iodides, bearing a protected chiral amino 
group, was described by Knochel. Due to the assumed radical nature of the zinc insertion, the 
stereoinformation is usually lost during the reaction. However, in the strained system shown in Scheme 
14, the conversion of the iodide to the corresponding alkylzinc iodide as well as the following copper 
mediated stannylation, proceeds with full retention of configuration to the exo product.58 
 
Scheme 14: Preparation of an alkylzinc iodide by oxidative insertion of zinc with retention of configuration and 
subsequent stannylation leads selectively to the exo tin derivative.58 
Another strategy to obtain alkylzinc reagents with defined stereocenters is an oxygen-zinc chelatization 
during the insertion reaction. For example, an ester in proximity to the iodide coordinates to the inserting 
zinc and therefore specifies its configuration. In Scheme 15, two examples for this kind of reaction are 
displayed.  
 
Scheme 15: Preparation of chiral organozinc compounds with defined stereocenters due to oxygen-zinc chelation 
and following palladium catalyzed reaction with acyl chlorides.59,60b   
 
57  a) J. Ross, F. Dreiocker, M. Schäfer, J. Oomens, A. J. H. M. Meijer, B. T. Pickup, R. F. W. Jackson, J. Org. 
Chem. 2011, 76, 1727; b) A. J. Ross, H. L. Lang, R. F. W. Jackson, J. Org. Chem. 2010, 75, 245; c) T. Carrillo-
Marquez, L. Caggiano, R. F. W. Jackson, U. Grabowska, A. Rae, M. J. Tozer, Org. Biomol. Chem. 2005, 3, 4117; 
d) H. J. C. Deboves, U. Grabowska, A. Rizzo, R. F. W. Jackson, J. Chem. Soc., Perkin Trans. 1 2000, 4284; e) R. 
F. W. Jackson, K. James, M. J. Wythes, A. Wood, J. Chem. Soc., Chem. Commun. 1989, 644.  
58 R. Duddu, M. Eckhardt, M. Furlong, H.P. Knoess, S. Berger, P. Knochel, Tetrahedron 1994, 50, 2415. 
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For the cyclopentyl derivative, insertion of the trans-iodide leads to the cis-complexed zinc reagents, 
which after palladium-catalyzed acylation also provides the cis-ketone.59 The reaction of the alkyliodide 
bearing an diisopropyl amide in 3-position also leads to a coordination during the insertion, which 
causes a diastereoselective acylation with both methyl groups in cis-configuration with a diastereomeric 
ratio of 99:1.60 
Besides chelatization, thermodynamic and steric effects can also be used to achieve stereoselectivity. 
In Scheme 16, the stereocenter of the iodide of the menthol derivative racemizes during the oxidative 
zinc insertion. After transmetalation to a bulky palladium-catalyst, the cross-coupling with  
5-bromopyrimidine diastereoselectively leads to the equatorial coupling product due to steric effects.61 
 
Scheme 16: Highly diastereoselective Csp3–Csp2 Negishi cross-coupling reaction of a 1,2,4-substituted 
cyclohexylzinc reagent with a heteroaryl bromide, promoted by a bulky palladium catalyst.62 
The steric effect was also used by the group of Wang. A norephedrine derivative protected with a bulky 
amino protecting group (Scheme 17) was treated with activated zinc to obtain the corresponding 
alkylzinc iodide. Following palladium-catalyzed cross-coupling reaction with 4-bromobenzonitrile 
selectively leads to the trans-product with a diastereomeric ratio of >95:5.62 
 
Scheme 17: Preparation of a norephedrine based organozinc reagent with a bulky N-protecting group leading to 
highly diastereoselective Negishi cross-coupling products.62 
 
  
 
59 Mitsuya Sakurai, Tadashi Hata, Yuichiro Yabe, Tetrahedron Lett. 1993, 34, 5939. 
60 a) S. Sakami, T. Houkawa, M. Asaoka, H. Takei, J. Chem. Soc., Perkin Trans. 1 1995, 285; b) T. Houkawa, T. 
Ueda, S. Sakami, M. Asaoka, H. Takei, Tetrahedron Lett. 1996, 37, 1045. 
61 T. Thaler, B. Haag, A. Gavryushin, K. Schober, E. Hartmann, R. M. Gschwind, H. Zipse, P. Mayer, P. Knochel, 
Nat. Chem. 2010, 2, 125. 
62 S. Tang, S. Li, D. Zhou, H. Zeng, N. Wang, Sci. China Chem. 2013, 56, 1293. 
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3 Objectives 
The late-stage functionalization of peptides and cyclopeptides is an important way to adjust biophysical 
properties during the drug discovery process. By attaching various moieties e.g. aryl or heteroaryl 
groups to the peptide side chain, biophysically relevant properties such as solubility or membrane 
permeability can be altered and further optimized. For this purpose, C-H activations or Suzuki-Miyaura 
cross-coupling reactions have already been described. Nevertheless, the application of those methods 
is often limited to a few target-sides and the functionalization scope is restricted. For this reason, a new 
versatile method for peptide modification with a broad functional group tolerance should be developed. 
Previous applications of organozinc pivalates in Negishi cross-coupling reactions displayed great 
tolerance towards functional groups and should therefore be investigated for the late-stage modification 
of peptides. To use peptides in cross-coupling reactions, a suitable side-chain moiety has to be converted 
into the corresponding halide. Since iodides have shown very fast reaction rates in cross-coupling 
reactions, a straightforward and universally applicable procedure for the conversion of a peptide into 
an iodinated peptide was envisioned (Scheme 18). Finally, a fast cross-coupling protocol has to be found 
to make the reaction feasible in the presence of peptides containing acidic protons. 
 
Scheme 18: Schematic representation of the peptide iodination and following late-stage functionalization via 
Negishi cross-coupling. 
 
Furthermore, new chiral alkylzinc reagents containing an amino-group in β-position would be of major 
interest. Proteinogenic α-amino acids contain a predefined stereo-center and are easily reduced to the 
corresponding amino-alcohol without loss of optical purity. Therefore, those compounds should be 
excellent starting materials towards chiral alkylzinc compounds. Since alkylzinc compounds and most 
of the cross-coupling catalysts are sensitive to free amines, a suitable protecting group is necessary. 
There are several requirements for an ideal protecting group. It must be inert, insensitive towards 
nucleophilic organozinc reagents and should not contain acidic protons which might hydrolyze the zinc 
reagent. Furthermore, it should not promote other unintended reactions: Whereas an electrophilic amino 
protecting group destabilizes the resulting organozinc reagent and leads to elimination, a donating 
amino protecting group on the other hand destabilizes the starting iodide derivatives by formation of 
aziridine, see Scheme 19. Additionally, the removal of the protecting group at the end of the sequence 
must be feasible while the introduced functional groups as well as the stereocenters remain unchanged.   
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Scheme 19: Possible side-reactions during the zinc-insertion using inappropriate protecting groups. 
Starting from the chiral amino-alcohol, straightforward protection and iodination reaction should 
provide chiral alkyl iodides which then can be used for oxidative insertion of zinc dust to obtain the 
corresponding alkylzinc reagents. A valuable addition would be the application of these reagents in 
following cross-coupling and acylation reactions, which should deliver 1,2-substituted amino-
derivatives (Scheme 20).  
 
Scheme 20: Schematic representation for the preparation of β-amino alkylzinc reagent starting from chiral 
amino-alcohols and the subsequent application in Negishi cross-coupling and acylation reactions.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. RESULTS AND DISCUSSION 
  
B. RESULTS AND DISCUSSION    17 
1 Late-Stage Functionalization of Peptides and Cyclopeptides Using 
Organozinc Reagents 
1.1 Introduction 
The late-stage functionalization of peptides using C-H activation63 or Suzuki-Miyaura cross-couplings64 
is already known and has found useful application (Scheme 21). For this purpose, various transition 
metals, such as palladium, nickel, gold, ruthenium and manganese, have been used65. However, there is 
still a strong need to extend the toolbox of peptide modification and to broaden the scope of targets as 
well as introducible moieties. Therefore, the development of a new universal method using a non-
specialized target side and exhibiting a diverse functional group tolerance is necessary. Since 
organozinc chemistry is known for the high functional group tolerance and mild reaction conditions, it 
should be well suited for this purpose.66 
 
Scheme 21: Palladium catalyzed peptide modifications using C-H arylations with diaryliodonium salts67 or 
Suzuki-Miyaura cross-coupling reactions68. 
 
63 a) J. Ruiz‐Rodríguez, F. Albericio, R. Lavilla, Chem. Eur. J. 2010, 16, 1124; b) Z. Ruan, N. Sauermann, E. 
Manoni, L. Ackermann, Angew. Chem. Int. Ed. 2017, 56, 3172; c) A. Schischko, H. Ren, N. Kaplaneris, L. 
Ackermann, Angew. Chem. Int. Ed. 2017, 56, 1576; d) H. G. Lee, G. Lautrette, B. L. Pentelute, S. L. Buchwald, 
Angew. Chem. Int. Ed. 2017, 56, 3177. 
64 G. Espuña, G. Arsequell, G. Valencia, J. Barluenga, J. M. Alvarez-Gutiérrez, A. Ballesteros, J. M. González, 
Angew. Chem. Int. Ed. 2003, 43, 325. 
65 a) W. Wang, M. M. Lorion, J. Shah, A. R. Kapdi, L. Ackermann, Angew. Chem. Int. Ed. 2018, 57, 14700; b) S. 
E. Hooshmand, B. Heidari, R. Sedghi, R. S. Varma, Green Chem. 2019, 21, 381; c) T. Willemse, W. Schepens, 
H. Vlijmen, B. Maes, S. Ballet, Catalysts 2017, 7, 74. 
66 a) E. Negishi, L. F. Valente, M. Kobayashi, J. Am. Chem. Soc. 1980, 102, 3298 b) E. Negishi, Acc. Chem. Res. 
1982, 15, 340. c) N. Hadei, E. A. B. Kantchev, C. J. O'Brie, M. G. Organ, Org. Lett. 2005, 7, 3805. d) C. Valente, 
M. E. Belowich, N. Hadei, M. G. Organ, Eur. J. Org. Chem. 2010, 2010, 4343. e) D. Haas, J. M. Hammann, R. 
Greiner, P. Knochel, ACS Catal. 2016, 6, 1540. 
67 Y. Zhu, M. Bauer, L. Ackermann, Chem. Eur. J. 2015, 21, 9980. 
68 J. M. Chalker, C. S. C. Wood, B. G. Davis, J. Am. Chem. Soc. 2009, 131, 16346. 
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Recently, the group of Knochel reported organozinc reagents using pivalate salts as counterions which 
display an enhanced air- and moisture stability69. They have found broad application in a variety of 
reactions with all kinds of electrophiles.70  
Previously, a method for palladium- and nickel-catalyzed cross-coupling reactions has been reported 
using organozinc halides and electrophiles bearing acidic protons.71 The fast cross-coupling reaction 
combined with a slow addition of the zinc reagents allows for the tolerance of sensitive and acidic 
functional groups. 
Herein, a convenient late-stage functionalization of various highly functionalized polypeptides is 
reported. The procedure consists of a regioselective iodination of a tyrosine containing peptide and a 
subsequent highly selective palladium-catalyzed cross coupling reaction enabled by the slow addition 
of various polyfunctional organozinc pivalates (Scheme 22).  
 
Scheme 22: A generalized pathway for the late-stage functionalization of peptides using organozinc pivalates.  
1.2 Method Development for Iodination and Negishi Cross-Coupling Based on Tyrosine 
A Boc protected L-tyrosyl methyl ester was chosen as a model substrate since it contains most of the 
sensitive functional groups, such as phenolic hydroxyl groups, amides and α-acidic esters. To convert 
protected amino acid (2a) into an eligible cross-coupling electrophile, a selective mono-iodination 
procedure had to be found. Experiments showed that the use of the oxidation agent Chloramine T 
combined with sodium iodide72 proved to be successful to mainly obtain the mono-iodinated tyrosine 
derivative. To achieve the best results, the oxidant had to be added very slowly via a syringe pump at 
low temperatures (Scheme 23). A screening showed that 1.2 equivalents of the iodination mixture 
provided the best result in terms of reaction conversion and yield of the mono-iodo tyrosine 3a. The 
major by-product was the bis-iodo derivative which had to be separated first by column chromatography 
 
69 a) A. Hernán‐Gómez, E. Herd, E. Hevia, A. R. Kennedy, P. Knochel, K. Koszinowski, S. M. Manolikakes, R. 
E. Mulvey, C. Schnegelsberg, Angew. Chem. Int. Ed. 2014, 53, 2706; b) Y.-H. Chen, M. Ellwart, V. Malakhov, 
P. Knochel, Synthesis 2017, 49, 3215. 
70 a) S. Bernhardt, G. Manolikakes, T. Kunz, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 9205. b) C. I. Stathakis, 
S. Bernhardt, V. Quint, P. Knochel, Angew. Chem. Int. Ed. 2012, 51, 9428. c) S. M. Manolikakes, M. Ellwart, C. 
I. Stathakis, P. Knochel, Chem. Eur. J. 2014, 20, 12289. d) M. Ellwart, P. Knochel, Angew. Chem. Int. Ed. 2015, 
54, 10662. 
71 G. Manolikakes, C. Muñoz Hernandez, M. A. Schade, A. Metzger, P. Knochel, J. Org. Chem. 2008, 73, 8422. 
72 T. Kometani, D. S. Watt, T. Ji, Tetrahedron Lett. 1985, 26, 2043. 
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and subsequent RP-HPLC purification. Then, thus obtained iodotyrosyl methyl ester 3a was used as 
screening substrate to develop the procedure for the cross-coupling reaction. 
 
Scheme 23: Regioselective mono-iodination of protected L-tyrosine using sodium iodide and Chloramine T. 
The first attempts for the Negishi-cross coupling reaction were performed using aryl- and heteroaryl 
zinc pivalates according to standard literature procedures73. A catalytic system of Pd(OAc)2 combined 
with Buchwald’s phosphine ligand SPhos74 showed the best result in preliminary experiments and was 
used for the cross-coupling reactions. Since nitrogen can competitively bind as a ligand to palladium as 
well75, a slightly increased catalyst loading was necessary. To a pre-stirred mixture of the palladium salt 
and the ligand in THF, the iodo-tyrosine was added. The corresponding arylzinc pivalates were added 
dropwise over a period of 1 h via syringe pump and the reaction mixture was stirred until full conversion 
of the electrophile was observed. An electron-rich (1a) as well as an electron-poor (1b) organozinc 
pivalate was used for the test cross-coupling reactions of the protected iodo-tyrosine, affording the 
desired cross-coupling products 4a and 4b in 74% and 50% yield. Next, the scope with respect to the 
arylzinc reagent was examined. Since pyridine residues are interesting moieties for the late-stage 
functionalization, three different isomeric pyridylzinc pivalates (1c–e) have been used. To ensure full 
reaction conversion, the amount of pyridylzinc pivalate was increased to 2.0 equivalents. The three 
corresponding pyridyl-tyrosine derivatives 4c–e could be obtained in high yields of 73–87% (Table 1). 
 
  
 
73 a) S. Bernhardt, G. Manolikakes, T. Kunz, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 9205; b) J. R. Colombe, 
S. Bernhardt, C. Stathakis, S. L. Buchwald, P. Knochel, Org. Lett. 2013, 15, 5754; c) S. M. Manolikakes, M. 
Ellwart, C. I. Stathakis, P. Knochel, Chem. Eur. J. 2014, 20, 12289; d) S. Otsuka, D. Fujino, K. Murakami, H. 
Yorimitsu, A. Osuka, Chem. Eur. J. 2014, 20, 13146; e) M. Ellwart, P. Knochel, Angew. Chem. Int. Ed. 2015, 54, 
10662. 
74 T. E. Barder, S. D. Walker, J. R. Martinelli, S. L. Buchwald, J. Am. Chem. Soc. 2005, 127, 4685. 
75 T. E. Barder, S. L. Buchwald, J. Am. Chem. Soc. 2007, 129, 12003. 
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Table 1: Negishi cross-couplings of tyrosine derivative 3a with aryl- and heteroarylzinc pivalates 1a–e. 
 
Entry Zinc Pivalate Product Yield (%)[a] 
1 
 
 
74 
 1a 4a  
2 
 
 
50 
 1b 4b  
3 
 
 
87 
 1c 4c  
4 
 
 
80 
 1d 4d  
5 
 
 
73 
 1e 4e  
[a] Yield of the isolated analytically pure product. [b] 1.5 equiv of ArZnOPiv were used. [c] 2.0 equiv of 
HetArZnOPiv were used. 
 
1.3 Iodination of Tyrosine-based Peptides 
After the successful mono-iodination of the protected tyrosine, the procedure was extended to various 
small peptides (Table 2)76. First, a dipeptide consisting of N-Cbz-protected proline and a tyrosyl methyl 
ester (peptide 2b) was tested. Using the previously developed reaction conditions, the mono-iodinated 
dipeptide 3b was obtained in 79% yield. Furthermore, dipeptide 2c containing a tryptophan unit was 
 
76 Peptides were provided by Novartis Pharma AG, Basel, Switzerland. Special thanks to Dr. Guido Koch and Dr. 
Thomas Vorherr. 
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iodinated using the same protocol. However, the desired mono-iodo peptide was obtained in only 
30% yield, although 24% of the starting material were recovered. It seemed that the indole moiety of 
the tryptophan is too sensitive towards the oxidation reagent77 which caused many minor side products 
and an overall unclean reaction. In addition, increasing the amount of the iodination reagent did not 
improve the reaction outcome. Further optimization attempts to increase the yield were not successful.  
A tetrapeptide containing proline, glutamine, tyrosine and valine was also successfully iodinated 
followed the developed procedure leading to 52% yield of the mono-iodinated peptide 3d. 
Table 2: Mono-iodination of the tyrosine moiety on small peptides using Chloramine T and sodium iodide.  
 
Entry Peptide Iodinated peptide Yield (%)[a] 
1 
  
79 
 2b 3b  
2 
  
30[b] 
 2c 3c  
3 
 
 
52 
 2d 3d  
[a] Yield of the isolated analytically pure product. [b] 24% of the starting material were recovered.  
In addition to linear peptides, cyclopeptides were investigated because of their high potential for late-
stage functionalization due to possible medical applications78. Unfortunately, the iodination using the 
standard procedure did not provide any mono-iodinated product. Since optimization attempts including 
 
77 G. Mourier, L. Moroder, A. Previero Z. Naturforsch. B 1984, 39, 101. 
78 a) N. K. Gulavita, S. P. Gunasekera, S. A. Pomponi, E. V. Robinson, J. Org. Chem. 1992, 57, 1767; b) M. 
Cebrat, Z. Wieczorek, I. Z. Siemion, Peptides 1996, 17, 191; c) B. Vera, J. Vicente, A. D. Rodríguez, J. Nat. Prod. 
2009, 72, 1555; d) W.-Y. Fang, R. Dahiya, H.-L. Qin, R. Mourya, S. Maharaj, Mar. Drugs 2016, 14, 194. 
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varying the temperature, amount of the reagent and the reaction time were not successful, the use of an 
alternative method was necessary. It was found that the bis(pyridine)iodonium reagent of Barluenga79 
was perfectly suited for this cyclic peptide. The reaction of the cyclopeptide 2e with 1.3 equivalents of 
Barluenga's reagent in DCM led to the iodinated cyclopeptide 3e in 95% yield within 5 h (Scheme 24). 
 
Scheme 24: Iodination of the tyrosine-based cyclopeptide 2e using Barluenga’s reagent.  
1.4 Negishi Cross-Coupling of Tyrosine based Peptides Using Organozinc Pivalates 
With these four iodinated peptides in hand, further investigations on the late-stage functionalization via 
Negishi cross-coupling reaction have been made, using the reaction conditions developed in the 
preliminary experiments on the protected tyrosine. Therefore, the peptide 3b was coupled with various 
aryl and heteroaryl organozinc pivalate in the presence of palladium acetate and SPhos (Table 3). 
Crucial for this method was again the slow addition of the zinc reagent solution via syringe pump over 
a period of 1 h. The first experiments using 1.5 equivalents of the corresponding organozinc pivalate 
revealed that the yields were comparable to the ones of the previous cross-couplings. The modified 
peptide 7a using an electron deficient zinc pivalate 1a was obtained in 67% yield (tyrosine derivative: 
74% yield) and 7b using an electron rich zinc species in 48% yield (tyrosine derivative: 50% yield). 
Applying 1.5 equivalents of the pyridyl zinc pivalate 1g provided the corresponding peptide 7g in 61% 
yield. The experiments showed that no full conversion of the iodo-peptides was achieved during the 
reaction. Therefore, to obtain a higher yield for the following reaction, the amount of zinc reagent used 
was increased to 2.5 equiv. Thus, the arylated peptide 7f using the zinc pivalate 1f was obtained in a 
high yield of 80%. To extend the reaction scope to benzene-fused heterocycles, the benzothiophenylzinc 
1h as well as benzofuranylzinc 1i derivative have been used to obtain the modified peptides 7e and 7f 
in 47% and 87% yield. In conclusion, it was possible to use electron-rich and –poor arylzinc pivalates 
as well as heteroarylzinc pivalates to prepare the modified peptide 7e–f in 47–87% yield. It was shown 
that the method developed on the tyrosine test substrate was also suitable for dipeptides. 
  
 
79 G. Espuña, G. Arsequell, G. Valencia, J. Barluenga, J. M. Alvarez-Gutiérrez, A. Ballesteros, J. M. González, 
Angew. Chem. Int. Ed. 2003, 43, 325. 
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Table 3: Negishi cross-coupling of the dipeptide 3b with aryl- and heteroarylzinc pivalates of type 1. 
 
Entry Zinc Pivalate Product Yield (%)[a] 
1 
 
 
67[b] 
 1a 7a  
2 
 
 
48[b] 
 1b 7b  
3 
 
 
80[c] 
 1f 7c  
4 
 
 
61[b] 
 1g 7d  
5 
 
 
47[c] 
 1h 7c  
6 
 
 
87[c] 
 1i 7f  
[a] Yield of the isolated analytically pure product. [b] 1.5 equiv of ArZnOPiv were used. [c] 2.5 equiv of 
ArZnOPiv were used. 
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Table 4: Negishi cross-coupling reactions of the dipeptide 3c with aryl- and heteroarylzinc pivalates of type 1. 
 
Entry Zinc Pivalate Product Yield (%)[a] 
1 
 
 
92 
 1g 8a  
2 
 
 
72 
 1j 8b  
3 
 
 
76 
 1k 8c  
4 
 
 
38 
 1h 8d  
[a] Yield of the isolated analytically pure product. 
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The experiments were continued with the tryptophan containing peptide 3c. In contrast to the iodination, 
the presence of tryptophan did not pose a problem for cross-coupling reactions. Various aryl- as well 
as heteroarylzinc pivalates were successfully applied to the cross-coupling reaction leading to the 
modified peptide 8a–d in 38–92% isolated yield (Table 4).  
Table 5: Negishi cross-coupling of the tetrapeptide 3d with aryl- and heteroarylzinc pivalates of type 1. 
 
Entry Zinc Pivalate Product Yield (%)[a] 
1 
 
 
50 
 1g 9a  
2 
 
 
80 
 1f 9b  
3 
 
 
89 
 1l 9c  
[a] Yield of the isolated analytically pure product. 
After the successful Negishi cross-couplings on the previous dipeptides, this method was further 
extended to a tetrapeptide containing a primary amide from glutamine. The first cross-coupling using 
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the pyridylzinc derivative 1g furnished the desired product 9a in a moderate yield of 50%. In contrast, 
using the arylzinc pivalates 1f and 1l led to the products 9b and 9c in high yields between 80% and 
89%, respectively (Table 5). Thus, in conclusion, the increased size of the peptide and the presence of 
the primary amide did not compromise the cross-coupling reaction.  
Table 6: Negishi cross-coupling of the cyclopeptide 3e with heteroarylzinc pivalates of type 1. 
 
Entry Zinc Pivalate Product Yield (%)[a] 
1 
 
 
82 
 1g 10a  
2 
 
 
53 
 1d 10b  
3 
 
 
67 
 1e 10c  
[a] Yield of the isolated analytically pure product. 
Additionally, cross-coupling experiments were conducted on the mono-iodinated tyrosine-based 
cyclopeptide 3e. As a preliminary test for the following experiments (see 1.6), pyridylzinc pivalates 
were exclusively used to investigate the feasibility for the late-stage introduction of pyridyl moieties. 
Three different substituted pyridylzinc reagents were used to check if it is possible to achieve modified 
cyclopeptides with the pyridyl nitrogen atom in ortho-, meta- and para-position. Therefore, peptide 3e 
was used for Negishi cross-coupling reactions with the corresponding zinc reagents 1g, 1d or 1e and 
the modified cyclopeptides 10a–c were obtained in 53–82% yield (Table 6). It was found that the 
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performance of the cross-coupling is dependent on the position of the pyridyl nitrogen atom which is 
displayed in the deviated yields for the 2-, 3- and 4-position products.  
 
1.5 Negishi Cross-Coupling Reactions of Alkylzinc Halides with Tyrosine Derivatives 
In addition to the aryl and heteroaryl Negishi cross-coupling reactions discussed in the previous chapter, 
a new method for the coupling of alkylzinc reagents was also investigated.  
Attempts to extend the cross-coupling to alkylzinc pivalates proved to be difficult and a new 
optimization study was required. It was found, that zinc organometallics prepared by the direct oxidative 
insertion of zinc powder in the presence of LiCl were most suitable for a subsequent cross-coupling.80 
The previously used catalytic system (palladium acetate and SPhos) was not suitable for this reaction 
type and did not provide the desired products. It was found that the catalyst developed by Fu81 with 
4 mol% palladium dibenzylideneacetone (Pd(dba)2) and 8 mol% tri-tert-butylphosphine (PtBu3) gave 
the best results. Thus, the coupling of various functionalized primary and secondary alkylzinc halides 
(5a–e) bearing a chloro-, an ester- or a nitrile-function with the iodinated tyrosines 3a and 3b led to the 
modified tyrosines (6a–e) including the dipeptide 6f (Table 7) in 48–82% isolated yield. Remarkably, 
the use of the Fu-catalyst led to relatively fast cross-coupling reactions. Combined with the slow 
addition of the organozinc reagent, an excellent compatibility with the acidic amides and phenolic 
protons was achieved. 
  
 
80 a) I. Kalvet, T. Sperger, T. Scattolin, G. Magnin, F. Schoenebeck, Angew. Chem. Int. Ed. 2017, 56, 7078; b) C. 
Feng, D. W. Cunningham, Q. T. Easter, S. A. Blum, J. Am. Chem. Soc. 2016, 138, 11156; c) T. D. Blümke, F. M. 
Piller, P. Knochel, Chem. Commun. 2010, 46, 4082; d) A. Krasovskiy, V. Malakhov, A. Gavryushin, P. Knochel, 
Angew. Chem. Int. Ed. 2006, 45, 6040. 
81 C. Dai, G. C. Fu, J. Am. Chem. Soc. 2001, 123, 2719. 
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Table 7: Negishi cross-coupling of tyrosine derivative 3a and 3b with alkylzinc halides 5a–e. 
 
Entry Tyrosine Alkylzinc reagent Product Yield (%)[a] 
1 3a  
 
82 
  5a 6a
  
2 3a 
 
 
71 
  5b 6b  
3 3a  
 
72 
  5c 6c  
4 3a  
 
58 
  5d 6d  
5 3a  
 
48 
  5e 6e  
6 3b  
 
61 
  5a 6f  
[a] Yield of the isolated analytically pure product. 
  
B. RESULTS AND DISCUSSION    29 
1.6 Negishi Cross-Couplings of Iodo-Phenylalanine-based Cyclopeptides with 
Pyridylzinc Pivalates 
The previous experiments have shown that the late-stage functionalization using Negishi cross-coupling 
in combination with arylzinc pivalates is well suitable for the modification of linear and cyclic tyrosine-
based peptides. With this tool in hands, it should be possible to functionalize even large peptides based 
on similar amino acids used before.  
For the following experiments, hexameric-cyclopeptides consisting of three valine-, one proline- and 
one iodo-phenylalanine-blocks provided by Novartis82 were used. The position of the iodo moiety in 
the phenylalanine side-chain was varying, so three different cyclopeptides (ortho-11, meta-12 and 
para-13) were used as electrophile. The aim of this study was to introduce a 2-, 3- and 4-pyridyl moiety 
into each of the three cyclopeptide to get a set of nine different peptide-modifications. Then, the 
biophysical properties of these products were investigated (see the end of this chapter).   
The first experiments were performed on the ortho-iodophenylalanine cyclohexapeptide using 
pyridylzinc pivalates 1c–e and the same reaction conditions as for previous cross-couplings (Table 
8).Whereas the 3- and 4- pyridylzinc reagents provided the desired modified peptides 14b and 14c in 
reasonable yield of 62% and 67 respectively, the 2-pyridyl did not provide the coupling product using 
those conditions. Further optimization experiments showed that increasing the catalyst loading (8 mol% 
palladium acetate and 16 mol% SPhos) as well as increasing the amount of zinc reagent 
(3.0 equivalents) and raising the reaction temperature to 60 °C led to the desired product 14a in a 
moderate yield of 38% after 24 h (Table 8, Entry 1). As the de-iodinated cyclopeptide was detected as 
the main side-product, the problem might be the reductive elimination during the cross-coupling cycle83. 
A reason for this phenomenon was not determined, but steric hindrance of the ortho-iodide with the 
2-pyridyl residue might play a significant role. Further increasing the amount of catalyst and reagent or 
a different catalytic system did not provide higher amounts of product but more undesired de-iodination 
product. 
  
 
82 Peptides were provided by Novartis Pharma AG, Basel, Switzerland. Special thanks to Dr. Guido Koch and Dr. 
Thomas Vorherr. 
83 Q. Liu, Y. Lan, J. Liu, G. Li, Y.-D. Wu, A. Lei, J. Am. Chem. Soc. 2009, 131, 10201. 
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Table 8: Negishi cross-coupling of the cyclopeptide 11 with pyridylzinc pivalates 1c–e. 
 
Entry Zinc Pivalate Product Yield (%)[a] 
1 
 
 
38[b] 
 1c 14a  
2 
 
 
62 
 1d 14b  
3 
 
 
67 
 1e 14c  
[a] Yield of the isolated analytically pure product. [b] Different reaction conditions were used: 2-pyridylzinc 
pivalate (3.0 equiv), 8 mol% Pd(OAc)2, 16 mol% SPhos, THF, 60 °C, 24 h. 
Experiments were continued with the meta-iodo cyclopeptide 12. Applying the standard reaction 
conditions using the three different substituted pyridylzinc reagents provided the modified meta-
cyclohexapeptides 15a–c in 62–77% yield (Table 9). For this meta-iodo peptide, the 2-pyridylzinc 
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pivalate coupling led to an even better yield as for the other cross-couplings, which indicates that the 
zinc reagent was not the reason for the low yields of 14a but the ortho-substituted peptide. 
Table 9: Negishi cross-coupling of the cyclopeptide 12 with pyridylzinc pivalates 1c–e. 
 
Entry Zinc Pivalate Product Yield (%)[a] 
1 
 
 
72 
 1c 15a  
2 
 
 
62 
 1d 15b  
3 
 
 
77 
 1e 14c  
[a] Yield of the isolated analytically pure product. 
The last set of cross-coupling reaction was performed using the para-iodophenylalanine 
cyclopeptide 13 and the 2-,3- and 4-pyridylzinc pivalates (1c–e). After Negishi cross-coupling 
reactions, the para-pyridyl modified cyclopeptides 16a–c were obtained in 62–84% yield (Table 10). 
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Table 10: Negishi cross-coupling of the cyclopeptide 13 with pyridylzinc pivalates 1c–e. 
 
Entry Zinc Pivalate Product Yield (%)[a] 
1 
 
 
84 
 1c 16a  
2 
 
 
62 
 1d 16b  
3 
 
 
80 
 1e 16c  
[a] Yield of the isolated analytically pure product. 
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This set of nine modified cyclopeptides as well as the three starting iodophenylalanine-cyclopeptides 
were used for biophysical studies to investigate the influence of the pyridyl-substituents on properties 
like solubility under physiological conditions, cell-membrane permeability and transport rate through 
membranes. All measurements and calculations of the biophysical properties were conducted and 
evaluated by Novartis Pharma AG.84 
The membrane permeability- and solubility-parameters of the cyclopeptides 11–16 were compared to 
the results of in-silico calculations. Therefore, the nine cross-coupling products (14–16) have been 
submitted for MD (molecular dynamics) simulations followed by calculation of the solvent-accessible 
polar surface area (abbreviated SAPSA) to result in an in-silico assessment regarding their permeability 
properties in the first instance. Interestingly, different SAPSA values were observed and as expected in 
the cases, in which the pyridyl moiety is more exposed (meta and para substituted phenylalanine 
residues) more polar surface area is accessible. Next, solubility and permeability parameters were 
assessed. The low solubility measured for the starting materials (11–13) was improved by the pyridyl 
core in most of the cases (see Table 11, Entries 4–9 and 12), and on the basis of the PAMPA (Parallel 
Artificial Membrane Permeability Assay) results, all cyclic peptides display high permeability. 
However, in the cellular assessment (MDCK; Madin Darby canine kidney cells assay), the position of 
the pyridyl linkage seemed to be sensitive regarding transport across. As for the in-silico analyses, the 
para-phenylalanine substituted analogues showed reduced transport rates.  
Table 11: Biophysical properties of the iodo-cyclopeptides and the modified cyclopeptides.84 
Entry Peptide SAPSA (Å2) Solubility[b] (µM) PAMPA MDCK (10-6cm/s) SFC (min) 
1 11 62 < 4 -4.2[b] n.d. [a] 3.15 
2 12 74 3 -4.3[b] n.d. [a] 3.14 
3 13 75 < 4 -5.4[b] n.d. [a] 3.23 
4 14a 76 24 -4.7[c] n.d. [a] 3.37 
5 14b 84 46 -4.3[b] 15.7 3.31 
6 14c 83 52 -4.5[b] 19.3 3.39 
7 15a 74 21 -4.5[b] 3.3 3.51 
8 15b 101 26 -4.7[b] 3.2 3.60 
9 15c 94 31 -4.8[b] 13.6 3.76 
10 16a 84 9 -4.5[b] 1.4 3.61 
11 16b 99 < 4 -4.6[b] 2.1 3.72 
12 16c 106 22 -4.6[b] 2.9 3.89 
[a] not determined due to QC or recovery problems. [b] at pH 6.8, [c] at pH 8.0. 
 
84 Experiments and calculations were performed by Dr. Thomas Vorherr, Dr. Ian Lewis, Dr. Michael Schaefer of 
the Novartis Pharma AG, Basel. 
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However, this assay reflects the sum of active and passive transport properties, whereas the SFC 
(supercritical fluid chromatography) method rank-orders only for passive permeability. Nevertheless, 
the cross-coupling products resulting from ortho-phenylalanine substitutions clearly showed a higher 
passive permeability. This finding was in line with the MD simulations followed by SAPSA calculation 
of the preferred conformational clusters.85 
  
 
85 M. Leroux, T. Vorherr, I. Lewis, M. Schaefer, G. Koch, K. Karaghiosoff, P. Knochel, Angew. Chem. Int. 
Ed. 2019, 58, 8231. 
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2 Pyrrole Protected 2-Aminoalkylzinc Reagents for the Enantioselective 
Synthesis of Amino Derivatives 
2.1 Introduction 
The preparation of organozinc reagents bearing a nitrogen in β-position in cyclic systems was already 
described in the literature. Using a N-Boc protected azetidine, the zinc compound can be easily produced 
from the corresponding iodide and used in cross-couplings as well as allylation reactions (Scheme 25). 
 
Scheme 25: Preparation of (N-Boc-azetidin-3-yl)zinc(II) iodide and application in cross-coupling and allylation 
reactions.86 
In general, the preparation of chiral amino-derivatives is of great synthetic importance in the 
development of new pharmaceuticals and agrochemicals.87 A straightforward and fast way to obtain 
chiral amino-derivatives is the use of enantiopure amino acids as precursors. Since they can be produced 
industrially by fermentation in big scale without the use of expensive catalysts, they are cheap and 
therefore excellent suited for this application.88 
Recently, the group of Knochel already utilized chiral amino-alcohols obtained from amino acids to 
prepare mixed zinc-copper reagents which were used for various allylation reactions (Scheme 26).89 
 
Scheme 26: Preparation of a chiral amino-alcohol based zinc-copper reagent and following reaction with a 
functionalized allyl bromide.89 
  
 
86 S. Billotte, Synlett 1998, 1998, 379. 
87 a) T. C. Nugent, M. El-Shazly, Adv. Synth. Catal. 2010, 352, 753; b) T. C. Nugent, Chiral Amine Synthesis, 
Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 2010; c) M. Breuer, K. Ditrich, T. Habicher, B. 
Hauer, M. Kesseler, R. Stürmer, T. Zelinski, Angew. Chem. Int. Ed. 2004, 43, 788. 
88 a) M. D'Este, M. Alvarado-Morales, I. Angelidaki, Biotechnol. Adv. 2018, 36, 14; b) N. Tonouchi, H. Ito Amino 
Acid Fermentation (Eds.: A. Yokota, M. Ikeda), Springer Japan, Tokyo, Japan, 2017, 3–14. 
89 R. Duddu, M. Eckhardt, M. Furlong, H.P. Knoess, S. Berger, P. Knochel, Tetrahedron 1994, 50, 2415. 
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In the approach of Jackson, chiral C- and N-protected amino acids have been converted to alkyl iodides 
and after oxidative zinc insertion, used for cross-coupling reactions.90 Especially, starting from serine, 
side-chain modified amino acid derivatives can be produced, as displayed in Scheme 27. 
 
Scheme 27: Preparation of a chiral amino-acid alkylzinc reagent and its application in a Negishi cross-coupling 
reaction.91 
In addition to these approaches, a new method was envisioned to prepare a broad range of chiral amino 
organozinc reagent starting from readily accessible amino-alcohols to obtain a powerful and universally 
applicable tool for the synthesis of functionalized amino derivatives. 
Herein, a convenient and quite general preparation of chiral pyrrole-protected organozinc reagents and 
their application in transition-metal catalyzed reactions with electrophiles, bearing various functional 
groups, is reported (Scheme 28). 
 
Scheme 28: A new approach towards chiral amino-organozinc reagents using pyrrole as a protecting group. 
 
 
 
 
 
 
 
 
 
 
 
90 a) J. Ross, F. Dreiocker, M. Schäfer, J. Oomens, A. J. H. M. Meijer, B. T. Pickup, R. F. W. Jackson, J. Org. 
Chem. 2011, 76, 1727; b) T. Carrillo-Marquez, L. Caggiano, R. F. W. Jackson, U. Grabowska, A. Rae, M. J. 
Tozer, Org. Biomol. Chem. 2005, 3, 4117; c) H. J. C. Deboves, U. Grabowska, A. Rizzo, R. F. W. Jackson, J. 
Chem. Soc., Perkin Trans. 1 2000, 4284; d) R. F. W. Jackson, K. James, M. J. Wythes, A. Wood, J. Chem. Soc., 
Chem. Commun. 1989, 644. 
91 A. J. Ross, H. L. Lang, R. F. W. Jackson, J. Org. Chem. 2010, 75, 245. 
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2.2 Proof of Principle for β-Amino Alkylzinc Reagents Starting from Glycinol 
Preliminary experiments were performed using glycinol (2-aminoethanol) as test substrate. It was 
found, that achiral glycinol offers a promising opportunity to obtain the simplest β-iodo-alkyl amine by 
treating glycinol with hydroiodic acid at high temperatures (pc1, Scheme 29). Therefore, this substrate 
was used for the determination of an amino protecting group compatible with a zinc insertion. 
Experiments revealed that benzyl-, alkyl-, allyl-, Boc-, phthaloyl- or silyl-protecting groups were not 
suited for this purpose. It was found that 1H-pyrrole is an excellent protecting group for this study which 
met all requirements. Protection of the amino-group was easily performed by refluxing the 
β-iodo-alkylamine in 2,5-dimethoxy tetrahydrofuran with sodium acetate and acetic acid in a 
1,2-dichloroethane/water mixture for 1 h and provided the desired pyrrole-protected alkyl iodide 19a in 
71% yield (Scheme 29). Zinc powder was suspended in dry THF together with lithium chloride92 and 
activated with 1,2-dibromoethane and chlorotrimethylsilane93 for the oxidative insertion. The previous 
prepared alkyl iodide was added to this mixture at room temperature and the corresponding organozinc 
reagent 20a was obtained in a good yield of 93% after 10 min (Scheme 29). This reagent showed no 
tendency to undergo elimination reactions and was stable at 25 °C for several days without 
decomposition. 
 
Scheme 29: Preparation of a pyrrole protected organozinc reagent starting from glycinol. 
In the next step, this new organozinc reagent was used in a broad range of palladium catalyzed cross-
coupling reaction to determine the functional group tolerance. Experiments revealed that the use of 
2 mol% Pd(OAc)2 and 4% SPhos
94 provided the best results. Thus, electron-rich as well as electron 
poor cross-coupling products (21a–e) were obtained in yields between 85% and 98%. Additionally, it 
was possible to use heteroaryl halides in this cross-coupling protocol providing the modified heteroaryl 
compounds 21f–h in 83–95% yield (Table 12). The pyrrole-containing organozinc reagent was also 
successfully applied in palladium catalyzed acylation reactions. Therefore, the reaction of various acyl 
chlorides with reagent 20a in the presence of 4 mol% Pd(PPh3)4 at 50 °C provided aryl- and 
heteroarylketones 21i–k as well as a cyclopropyl-ketone 21l in 73–87% yield (Table 12). 
 
92 A. Krasovskiy, V. Malakhov, A. Gavryushin, P. Knochel, Angew. Chem. Int. Ed. 2006, 45, 6040. 
93 P. Knochel, M. J. Rozema, C. E. Tucker, Organocopper reagents (Ed.: R. J. K. Taylor), Oxford University 
press, Oxford, 1994, 85. 
94 Y. Yang, N. J. Oldenhuis, S. L. Buchwald, Angew. Chem. Int. Ed. 2013, 52, 615. 
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Table 12: Palladium catalyzed cross-coupling and acylation reactions of the glycinol-based N-alkylpyrrolezinc 
reagent 20a with (hetero-)aryl halides and acid chlorides. 
 
Entry Electrophile Product Yield (%)[c] 
1 
  
98[a] 
  21a
 
 
2 
  
95[a] 
  21b  
3 
  
83[a] 
  21c  
4 
  
97[a] 
  21d  
5 
 
 
85[a] 
  21e  
6 
  
83[a] 
  21f  
7 
  
95[a] 
  21g  
8 
  
90[a] 
  21h  
9 
  
87[b] 
  21i  
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Entry Electrophile Product Yield (%)[c] 
10 
  
82[b] 
  21j  
11 
  
73[b] 
  21k  
12 
  
83[b] 
  21l  
[a] 2 mol% Pd(OAc)2, 4 mol% SPhos, 25 °C, 16 h. [b] 4 mol% Pd(PPh3)4, 50 °C, 16 h. [c] Yield of analytically 
pure isolated product. 
 
2.3 Preparation of Pyrrole-protected 2-Amino Alcohols 
With the proof-of-principle established for glycinol, this method should be extended to commercially 
available chiral 2-amino alcohols obtained from amino acids (natural L or unnatural D-enantiomer). 
Since the iodination conditions using hydroiodic acid were too harsh for most of the amino-alcohols 
and due to possible racemization of the chiral amino-group, another approach had to be found. 
In a newly developed pathway, the optical pure amino-alcohols were first transformed into the 
corresponding N-pyrrolyl-alkyl alcohol using the same procedure as previously for the glycinol 
derivative and then iodinated afterwards (see chapter 2.4). Thus, the chiral amino-alcohols 17b–f were 
treated with 2,5-dimethoxytetrahydrofuran and sodium acetate in the presence of acetic acid in a 
1,2-dichlorethane/water emulsion at 90 °C for 16 h, providing the pyrrole-derivatives 18b–f in 71–92% 
yield (Table 13). Additional to these amino acids-based precursors, optical pure cyclic trans-2-amino 
alcohols were used. Applying the same conditions, the 2-aminocyclohexanol (S,S)-17h and the 
2-aminocyclopentanol (R,R)-17i were converted to the corresponding pyrrole derivatives (S,S)-18h and 
(R,R)-18i in 83% and 77% yield with full retention of stereochemistry (Table 13). 
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Table 13: Preparation of chiral pyrrole-protected 2-amino alcohols of type 18. 
 
Entry 2-Aminoalcohol Pyrrole Derivative Yield (%)[a] 
1 
 
 
79[b] 
 (R)-17b (R)-18b  
2 
 
 
84 
 (R)-17c (R)-18c  
3 
 
 
85 
 (S)-17d (S)-18d  
4 
 
 
92 
 (S)-17e (S)-18e  
5 
 
 
71 
 (R)-17f (R)-18f  
6 
  
83  
d.r. 99:1 
 (S,S)-17h (S,S)-18h  
7 
  
77  
d.r. 99:1 
 (R,R)-17i (R,R)-18i  
[a] Yield of the isolated analytically pure product. [b] Reaction was finished after 5 h. 
Besides these N-pyrrolyl-alcohols, a tyrosine-based precursor was also of interest. Since the phenolic 
hydroxyl group might destabilize the desired organozinc reagent, methylation was necessary. For the 
reduction with mild reducing agents, the free acid was converted to the methyl ester. Starting from L-
tyrosine, an easy and straightforward synthesis pathway including pyrrole formation, phenol protection 
and methyl esterification ((S)-pc3) was performed in 58% yield over two steps without purification in 
between: Initially, the pyrrole group was formed using the default method followed by treatment with 
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methyl iodide and potassium hydroxide to achieve the methoxy group as well as the methyl ester. The 
methyl ester was then reduced with sodium borohydride to obtain the desired N-pyrrolyl-alkyl alcohol 
(S)-18g in 69% yield (Scheme 30).  
 
Scheme 30: Preparation of a pyrrole protected 2-aminoalcohol based on L-tyrosine. 
 
2.4 Preparation of N-Pyrrolyl Alkyl Iodides 
In the last step of the synthesis, the N-pyrrolylalkyl alcohol was converted into the corresponding alkyl 
iodide. 
Table 14: Appel typed iodination of the chiral amino-alcohols 18 providing in the alkyl iodides 19. 
 
Entry Pyrrole Derivative Iodide  Equiv Reagents Yield (%)[a] 
1 
  
1.20 
79 
ee = 99% 
 (R)-18b (R)-19b   
2 
  
1.10 
84 
ee = 99% 
 (R)-18c (R)-19c   
3 
  
1.10 
85 
ee = 99% 
 (S)-18d (S)-19d   
4 
  
1.10 
92 
ee = 99% 
 (S)-18e (S)-19e   
5 
  
1.05 
71 
ee = 99% 
 (R)-18f (R)-19f   
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Entry Pyrrole Derivative Iodide  Equiv Reagents Yield (%)[a] 
6 
  
1.05 
95 
ee = 92% 
 (S)-18g (S)-19g   
7 
  
1.20 
76[b,c] 
ee = 99% 
 (S,S)-18h (S,R)-19h   
8 
  
1.10 
43[b,c] 
ee = 98% 
 (R,R)-18i (R,S)-19i   
[a] Yield of the isolated analytically pure product. [b] Reaction was carried out at 50 °C for 16 h. [c] d.r. > 99:1. 
For this purpose, the N-pyrrolyl-alcohols 18b–g were iodinated95 by treatment of the alcohol with 
triphenylphosphine, iodine and 1H-imidazole in DCM starting from 0 °C to 25 °C within 2–4 h. After 
purification the resulting alkyl iodides 19b–g were obtained in 71–95% yield (Table 14). For these 
compounds, the optical purity was determined using chiral HPLC analysis. Alkyl iodides 19b–f display 
a very high purity with an enantiomeric excess of 99%. This finding proved that the protection and the 
iodination procedure proceeded without racemization. Notably, for the tyrosine derivative (S)-19g a 
decreased optical purity down to 92% ee was found which might be caused by the harsh reaction 
conditions during precursor synthesis. 
The cyclic N-pyrrolyl alcohols (S,S)-18h and (R,R)-18i could not be iodinated using these reaction 
conditions. For seeing a conversion of the alcohol, the reaction temperature had to be raised to 50 °C 
and the reaction time drastically increased to 16 h. Using these modified conditions, the iodinated 
products (S,R)-19h and (R,S)-19i  could be obtained in 76% and 43% yield with inversion of the 
stereocenter. Due to the elevated temperatures, the elimination reaction was more favored than usual 
and was observed as main side product for both reactions. The cis-conformation of (S,R)-19h was 
verified by comparing the coupling constants in the 1H-NMR spectrum. For the five-membered alkyl 
iodide (R,S)-19i, a single crystal could be obtained and following x-ray crystallography analysis 
confirmed the cis-configuration, as displayed in Figure 6. 
 
95 a) V. Morozova, J. Skotnitzki, K. Moriya, K. Karaghiosoff, P. Knochel, Angew. Chem. Int. Ed. 2018, 57, 5516; 
b) G. L. Lange, C. Gottardo, Synth. Commun. 1990, 20, 1473; c) P. J. Garegg, B. Samuelsson, J. Chem. Soc., 
Perkin Trans. 1 1980, 2866; d) R. Appel, Angew. Chem. Int. Ed. 1975, 14, 801. 
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Figure 6: Crystal structure of iodide (R,S)-19i is showing the cis-configuration of pyrrole and iodide. Thermal 
ellipsoids are drawn at 50% probability level. 
 
2.5 Oxidative Zinc Insertion of 1,2-substituted N-Pyrrolyl-Alkyl Iodides 
With the previously prepared N-pyrrolyl-alkyl iodides in hand, the preparation of the organozinc 
reagents was investigated.  
Table 15: Preparation of β-amino alkylzinc iodides via oxidative insertion of activated zinc dust in the presence 
of lithium chloride. 
 
Entry Iodide  Alkylzinc Compound Time (min) Yield (%)[a] 
1 
  
20 76 
 (R)-19b (R)-20b   
2 
  
10 80 
 (R)-19c (R)-20c   
3 
  
10 82 
 (S)-19d (S)-20d   
4 
  
90 71 
 (S)-19e (S)-20e   
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Entry Iodide  Alkylzinc Compound Time (min) Yield (%)[a] 
5 
  
30 91 
 (R)-19f (R)-20f   
6 
  
15 95 
 (S)-19g (S)-20g   
7 
  
10 
79 
 
 (S,R)-19h (S)-20h   
8 
  
10 96 
 (R,S)-19i (R)-20i   
[a] Yield of the zinc species was determined by titration against iodine in THF. 
Using activated zinc dust with lithium chloride in THF at 25 °C afforded the iodides 19b–i (Table 15). 
For most of the alkyl iodides, the reaction proceeded smoothly with slight heat generation within 10 min 
to 20 min. For the phenylglycinol- ((S)-19e) and the tryptophanol-derivative ((R)-19f) longer reaction 
times of 90 min and 30 min respectively were necessary to achieve full conversion of the alkyl iodides. 
Yield determination for the zinc reagents in THF was performed by titration against iodine96 and 
measuring the volume which resulted in 71–96% yield of the corresponding reagents 20a–i. 
Interestingly, the secondary amine of the indole side-chain of the tryptophanol-based iodide (R)-19f did 
not lead to hydrolysis or decreased output during the zinc insertion and the resulting reagent did not 
show tendencies for fast decomposition.  
 
2.6 Negishi Cross-Coupling and Acylation Reactions of Pyrrole-protected Organozinc 
Reagents 
With these eight different chiral pyrrole-protected alkylzinc halides in hand, various transition-metal 
catalyzed cross-coupling reactions as well as acylation reactions were performed. 
 
Based on Alaninol 
Starting with the alaninol-based reagent, four different cross-coupling reaction were carried out using 
different electron-rich and –poor electrophiles. The products (R)-22a–d were obtained in 83–99% yield 
 
96 A. Krasovskiy, P. Knochel, Synthesis 2006, 5, 890. 
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with a high optical purity of >95% ee (Table 16). Thus, the method developed for the achiral glycinol 
derivative is also applicable for chiral amino-alcohol derivatives without racemization.  
 
Table 16: Cross-coupling reactions using an alaninol based organozinc reagent. 
 
Entry Electrophile  Product ee (%) Yield (%)[a] 
1 
 
 
>95 83 
  (R)-22a
 
  
2 
 
 
98 86 
  (R)-22b   
3 
 
 
99 91 
  (R)-22c   
4 
  
99 99 
  (R)-22d   
[a] Yield of analytically pure isolated product. 
Furthermore, acylation reactions were investigated using the organozinc reagent (R)-20b. Pd(PPh3)4 
catalyzed acylation reactions were successful for the glycinol derivative. However, using the 
brominated acid chloride, unintended cross-coupling side-reactions with the aryl bromide occurred. For 
this reason and to evaluate a cheaper alternative to palladium, copper(I) iodide97 was used for the 
reaction of the alaninol-based zinc reagent with acid chlorides. It was found, that using 10 mol% of 
catalyst at 0 °C provided the aryl- and heteroaryl-ketones (R)-22e–h in acceptable yields between 59% 
and 79% with high optical purities of 99% ee (Table 17). 
  
 
97 H.-S. Jung, S.-H. Kim, Tetrahedron Lett. 2015, 56, 1004. 
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Table 17: Copper(I) iodide catalyzed acylation reactions of the organozinc reagent (R)-20b with acid chlorides. 
 
Entry Electrophile  Product ee (%) Yield (%)[a] 
1 
 
 
99 73 
  (R)-22e
 
  
2 
 
 
99 67 
  (R)-22f   
3 
 
 
99 79 
  (R)-22g   
4 
 
 
99 59 
  (R)-22h   
[a] Yield of analytically pure isolated product. 
 
Based on Valinol 
The same type of experiment was conducted for the valinol-based organozinc reagents (R)-20c. For the 
cross-coupling reaction, different electrophiles bearing sensitive functional groups such as amines, 
aldehydes or nitriles were tested. The reactions provided the cross-coupling products (S)-23a–e in yields 
between 86% and 93% (Table 18) while maintaining the high enantiomeric excess of 99% previously 
measured for the iodide (R)-19c. 
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Table 18: Cross-coupling reactions using the valinol-based organozinc reagent (R)-20c. 
 
Entry Electrophile  Product ee (%) Yield (%)[a] 
1 
 
 
99 93 
  (S)-23a
 
  
2 
 
 
99 89 
  (S)-23b
 
  
3 
 
 
99 86 
  (S)-23c   
4 
 
 
99 88 
  (S)-23d   
5 
 
 
99 93 
  (S)-23e   
[a] Yield of analytically pure isolated product. 
Additionally, acylation reaction using Pd(PPh3)4 or copper(I) iodide (for halogen-containing acid 
chlorides) as catalyst were performed providing aryl- and hetero-aryl ketones (S)-23f–i as well as the 
alkyl ketone (S)-23j in 66–85% yield (Table 19). All prepared ketones exhibit a high optical purity with 
99% ee. 
  
B. RESULTS AND DISCUSSION    48 
Table 19: Palladium and copper catalyzed acylation reactions using the valinol-based zinc reagent (R)-20a. 
 
Entry Electrophile  Product Method ee (%) Yield (%)[a] 
1 
 
 
A 99 85 
  (S)-23f    
2 
 
 
B 99 80 
  (S)-23g    
3 
 
 
B 99 70 
  (S)-23h    
4 
 
 
A 99 72 
  (S)-23i    
5 
 
 
A 99 66 
  (S)-23j    
[a] Yield of analytically pure isolated product. 
 
Based on Phenylalaninol 
With the organozinc reagent (S)-20d, derived from L-phenylalaninol, the first organometallic of this 
study containing a benzyl instead of an alkyl residue, palladium catalyzed reactions were investigated. 
For this purpose, selected electrophiles containing donating as well as withdrawing functional groups 
were employed for Negishi cross-coupling reaction. The corresponding coupling-products (S)-24a–d 
were successfully obtained in high yields of 84–96% and high optical purity (Table 20).  
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Table 20: Cross-coupling reactions using the phenylalaninol-based organozinc reagent (S)-20d. 
 
Entry Electrophile  Product ee (%) Yield (%)[a] 
1 
  
99 84 
  (S)-24a
 
  
2 
  
99 91 
  (S)-24b   
3 
  
99 96 
  (S)-24c   
4 
  
99 94 
  (S)-24d   
[a] Yield of analytically pure isolated product. 
Next, the reaction scope of this reagent was extended to acylation reactions using Pd(PPh3)4 as catalyst. 
The reaction of different aryl- and alkyl-acid chlorides provided the products (S)-24e–h with an 
enantiomeric excess of 99% and yields between 70% and 85% (Table 21). It was necessary to obtain 
the opposite enantiomers of ketone (S)-24f for further experiments. Therefore, the zinc reagent (R)-20d 
derived from D-phenylalaninol was reacted with 3-chlorobenzoyl chloride providing the ketone (R)-24f 
in 82% yield and 99% ee (Table 21, Entry 3). 
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Table 21: Palladium catalyzed acylation reactions using the phenylalaninol-based organozinc reagent 20d. 
 
Entry Electrophile  Product ee (%) Yield (%)[a] 
1 
 
 
99 73 
  (S)-24e   
2 
 
 
99 85 
  (S)-24f   
3[b] 
 
 
99 82[b] 
  (R)-24f   
4 
 
 
99 84 
  (S)-24g   
5 
 
 
99 70 
  (S)-24h   
[a] Yield of the isolated analytically pure product. [b] (R)-20d was used instead of (S)-20d to obtain the 
corresponding enantiomer for further experiments. 
 
Based on Phenylglycinol 
Due to the positive results for the benzyl side-chain containing reagent 20d the scope for the 
nucleophilic reagent was extended towards a reagent with a phenyl side-chain. Therefore, the 
organozinc reagent (S)-20e derived from the unnatural amino acid α-phenylglycine was prepared. 
Because of the benzylic position of the chiral pyrrole center, this reagent was most liable to undergo 
racemization reaction and showed special behavior during the zinc insertion due to the prolonged 
reaction time. On the other hand, the palladium catalyzed cross-couplings revealed that a broad range 
of functionalized electrophiles can be applied and the products (R)-25a–e were obtained in 75% to 
95% yield (Table 22). Remarkably, even bearing the pyrrole in the sensitive benzylic position, the 
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optical purity did not decrease during the zinc insertion or the cross-coupling reaction and all products 
showed an enantiomeric excess of 99%. 
Table 22: Cross-couplings using a phenylglycinol-based organozinc reagent (S)-20e with different 
electrophiles. 
 
Entry Electrophile  Product ee (%) Yield (%)[a] 
1 
 
 
99 75 
  (R)-25a   
2 
 
 
99 75 
  (R)-25b   
3 
 
 
99 84 
  (R)-25c   
4 
 
 
99 92 
  (R)-25d   
5 
 
 
99 95 
  (R)-25e   
[a] Yield of analytically pure isolated product. 
To complete this set, one copper(I) iodide acylation was performed using 3-bromobenzoyl chloride 
combined with (S)-20e and the ketone (R)-25f was obtained in 80% yield with 99% ee (Scheme 31). 
 
Scheme 31: Copper catalyzed acylation of N-alkylzinc pyrrole (S)-20e with 3-bromobenzoyl chloride. 
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Based on Tryptophanol 
After successfully testing various N-pyrrolyl-alkylzinc reagents bearing alkyl, benzyl, or phenyl 
residues, a more sensitive substrate was tested. Starting from tryptophanol the corresponding iodide 
was successfully converted into the organozinc reagent while tolerating the –NH group of the indole 
moiety. Then, this reagent was evaluated for the application in cross-coupling reactions to check its 
tolerance towards the catalytic system and the electrophiles. For these experiments, even more 
demanding and sensitive coupling-compounds were chosen containing e.g. ketones, nitriles or nitro 
groups and a pyrazine scaffold.  
Table 23: Cross-coupling reactions using the tryptophanol-based organozinc reagent (R)-20f. 
 
Entry Electrophile  Product ee (%) Yield (%)[a] 
1 
 
 
99 68 
  (S)-26a
 
  
2 
 
 
99 98 
  (S)-26b   
3 
 
 
99 97 
  (S)-26c   
4 
  
99 92 
  (S)-26d   
5 
 
 
99 91 
  (S)-26e   
6 
 
 
99 98 
  (R)-26f   
[a] Yield of analytically pure isolated product. 
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The experiments revealed that the indole-containing reagent was fully tolerating the reaction conditions 
and the products 26a–f were successfully obtained in 68–98% yield with high enantiomeric excess.  
 
Based on Tyrosinol 
In this set of organozinc reagent, the last compound derived from natural amino acids was the protected 
tyrosinol derivative (S)-20g. Application in Negishi cross-coupling reactions using palladium acetate 
and SPhos as catalyst provided the electron-rich and –deficient products (S)-27a–c in excellent yields 
between 93% and 96% yield (Table 24). Due to the decreased optical purity of the alkyl iodide (S)-19g 
(92% ee) the cross-coupling products also exhibit a lower enantiomeric excess of 92%. 
Table 24: Cross-coupling reactions using the tyrosinol-based organozinc reagent (S)-20g. 
 
Entry Electrophile  Product ee (%) Yield (%)[a] 
1 
  
92 95 
  (S)-27a
 
  
2 
 
 
92 96 
  (S)-27b   
3 
  
92 93 
  (S)-27c   
[a] Yield of analytically pure isolated product. 
Conducting acylation reactions with the tyrosinol-based reagent using the previously applied copper 
and palladium catalyzed methods provided the three different halogenated ketones (S)-27d–f in 75% to 
84% yield (Table 25). As shown for the cross-coupling products, the acylation also displayed lower 
optical purities of 92% ee which was caused by the reduced optical purity of the starting N-
pyrrolylalkyl-iodide. 
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Table 25: Cooper and palladium acylation reactions using the tyrosinol-based organozinc reagent (S)-20g. 
 
Entry Electrophile  Product Method ee (%) 
Yield 
(%)[a] 
1 
 
 
A 92 78 
  (S)-27d
    
2 
 
 
B 92 84 
  (S)-27e    
3 
 
 
B 92 75 
  (S)-27f    
[a] Yield of analytically pure isolated product. 
 
Based on 2-Aminocyclohexanol 
In addition to the amino acid based organozinc reagents, the 2-aminocyclohexylzinc derivative was 
further investigated for cross-coupling reactions. During the zinc insertion of (S,R)-19h, the stereo-
information is lost due to the radical insertion mechanism. Using a palladium catalyst with bulky-
ligands, the selectivity for the following bond formation can be driven to the sterically less hindered 
product as already described in the literature.98 Reaction of the organozinc reagent (S)-20h using the 
same procedure as for the previous experiments with different substituted electron-rich and -deficient 
electrophiles provided the cross-coupling products 28a–d in high yields between 84% and 97% (Table 
26). Remarkably, the reactions using the palladium-SPhos catalyst led selectively to the trans-product 
with a diastereomeric ratio of 99:1. The alignment of the pyrrole to the introduced aryl substituent was 
determined by evaluating the coupling-constants of the involved protons in the 1H-NMR spectrum. The 
optical purity was determined via chiral HPLC and showed an enantiomeric excess of 99% for all 
products.  
 
98 T. Thaler, B. Haag, A. Gavryushin, K. Schober, E. Hartmann, R. M. Gschwind, H. Zipse, P. Mayer, P. Knochel, 
Nat. Chem. 2010, 2, 125. 
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Table 26: Selective cross-coupling reactions using the reagent (S)-20h leading to the trans-products 28a–d. 
 
Entry Electrophile  Product ee (%) / dr Yield (%)[a] 
1 
 
 
99 / 99:1 92 
  (R,S)-28a
 
  
2 
 
 
99 / 99:1 84 
  (S,R)-28b   
3 
 
 
99 / 99:1 97 
  (S,R)-28c   
4 
 
 
99 / 99:1 96 
  (R,S)-28d   
[a] Yield of analytically pure isolated product. 
For the acylation reaction, the choice of the catalyst is crucial for the success of the reaction. Reaction 
of the organozinc reagent (S)-20h with 4-fluorobenzoyl chloride and substoichiometric amounts of 
cooper(I) iodide resulted in the desired product 28e, but with a ratio of 83% trans- to 17% cis-isomer. 
Using catalytic amounts of the bulky Pd(PPh3)4 catalyst at room temperature, the reaction provided only 
the trans-isomer with a diastereomeric ratio of 99:1 and a yield of 94% (Scheme 32).  
 
Scheme 32: Copper and palladium catalyzed acylation reaction of (S)-20h with 4-fluorobenzoyl chloride. 
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Based on 2-Aminocyclopentanol 
Furthermore, the application of a 2-aminocyclopentanol derived reagent for Negishi cross-coupling 
reactions was investigated. As for the six-membered reagent, the zinc insertion induced a loss of the 
stereo-configuration of the iodine bearing carbon. Therefore, the palladium catalyst should predefine 
the position of the introduced aryl moiety.  
Table 27: Cross-coupling reactions using a 2-aminocyclopentanol-based organozinc reagent (R)-20i. 
 
Entry Electrophile  Product ee (%) / dr Yield (%)[a] 
1 
 
 
99 / 99:1 79 
  (R,S)-29a
 
  
2 
 
 
99 / 99:1 93 
  (R,S)-29b   
3 
 
 
99 / 98:2 85 
  (S,R)-29c   
4 
 
 
99 / 99:1 84 
  (S,R)-29d   
5 
 
 
99 / 99:1 85 
  (S,R)-29e   
6 
 
 
99 / 99:1 75 
  (R,S)-29f   
[a] Yield of analytically pure isolated product. 
B. RESULTS AND DISCUSSION    57 
Experiments showed that the reaction of the organozinc reagent (R)-20i with different electrophiles 
bearing electron-donating as well as –withdrawing functional groups using the standard method 
successfully provided the coupling-products 29a–f in 75% to 93% yield. Interestingly, only one 
diastereomer was selectively formed and all products exhibit high dr and ee of 99%. Determining the 
configuration of the aryl ring via NMR analysis was difficult due to the low differences of the coupling 
constants in five-membered rings. Fortunately, a single-crystal X-ray structure analysis of product 
(S,R)-29c could be performed. The structure displayed in Figure 7 shows a trans relation between the 
pyrrole and the aryl residue. Conclusively, the trans-configuration in the cyclopentane derivatives is 
also induced by the catalyst and favored as already determined for the cyclohexane products.  
 
Figure 7: Molecular crystal structure of the cross-coupling product (S,R)-29c is showing the trans-configuration 
of pyrrole to the aryl residue. Thermal ellipsoids are drawn at 50% probability level. 
 
2.7 Selective CBS-Reduction of Chiral Pyrrole-containing Acylation Products 
In order to demonstrate the versatility of the methodology, other options to further functionalize and 
utilize the chiral pyrrole-containing products were investigated. After acylation reaction, chiral ketones 
in 3-position were obtained which are interesting for selective reduction to generate chiral 
1,3-substituted N-pyrrolyl-alcohols, which then can be converted to the corresponding amino alcohol. 
For the asymmetric reduction, the Corey-Bakshi-Shibata99 protocol was applied. Both enantiomers of 
the phenylalaninol derived ketone (R)-24f and (S)-24f were used with a (R)- and (S)-CBS catalyst in 
order to exploit a pathway to all four possible stereoisomers. 
For the experiments, the corresponding CBS catalyst was mixed with reducing agent borane 
dimethylsulfide at 0 °C and the selected ketone was added slowly. After conducting the four desired 
 
99 a) E. J. Corey, C. J. Helal, Angew. Chem. Int. Ed. 1998, 37, 1986; b) E. J. Corey, S. Shibata, R. K. Bakshi, J. 
Org. Chem. 1988, 53, 2861. 
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reactions, the chiral alcohols 30a–d were obtained in excellent yields of 92–98% with a diastereomeric 
ratio of 99:1 and high enantiomeric excess of 99% (Scheme 33).  
 
Scheme 33: Selective CBS reduction of the acylation products (R)-24f and (R)-24f provide a pathway to obtain 
all four configurational isomers.  
The absolute configuration of the alcohols was predicted with the CBS-model in first instance. To 
confirm this assumption, the alcohol (R,S)-30d which was prepared using the (R)-CBS catalyst, was 
esterificated. The (R)- as well as the (S)-Mosher acid (MTPA) were used to obtain two diastereomers 
for NMR analysis. With both NMR-spectra of the ester-diastereomers in hand, the chemical shifts were 
compared and evaluated as reported in the literature100 (see Appendix). The analysis confirmed the 
absolute configuration. The conclusion for this system is that (R)-CBS catalyst provides the (S)-alcohol 
and vice versa (S)-CBS catalyst provides the (R)-alcohol. 
 
2.8 Deprotection of the Pyrrole-Group Using Ozonolysis 
To complete this reaction sequence, it was desired to develop a deprotection procedure for the pyrrole 
group in the last step. An important aspect for the deprotection reaction was the preservation of the 
stereocenters. Harsh reaction conditions involving e.g. strong bases or high temperatures might lead to 
racemization and must be avoided. It was found, that ozonolysis was suitable for the removal of the 
pyrrole ring. Subsequent reductive work-up of the ozonide should provide the diformylamide product. 
 
100 a) T. R. Hoye, C. S. Jeffrey, F. Shao, Nat. Protoc. 2007, 2, 2451; b) J. M. Seco, E. Quiñoá, R. Riguera, Chem. 
Rev. 2004, 104, 17. 
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Experiments revealed that the reaction can be performed quickly by treating the pyrrole derivative with 
ozone-gas at –78 °C in a DCM/methanol mixture for a few minutes. After reductive treatment with 
methyl sulfide, a mixture of the formamide and the diformylamide was obtained. For obtaining solely 
the formamide, the mixture was stirred in a diluted potassium hydroxide solution in ethanol for 1 h.  
Table 28: Pyrrole deprotection reactions of selected products via ozonolysis to the corresponding formamide. 
 
Entry Functionalized Pyrrole Deprotection Product Yield (%)[a] 
1 
  
71 
 21c 31a  
2 
  
74 
 (S)-24c, 99% ee (S)-31b, 99% ee  
3 
  
65 
 (S)-24d, 99% ee (S)-31c, 99% ee  
4 
  
84 
 (S)-27a, 92% ee (S)-31d, 92% ee  
5 
  
74 
 (S,R)-28c, dr 99:1, 99% ee (S,R)-31e, dr 99:1, 99% ee  
6 
  
71 
 (R,S)-29f, dr 99:1, 99% ee (R,S)-31f, dr 99:1, 99% ee  
7 
  
76 
 (S,R)-30a, dr 99:1, 99% ee (R,S)-31g, dr 99:1, 99% ee  
[a] Yield of analytically pure isolated product. 
Selected cross-coupling products as well as a CBS-reduced alcohol have been examined for this 
deprotection strategy and the formamide derivatives 31a–g were obtained in yields between 65% and 
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84% (Table 28). Remarkably, the stereocenters were not affected by this method and all diastereomeric 
ratios as well as the enantiomeric excesses were preserved. All formamide products were stable solids 
and easy to handle. 
Two crystal structures could be obtained from single-crystals of the deprotected products. In Figure 8, 
the molecular structure of (S,R)-31e is displayed. It confirms the trans-configuration of the formamide 
group to the aryl moiety which was previously determined by NMR studies for the pyrrole derivative 
(S,R)-28c.  
 
Figure 8: Molecular structure of the deprotected formamide (S,R)-31e in the crystal is showing the trans-
configuration of the formamide and aryl residue. Thermal ellipsoids are drawn at 50% probability level. The 
fluorine atoms of both CF3 groups are disordered. 
 
Figure 9: Molecular structure of the deprotected formamide (R,S)-31g in the crystal is showing the anti-
configuration of the formamide and alcohol. Thermal ellipsoids are drawn at 50% probability level.  
Figure 9 shows the molecular structure of the deprotected CBS-product (R,S)-31g. The assumptions 
made by the Mosher’s ester analysis using NMR-spectroscopy for the correlation of the CBS-catalyst 
to the configuration of the alcohol was also confirmed by this structure, since the anti-product was 
predicted.  
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3 Summary 
In this thesis, two major subjects were investigated and discussed.  
First, the late-stage functionalization of peptides and cyclopeptides was investigated. For this purpose, 
tyrosine-based peptides were selectively iodinated and subsequently used in Negishi cross-coupling 
experiments. The use of functionalized aryl- and heteroarylzinc pivalates in presence of a palladium 
catalyst furnished sidechain arylated peptides tolerating various sensitive and acidic functional groups. 
Furthermore, iodophenylalanine-containing cyclopeptides were modified via cross-couplings of 
isomeric pyridylzinc pivalates to obtain cyclopeptides with differently linked pyridyl-moieties. 
Secondly, a new method was developed for the preparation of chiral β-aminoalkylzinc reagents for the 
synthesis of functionalized amino-derivatives. Starting from chiral amino alcohols, the amino functions 
were converted into 1H-pyrroles as protecting groups and subsequently the alcohols were converted to 
the corresponding iodides. After oxidative insertion of zinc powder into these pyrrole-protected alkyl 
iodides, the resulting organozinc reagents were applied in transition-metal catalyzed Negishi cross-
couplings as well as acylation reactions.  
3.1 Late-Stage Functionalization of Peptides and Cyclopeptides using Organozinc 
Pivalates 
A range of tyrosine-containing oligopeptides was selectively iodinated in ortho-position to the phenolic 
hydroxyl group of the tyrosine sidechain using Chloramine T and NaI. Cross-coupling reactions were 
successfully performed with electron-rich as well as electron-poor aryl- and heteroarylzinc pivalates in 
the presence of a catalytic system consisting of Pd(OAc)2 and SPhos. Despite a slight excess of 
organozinc reagent, this protocol showed a high tolerance towards functional groups and provided the 
functionalized peptides in good yields (Scheme 34). 
 
Scheme 34: Summary of the late-stage functionalization of tyrosine-based peptides. 
B. RESULTS AND DISCUSSION    62 
Additionally, the high practicality of this late-stage functionalization was demonstrated by applying it 
to cyclic hexamer-peptides. Three isomeric cyclopeptides containing ortho-, meta- and para-iodinated 
phenylalanine sidechains were employed in cross-coupling reactions with 2-, 3- and 4-pyridylzinc 
pivalates and nine different pyridyl-substituted peptides were successfully obtained (Scheme 35). As a 
part of a cooperation with Novartis Pharma AG, the biophysical properties of these modified 
compounds were investigated and evaluated regarding solubility as well as cell-membrane permeability. 
 
Scheme 35: Summary of the late-stage functionalization of iodophenylalanine-containing cyclopeptides. 
 
3.2 Pyrrole Protected 2-Aminoalkylzinc Reagents for the Enantioselective Synthesis of 
Amino Derivatives 
Chiral amino-alcohols, mostly derived from natural and unnatural amino acids, were used for the 
syntheses of chiral organozinc reagents. After pyrrole-protection of the amino-groups and conversion 
of the alcohols into the corresponding alkyl iodides, various organozinc reagents containing different 
alkyl, aryl- and heteroaryl-moieties were prepared via oxidative zinc insertion. The application of these 
reagents in Negishi cross-couplings was investigated. Differently substituted electron-poor and -rich 
electrophiles bearing sensitive groups were successfully deployed in coupling reactions using Pd(OAc)2 
and SPhos as catalyst and a broad range of functionalized chiral pyrrole derivatives were obtained. 
Furthermore, palladium and copper catalyzed acylation experiments were conducted providing various 
chiral aryl-, heteroaryl- and alkyl-ketones in good yields. The application of β-N-pyrrolyl cyclopentyl- 
and cyclohexylzinc reagents exclusively provided the trans-substituted products in an excellent 
diastereoselectivity. All cross-coupling and acylation products were obtained with full retention of the 
stereocenters and thus exhibited high optical purity (Scheme 36). 
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Scheme 36: Summary for the preparation of the 2-aminoalkylzinc reagents and their application. 
Additionally, a post-functionalization of acylation products using the asymmetric CBS-reduction was 
performed to achieve the synthesis of chiral 1,3-amino alcohol derivatives. Thus, two enantiomerically 
pure ketones were reduced in presence of either the (R)- or (S)-CBS catalyst resulting in all four possible 
configurational isomers in excellent yield and high optical purity (Scheme 37a). 
 
Scheme 37: Summary of the post-functionalization and pyrrole deprotection. 
Finally, a suitable deprotection method was developed to convert the pyrrole into a viable formamide. 
Therefore, selected cross-coupling and post-functionalized products were treated with ozone at low 
temperatures. After reductive and subsequent mild basic work-up, the formamide products were 
obtained without decay of functional groups or racemization of stereocenters in moderate yields 
(Scheme 37b).
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1 General Considerations 
All reactions including organometallic compounds have been carried out using standard Schlenk-
techniques in flame-dried glassware equipped with rubber septum and magnetic stirring bars under 
argon. Syringes for transferring anhydrous solvents or reagents were purged with argon prior to use. 
Yields are referred to isolated yields of compounds with a purity >95% as determined by 1H-NMR 
(25 °C) or capillary GC. 
1.1 Solvents 
For the preparation of anhydrous solvents, the crude solvents were first purified by distillation and then 
dried according to standard methods by distillation from drying agents as stated below and were stored 
under argon.  Non-anhydrous solvents were obtained from commercial sources and used without further 
purification. 
THF was continuously refluxed and freshly distilled from sodium benzophenone ketyl under nitrogen 
and stored over molecular sieves.  
DCM was continuously refluxed and freshly distilled from CaH2 under nitrogen. 
Solvents for column chromatography were distilled prior to use. 
1.2 Reagents 
All reagents and starting materials were obtained from commercial sources and used without further 
purification unless otherwise stated. 
iPrMgCl•LiCl was prepared by careful addition of iPrCl (78.5 g, 91.3 mL, 1.00 mol, 1.00 equiv) to a 
suspension of Mg (26.74 g, 1.10 mol, 1.10 equiv) and LiCl (46.63 g, 1.10 mol, 1.10 equiv) in dry THF 
(900 mL). The reaction mixture was stirred for 12 h and afterwards the floating particles were filtered. 
The solution was cannulated into a flame-dried and argon flushed Schlenk-flask and the concentration 
of the active species was determined by titration against I2 in THF.
101 
Zn(OPiv)2 was prepared by successive addition of zinc oxide (4.07 g, 50 mmol) to a solution of pivalic 
acid (11.3 g,110 mmol) in toluene (250 mL) and refluxing in a Dean-Stark apparatus for 16 h. The 
solvent was removed by rotary evaporation and the zinc pivalates then dried under high vacuum.102 
nBuLi solution in hexane was purchased from Albemarle and the concentration was determined by 
titration against N-benzylbenzamide in THF at −20 °C.103 
nBuMgCl solution in THF was purchased from Albemarle (Frankfurt, Germany) and the concentration 
was determined by titration with iodine in the presence of LiCl in THF at 0 °C.101 
 
101 A. Krasovskiy, P. Knochel, Synthesis 2006, 5, 890. 
102 M. Ellwart, Y.H. Chen, C.P. Tüllmann, V. Malakov, P. Knochel, Org. Synth. 2018, 95, 127. 
103 A. F. Burchat, J. M. Chong, N. Nielsen, J. Organomet. Chem. 1997, 542, 281. 
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ZnCl2 solution (1.00 M in THF) was prepared by drying ZnCl2 (68.15 g, 500 mmol, 1.0 equiv) in a 
Schlenk-flask under vacuum for 5 h at 150 °C. After cooling to 25 °C, dry THF (480 mL) was added 
and stirred until all salts were dissolved. Then, dry THF was added until a previously set 500 mL mark 
was matched. 
1.3 Chromatography 
Flash column chromatography (FCC) was performed using SiO2 60 (0.040–0.063 mm, 230–400 mesh 
ASTM) from Merck. Thin layer chromatography (TLC) was performed using aluminum plates covered 
with SiO2 (Merck 60, F–254). Spots were visualized by UV light irradiation and/or by staining of the 
TLC plate with one of the solutions below, followed by heating with a heat gun. 
KMnO4 (0.3 g), K2CO3 (20 g) and KOH (0.3 g) in water (300 mL). 
Ce(SO4)2 (5.0 g), (NH4)6Mo7O24•4H2O (25 g) and conc. H2SO4 (50 mL) in water (450 mL). 
Ninhydrin (1.5 g) and acetic acid (3.0 mL) in ethanol (100 mL). 
1.4 Preparative RP-HPLC 
For purification, an Agilent Technologies 1260 Infinity HPLC-System was used, consisting of two prep-
pumps (acetonitrile/water, no additives), a MWD-detector (210 nm wavelength, 40 nm bandwidth, ref-
wavelength 400 nm, ref-bandwidth 100 nm) and a fraction collector. Three different columns were 
used: 1) Kinetix EVO C18 5 µm column (length: 150 mm, diameter: 10 mm), 2) Kinetix EVO C18 5 µm 
column (length: 150 mm, diameter: 21.2 mm) and 3) Waters XBridge Prep C8 5 µm column (length: 
150 mm, diameter: 30 mm). 
1.5 Analytical data 
NMR spectra were recorded on Bruker ARX 200, AC 300, WH 400 or AMX 600 instruments. 
Chemical shifts are reported as δ-values in parts-per-million (ppm) relative to the residual solvent peak: 
CDCl3 (δH: 7.26; δC: 77.16) or d6-DMSO (δH: 2.50; δC: 39.52). For the observation of the observed 
signal multiplicities, the following abbreviations and combinations thereof were used: s (singlet), 
d (doublet), t (triplet), q (quartet), quint (quintet), sext (sextet), sept (septet), m (multiplet) and br 
(broad). If not otherwise noted, the coupling constants given are either H-H or H-F coupling constants 
for proton signals and C-F coupling constants for carbon signals. To overcome the rotation barrier of 
peptide-rotamers, spectra were measured in d6-DMSO at 80 °C to receive the one averaged set of 
signals.104 
Melting points are uncorrected and were measured on a Büchi B.540 apparatus.  
Infrared spectra were recorded from 4000–650 cm−1 on a Perkin Elmer Spectrum BX-59343 
instrument. For detection a Smiths Detection DuraSampl IR II Diamond ATR sensor was used. The 
main absorption peaks are reported in cm−1.  
 
104 D. X. Hu, P. Grice, S. V. Ley, J. Org. Chem. 2012, 77, 5198. 
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Gas chromatography (GC) was performed with instruments of the type Hewlett-Packard 6850 Series 
II, using a column of the type HP 5 (Hewlett-Packard, 5% phenylmethylpolysiloxane; length: 10 m, 
diameter: 0.25 mm, film thickness 0.25 μm). The detection was accomplished using a flame ionization 
detector.  
High resolution mass spectra (HRMS) were recorded on a Finnigan MAT 95Q or Finnigan MAT 
90 instrument for electron impact ionization (EI). Electron spray ionization (ESI) high resolution mass 
spectra were measured on a Thermo Finnigan LTQ FT Ultra High Performance Mass Spectrometer 
with a resolution of 100.000 at m/z 400. The spray-capillary voltage of the IonMax ESI-unit is set to 
4 kV while the heating-capillary temperature is set to 250 °C.  
For the combination of gas chromatography with mass spectroscopic detection, a GC–MS of the type 
Hewlett-Packard 6890/MSD 5793 networking was used (column: HP 5–MS, Hewlett–Packard; 
5% phenylmethylpolysiloxane; length: 15 m, diameter: 0.25 mm, film thickness: 0.25 μm). 
LCMS. For reaction/product control and purity determination of polar molecules and peptides, an 
analytical Agilent Technologies 1260 Infinity LC with a binary pump (acetonitrile/water, additive: TFA) 
and a Kinetix EVO C18 5 µm column (length: 150 mm, diameter: 4.6 mm) was used. LC-
chromatograms were recorded with a DAD detector (210 nm wavelength, 40 nm bandwidth, ref-
wavelength 400 nm, ref-bandwidth 100 nm) combined with a low-mass Agilent Technologies 6120 
Quadrupole Mass Spectrometer. 
Enantiomeric Excess (ee) of chiral products were determined via chiral HPLC analysis on a Shimadzu 
Prominence 20A HPLC system. For developing a chiral resolution method, different chiral normal 
phase columns (Daicel Chemical Industries Chiralcel OD-H, OJ, OB-H or Chiralpak AS-H, ADH) were 
tested with n-heptane and iPrOH as mobile phase (isocratic) using a racemic mixture of the compound.   
If racemic resolution via chiral hplc was not successful, a chiral GC was used for analysis. 
Measurements were made on an Agilent HP 6890 Series gas chromatograph using a Varion capillary 
column (CP-Chiralsil Dex-CB 25 m, 0.25 m, 0.25 µm) with an average velocity of 45 cm/s. 
The diastereomeric ratio (dr) was determined either by NMR, GC or HPLC analysis. 
Specific Rotation [𝜶]D
𝟐𝟎 values of chiral products were measured in CHCl3 at 20 °C using a wavelength 
λ = 589 nm and a 1 dm cuvette on a Anton Paar MCP 200 instrument. The sample concentration was 
0.01 g/mL and the values are reported in °⋅mL⋅dm−1⋅g−1. 
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1.6 Single Crystal X-Ray Diffraction Studies 
Single crystals suitable for X-ray diffraction, were obtained by slow solvent. The crystals were 
introduced into perfluorinated oil and a suitable single crystal was carefully mounted on the top of a 
thin glass wire. Data collection was performed with an Oxford Xcalibur 3 diffractometer equipped 
with a Spellman generator (50 kV, 40 mA) and a Kappa CCD detector, operating with Mo-Kα 
radiation (λ = 0.71071 Ǻ).  
Data collection and data reduction were performed with the CrysAlisPro software.105 Absorption 
correction using the multiscan method105 was applied. The structures were solved with SHELXS-
97,106 refined with SHELXL-97107 and finally checked using PLATON.108 The single crystal 
structures are shown in DIAMOND109 representation. 
  
 
105 Program package CrysAlisPro 1.171.39.46e (Rigaku OD, 2018). 
106 Sheldrick, G. M. SHELXS-97: Program for Crystal Structure Solution 1997 University of Göttingen, 
Germany. 
107 Sheldrick, G. M. SHELXL-97: Program for the Refinement of Crystal Structures 1997 University of Göttingen, 
Germany. 
108 Spek, A. L. PLATON: A Multipurpose Crystallographic Tool 1999 Utrecht University, Utrecht, The 
Netherlands. 
109 DIAMOND, Crystal Impact GbR., Version 3.2i. 
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2 Late-Stage Functionalization of Peptides and Cyclopeptides using 
Organozinc Reagents 
2.1 Typical Procedures (TP1–8) 
Typical procedure for the iodination of tyrosine-based peptides (TP1): 
 
A 100 mL round bottom flask, equipped with a magnetic stirring bar and rubber septum, was charged 
with the corresponding tyrosine containing peptide of type 2 (2.00 mmol, 1.00 equiv), sodium iodide 
(360 mg, 2.40 mmol, 1.20 equiv) and DMF (10 mL). Chloramine-T trihydrate110 (676 mg, 2.40 mmol, 
1.20 mmol) was dissolved in DMF (4.8 mL) and then added dropwise via syringe pump over 2 h at 
−10 °C. Afterwards, the reaction mixture was stirred additional 3 h at 0 °C before slowly warming up 
to 25 °C within 1–7 h. The yellow reaction mixture was quenched with water (50 mL) and extracted 
with EtOAc (3 x 150 mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude product was purified by flash column chromatography 
(SiO2, DCM/MeOH) and following reversed-phase HPLC-chromatography (MeCN/H2O). 
Typical procedure for the iodination of tyrosine-based peptides (TP2): 
 
A 100 mL round bottom flask equipped with a magnetic stirring bar and rubber septum, was charged 
with the corresponding tyrosine-based peptide 2e (2.00 mmol, 1.00 equiv) and freshly distilled 
dichloromethane (16 mL). Bis(pyridine)iodonium tetrafluoroborate111 (Ipy2BF4; 967 mg, 2.60 mmol, 
1.30 equiv) was dissolved in freshly distilled DCM (7.8 mL) and added to the flask over 1 h via syringe 
pump After additional 4 h of stirring, water (50 mL) was added and the reaction mixture was extracted 
with EtOAc (3 x 150 mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude product was purified by flash column chromatography 
(SiO2, ihexanes/ethyl acetate or DCM/MeOH) and following reversed-phase HPLC-chromatography 
(MeCN/H2O). 
 
110 T. Kometani, D. S. Watt, T. Ji, Tetrahedron Lett. 1985, 26, 2043. 
111 G. Espuña, G. Arsequell, G. Valencia, J. Barluenga, J. M. Alvarez-Gutiérrez, A. Ballesteros, J. M. González, 
Angew. Chem. Int. Ed. 2003, 43, 325. 
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Typical procedure for the preparation of arylzinc pivalates using halogen-metal exchange (TP3) 
A dry and argon-flushed Schlenk-tube, equipped with a magnetic stirring bar and a rubber septum, was 
charged with the corresponding aryl halide (1.00 equiv) and freshly distilled THF. The reaction mixture 
was cooled down to –20 °C before iPrMgCl·LiCl (solution in THF, 1.10 equiv) was added dropwise. 
The solution was stirred at this temperature for a given time until full conversion of the starting material 
was observed by GC-analysis of hydrolyzed and iodolyzed aliquots. Afterwards, the magnesium species 
was transmetalated with Zn(OPiv)2 (1.20 equiv) and the resulting arylzinc pivalate solution was titrated 
with iodine in THF.112 
Typical procedure for the preparation of arylzinc pivalates using oxidative insertion and 
transmetalation (TP4) 
To a dry and argon-flushed Schlenk-tube, fitted with a magnetic stirring bar and a rubber septum, LiCl 
(1.20 equiv) was added and dried at ca. 450 °C for 5 min under high vacuum using a heat gun. 
Afterwards, magnesium turnings (1.20 equiv) were added and the solids were suspended with freshly 
distilled THF. The magnesium turnings were activated by adding trimethylsilyl chloride (TMSCl; 
5 mol%) and 1,2-dibromoethane (DBE; 5 mol%) and heating for a short period until the gas evolution 
stopped. The corresponding aryl halide (1.00 equiv) was added dropwise at 25 °C. and the reaction 
progress was monitored by GC-analysis of hydrolyzed and iodolyzed aliquots. After full conversion of 
the starting material, the suspension was filtered with a syringe-filter and transferred in another dry and 
argon flushed Schlenk-tube. Zn(OPiv)2 (1.20 equiv) was added at 0 °C and the suspension was stirred 
until a clear solution was formed. The concentration was determined by titration with iodine in THF. 
Typical procedure for the Negishi cross-coupling reaction of iodotyrosine containing peptides 
(TP5): 
 
A flame-dried and argon-flushed 10 mL Schlenk-tube, equipped with a magnetic stirring bar and a 
rubber septum, was charged with Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos
113 (9.85 mg, 
24.0 µmol, 8.00 mol%) and freshly distilled THF (0.6 mL). After 10 min of stirring, the corresponding 
iodotyrosine-peptide of type 3 (0.30 mmol, 1.0 equiv) was added. The arylzinc pivalate solution of type 
1 in THF (1.50–2.50 equiv) was added gradually via syringe-pump over a period of 1 h. After complete 
addition, the reaction mixture was stirred for further 3 h. Afterwards, the reaction mixture was quenched 
 
112 A. Krasovskiy, P. Knochel, Synthesis 2006, 5, 890. 
113 T. E. Barder, S. D. Walker, J. R. Martinelli, S. L. Buchwald, J. Am. Chem. Soc. 2005, 127, 4685. 
C. EXPERIMENTAL PART    71 
with a sat. aq. NH4Cl solution (3 mL). The reaction mixture extracted with ethyl acetate (3 x 100 mL) 
and the combined organic layers were dried over MgSO4, filtered and concentrated under reduced 
pressure. The crude product was purified by flash column chromatography (SiO2, ihexanes/ethyl 
acetate), followed by preparative reversed-phase HPLC-chromatography (MeCN/H2O). 
Typical procedure for the preparation of alkylzinc halides using an oxidative insertion of zinc 
dust (TP6) 
To a dry and argon-flushed Schlenk-tube, fitted with a magnetic stirring bar and a rubber septum, LiCl 
(1.00–1.50 equiv) was added and dried at ca. 450 °C for 5 min under high vacuum using a heat gun. 
Afterwards, zinc dust (1.40–2.50 equiv) was added and the solids were suspended in freshly distilled 
THF. Zinc dust was activated by adding trimethylsilyl chloride (TMSCl; 0.05 equiv) and 
1,2-dibromoethane (DBE; 0.05 equiv) and heating for a short period until the gas evolution stopped. 
The corresponding alkyl halide (1.00 equiv) was added dropwise at 25 °C and reaction progress was 
monitored by GC-analysis of hydrolyzed and iodolyzed aliquots. After full conversion of the starting 
material, the suspension was filtered with a syringe-filter and transferred in another dry and argon 
flushed Schlenk-tube. The concentration was determined by titration with iodine in THF. 
Typical procedure for Negishi cross-coupling reactions of iodotyrosine containing peptides with 
alkylzinc halides (TP7): 
 
A flame-dried and argon-flushed 10 mL Schlenk-tube, equipped with a magnetic stirring bar and a 
rubber septum, was charged with Pd(dba)2 (6.90 mg, 12.0 µmol, 4.00 mol%), PtBu3
114 (0.03 mL, 1.00 M 
in toluene, 24.0 µmol, 8.00 mol%) and freshly distilled THF (0.6 mL). After 10 min stirring, the 
corresponding iodotyrosine-peptide of type 3 (0.30 mmol, 1.0 equiv) was added. The corresponding 
alkylzinc halide solution of type 5 in THF (2.00 equiv) was added gradually via syringe-pump over a 
period of 1 h. After complete addition, the reaction mixture was stirred for further 7 h. Afterwards, the 
reaction mixture was quenched with sat. aq. NH4Cl solution (3 mL). The reaction mixture extracted 
with ethyl acetate (3 x 100 mL) and the combined organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude product was purified by flash column chromatography 
(SiO2, ihexanes/ethyl acetate) and following reversed-phase HPLC-chromatography (MeCN/H2O). 
 
114 C. Dai, G. C. Fu, J. Am. Chem. Soc. 2001, 123, 2719. 
C. EXPERIMENTAL PART    72 
Typical procedure for the Negishi cross-coupling reaction of macrocyclic iodophenylalanine 
containing peptides (TP8): 
 
A flame-dried and argon-flushed 10 mL Schlenk-tube, equipped with a magnetic stirring bar and a 
rubber septum, was charged with Pd(OAc)2 (0.72 mg, 3.20 µmol, 4.00 mol%), SPhos
115 (2.63 mg, 
6.40 µmol, 8.00 mol%) and freshly distilled THF (0.8 mL). After 10 min stirring, the corresponding 
macrocyclic iodo-peptide (68.1 mg, 0.08 mmol, 1.0 equiv) was added. The pyridylzinc pivalate solution 
of type 1 in THF (2.5 equiv) was added gradually via syringe-pump over a period of 1 h. After complete 
addition, the reaction mixture was stirred further for 5 h. Afterwards, the reaction was quenched with a 
sat. aq. NH4Cl solution (1 mL). The reaction mixture was extracted with ethyl acetate (3 x 50 mL) and 
the combined organic layers were dried over MgSO4, filtered and concentrated under reduced pressure. 
The residue was flushed through a short silica column (10 cm) with MeCN and the crude product was 
purified via reversed-phase HPLC-chromatography. 
2.2  Characterization of the Tyrosine containing Peptides 
Cbz-L-Pro-L-Tyr-OMe (2b) 
 
Compound 2b was obtained from the Novartis archive.116 
1H-NMR (400 MHz, 80 °C, DMSO-d6, ppm): δ = 8.93 (s, 1H), 7.93 (d, J = 7.7 Hz, 1H), 7.40 – 7.25 
(m, 5H), 7.01 – 6.93 (m, 2H), 6.69 – 6.63 (m, 2H), 5.10 – 4.95 (m, 2H), 4.46 (td, J =7.9, 6.1 Hz, 1H), 
4.29 – 4.23 (m, 1H), 3.57 (s, 3H), 3.41 (qt, J = 10.2, 6.9 Hz, 2H), 2.87 (qd, J = 14.0, 7.1 Hz, 2H), 2.16 
– 2.01 (m, 1H), 1.85 – 1.72 (m, 3H). 
 
115 T. E. Barder, S. D. Walker, J. R. Martinelli, S. L. Buchwald, J. Am. Chem. Soc. 2005, 127, 4685. 
116 M. Cortes-Clerget, J.-Y. Berthon, I. Krolikiewicz-Renimel, L. Chaisemartin, B. H. Lipshutz, Green Chem. 
2017, 19, 4263. 
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13C-NMR (101 MHz, 80 °C, DMSO-d6, ppm): δ = 171.5, 171.4, 155.7, 153.7, 136.7, 129.4, 127.8, 
127.2, 126.8, 126.8, 114.7, 65.6, 59.2, 53.3, 51.2, 46.4, 35.7, 29.9, 22.8.l 
HRMS (ESI): m/z calc. for [M+Na; C23H26N2NaO6
+]: 449.1689; found: 449.1683; m/z calc. for 
[M+H; C23H27N2O6
+]: 427.1864; found: 427.1867; calc. for [M-H; C23H25N2O6
-]: 425.1718; found: 
425.1730. 
IR (Diamond-ATR, neat): 𝜈 = 3311 (w), 2952 (w), 2360 (w), 2340 (w), 1742 (m), 1693 (s), 1647 (vs), 
1614 (m), 1515 (vs), 1411 (s), 1354 (s), 1262 (s), 1210 (s), 1173 (s), 1113 (s), 1028 (w), 985 (m), 826 
(m), 766 (m), 744 (m), 697 (m). 
M.p. 74.7 °C. 
Boc-L-Tyr-D-Trp-OMe (2c) 
 
Compound 2c was obtained from the Novartis archive.117 
1H-NMR (400 MHz, 80 °C, DMSO-d6, ppm): δ = 10.67 (s, 1H), 8.84 (s, 1H), 7.99 (d, J = 7.8 Hz, 1H), 
7.50 (d, J = 7.8 Hz, 1H), 7.34 (dt, J = 8.1, 0.9 Hz, 1H), 7.11 (d, J = 2.4 Hz, 1H), 7.07 (ddd, J = 8.2, 7.0, 
1.3 Hz, 1H), 7.00 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 6.91 (d, J = 8.4 Hz, 2H), 6.64 – 6.56 (m, 2H), 6.27 (s, 
1H), 4.59 (td, J = 7.7, 6.0 Hz, 1H), 4.16 (td, J = 8.8, 4.8 Hz, 1H), 3.61 (s, 2H), 3.17 (dd, J = 14.6, 5.9 
Hz, 1H), 3.07 (dd, J = 14.7, 7.7 Hz, 1H), 2.77 (dd, J = 13.9, 4.8 Hz, 1H), 2.58 (dd, J = 14.0, 9.0 Hz, 
1H), 1.32 (s, 9H). 
13C-NMR (101 MHz, 80 °C, DMSO-d6, ppm): δ = 171.6, 171.1, 155.4, 154.5, 135.9, 129.6, 127.5, 
126.8, 123.3, 120.6, 118.1, 117.6, 114.5, 111.0, 109.0, 77.8, 55.5, 52.7, 51.2, 36.6, 27.7, 27.0. 
HRMS (ESI): m/z calc. for [M+Na; C26H31N3NaO6
+]: 504.2111; found: 504.2106; m/z calc. for 
[M+H; C26H32N3O6
+]: 482.2286; found: 482.2286; calc. for [M-H; C26H30N3O6
-]: 480.2140; found: 
480.2149. 
IR (Diamond-ATR, neat): 𝜈 = 3340 (w), 2964 (vw), 2359 (w), 2332 (w), 1733 (w), 1684 (m), 1655 
(vs), 1539 (m), 1517 (s), 1457 (w), 1437 (m), 1366 (w), 1307 (w), 1270 (m), 1242 (m), 1226 (m), 1174 
(m), 1166 (s), 1049 (w), 1026 (w), 1012 (w), 825 (w), 811 (w), 745 (m). 
M.p. 131.4 °C. 
 
117 C. J. Chapman, A. Matsuno, C. G. Frost, M. C. Willis, Chem. Commun. 2007, 3903. 
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Cbz-L-Pro-L-Glu-D-Tyr-L-Val-OtBu (2d) 
 
Compound 2d was obtained from the Novartis archive.118 
1H-NMR (400 MHz, 80 °C, DMSO-d6, ppm): δ = 8.86 (s, 1H), 7.92 (s, 1H), 7.72 (dd, J = 25.3, 8.3 Hz, 
2H), 7.41 – 7.24 (m, 5H), 7.01 (d, J = 8.4 Hz, 2H), 6.94 – 6.33 (m, 2H), 6.68 – 6.60 (m, 2H), 5.18 – 
4.98 (m, 2H), 4.56 (q, J = 8.6 Hz, 1H), 4.23 (ddd, J = 22.4, 10.9, 5.6 Hz, 2H), 4.05 (dd, J = 8.3, 5.9 Hz, 
1H), 3.44 (h, J = 10.7, 10.1 Hz, 3H), 2.93 (dd, J = 13.9, 5.3 Hz, 1H), 2.73 (dd, J = 13.9, 8.9 Hz, 1H), 
2.18 – 1.93 (m, 3H), 1.92 – 1.75 (m, 4H), 1.68 (dq, J = 14.6, 7.6 Hz, 1H), 1.42 (s, 9H), 0.84 (dd, J = 6.8, 
4.5 Hz, 6H). 
13C-NMR (101 MHz, 80 °C, DMSO-d6, ppm): δ = 173.4, 171.5, 170.7, 170.6, 169.8, 155.5, 153.8, 
136.7, 129.6, 127.9, 127.3, 127.2, 127.1, 126.9, 126.8, 114.6, 80.3, 65.6, 59.3, 57.7, 53.9, 52.3, 46.4, 
36.8, 31.1, 29.7, 27.4, 23.1, 18.4, 17.6. 
HRMS (ESI): m/z calc. for [M+Na; C36H49N5NaO9
+]: 718.3428; found: 718.3422; m/z calc. for 
[M+H; C36H50N5O9
+]: 696.3603; found: 696.3607. 
IR (Diamond-ATR, neat): 𝜈 = 3287 (w), 2963 (w), 2360 (w), 2334 (w), 1732 (w), 1638 (vs), 1540 
(m), 1517 (m), 1448 (m), 1436 (m), 1358 (m), 1274 (m), 1226 (m), 1211 (w), 1171 (m), 1140 (m), 695 
(w). 
M.p. 160.4 °C. 
Methyl (8S,11S)-16-hydroxy-8-methyl-6,9-dioxo-4-oxa-7,10-diaza-1(1,3),3(1,2)-
dibenzenacyclododecaphane-11-carboxylate (2e) 
 
Compound 2e was obtained from the Novartis archive. 
1H-NMR (599 MHz, DMSO-d6, ppm): δ = 9.31 (s, 1H), 8.07 (d, J = 8.4 Hz, 1H), 7.34 (dd, J = 7.4 Hz, 
1.8, 1H), 7.22 – 7.17 (m, 2H), 7.00 (dd, J = 8.4, 1.1 Hz, 1H), 6.94 (d, J = 2.2 Hz, 1H), 6.91 (td, J = 7.4, 
1.1 Hz, 1H), 6.82 (dd, J = 8.3, 2.2 Hz, 1H), 6.70 (d, J = 8.2 Hz, 1H), 4.68 (d, J = 14.3 Hz, 1H), 4.52 (d, 
 
118 M. Amblard, J.-A. Fehrentz, J. Martinez, G. Subra, Mol. Biotechnol. 2006, 33, 239. 
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J = 14.2 Hz, 1H), 4.45 (dq, J = 8.6, 6.9 Hz, 1H), 4.37 (ddd, J = 11.4, 8.3, 3.2 Hz, 1H), 3.97 (d, 
J = 14.4 Hz, 1H), 3.77 (d, J = 14.4 Hz, 1H), 3.66 (s, 3H), 2.89 (dd, J = 13.7, 3.2 Hz, 1H), 2.69 (dd, 
J = 13.7, 11.1 Hz, 1H), 1.03 (d, J = 7.0  Hz, 3H). 
13C-NMR (151 MHz, DMSO-d6, ppm): δ = 172.0, 170.8, 167.6, 155.5, 153.8, 132.0, 131.0, 128.1, 
127.5, 127.4, 127.3, 126.3, 120.9, 115.0, 111.2, 66.6, 53.8, 52.0, 46.9, 35.8, 30.3, 16.4. 
HRMS (ESI): m/z calc. for [M+Na; C22H24N2NaO6
+]: 435.1532; found: 435.1529; m/z calc. for 
[M+H; C22H25N2O6
+]: 413.1707; found: 413.1710; calc. for [M-H; C26H30N3O6
-]: 411.1562; found: 
411.1556. 
IR (Diamond-ATR, neat): 𝜈 = 3416 (w), 3393 (w), 3209 (w), 3055 (w), 2355 (vw), 1724 (s), 1655 
(s), 1566 (m), 1524 (m), 1489 (m), 1438 (s), 1356 (m), 1259 (s), 1230 (s), 1216 (m), 1143 (m), 1114 
(s), 1042 (m), 819 (w), 800 (w), 759 (vs), 698 (w), 686 (w). 
M.p. 214.7 °C. 
 
2.3  Preparation of Iodotyrosine containing Peptides 
Boc-L-(ortho-iodo)Tyr-OMe (3a) 
 
According to TP1, commercially available Boc-L-tyrosine methyl ester 2a (591 mg, 2.00 mmol, 
1.00 equiv) and sodium iodide (360 mg, 2.40 mmol, 1.20 equiv) were dissolved in DMF (10 mL) and 
cooled to –10 °C. Chloramine-T trihydrate (676 mg, 2.40 mmol, 1.20 mmol) as solution in DMF 
(4.8 mL) was added dropwise over 2 h and the suspension was stirred for 3 h. Afterwards, the reaction 
mixture was warmed to 25 °C and stirred for additional 2 h. The crude product was extracted and 
purified by flash column chromatography. After final prep-HPLC purification, the title compound 3a 
was obtained as white solid (581 mg, 1.38 mmol, 69% yield). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.42 (d, J = 2.0 Hz, 1H), 6.99 (dd, J = 8.3, 2.1 Hz, 1H), 6.88 
(d, J = 8.3 Hz, 1H), 5.39 (s, 1H), 5.00 (d, J = 8.2 Hz, 1H), 4.51 (d, J = 7.4 Hz, 1H), 3.72 (s, 3H), 3.03 
(dd, J = 13.9, 5.7 Hz, 1H), 2.93 (dd, J = 13.9, 6.0 Hz, 1H), 1.43 (s, 9H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 172.3, 155.2, 154.2, 139.0, 131.2, 130.3, 115.2, 85.7, 80.3, 
54.6, 52.5, 37.1, 28.5. 
HRMS (ESI): m/z calc. for [M+H; C15H21INO5
+]: 422.0459; found: 422.0470; calc. for [M-H; 
C15H21INO5
-]: 420.0313; found: 420.0320.  
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IR (Diamond-ATR, neat): 𝜈 = 3386 (w), 3334 (w), 1713 (m), 1686 (vs), 1605 (w), 1576 (w), 1523 (s), 
1508 (s), 1444 (m), 1419 (m), 1395 (w), 1349 (w), 1304 (m), 1289 (m), 1272 (m), 1254 (s), 1219 (m), 
1156 (s), 1067 (m), 1027 (m), 993 (m), 828 (m), 810 (m), 759 (w). 
M.p. 135.7 °C. 
Cbz-L-Pro-L-(ortho-iodo)Tyr-OMe (3b) 
 
According to TP1, tyrosine-peptide 2b (852 mg, 2.00 mmol, 1.00 equiv) and sodium iodide (360 mg, 
2.40 mmol, 1.20 equiv) were dissolved in DMF (10 mL) and cooled to –10 °C. Chloramine-T trihydrate 
(676 mg, 2.40 mmol, 1.20 mmol) as solution in DMF (4.8 mL), was added dropwise over 2 h and the 
suspension was stirred for 3 h at this temperature, before warming to 25 °C and stirring additional 6 h. 
The crude product was extracted and purified by flash column chromatography. After final prep-HPLC 
purification, the title compound 3b was obtained as white solid (873 mg, 1.58 mmol, 79% yield). 
1H-NMR (400 MHz, 80 °C, DMSO-d6, ppm): δ = 9.82 (d, J = 8.2 Hz, 1H), 7.98 (d, J = 7.9 Hz, 1H), 
7.49 (d, J = 2.1 Hz, 1H), 7.38 – 7.25 (m, 5H), 7.00 (d, J = 8.9 Hz, 1H), 6.77 (d, J = 8.2 Hz, 1H), 5.12 – 
4.94 (m, 2H), 4.45 (q, J = 7.6 Hz, 1H), 4.24 (dd, J = 8.5, 2.8 Hz, 1H), 3.58 (s, 3H), 3.50 – 3.35 (m, 2H), 
2.86 (qd, J = 14.1, 7.1 Hz, 2H), 2.15 – 2.00 (m, 1H), 1.77 (q, J = 7.1, 6.4 Hz, 3H). 
13C-NMR (101 MHz, 80 °C DMSO-d6, ppm): δ = 171.5, 171.2, 154.9, 153.7, 138.8, 136.7, 129.7, 
129.4, 127.8, 127.2, 126.9, 114.5, 83.7, 65.6, 59.3, 53.1, 51.2, 46.4, 34.9, 22.8. 
HRMS (ESI): m/z calc. for [M+Na; C23H25IN2NaO6
+]: 575.0650; found: 553.0653; m/z calc. for [M+H; 
C23H26IN2O6
+]:553.0830; found: 553.0833; calc. for [M-H; C23H24IN2O6
-]: 551.0685; found: 551.0681.  
IR (Diamond-ATR, neat): 𝜈 = 3314 (w), 3226 (w), 1746 (m), 1691 (s), 1644 (vs), 1603 (m), 1536 (m), 
1502 (m), 1446 (m), 1413 (s), 1351 (s), 1282 (m), 1262 (m), 1210 (s), 1176 (m), 1124 (m), 1088 (w), 
1034 (m), 983 (w), 823 (w), 804 (w), 766 (m), 737 (m), 693 (m), 665 (m). 
M.p. 165.4 °C. 
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Boc-L-(ortho-iodo)Tyr-D-Trp-OMe (3c) 
 
According to TP1, tyrosine-peptide 2c (963 mg, 2.00 mmol, 1.00 equiv) and sodium iodide (360 mg, 
2.40 mmol, 1.20 equiv) were dissolved in DMF (10 mL) and cooled to –10 °C. Chloramine-T trihydrate 
(676 mg, 2.40 mmol, 1.20 mmol) as solution in DMF (4.8 mL), was added dropwise over 2 h and the 
suspension was stirred for 3 h at this temperature, before warming to 25 °C and stirring additional for 
7 h. The crude product was extracted and purified by flash column chromatography. During final prep-
HPLC purification, the title compound 3c was obtained as reddish solid (365 mg, 0.60 mmol, 
30% yield) and remaining starting material was recovered (231 mg, 0.48 mmol, 24% yield). 
1H-NMR (400 MHz, 80 °C, DMSO-d6, ppm): δ = 10.67 (s, 1H), 9.74 (s, 1H), 8.06 (d, J = 7.9 Hz, 1H), 
7.53 (d, J = 2.1 Hz, 1H), 7.54 – 7.47 (m, 2H), 7.34 (dt, J = 8.1, 0.9 Hz, 1H), 7.11 (d, J = 2.4 Hz, 1H), 
7.07 (ddd, J = 8.1, 7.0, 1.3 Hz, 1H), 6.99 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 6.94 (dd, J = 8.3, 2.1 Hz, 1H), 
6.73 (d, J = 8.2 Hz, 1H), 6.39 (s, 1H), 4.60 (td, J = 7.7, 6.0 Hz, 1H), 4.15 (td, J = 9.2, 4.5 Hz, 1H), 3.61 
(s, 3H), 3.18 (ddd, J = 14.6, 6.1, 0.8 Hz, 1H), 3.08 (dd, J = 15.8, 6.4 Hz, 1H), 2.73 (dd, J = 13.9, 4.5 Hz, 
1H), 1.31 (s, 9H). 
13C-NMR (101 MHz, 80 °C, DMSO-d6, ppm): δ = 171.6, 170.9, 154.6, 154.5, 138.8, 135.9, 130.3, 
129.9, 126.8, 123.3, 120.6, 118.1, 117.6, 114.3, 111.0, 109.0, 83.6, 77.8, 55.3, 52.7, 51.3, 36.0, 27.7, 
27.1. 
HRMS (ESI): m/z calc. for [C26H30IN3O6]: 607.1179; found: 607.1153; calc. for [M+H; C26H31IN3O6
+]: 
608.1252; found: 608.1261; calc. for [M-H; C26H29IN3O6
-]: 606.1107; found: 606.1118.  
IR (Diamond-ATR, neat): 𝜈 = 3414 (m), 3398 (w), 3344 (w), 3310 (w), 1716 (m), 1682 (m), 1659 
(vs), 1605 (w), 1519 (s), 1504 (s), 1456 (m), 1438 (m), 1414 (m), 1391 (m), 1365 (m), 1318 (m), 1291 
(m), 1253 (m), 1238 (m), 1221 (m), 1193 (m), 1169 (s), 1038 (m), 1011 (m), 825 (w), 743 (s), 691 (w), 
664 (w). 
M.p. 160.7 °C. 
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Cbz-L-Pro-L-Glu-D-(ortho-iodo)Tyr-L-Val-OtBu (3d) 
 
According to TP1, tyrosine-peptide 2d (1.39 g, 2.00 mmol, 1.00 equiv) and sodium iodide (360 mg, 
2.40 mmol, 1.20 equiv) were dissolved in DMF (10 mL) and cooled to –10 °C. Chloramine-T trihydrate 
(676 mg, 2.40 mmol, 1.20 mmol) as solution in DMF (4.8 mL), was added dropwise over 2 h and the 
suspension was stirred for 1 h at this temperature, before warming to 25 °C and stirring additional for 
2 h. The crude product was extracted and purified by flash column chromatography. After final prep-
HPLC purification, the title compound 3d was obtained as white solid (855 mg, 1.04 mmol, 52% yield). 
1H-NMR (400 MHz, 80 °C, DMSO-d6, ppm): δ = 9.75 (s, 1H), 7.92 (d, J = 7.7 Hz, 1H), 7.78 (t, 
J = 9.9 Hz, 2H), 7.55 (d, J = 2.1 Hz, 1H), 7.42 – 7.25 (m, 5H), 7.03 (dd, J = 8.3, 2.1 Hz, 1H), 6.76 (d, 
J = 8.2 Hz, 1H), 6.92 – 6.33 (m, 2H), 5.07 (s, 2H), 4.58 (td, J = 8.5, 5.4 Hz, 1H), 4.29 – 4.17 (m, 2H), 
4.06 (dd, J = 8.3, 5.8 Hz, 1H), 3.42 (t, J = 8.2 Hz, 2H), 2.90 (dd, J = 13.9, 5.5 Hz, 1H), 2.70 (dd, J = 13.8, 
8.8 Hz, 1H), 2.10 (dq, J = 8.1, 4.1 Hz, 1H), 2.07 – 1.94 (m, 3H), 1.90 – 1.75 (m, 4H), 1.70 (p, J = 7.6, 
7.1 Hz, 1H), 1.42 (s, 9H), 0.84 (t, J = 7.0 Hz, 6H). 
13C-NMR (101 MHz, 80 °C, DMSO-d6, ppm): δ = 173.4, 171.5, 170.6, 170.4, 169.8, 154.7, 153.8, 
138.8, 136.7, 129.9, 129.8, 127.9, 127.2, 126.9, 114.4, 83.7, 80.3, 65.6, 59.3, 57.6, 53.6, 52.3, 46.4, 
36.4, 31.2, 29.7, 27.4, 23.2, 18.4, 17.6. 
HRMS (ESI): m/z calc. for [M+H; C36H49IN5O9
+]: 822.2569; found: 822.2593; calc. for [M-H; 
C36H47IN5O9
-]: 820.2424; found: 820.2426. 
IR (Diamond-ATR, neat): 𝜈 = 3285 (m), 3199 (w), 2963 (w), 2358 (w), 1737 (w), 1680 (s), 1665 (s), 
1631 (vs), 1543 (m), 1508 (m), 1467 (w), 1437 (m), 1418 (m), 1358 (m), 1295 (w), 1278 (m), 1232 (m), 
1211 (w), 1164 (m), 1133 (m), 1038 (w), 825 (w), 766 (w), 734 (w), 696 (w), 661 (w). 
M.p. 174.5 °C. 
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Methyl (8S,11S)-16-hydroxy-15-iodo-8-methyl-6,9-dioxo-4-oxa-7,10-diaza-1(1,3),3(1,2)-
dibenzenacyclododecaphane-11-carboxylate (3e) 
 
According to TP2, tyrosine-cyclopeptide 2e (825 mg, 2.00 mmol, 1.00 equiv) was dissolved in freshly 
distilled DCM (16 mL). Bis(pyridine)iodonium tetrafluoroborate (967 mg, 2.60 mmol, 1.30 equiv) was 
dissolved in freshly distilled DCM (8 mL) and added to the reaction mixture within 1 h. After stirring 
for 4 h, water (50 mL) was added and the crude product was extracted and purified by flash column 
chromatography. After final prep-HPLC purification, the title compound 3e was obtained as beige solid 
(1.02 g, 1.90 mmol, 95% yield). 
1H-NMR (400 MHz, DMSO-d6, ppm): δ = 8.93 (s, 1H), 8.09 (d, J = 8.4 Hz, 1H), 7.41 (d, J = 2.1 Hz, 
1H), 7.35 – 7.28 (m, 2H), 7.23 (ddd, J = 8.3, 7.4, 1.8 Hz, 1H), 7.04 (dd, J = 8.4, 1.1 Hz, 1H), 6.92 (td, 
J = 7.6, 1.2 Hz, 1H), 6.89 (d, J = 2.1 Hz, 1H), 4.67 (d, J = 14.2 Hz, 1H), 4.51 (d, J = 14.2, 1H), 4.44 
(dd, J = 8.8, 7.0 Hz, 1H), 4.36 (ddd, J = 11.4, 8.3, 3.2 Hz, 1H), 4.11 (d, J = 14.9 Hz, 1H), 3.84 (d, 
J = 14.9 Hz, 1H), 3.66 (s, 3H), 2.90 (dd, J = 13.7, 3.2, 1H), 2.65 (dd, J = 13.7, 11.3 Hz, 1H), 1.06 (d, 
J = 6.9 Hz, 3H). 
13C-NMR (101 MHz, DMSO-d6, ppm): δ = 171.8, 170.9, 167.5, 155.5, 152.5, 136.6, 131.8, 131.3, 
131.2, 128.9, 127.8, 127.3, 121.0, 111.5, 88.6, 66.7, 53.7, 52.0, 46.9, 34.9, 31.0, 16.4. 
HRMS (ESI): m/z calc. for [M; C22H23IN2O6]: 538.0601; found: 538.0565; calc. for 
[M+H; [C22H24IN2O6
+]: 539.0674; found: 539.0682; calc. for [M-H; C22H22IN2O6
-]: 537.0528; found: 
537.0529. 
IR (Diamond-ATR, neat): 𝜈 = 3272 (w), 2359 (w), 1751 (s), 1641 (vs), 1552 (m), 1492 (w), 1468 (m), 
1448 (m), 1432 (m), 1367 (m), 1286 (w), 1244 (m), 1217 (s), 1146 (m), 1117 (m), 1052 (w), 1042 (w), 
994 (w), 938 (w), 915 (w), 807 (w), 749 (s), 719 (m), 706 (m). 
M.p. decomposition at 280 °C. 
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2.4 Preparation of Arylzinc Pivalates 
(4-(Ethoxycarbonyl)phenyl)zinc pivalate (1a) 
 
According to TP3, ethyl 4-iodobenzoate (4.14 g, 15.0 mmol, 1.00 equiv) was dissolved in 30 mL freshly 
distilled THF and cooled to –20 °C. iPrMgCl⋅LiCl (15.5 mL, 17.0 mmol, 1.10 equiv, 1.10 M in THF) 
was added dropwise and the solution stirred for 2 h. Zn(OPiv)2 (4.82 g, 18.0 mmol, 1.20 equiv) was 
added and the mixture stirred at 25 °C until a clear solution was obtained. The concentration was 
determined by titration with iodine (0.39 M, 83% yield).119 
(4-Methoxyphenyl)zinc pivalate (1b) 
 
According to TP3, 4-iodoansiole (3.51 g, 15.0 mmol, 1.00 equiv) was dissolved in 20 mL freshly 
distilled THF and cooled to –20 °C. iPrMgCl⋅LiCl (15.5 mL, 17.0 mmol, 1.10 equiv, 1.10 M in THF) 
was added dropwise and the solution stirred for 2 h. Zn(OPiv)2 (4.82 g, 18.0 mmol, 1.20 equiv) was 
added and the mixture stirred at 25 °C until a clear solution was obtained. The concentration was 
determined by titration with iodine (0.55 M, 73% yield). 20 
(Pyridin-2-yl)zinc pivalate (1c) 
 
According to a modified version of TP3, iPrMgCl⋅LiCl (3.64 mL, 4.40 mmol, 1.10 equiv, 1.21 M in 
THF) was cooled to 0 °C and 2-bromopyridine (632 mg, 4.00 mmol, 1.00 equiv) was added dropwise 
over 15 min. After complete addition, the mixture was stirred for 1 h and again cooled to 0 °C. 
Zn(OPiv)2 (1.29 g, 4.80 mmol, 1.20 equiv) was added and the mixture stirred at 25 °C until a clear 
solution was obtained. The concentration was determined by titration with iodine (0.52 M, 
67% yield).120 
(Pyridin-3-yl)zinc pivalate (1d) 
 
According to TP3, 3-bromopyridine (632 mg, 4.00 mmol, 1.00 equiv) was dissolved in 4 mL freshly 
distilled THF and cooled to 0 °C. iPrMgCl⋅LiCl (3.64 mL, 4.40 mmol, 1.10 equiv, 1.21 M in THF) was 
 
119 S. M. Manolikakes, M. Ellwart, C. I. Stathakis, P. Knochel, Chem. Eur. J. 2014, 20, 12289. 
120 J. R. Colombe, S. Bernhardt, C. Stathakis, S. L. Buchwald, P. Knochel, Org. Lett. 2013, 15, 5754. 
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added dropwise and the solution stirred for 2 h. Zn(OPiv)2 (1.29 g, 4.80 mmol, 1.20 equiv) was added 
and the mixture stirred at 25 °C until a clear solution was obtained. The concentration was determined 
by titration with iodine (0.42 M, 93% yield).21 
(Pyridin-4-yl)zinc pivalate (1e) 
 
According to TP3, 4-iodopyridine (410 mg, 2.00 mmol, 1.00 equiv) was dissolved in 4 mL freshly 
distilled THF and cooled to –20 °C. iPrMgCl⋅LiCl (1.81 mL, 2.2 mmol, 1.10 equiv, 1.21 M in THF) 
was added dropwise and the solution stirred for 30 min. Zn(OPiv)2 (643 mg, 2.40 mmol, 1.20 equiv) 
was added and the mixture stirred at 25 °C until a clear solution was obtained. The concentration was 
determined by titration with iodine (0.23 M, 76% yield).23 
(4-(Trifluoromethyl)phenyl)zinc pivalate (1f) 
 
According to TP4, LiCl (509 mg, 12.0 mmol, 1.20 equiv) and magnesium turnings (292 mg, 12.0 mmol, 
1.20 equiv) were mixed with 10 mL freshly distilled THF and cooled to 0 °C. 4-Bromobenzotrifluoride 
(509 mg, 10.0 mmol, 1.00 equiv) was added dropwise and the suspension stirred for 4 h. The solution 
was transferred with a syringe-filter to a fresh Schlenk-flask, and Zn(OPiv)2 (3.21 g, 12.0 mmol, 
1.20 equiv) was added at 0 °C. After stirring at 25 °C for 15 min, the concentration was determined by 
titration with iodine (0.69 M, 75% yield). 121 
(6-methoxypyridin-2-yl)zinc pivalate (1g) 
 
Under Schlenk-conditions, 2-bromo-6-methoxypyridine (2.82 g, 15.0 mmol, 1.00 equiv) was dissolved 
in 24 mL freshly distilled THF and cooled to –78 °C. nBuLi (5.80 mL, 15.0 mmol, 2.60 M in nhexane) 
was added dropwise and the mixture was stirred additional 30 min before Zn(OPiv)2 (4.82 g, 18.0 mmol, 
1.20 equiv) was added. After stirring at 25 °C for 1 h, the concentration was determined by titration 
with iodine (0.24 M, 50% yield).122 
 
121 S. M. Manolikakes, M. Ellwart, C. I. Stathakis, P. Knochel, Chem. Eur. J. 2014, 20, 12289. 
122 J. R. Colombe, S. Bernhardt, C. Stathakis, S. L. Buchwald, P. Knochel, Org. Lett. 2013, 15, 5754. 
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(Benzo[b]thiophen-3-yl)zinc pivalate (1h) 
 
According to TP3, 3-bromobenzo[b]thiophene (2.13 g, 10.0 mmol, 1.00 equiv) was dissolved in 10 mL 
freshly distilled THF and cooled to –20 °C. iPrMgCl⋅LiCl (11.0 mL, 11.0 mmol, 1.10 equiv, 1.00 M in 
THF) was added dropwise and the solution stirred for 1 h. Zn(OPiv)2 (3.21 g, 12.0 mmol, 1.20 equiv) 
was added and the mixture stirred at 25 °C until a clear solution was obtained. The concentration was 
determined by titration with iodine (0.46 M, 96% yield).23 
(Benzofuran-2-yl)zinc pivalate (1i) 
 
Under Schlenk-conditions, 2,3-Benzofuran (355 mg, 3.00 mmol, 1.00 equiv) was dissolved in 6 mL 
freshly distilled THF and cooled to 0 °C. nBuLi (1.09 mL, 3.00 mmol, 2.75 M in nhexane) was added 
dropwise and the mixture was stirred additional 5 min. Zn(OPiv)2 (964 mg, 3.60 mmol, 1.20 equiv) and 
4.00 mL freshly distilled THF were added. After stirring at 25 °C for 1 h, the concentration was 
determined by titration with iodine (0.12 M, 40% yield).123 
(3,5-dimethylphenyl)zinc pivalate (1j) 
 
According to TP3, 1-iodo-3,5-dimethylbenzene (1.16 g, 5.00 mmol, 1.00 equiv) was dissolved in 5 mL 
freshly distilled THF. iPrMgCl⋅LiCl (5.00 mL, 5.50 mmol, 1.10 equiv, 1.10 M in THF) was added 
dropwise and the solution stirred for 1 h. Zn(OPiv)2 (643 mg, 2.40 mmol, 1.20 equiv) was added and 
the mixture stirred until a clear solution was obtained. The concentration was determined by titration 
with iodine (0.45 M, 99% yield).124 
(2,6-dimethoxypyrimidin-4-yl)zinc pivalate (1k) 
 
 
123 S. Otsuka, D. Fujino, K. Murakami, H. Yorimitsu, A. Osuka, Chem. Eur. J. 2014, 20, 13146. 
124 S. M. Manolikakes, M. Ellwart, C. I. Stathakis, P. Knochel, Chem. Eur. J. 2014, 20, 12289. 
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According to TP4, LiCl (255 mg, 6.00 mmol, 1.20 equiv) and Mg turnings (146 mg, 6.00 mmol, 
1.20 equiv) were mixed with 10 mL freshly distilled THF.  5-bromo-2,4-dimethoxypyrimidine (1.10 g, 
5.00 mmol, 1.00 equiv) was added dropwise and the suspension stirred for 2 h at 25 °C. The solution 
was transferred with a syringe-filter to a fresh Schlenk-flask and Zn(OPiv)2 (1.61 g, 6.00 mmol, 
1.20 equiv) was added at 0 °C. After stirring at 25 °C for 15 min, the concentration was determined by 
titration with iodine (0.64 M, 65% yield).25 
(3-cyanophenyl)zinc pivalate (1l) 
 
According to TP3, 3-iodobenzonitrile (458 mg, 2.00 mmol, 1.00 equiv) was dissolved in 2 mL freshly 
distilled THF and cooled to –30 °C. iPrMgCl⋅LiCl (2.00 mL, 2.20 mmol, 1.10 equiv, 1.10 M in THF) 
was added dropwise and the solution stirred for 30 min. Zn(OPiv)2 (643 mg, 2.40 mmol, 1.20 equiv) 
was added and the mixture stirred at 25 °C until a clear solution was obtained. The concentration was 
determined by titration with iodine (0.44 M, 96% yield).24 
 
2.5 Negishi Cross-Coupling reactions of Iodotyrosine with Arylzinc Pivalates 
Ethyl (S)-5'-(2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)-2'-hydroxy-[1,1'-
biphenyl]-4-carboxylate (4a) 
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before tyrosine-
derivate 3a (126 mg, 0.30 mmol, 1.00 equiv) was added. The arylzinc pivalate solution 1a in THF 
(1.15 mL, 0.39 M, 0.45 mmol, 1.50 equiv) was added dropwise over 1 h and the reaction mixture stirred 
at 25 °C for further 3 h. After quenching, extracting and evaporation, the crude product was pre-purified 
by flash column chromatography. After final preparative reversed-phase HPLC-chromatography 
(MeCN/H2O), the modified tyrosine-derivate 4a was obtained as colorless solid (99.0 mg, 0.22 mmol, 
74% yield). 
1H-NMR (599 MHz, CDCl3, ppm) δ = 8.08 (d, J = 8.2 Hz, 2H), 7.57 (d, J = 8.3 Hz, 2H), 7.01 (d, 
J = 2.3 Hz, 1H), 6.98 (dd, J = 8.3, 2.2 Hz, 1H), 6.86 (d, J = 8.2 Hz, 1H), 5.08 (d, J = 8.4 Hz, 1H), 4.56 
(dt, J = 8.6, 6.0 Hz, 1H), 4.39 (q, J = 7.1 Hz, 2H), 3.70 (s, 3H), 3.09 (dd, J = 14.0, 5.7 Hz, 1H), 3.00 
(dd, J = 14.1, 6.1 Hz, 1H), 1.43 – 1.35 (m, 12H). 
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13C-NMR (101 MHz, CDCl3, ppm) δ = 172.6, 166.7, 155.3, 152.1, 142.4, 131.4, 130.4, 130.0, 129.4, 
129.2, 128.2, 127.4, 116.6, 80.3, 61.2, 54.7, 52.4, 37.6, 28.4, 14.4. 
HRMS (ESI): m/z calc. for [M; C24H29NO7]: 443.1944; found: 443.1916; m/z calc. for 
[M+H; C24H30NO7
+]: 444.2017; found: 444.2021; calc. for [M-H; C24H28NO7
-]: 442.1871; found: 
442.1881. 
IR (Diamond-ATR, neat): 𝜈 = 3357 (w), 2978 (w), 2359 (w), 2340 (w), 1712 (s), 1691 (s), 1608 (m), 
1502 (m), 1435 (m), 1399 (m), 1367 (s), 1278 (vs), 1216 (m), 1166 (s), 1103 (m), 1059 (w), 1019 (m), 
859 (w), 757 (m), 705 (w), 668 (w). 
M.p. 67.8 °C. 
Methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(6-hydroxy-4'-methoxy-[1,1'-biphenyl]-3-
yl)propanoate (4b) 
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before tyrosine-
derivate 3a (126 mg, 0.30 mmol, 1.00 equiv) was added. The arylzinc pivalate solution 1b in THF 
(0.82 mL, 0.55 M, 0.45 mmol, 1.50 equiv) was added dropwise over 1 h and the reaction mixture stirred 
at 25 °C for further 3 h. After quenching, extracting and evaporating, the crude product was pre-purified 
by flash column chromatography. After purification via preparative reversed-phase HPLC-
chromatography (MeCN/H2O), the modified tyrosine-derivate 4b was obtained as colorless solid 
(60.0 mg, 0.15 mmol, 50% yield). 
1H-NMR (599 MHz, CDCl3, ppm) δ = 7.39 – 7.36 (m, 2H), 7.02 – 6.98 (m, 2H), 6.96 (d, J = 7.6 Hz, 
2H), 6.87 (d, J = 8.5 Hz, 1H), 5.01 (d, J = 8.3 Hz, 1H), 4.56 (dt, J = 8.6, 5.9 Hz, 1H), 3.85 (s, 3H), 3.71 
(s, 3H), 3.08 (dd, J = 14.0, 5.8 Hz, 1H), 3.01 (dd, J = 14.0, 6.0 Hz, 1H), 1.41 (s, 9H). 
13C-NMR (101 MHz, CDCl3, ppm) δ = 172.6, 159.4, 155.3, 151.8, 131.3, 130.3, 129.6, 129.3, 128.1, 
128.0, 116.0, 114.7, 80.1, 55.5, 54.7, 52.3, 37.6, 28.4. 
HRMS (ESI): m/z calc. for [M; C22H27NO6]: 401.1838; found: 401.1801; m/z calc. for 
[M+H; C22H28NO6
+]: 402.1911; found: 402.1915; calc. for [M-H; C22H26NO6
-]: 400.1766; found: 
400.1768. 
IR (Diamond-ATR, neat): 𝜈 = 3371 (w), 2975 (w), 2359 (vw), 1742 (m), 1689 (s), 1609 (m), 1516 
(s), 1504 (vs), 1437 (m), 1392 (m), 1366 (m), 1277 (s), 1245 (vs), 1176 (s), 1045 (m), 1026 (m), 834 
(m), 797 (w), 757 (m). 
M.p. 58.3 °C. 
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Methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-3-(pyridin-2-yl)phenyl) propanoate 
(4c) 
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before tyrosine-
derivate 3a (126 mg, 0.30 mmol, 1.00 equiv) was added. The 2-pyridylzinc pivalate solution 1c in THF 
(1.15 mL, 0.52 M, 0.60 mmol, 2.00 equiv) was added dropwise over 1 h and the reaction mixture stirred 
at 25 °C for further 3 h. After quenching, extracting and evaporating, the crude product was pre-purified 
by flash column chromatography. After purification via preparative reversed-phase HPLC-
chromatography (MeCN/H2O), the modified tyrosine-derivate 4c was obtained as colorless solid 
(97.0 mg, 0.26 mmol, 87% yield). 
1H-NMR (400 MHz, CDCl3, ppm) δ = 13.85 (s, 1H), 8.53 (dt, J = 5.1, 1.4 Hz, 1H), 7.91 (d, J = 8.3 
Hz, 1H), 7.85 (td, J = 8.3, 7.8, 1.8 Hz, 1H), 7.56 (d, J = 2.1 Hz, 1H), 7.29 – 7.24 (m, 1H), 7.06 (dd, 
J = 8.4, 2.1 Hz, 1H), 6.97 (d, J = 8.4 Hz, 1H), 5.02 (d, J = 8.4 Hz, 1H), 4.59 (dd, J = 13.2, 5.7 Hz, 1H), 
3.71 (s, 3H), 3.11 (dd, J = 14.0, 5.9 Hz, 1H), 3.04 (dd, J = 14.1, 6.1 Hz, 1H), 1.41 (s, 9H). 
13C-NMR (101 MHz, CDCl3, ppm) δ = 172.6, 159.1, 157.6, 155.2, 145.9, 138.2, 132.6, 127.1, 126.2, 
121.8, 119.4, 118.9, 118.7, 80.1, 54.7, 52.4, 37.9, 28.5. 
HRMS (ESI): m/z calc. for [M; C20H24N2O5]: 372.1685; found: 372.1648; m/z calc. for 
[M+H; C20H25N2O5
+]: 373.1758; found: 373.17560; calc. for [M-H; C20H23N2O5
-]: 371.1612; found: 
371.1613. 
IR (Diamond-ATR, neat): 𝜈 = 3352 (w), 2976 (w), 2359 (w), 2341 (w), 1742 (m), 1705 (s), 1594 (s), 
1564 (m), 1493 (s), 1485 (s), 1456 (m), 1435 (m), 1391 (m), 1365 (s), 1299 (m), 1270 (s), 1245 (s), 
1216 (s), 1160 (vs), 1099 (w), 1057 (m), 1018 (m), 826 (m), 789 (m), 754 (s), 666 (w). 
M.p. 164.2 °C. 
Methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-3-(pyridin-3-yl)phenyl) propanoate 
(4d) 
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before tyrosine-
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derivate 3a (126 mg, 0.30 mmol, 1.00 equiv) was added. The 3-pyridylzinc pivalate solution 1d in THF 
(1.43 mL, 0.42 M, 0.60 mmol, 2.00 equiv) was added dropwise over 1 h and the reaction mixture stirred 
at 25 °C for further 3 h. After quenching, extracting and evaporating the crude product was pre-purified 
by flash column chromatography. After purification via preparative reversed-phase HPLC-
chromatography (MeCN/H2O), the modified tyrosine-derivate 4d was obtained as colorless solid 
(88.0 mg, 0.24 mmol, 80% yield). 
1H-NMR (400 MHz, CDCl3, ppm) δ = 8.88 (s, 1H), 8.50 (dd, J = 5.1, 1.6 Hz, 1H), 8.00 (dt, J = 8.0, 
1.9 Hz, 1H), 7.45 (dd, J = 8.0, 5.0 Hz, 1H), 7.03 (s, 1H), 7.00 (d, J = 2.1 Hz, 1H), 6.99 (s, 1H), 5.07 (d, 
J = 8.3 Hz, 1H), 4.56 (q, J = 5.7 Hz, 1H), 3.71 (s, 3H), 3.09 (dd, J = 13.9, 5.8 Hz, 1H), 3.00 (dd, J = 14.0, 
6.1 Hz, 1H), 1.39 (s, 9H). 
13C-NMR (101 MHz, CDCl3, ppm) δ = 172.6, 155.3, 153.3, 148.5, 145.7, 138.4, 135.3, 131.3, 131.0, 
128.2, 124.2, 124.0, 117.0, 80.2, 54.7, 52.5, 37.7, 28.4. 
HRMS (ESI): m/z calc. for [M; C20H24N2O5]: 372.1685; found: 372.1647; m/z calc. for 
[M+H; C20H25N2O5
+]: 373.1758; found: 373.1757; calc. for [M-H; C20H23N2O5
-]: 371.1612; found: 
371.1611. 
IR (Diamond-ATR, neat): 𝜈 = 3326 (vw), 2976 (w), 2359 (w), 1741 (m), 1696 (m), 1612 (w), 1573 
(w), 1509 (m), 1436 (m), 1405 (m), 1392 (m), 1365 (m), 1287 (m), 1249 (m), 1215 (m), 1161 (s), 1059 
(m), 1027 (m), 853 (vw), 823 (w), 749 (vs), 710 (m), 667 (w). 
M.p. 132.9 °C. 
Methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-3-(pyridin-4-yl)phenyl) propanoate 
(4e) 
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before tyrosine-
derivate 3a (126 mg, 0.30 mmol, 1.00 equiv) was added. The 4-pyridylzinc pivalate solution 1e in THF 
(2.61 mL, 0.23 M, 0.60 mmol, 2.00 equiv) was added dropwise over 1 h and the reaction mixture stirred 
at 25 °C for further 3 h. After quenching, extracting and evaporating, the crude product was pre-purified 
by flash column chromatography. After purification via preparative reversed-phase HPLC-
chromatography (MeCN/H2O), the modified tyrosine-derivate 4e was obtained as yellow solid 
(82.0 mg, 0.22 mmol, 73% yield). 
1H-NMR (599 MHz, CDCl3, ppm) δ = 8.58 (d, J = 5.2 Hz, 2H), 7.63 (d, J = 5.2 Hz, 2H), 7.08 (d, 
J = 2.2 Hz, 1H), 7.01 (dd, J = 8.3, 2.2 Hz, 1H), 6.92 (d, J = 8.3 Hz, 1H), 5.09 (d, J = 8.4 Hz, 1H), 4.57 
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(q, J = 6.6 Hz, 1H), 3.72 (s, 3H), 3.10 (dd, J = 14.0, 5.8 Hz, 1H), 3.00 (dd, J = 14.0, 6.2 Hz, 1H), 1.40 
(s, 9H). 
13C-NMR (101 MHz, CDCl3, ppm) δ = 172.5, 155.3, 153.7, 148.6, 147.6, 131.3, 131.3, 127.9, 125.3, 
124.6, 117.0, 80.3, 54.7, 52.4, 37.7, 28.4. 
HRMS (ESI): m/z calc. for [M; C20H24N2O5]: 372.1685; found: 372.1649; m/z calc. for 
[M+H; C20H25N2O5
+]: 373.1758; found: 373.1753; calc. for [M-H; C20H23N2O5
-]: 371.1612; found: 
371.1613. 
IR (Diamond-ATR, neat): 𝜈 = 3344 (w), 2976 (w), 2359 (w), 2341 (w), 1741 (m), 1696 (m), 1601 
(m), 1542 (w), 1509 (m), 1435 (m), 1410 (m), 1391 (m), 1365 (m), 1289 (m), 1251 (m), 1215 (s), 1162 
(s), 1058 (m), 1007 (m), 832 (m), 806 (w), 751 (vs), 667 (w). 
M.p. 129.4 °C. 
 
2.6 Preparation of Alkylzinc Halides 
nButylzinc(II) chloride (5a) 
 
Under Schlenk-conditions, nBuMgCl (3.23 mL, 5.00 mmol, 1.00 equiv, 1.55 M in THF) was cooled 
down to 0 °C and ZnCl2 (5.00 mL, 5.00 mmol, 1.00 M in THF, 1.00 equiv) was added. The mixture 
was stirred at 25 °C for 30 min and then titrated with iodine (0.59 M, 97% yield).125 
Cyclohexylzinc(II) iodide (5b) 
 
According to TP6, LiCl (382 mg, 9.00 mmol. 1.50 equiv) and zinc dust (1.18 g, 18.0 mmol, 2.50 equiv) 
were suspended in 6 mL freshly distilled THF and activated with TMSCl and DBE. Iodcylcohexan 
(1.26 g, 6.00 mmol, 1.00 equiv) was added dropwise and the reaction mixture was stirred for 2 h. After 
filtration, the concentration was determined by titration with iodine (0.79 M, 76% yield).126 
(4-Chlorobutyl)zinc(II) iodide (5c) 
 
According to TP6, LiCl (305 mg, 7.20 mmol. 1.20 equiv) and zinc dust (785 mg, 12.0 mmol, 2.00 
equiv) were suspended in 6 mL freshly distilled THF and activated with TMSCl and DBE. 
1-Chloro-4-iodobutane (1.31 g, 6.00 mmol, 1.00 equiv) was added dropwise and the reaction mixture 
 
125 I. Kalvet, T. Sperger, T. Scattolin, G. Magnin, F. Schoenebeck, Angew. Chem. Int. Ed. 2017, 56, 7078. 
126 A. Krasovskiy, V. Malakhov, A. Gavryushin, P. Knochel, Angew. Chem. Int. Ed. 2006, 45, 6040. 
C. EXPERIMENTAL PART    88 
was stirred for 1 h. After filtration, the concentration was determined by titration with iodine (0.84 M, 
84% yield). 
(4-Cyanobutyl)zinc(II) bromide (5d) 
 
According to TP6, LiCl (424 mg, 10.0 mmol. 1.00 equiv) and zinc dust (915 mg, 14.0 mmol, 
1.40 equiv) were suspended in 10 mL freshly distilled THF and activated with TMSCl and DBE. 
4-Bromobutyronitrile (1.48 g, 10.0 mmol, 1.00 equiv) was added dropwise and the reaction mixture 
was stirred for 16 h at 50 °C. After filtration, the concentration was determined by titration with iodine 
(0.86 M, 86% yield). 
(6-Ethoxy-6-oxohexyl)zinc(II) bromide (5e) 
 
According to TP6, LiCl (255 mg, 6.00 mmol. 1.00 equiv) and zinc dust (550 mg, 8.40 mmol, 
1.40 equiv) were suspended in 6 mL freshly distilled THF and activated with TMSCl and DBE. Ethyl 
6-bromohexanoate (1.34 g, 6.00 mmol, 1.00 equiv) was added dropwise and the reaction mixture was 
stirred for 50 h at 50 °C. After filtration, the concentration was determined by titration with iodine 
(0.81 M, 81% yield). 
 
2.7 Negishi Cross-Coupling reactions of Iodotyrosine with Alkylzinc Halides 
Methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(3-butyl-4-hydroxyphenyl)propanoate (6a) 
 
According to TP7, Pd(dba)2 (6.90 mg, 12.0 µmol, 4.00 mol%), PtBu3 (0.03 mL, 1.00 M in toluene, 
24.0 µmol, 8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before 
tyrosine-derivate 3a (126 mg, 0.30 mmol, 1.00 equiv) was added. The butylzinc chloride solution 5a in 
THF (1.02 mL, 0.59 M, 0.60 mmol, 2.00 equiv) was added dropwise over 1 h and the reaction mixture 
stirred at 25 °C for further 7 h. After quenching, extracting and evaporating, the crude product was 
purified by flash column chromatography. Final purification via preparative reversed-phase HPLC-
chromatography (MeCN/H2O) yielded the modified alkyltyrosine-derivate 6a as colorless solid 
(88.0 mg, 0.25 mmol, 82% yield). 
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1H-NMR (599 MHz, CDCl3, ppm) δ = 6.84 (d, J = 2.2 Hz, 1H), 6.79 (dd, J = 8.1, 2.3 Hz, 1H), 6.65 
(d, J = 8.0 Hz, 1H), 5.11 (s, 1H), 4.97 (d, J = 8.4 Hz, 1H), 4.53 (q, J = 6.5 Hz, 1H), 3.71 (s, 3H), 2.99 
(qd, J = 14.0, 5.9 Hz, 2H), 2.56 (t, J = 7.8 Hz, 2H), 1.61 – 1.54 (m, 2H), 1.43 (s, 9H), 1.37 (dq, J = 14.7, 
7.4 Hz, 2H), 0.93 (t, J = 7.4 Hz, 3H). 
13C-NMR (151 MHz, CDCl3, ppm) δ = 172.7, 155.3, 152.8, 131.2, 128.9, 127.8, 127.7, 115.4, 80.1, 
54.7, 52.3, 37.6, 32.0, 29.8, 28.5, 22.7, 14.1. 
HRMS (ESI): m/z calc. for [M+Na; C19H29NNaO5
+]: 374.1943; found: 374.1940; calc. for [M-H; 
C19H28NO5
-]: 350.1973; found: 350.1979. 
IR (Diamond-ATR, neat): 𝜈 = 3467 (m), 3371 (w), 2954 (w), 2922 (w), 2854 (w), 2359 (vw), 1739 
(s), 1690 (vs), 1526 (s), 1507 (m), 1436 (m), 1361 (s), 1264 (s), 1243 (m), 1218 (s), 1167 (s), 1124 (m), 
1052 (s), 1010 (m), 999 (m), 817 (m), 810 (m), 775 (w), 716 (w). 
M.p. 87.2 °C. 
Methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(3-cyclohexyl-4-hydroxyphenyl) propanoate (6b) 
 
According to TP7, Pd(dba)2 (6.90 mg, 12.0 µmol, 4.00 mol%), PtBu3 (0.03 mL, 1.00 M in toluene, 
24.0 µmol, 8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before 
tyrosine-derivate 3a (126 mg, 0.30 mmol, 1.00 equiv) was added. The cyclohexylzinc iodide solution 
5b in THF (0.76 mL, 0.79 M, 0.60 mmol, 2.00 equiv) was added dropwise over 1 h and the reaction 
mixture stirred at 25 °C for further 7 h. After quenching, extracting and evaporating, the crude product 
was purified by flash column chromatography. Final purification via preparative reversed-phase HPLC-
chromatography (MeCN/H2O) yielded the modified alkyltyrosine-derivate 6b as colorless solid 
(79.0 mg, 0.21 mmol, 71% yield). 
1H-NMR (599 MHz, CDCl3, ppm) δ = 6.88 (d, J = 2.2 Hz, 1H), 6.78 (dd, J = 8.1, 2.2 Hz, 1H), 6.65 
(d, J = 8.1 Hz, 1H), 5.01 – 4.89 (m, 2H), 4.54 (dt, J = 8.2, 5.6 Hz, 1H), 3.71 (s, 3H), 3.00 (d, J = 5.8 Hz, 
2H), 2.78 (tt, J = 11.5, 2.9 Hz, 1H), 1.88 – 1.80 (m, 4H), 1.80 – 1.72 (m, 1H), 1.46 – 1.37 (m, 14H), 
1.35 – 1.19 (m, 1H). 
13C-NMR (101 MHz, CDCl3, ppm) δ = 172.7, 155.2, 152.0, 133.8, 128.1, 128.0, 127.4, 115.5, 80.0, 
54.6, 52.4, 37.8, 37.2, 33.3, 33.2, 28.5, 27.1, 26.4.z 
HRMS (ESI): m/z calc. for [M+Na; C21H31NNaO5
+]: 400.2100; found: 400.2098; calc. for [M-H; 
C21H30NO5
-]: 376.2129; found: 376.2139. 
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IR (Diamond-ATR, neat): 𝜈 = 3378 (w), 2977 (w), 2925 (m), 2851 (m), 2359 (w), 1688 (vs), 1610 
(w), 1506 (s), 1436 (m), 1392 (m), 1366 (s), 1273 (m), 1250 (s), 1223 (m), 1164 (vs), 1100 (w), 1060 
(m), 1022 (w), 910 (w), 823 (w), 733 (m). 
M.p. 67.1 °C. 
Methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(3-(4-chlorobutyl)-4-hydroxyphenyl) propanoate 
(6c) 
 
According to TP7, Pd(dba)2 (6.90 mg, 12.0 µmol, 4.00 mol%), PtBu3 (0.03 mL, 1.00 M in toluene, 
24.0 µmol, 8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before 
tyrosine-derivate 3a (126 mg, 0.30 mmol, 1.00 equiv) was added. The 4-chlorobutylzinc iodide solution 
5c in THF (0.72 mL, 0.84 M, 0.60 mmol, 2.00 equiv) was added dropwise over 1 h and the reaction 
mixture stirred at 25 °C for further 7 h. After quenching, extracting and evaporating, the crude product 
was purified by flash column chromatography. Final purification via preparative reversed-phase HPLC-
chromatography (MeCN/H2O) yielded the modified alkyltyrosine-derivate 6c as colorless solid 
(85.0 mg, 0.22 mmol, 72% yield). 
1H-NMR (599 MHz, CDCl3, ppm) δ = 6.84 (d, J = 2.2 Hz, 1H), 6.80 (dd, J = 8.2, 2.2 Hz, 1H), 6.64 
(d, J = 8.1, 1H), 5.18 (s, 1H), 4.98 (d, J = 8.3 Hz, 1H), 4.53 (q, J = 6.7 Hz, 1H), 3.71 (s, 3H), 3.56 (t, 
J = 6.6, 2H), 2.99 (qd, J = 13.9, 5.8 Hz, 2H), 2.60 (t, J = 7.4 Hz, 2H), 1.86 – 1.78 (m, 2H), 1.74 (p, 
J = 7.2 Hz, 2H), 1.42 (s, 9H). 
13C-NMR (151 MHz, CDCl3, ppm) δ = 172.7, 155.3, 152.9, 131.3, 128.2, 128.0, 115.5, 80.2, 54.7, 
52.4, 45.1, 45.1, 37.7, 32.3, 29.3, 28.5, 27.1. 
HRMS (ESI): m/z calc. for [M+Na; C19H28ClNNaO5
+]: 408.1554; found: 408.1550; calc. for [M-H; 
C19H27ClNO5
-]: 384.1583; found: 384.1588. 
IR (Diamond-ATR, neat): 𝜈 = 3417 (m), 3376 (m), 2976 (w), 1725 (s), 1687 (vs), 1609 (w), 1503 (s), 
1437 (m), 1367 (m), 1306 (m), 1298 (m), 1267 (s), 1225 (s), 1163 (s), 1110 (m), 1017 (m), 986 (m), 
851 (w), 821 (s), 721 (s). 
M.p. 103.3 °C. 
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Methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(3-(3-cyanopropyl)-4-hydroxyphenyl) propanoate 
(6d) 
 
According to TP7, Pd(dba)2 (6.90 mg, 12.0 µmol, 4.00 mol%), PtBu3 (0.03 mL, 1.00 M in toluene, 
24.0 µmol, 8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before 
tyrosine-derivate 3a (126 mg, 0.30 mmol, 1.00 equiv) was added. The 4-cyanobutylzinc bromide 
solution 5d in THF (0.70 mL, 0.86 M, 0.60 mmol, 2.00 equiv) was added dropwise over 1 h and the 
reaction mixture stirred at 25 °C for further 7 h. After quenching, extracting and evaporating, the crude 
product was purified by flash column chromatography. Final purification via preparative reversed-phase 
HPLC-chromatography (MeCN/H2O) yielded the modified alkyltyrosine-derivate 6d as colorless solid 
(62.0 mg, 0.17 mmol, 58% yield). 
1H-NMR (400 MHz, CDCl3, ppm) δ = 6.85 – 6.78 (m, 2H), 6.64 (d, J = 8.7 Hz, 1H), 5.74 (s, 1H), 5.00 
(d, J = 8.5 Hz, 1H), 4.53 (q, J = 6.1 Hz, 1H), 3.73 (s, 3H), 2.98 (qd, J = 14.0, 6.0 Hz, 2H), 2.80 – 2.65 
(m, 2H), 2.32 (t, J = 7.2 Hz, 2H), 1.96 (p, J = 7.3 Hz, 2H), 1.42 (s, 9H). 
13C-NMR (101 MHz, CDCl3, ppm) δ = 172.7, 155.3, 153.2, 131.6, 128.6, 128.0, 126.4, 120.0, 115.6, 
80.3, 54.7, 52.5, 37.6, 29.2, 28.4, 25.5, 16.6. 
HRMS (ESI): m/z calc. for [M+Na; C19H26N2NaO5
+]: 385.1739; found: 385.1737; calc. for [M-H; 
C19H25N2O5
-]: 361.1769; found: 361.1776. 
IR (Diamond-ATR, neat): 𝜈 = 3366 (m), 2977 (m), 2933 (m), 2360 (m), 2339 (w), 1743 (m), 1711 
(s), 1686 (s), 1612 (m), 1510 (s), 1437 (m), 1393 (m), 1366 (s), 1259 (s), 1212 (m), 1164 (vs), 1114 
(m), 1060 (m), 1022 (m). 
M.p. 94.9 °C. 
Ethyl (S)-6-(5-(2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)-2-
hydroxyphenyl)hexanoate (6e) 
 
According to TP7, Pd(dba)2 (6.90 mg, 12.0 µmol, 4.00 mol%), PtBu3 (0.03 mL, 1.00 M in toluene, 
24.0 µmol, 8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before 
tyrosine-derivate 3a (126 mg, 0.30 mmol, 1.00 equiv) was added. The alkylzinc halide solution 5e in 
THF (0.74 mL, 0.81 M, 0.60 mmol, 2.00 equiv) was added dropwise over 1 h and the reaction mixture 
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stirred at 25 °C for further 7 h. After quenching, extracting and evaporating, the crude product was 
purified by flash column chromatography. Final purification via preparative reversed-phase HPLC-
chromatography (MeCN/H2O) yielded the modified alkyltyrosine-derivate 6e as colorless, viscous oil 
(61.0 mg, 0.14 mmol, 48% yield). 
1H-NMR (800 MHz, CDCl3, ppm) δ = 6.82 (d, J = 2.1 Hz, 1H), 6.80 (dd, J = 8.0, 2.3 Hz, 1H), 6.66 
(d, J = 8.0 Hz, 1H), 5.31 (s, 1H), 4.98 (d, J = 8.4 Hz, 1H), 4.52 (dt, J = 8.4, 5.8 Hz, 1H), 4.12 (q, 
J = 7.1 Hz, 2H), 3.70 (s, 3H), 3.04 – 2.91 (m, 2H), 2.56 (dd, J = 8.9, 6.6 Hz, 2H), 2.30 (t, J = 7.5 Hz, 
2H), 1.67 (dd, J = 9.0, 6.2 Hz, 2H), 1.63 – 1.55 (m, 2H), 1.44 – 1.34 (m, 11H), 1.24 (t, J = 7.1 Hz, 3H). 
13C-NMR (201 MHz, CDCl3, ppm) δ = 174.2, 172.7, 155.3, 152.9, 131.2, 128.7, 127.8, 127.8, 115.5, 
80.1, 60.4, 54.7, 52.3, 37.6, 34.4, 29.9, 29.5, 29.1, 28.5, 24.8, 14.4. 
HRMS (ESI): m/z calc. for [M+Na; C23H35NNaO7
+]: 460.2311; found: 460.2308; calc. for [M-H; 
C23H34NO7
-]: 436.2341; found: 436.2357. 
IR (Diamond-ATR, neat): 𝜈 = 3383 (w), 2978 (w), 2934 (m), 2859 (w), 2358 (w), 1732 (s), 1715 (vs), 
1611 (w), 1508 (s), 1437 (m), 1392 (m), 1367 (s), 1259 (s), 1205 (s), 1166 (vs), 1114 (w), 1060 (m), 
1023 (m), 856 (vw), 822 (w). 
Benzyl (S)-2-(((S)-3-(3-butyl-4-hydroxyphenyl)-1-methoxy-1-oxopropan-2-
yl)carbamoyl)pyrrolidine-1-carboxylate (6f) 
 
According to TP7, Pd(dba)2 (6.90 mg, 12.0 µmol, 4.00 mol%), PtBu3 (0.03 mL, 1.00 M in toluene, 
24.0 µmol, 8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before 
iodotyrosine-peptide 3b (166 mg, 0.30 mmol, 1.00 equiv) was added. The butylzinc chloride solution 
5a in THF (1.02 mL, 0.59 M, 0.60 mmol, 2.00 equiv) was added dropwise over 1 h and the reaction 
mixture stirred at 25 °C for further 7 h. After quenching, extracting and evaporating, the crude product 
was purified by flash column chromatography. Final purification via preparative reversed-phase HPLC-
chromatography (MeCN/H2O) yielded the modified alkyltyrosine-peptide 6f as colorless solid 
(87.0 mg, 0.18 mmol, 61% yield). 
1H-NMR (400 MHz, 80 °C, DMSO-d6, ppm) δ = 8.69 (s, 1H), 7.86 (d, J = 7.7 Hz, 1H), 7.28 (q, J = 7.6, 
6.6 Hz, 5H), 6.81 (d, J = 2.2 Hz, 1H), 6.75 (dd, J = 8.2, 2.3 Hz, 1H), 6.63 (d, J = 8.1 Hz, 1H), 5.01 (d, 
J = 11.3 Hz, 2H), 4.42 (td, J = 7.7, 6.3 Hz, 1H), 4.23 (dd, J = 8.7, 3.1 Hz, 1H), 3.53 (s, 3H), 3.44 – 3.30 
(m, 2H), 2.88 – 2.74 (m, 2H), 2.46 – 2.42 (m, 2H), 2.12 – 1.98 (m, 1H), 1.81 – 1.67 (m, 3H), 1.48 (tt, 
J = 7.8, 6.3 Hz, 2H), 1.33 – 1.22 (m, 2H), 0.86 (t, J = 7.3 Hz, 3H). 
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13C-NMR (101 MHz, 80 °C, DMSO-d6, ppm) = 171.5, 171.4, 153.7, 153.4, 136.7, 129.9, 128.0, 127.8, 
127.1, 126.8, 126.7, 126.6, 114.5, 65.5, 59.3, 53.4, 51.1, 46.4, 35.9, 31.1, 29.9, 28.8, 22.8, 21.5, 13.3. 
HRMS (ESI): m/z calc. for [M+Na; C27H34N2NaO6
+]: 505.2315; found: 505.2312; m/z calc. for 
[M+H; C27H35N2O6
+]: 483.2490; found: 483.2492; calc. for [M-H; C27H33N2O6
-]: 481.2344; found: 
481.2348. 
IR (Diamond-ATR, neat): 𝜈 = 3347 (w), 2951 (w), 1745 (m), 1696 (s), 1648 (vs), 1609 (w), 1538 (m), 
1509 (w), 1449 (m), 1409 (s), 1357 (s), 1260 (m), 1206 (s), 1176 (m), 1122 (m), 985 (w), 956 (w), 825 
(w), 802 (w), 766 (m), 743 (m), 697 (m). 
M.p. 106.7 °C. 
 
2.8 Negishi Cross-Coupling Reactions of Tyrosine containing Peptides with Arylzinc 
Pivalates 
Benzyl (S)-2-(((S)-3-(4'-(ethoxycarbonyl)-6-hydroxy-[1,1'-biphenyl]-3-yl)-1-methoxy-1-
oxopropan-2-yl)carbamoyl)pyrrolidine-1-carboxylate (7a) 
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before iodotyrosine-
peptide 3b (166 mg, 0.30 mmol, 1.00 equiv) was added. The arylzinc pivalate solution 1a in THF 
(1.15 mL, 0.39 M, 0.45 mmol, 1.50 equiv) was added dropwise over 1 h and the reaction mixture stirred 
at 25 °C for further 3 h. After quenching, extracting and evaporating, the crude product was pre-purified 
by flash column chromatography. After final preparative reversed-phase HPLC-chromatography 
(MeCN/H2O), the modified tyrosine-peptide 7a was obtained as colorless solid (116 mg, 0.20 mmol, 
67% yield). 
1H-NMR (400 MHz, 80 °C, DMSO-d6, ppm) δ = 9.28 (s, 1H), 8.02 – 7.93 (m, 3H), 7.69 (d, J = 8.2 
Hz, 2H), 7.30 (d, J = 7.3 Hz, 5H), 7.15 (d, J = 2.3 Hz, 1H), 7.02 (dd, J = 8.2, 2.3 Hz, 1H), 6.87 (d, 
J = 8.2 Hz, 1H), 4.99 (s, 2H), 4.54 (td, J = 8.1, 5.8 Hz, 1H), 4.35 (q, J = 7.1 Hz, 2H), 4.26 (dd, J = 8.6, 
3.3 Hz, 1H), 3.60 (s, 3H), 3.44 – 3.31 (m, 2H), 3.04 – 2.86 (m, 2H), 2.06 (p, J = 8.1, 7.5 Hz, 1H), 1.83 
– 1.65 (m, 3H), 1.35 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, 80 °C, DMSO-d6, ppm) δ = 171.5, 171.3, 165.3, 153.7, 152.7, 143.1, 136.6, 
130.5, 129.4, 128.7, 128.2, 127.8, 127.7, 127.6, 127.1, 126.8, 125.9, 115.9, 65.5, 60.0, 59.3, 53.1, 51.2, 
46.4, 35.6, 29.9, 22.8, 13.7 
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HRMS (ESI): m/z calc. for [M; C32H34N2O8]: 574.2315; found: 574.2278; m/z calc. for 
[M+H; C32H35N2O8
+]: 575.2388; found: 575.2399; calc. for [M-H; C32H33N2O8
-]: 573.2242; found: 
573.2242. 
IR (Diamond-ATR, neat): 𝜈 = 3334 (w), 2951 (w), 2359 (w), 2341 (w), 1744 (m), 1709 (s), 1697 (s), 
1607 (m), 1514 (m), 1432 (m), 1401 (m), 1356 (m), 1312 (m), 1275 (vs), 1231 (m), 1211 (s), 1180 (m), 
1110 (m), 1103 (m), 1018 (w), 754 (m), 699 (w). 
M.p. 89.6 °C. 
Benzyl (S)-2-(((S)-3-(6-hydroxy-4'-methoxy-[1,1'-biphenyl]-3-yl)-1-methoxy-1-oxopropan-2-
yl)carbamoyl)pyrrolidine-1-carboxylate (7b) 
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before iodotyrosine-
peptide 3b (166 mg, 0.30 mmol, 1.00 equiv) was added. The arylzinc pivalate solution 1b in THF 
(0.82 mL, 0.55 M, 0.45 mmol, 1.50 equiv) was added dropwise over 1 h and the reaction mixture stirred 
at 25 °C for further 3 h. After quenching, extracting and evaporating, the crude product was pre-purified 
by flash column chromatography. After final preparative reversed-phase HPLC-chromatography 
(MeCN/H2O), the modified tyrosine-peptide 7b was obtained as colorless solid (75.0 mg, 0.14 mmol, 
48% yield). 
1H-NMR (400 MHz, 80 °C, DMSO-d6, ppm) δ = 8.96 (s, 1H), 7.94 (d, J = 7.8 Hz, 1H), 7.47 (d, 
J = 8.8 Hz, 2H), 7.37 – 7.24 (m, 5H), 7.05 (d, J = 2.3 Hz, 1H), 6.96 – 6.89 (m, 3H), 6.81 (d, J = 8.2 Hz, 
1H), 5.06 – 4.95 (m, 2H), 4.52 (td, J = 8.0, 6.0 Hz, 1H), 4.26 (dd, J = 8.6, 3.3 Hz, 1H), 3.79 (s, 3H), 
3.59 (s, 3H), 3.44 – 3.32 (m, 2H), 2.93 (qd, J = 13.9, 7.0 Hz, 2H), 2.15 – 1.99 (m, 1H), 1.84 – 1.66 (m, 
3H). 
13C-NMR (101 MHz, 80 °C, DMSO-d6, ppm) δ = 171.5, 171.4, 157.8, 153.7, 152.5, 136.6, 130.6, 
130.3, 129.6, 127.9, 127.8, 127.3, 127.1, 126.9, 126.8, 115.7, 113.1, 65.5, 59.3, 54.8, 53.2, 51.1, 46.4, 
35.7, 29.9, 22.8. 
HRMS (ESI): m/z calc. for [M; C30H32N2O7]: 532.2210; found: 532.2175; m/z calc. for 
[M+H; 30H33N2O7
+]: 533.2282; found: 533.2287; calc. for [M-H; C30H31N2O7
-]: 531.2137; found: 
531.2140. 
C. EXPERIMENTAL PART    95 
IR (Diamond-ATR, neat): 𝜈 = 3311 (w), 2951 (w), 2359 (w), 1742 (m), 1694 (s), 1667 (s), 1608 (m), 
1517 (s), 1504 (s), 1433 (s), 1417 (s), 1355 (s), 1277 (s), 1244 (vs), 1210 (s), 1177 (vs), 1116 (m), 1027 
(m), 987 (w), 834 (m), 797 (w), 751 (m), 697 (m). 
M.p. 90.9 °C. 
Benzyl (S)-2-(((S)-3-(6-hydroxy-4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)-1-methoxy-1-
oxopropan-2-yl)carbamoyl)pyrrolidine-1-carboxylate (7c) 
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before iodotyrosine-
peptide 3b (166 mg, 0.30 mmol, 1.00 equiv) was added. The arylzinc pivalate solution 1f in THF 
(1.09 mL, 0.69 M, 0.75 mmol, 2.50 equiv) was added dropwise over 1 h and the reaction mixture stirred 
at 25 °C for further 3 h. After quenching, extracting and evaporating, the crude product was pre-purified 
by flash column chromatography. After final preparative reversed-phase HPLC-chromatography 
(MeCN/H2O), the modified tyrosine-peptide 7c was obtained as colorless solid (137 mg, 0.24 mmol, 
80% yield). 
1H-NMR (400 MHz, 80 °C, DMSO-d6, ppm): δ = 9.35 (s, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.75 (d, 
J = 8.2 Hz, 2H), 7.69 (d, J = 8.3 Hz, 2H), 7.37 – 7.22 (m, 5H), 7.14 (d, J = 2.3 Hz, 1H), 7.03 (dd, J = 8.3, 
2.3 Hz, 1H), 6.88 (d, J = 8.3 Hz, 1H), 5.05 – 4.91 (m, 2H), 4.54 (td, J = 8.1, 5.8 Hz, 1H), 4.25 (dd, 
J = 8.6, 3.3 Hz, 1H), 3.59 (s, 3H), 3.43 – 3.31 (m, 2H), 3.05 – 2.87 (m, 2H), 2.13 – 1.99 (m, 1H), 
1.82 – 1.64 (m, 3H). 
13C-NMR (101 MHz, 80 °C, DMSO-d6, ppm): δ = 171.7, 171.5, 153.8, 152.8, 142.5, 136.7, 130.6, 
129.6, 129.4, 127.9, 127.8, 127.2, 126.8 (q, J = 31.5 Hz), 126.3, 125.7, 124.3 (q, J = 3.9 Hz), 116.0, 
65.6, 59.4, 53.2, 51.3, 46.5, 35.7, 30.0, 22.8. 
19F-NMR (377 MHz, 80 °C, DMSO-d6, ppm): δ = –60.9. 
HRMS (ESI): m/z calc. for [M; C30H29F3N2O6]: 570.1978; found: 570.1951; m/z calc. for 
[M+H; C30H30F3N2O6
+]: 571.2050; found: 571.2059; calc. for [M-H; C30H28F3N2O6
-]: 569.1905; found: 
569.1912. 
IR (Diamond-ATR, neat): 𝜈 = 3298 (w), 1742 (w), 1688 (m), 1658 (m), 1611 (w), 1524 (w), 1502 
(w), 1414 (m), 1401 (m), 1355 (m), 1323 (vs), 1278 (m), 1210 (m), 1162 (m), 1108 (vs), 1067 (s), 1016 
(m), 986 (w), 845 (m), 769 (w), 736 (w), 697 (m). 
M.p. 84.8 °C. 
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Benzyl (S)-2-(((S)-3-(4-hydroxy-3-(6-methoxypyridin-2-yl)phenyl)-1-methoxy-1-oxopropan-2-
yl)carbamoyl)pyrrolidine-1-carboxylate (7d) 
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before iodotyrosine-
peptide 3b (166 mg, 0.30 mmol, 1.00 equiv) was added. The pyridylzinc pivalate solution 1g in 
THF/nhexane (1.88 mL, 0.24 M, 0.45 mmol, 1.50 equiv) was added dropwise over 1 h and the reaction 
mixture stirred at 25 °C for further 3 h. After quenching, extracting and evaporating, the crude product 
was pre-purified by flash column chromatography. After final preparative reversed-phase HPLC-
chromatography (MeCN/H2O), the modified tyrosine-peptide 7d was obtained as colorless solid 
(96.0 mg, 0.18 mmol, 61% yield). 
1H-NMR (400 MHz, 80 °C, DMSO-d6, ppm) δ = 12.52 (s, 1H), 8.01 (d, J = 7.9 Hz, 1H), 7.89 – 7.83 
(m, 1H), 7.76 (d, J = 2.2 Hz, 1H), 7.68 (d, J = 7.7 Hz, 1H), 7.36 – 7.21 (m, 5H), 7.11 (dd, J = 8.3, 
2.2 Hz, 1H), 6.84 – 6.79 (m, 2H), 5.04 – 4.89 (m, 2H), 4.58 (td, J = 8.3, 5.8 Hz, 1H), 4.26 (dd, J = 8.7, 
3.2 Hz, 1H), 3.94 (s, 3H), 3.61 (s, 3H), 3.47 – 3.32 (m, 2H), 3.06 – 2.90 (m, 2H), 2.08 (q, J = 8.4 Hz, 
1H), 1.84 – 1.64 (m, 3H). 
13C-NMR (101 MHz, 80 °C, DMSO-d6, ppm) δ = 171.5, 171.3, 161.5, 156.3, 154.0, 153.7, 140.4, 
136.6, 131.3, 127.7, 127.6, 127.2, 127.1, 126.7, 119.1, 117.0, 112.7, 107.8, 65.5, 59.2, 53.2, 53.1, 51.2, 
46.4, 35.7, 30.0, 22.7. 
HRMS (ESI): m/z calc. for [M; C29H31N3O7]: 533.2162; found: 533.2112; m/z calc. for 
[M+H; C29H32N3O7
+]: 534.2235; found: 534.2237; calc. for [M-H; C29H30N3O7
-]: 532.2089; found: 
532.2077. 
IR (Diamond-ATR, neat): 𝜈 = 3322 (w), 2951 (w), 2879 (w), 2359 (w), 2340 (w), 1742 (m), 1685 (s), 
1597 (s), 1573 (s), 1461 (s), 1415 (s), 1355 (s), 1288 (m), 1264 (vs), 1208 (s), 1178 (m), 1117 (m), 1087 
(m), 1026 (m), 807 (m), 751 (s), 697 (m), 668 (w). 
M.p. 94.8 °C. 
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Benzyl (S)-2-(((S)-3-(3-(benzo[b]thiophen-3-yl)-4-hydroxyphenyl)-1-methoxy-1-oxopropan-2-
yl)carbamoyl)pyrrolidine-1-carboxylate (7e) 
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before iodotyrosine-
peptide 3b (166 mg, 0.30 mmol, 1.00 equiv) was added. The heteroarylzinc pivalate solution 1h in THF 
(1.63 mL, 0.46 M, 0.75 mmol, 2.50 equiv) was added dropwise over 1 h and the reaction mixture stirred 
at 25 °C for further 3 h. After quenching, extracting and evaporating, the crude product was pre-purified 
by flash column chromatography. After final preparative reversed-phase HPLC-chromatography 
(MeCN/H2O), the modified tyrosine-peptide 7e was obtained as colorless solid (78.0 mg, 0.14 mmol, 
47% yield). 
1H-NMR (400 MHz, 80 °C, DMSO-d6, ppm) δ = 9.07 (s, 1H), 8.01 – 7.95 (m, 2H), 7.64 – 7.59 (m, 
1H), 7.57 (s, 1H), 7.37 – 7.33 (m, 2H), 7.33 – 7.23 (m, 6H), 7.12 (d, J = 2.3 Hz, 1H), 7.06 (dd, J = 8.2, 
2.3 Hz, 1H), 6.91 (d, J = 8.2 Hz, 1H), 4.99 (s, 2H), 4.54 (td, J = 8.0, 6.0 Hz, 1H), 4.26 (dd, J = 8.6, 
3.4 Hz, 1H), 3.59 (s, 3H), 3.43 – 3.30 (m, 2H), 2.96 (qd, J = 14.1, 7.1 Hz, 2H), 2.13 – 1.99 (m, 1H), 
1.82 – 1.65 (m, 2H). 
13C-NMR (101 MHz, 80 °C, DMSO-d6, ppm) δ = 171.5, 171.4, 153.7, 153.2, 138.9, 138.1, 136.6, 
134.0, 131.2, 129.0, 127.8, 127.1, 127.1, 126.8, 124.2, 123.6, 123.4, 123.1, 122.1, 121.7, 115.6, 65.5, 
59.3, 53.2, 51.2, 46.4, 35.6, 30.1, 22.8. 
HRMS (ESI): m/z calc. for [M+Na; C31H30N2NaO6S
+]: 581.1722; found: 581.1722; m/z calc. for 
[M+H; C31H31N2O6S
+]: 559.1903; found: 559.1897; calc. for [M-H; C31H29N2O6S
-]: 557.1752; found: 
557.1752. 
IR (Diamond-ATR, neat): 𝜈 = 3325 (m), 2952 (w), 2359 (w), 2339 (w), 1742 (s), 1695 (vs), 1682 
(vs), 1668 (vs), 1609 (w), 1523 (m), 1498 (m), 1418 (vs), 1355 (s), 1243 (m), 1212 (s), 1177 (m), 1115 
(m), 986 (w), 819 (w), 759 (vs), 697 (m), 667 (w). 
M.p. 96.0 °C. 
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Benzyl (S)-2-(((S)-3-(3-(benzofuran-2-yl)-4-hydroxyphenyl)-1-methoxy-1-oxopropan-2-
yl)carbamoyl)pyrrolidine-1-carboxylate (7f) 
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before iodotyrosine-
peptide 3b (166 mg, 0.30 mmol, 1.00 equiv) was added. The heteroarylzinc pivalate solution 1i in 
THF/nhexane (6.25 mL, 0.12 M, 0.75 mmol, 2.50 equiv) was added dropwise over 1 h and the reaction 
mixture stirred at 25 °C for further 3 h. After quenching, extracting and evaporating, the crude product 
was pre-purified by flash column chromatography. After final preparative reversed-phase HPLC-
chromatography (MeCN/H2O), the modified tyrosine-peptide 7f was obtained as colorless solid 
(141 mg, 0.26 mmol, 87% yield). 
1H-NMR (400 MHz, 80 °C, DMSO-d6, ppm) δ = 10.00 (s, 1H), 8.00 (d, J = 7.8 Hz, 1H), 7.71 (d, 
J = 2.2 Hz, 1H), 7.64 (dd, J = 7.5, 1.5 Hz, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.42 – 7.37 (m, 1H), 7.35 – 
7.20 (m, 7H), 7.04 (dd, J = 8.3, 2.3 Hz, 1H), 6.93 (d, J = 8.3 Hz, 1H), 5.01 (s, 2H), 4.53 (td, J = 8.0, 6.1 
Hz, 1H), 4.26 (dd, J = 8.6, 3.2 Hz, 1H), 3.61 (s, 3H), 3.49 – 3.32 (m, 2H), 3.05 – 2.92 (m, 2H), 2.14 – 
1.99 (m, 1H), 1.87 – 1.67 (m, 3H). 
13C-NMR (101 MHz, 80 °C, DMSO-d6, ppm) δ = 171.5, 171.3, 153.7, 153.1, 152.9, 152.1, 136.6, 
129.6, 129.0, 127.7, 127.5, 127.1, 126.8, 126.4, 123.6, 122.3, 120.5, 116.2, 115.9, 110.1, 105.0, 65.5, 
59.3, 53.3, 51.2, 46.4, 35.7, 30.1, 22.8. 
HRMS (ESI): m/z calc. for [M; C31H30N2O7]: 542.2053; found: 542.2024; m/z calc. for 
[M+H; C31H31N2O7
+]: 543.2126; found: 543.2132; calc. for [M-H; C31H29N2O7
-]: 541.1980; found: 
541.1988. 
IR (Diamond-ATR, neat): 𝜈 = 3278 (w), 2951 (w), 2359 (w), 1741 (m), 1658 (vs), 1650 (s), 1612 (m), 
1529 (m), 1511 (s), 1453 (s), 1414 (vs), 1354 (vs), 1300 (m), 1258 (vs), 1208 (s), 1179 (s), 1123 (s), 
1088 (m), 1029 (m), 821 (m), 743 (vs), 696 (s). 
M.p. 94.4 °C. 
C. EXPERIMENTAL PART    99 
Methyl ((S)-2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-3-(6-methoxypyridin-2-
yl)phenyl)propanoyl)-D-tryptophanate (8a) 
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before iodotyrosine-
peptide 3c (182 mg, 0.30 mmol, 1.00 equiv) was added. The pyridylzinc pivalate solution 1g in 
THF/nhexane (3.13 mL, 0.24 M, 0.75 mmol, 2.50 equiv) was added dropwise over 1 h and the reaction 
mixture stirred at 25 °C for further 3 h. After quenching, extracting and evaporating, the crude product 
was pre-purified by flash column chromatography. After final preparative reversed-phase HPLC-
chromatography (MeCN/H2O), the modified tyrosine-peptide 8a was obtained as colorless solid 
(165 mg, 0.28 mmol, 92% yield). 
1H-NMR (599 MHz, 80 °C, DMSO-d6, ppm) δ = 12.50 (s, 1H), 10.66 (s, 1H), 8.04 (d, J = 7.8 Hz, 
1H), 7.87 (dd, J = 8.3, 7.7 Hz, 1H), 7.73 (d, J = 2.2 Hz, 1H), 7.66 – 7.59 (m, 1H), 7.50 (d, J = 7.9 Hz, 
1H), 7.34 (dt, J = 8.0, 0.9 Hz, 1H), 7.12 (d, J = 2.4 Hz, 1H), 7.11 – 7.02 (m, 2H), 6.98 (ddd, J = 8.0, 
7.0, 1.1 Hz, 1H), 6.82 (dd, J = 8.3, 0.6 Hz, 1H), 6.77 (d, J = 8.3 Hz, 1H), 6.43 (s, 1H), 4.62 (td, J = 7.7, 
6.0 Hz, 1H), 4.25 (dd, J = 13.1, 8.4 Hz, 1H), 3.94 (s, 3H), 3.61 (s, 3H), 3.19 (dd, J = 14.6, 6.0 Hz, 1H), 
3.08 (dd, J = 14.2, 7.9 Hz, 1H), 2.86 (dd, J = 13.9, 4.7 Hz, 1H), 2.66 (dd, J = 13.9, 9.5 Hz, 1H), 1.28 (s, 
9H). 
13C-NMR (101 MHz, 80 °C, DMSO-d6, ppm) δ = 171.6, 171.1, 161.6, 156.1, 154.6, 154.3, 140.4, 
135.9, 131.6, 128.0, 127.7, 126.8, 123.2, 120.6, 118.9, 118.0, 117.6, 116.8, 112.6, 111.0, 109.0, 107.7, 
77.8, 55.4, 53.3, 52.7, 51.3, 36.7, 27.7, 27.1. 
HRMS (ESI): m/z calc. for [M+Na; C32H36N4NaO7]: 611.2482; found: 611.2475; calc. for [M-H; 
C32H35N4O7
-]: 587.2511; found: 5877.2517. 
IR (Diamond-ATR, neat): 𝜈 = 3326 (m), 2976 (w), 2359 (m), 2340 (m), 1734 (m), 1697 (s), 1660 (s), 
1598 (s), 1573 (s), 1494 (s), 1460 (vs), 1435 (s), 1391 (m), 1366 (m), 1337 (m), 1288 (m), 1264 (vs), 
1210 (s), 1165 (s), 1066 (w), 1024 (m), 809 (m), 746 (s), 668 (w). 
M.p. 209.6 °C. 
C. EXPERIMENTAL PART    100 
Methyl ((S)-2-((tert-butoxycarbonyl)amino)-3-(6-hydroxy-3',5'-dimethyl-[1,1'-biphenyl]-3-
yl)propanoyl)-D-tryptophanate (8b) 
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before iodotyrosine-
peptide 3c (182 mg, 0.30 mmol, 1.00 equiv) was added. The arylzinc pivalate solution 1j in THF 
(1.67 mL, 0.45 M, 0.75 mmol, 2.50 equiv) was added dropwise over 1 h and the reaction mixture stirred 
at 25 °C for further 3 h. After quenching, extracting and evaporating, the crude product was pre-purified 
by flash column chromatography. After final preparative reversed-phase HPLC-chromatography 
(MeCN/H2O), the modified tyrosine-peptide 8b was obtained as yellowish solid (129 mg, 0.22 mmol, 
72% yield). 
1H-NMR (400 MHz, 80 °C, DMSO-d6, ppm): δ = 10.67 (s, 1H), 8.84 (s, 1H), 8.02 (d, J = 7.8 Hz, 1H), 
7.49 (d, J = 7.8 Hz, 1H), 7.33 (dt, J = 8.2, 0.9 Hz, 1H), 7.13 (d, J = 1.6 Hz, 2H), 7.09 (dd, J = 6.9, 
2.1 Hz, 2H), 7.05 (dd, J = 8.3, 1.0 Hz, 1H), 6.98 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 6.91 (dt, J = 1.8, 0.9 Hz, 
1H), 6.88 (dd, J = 8.3, 2.2 Hz, 1H), 6.76 (d, J = 8.2 Hz, 1H), 6.40 (s, 1H), 4.60 (q, J = 7.5 Hz, 1H), 4.26 
– 4.16 (m, 1H), 3.59 (s, 3H), 3.17 (dd, J = 14.6, 6.1 Hz, 1H), 3.07 (dd, J = 14.6, 7.6 Hz, 1H), 2.81 (dd, 
J = 13.9, 4.6 Hz, 1H), 2.61 (dd, J = 13.9, 9.5 Hz, 1H), 2.30 (s, 6H), 1.30 (s, 9H). 
13C-NMR (101 MHz, 80 °C, DMSO-d6, ppm): δ = 171.6, 171.2, 154.5, 152.3, 138.4, 136.1, 135.9, 
130.8, 128.5, 128.1, 127.3, 127.3, 126.8, 126.5, 123.2, 120.6, 118.0, 117.6, 115.4, 111.0, 109.0, 77.8, 
55.4, 52.7, 51.2, 36.7, 27.7, 27.1, 20.6. 
HRMS (ESI): m/z calc. for [M+Na; C34H39N3NaO6
+]: 608.2731; found: 608.2730; m/z calc. for [M-H; 
C34H38N3O6
-]: 584.2766; found: 584.2790. 
IR (Diamond-ATR, neat): 𝜈 = 3406 (w), 3318 (w), 1691 (m), 1659 (s), 1602 (m), 1509 (s), 1499 (s), 
1455 (m), 1439 (m), 1366 (s), 1232 (s), 1161 (vs), 1077 (w), 1048 (m), 1011 (m), 851 (m), 807 (w), 
740 (s), 701 (w). 
M.p. 111.3 °C. 
C. EXPERIMENTAL PART    101 
Methyl ((S)-2-((tert-butoxycarbonyl)amino)-3-(3-(2,6-dimethoxypyrimidin-4-yl)-4-
hydroxyphenyl)propanoyl)-D-tryptophanate (8c) 
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before iodotyrosine-
peptide 3c (182 mg, 0.30 mmol, 1.00 equiv) was added. The pyrimidylzinc pivalate solution 1k in THF 
(1.17 mL, 0.64 M, 0.75 mmol, 2.50 equiv) was added dropwise over 1 h and the reaction mixture stirred 
at 25 °C for further 3 h. After quenching, extracting and evaporating, the crude product was pre-purified 
by flash column chromatography. After final preparative reversed-phase HPLC-chromatography 
(MeCN/H2O), the modified tyrosine-peptide 8c was obtained as beige solid (143 mg, 0.23 mmol, 
76% yield). 
1H-NMR (400 MHz, 80 °C, DMSO-d6, ppm): δ = 10.66 (s, 1H), 8.88 (s, 1H), 8.12 (s, 1H), 8.01 (d, 
J = 7.8 Hz, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.33 (dt, J = 8.1, 0.8 Hz, 1H), 7.10 (d, J = 2.4 Hz, 1H), 7.06 
(ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.00 – 6.95 (m, 2H), 6.93 (dd, J = 8.2, 2.3 Hz, 1H), 6.74 (d, J = 8.2 Hz, 
1H), 6.35 (s, 1H), 4.65 – 4.54 (m, 1H), 4.25 – 4.15 (m, 1H), 3.95 (s, 3H), 3.88 (s, 3H), 3.59 (s, 3H), 
3.16 (dd, J = 14.6, 6.0 Hz, 1H), 3.10 – 3.01 (m, 1H), 2.80 (dd, J = 14.0, 4.7 Hz, 1H), 2.61 (dd, J = 14.0, 
9.3 Hz, 1H), 1.30 (s, 9H). 
13C-NMR (101 MHz, 80 °C, DMSO-d6, ppm): δ = 171.6, 171.1, 167.8, 163.8, 158.1, 154.6, 153.1, 
135.9, 131.5, 129.4, 127.7, 126.8, 123.2, 120.6, 119.4, 118.0, 117.6, 115.0, 113.0, 111.0, 109.0, 77.8, 
55.4, 53.9, 53.1, 52.7, 51.2, 36.5, 27.7, 27.1. 
HRMS (ESI): m/z calc. for [M+Na; C32H37N5NaO8
+]: 642.2534; found: 642.2534; m/z calc. for [M+H; 
C32H38N5O8
+]: 620.2715; found: 620.2718; calc. for [M-H; C32H36N5O8
-]: 618.2569; found: 618.2588.  
IR (Diamond-ATR, neat): 𝜈 = 3324 (w), 2359 (w), 1737 (m), 1690 (m), 1659 (m), 1594 (m), 1560 
(m), 1501 (m), 1469 (s), 1392 (s), 1381 (s), 1235 (m), 1163 (s), 1079 (m), 1059 (m), 1014 (s), 801 (m), 
742 (m). 
M.p. 151.7 °C. 
C. EXPERIMENTAL PART    102 
Methyl ((S)-3-(3-(benzo[b]thiophen-3-yl)-4-hydroxyphenyl)-2-((tert-
butoxycarbonyl)amino)propanoyl)-D-tryptophanate (8d) 
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before iodotyrosine-
peptide 3c (182 mg, 0.30 mmol, 1.00 equiv) was added. The heteroarylzinc pivalate solution 1h in THF 
(1.53 mL, 0.49 M, 0.75 mmol, 2.50 equiv) was added dropwise over 1 h and the reaction mixture stirred 
at 25 °C for further 3 h. After quenching, extracting and evaporating, the crude product was pre-purified 
by flash column chromatography. After final preparative reversed-phase HPLC-chromatography 
(MeCN/H2O), the modified tyrosine-peptide 8d was obtained as colorless solid (68.0 mg, 0.11 mmol, 
38% yield). 
1H-NMR (400 MHz, 80 °C, DMSO-d6, ppm) δ = 10.64 (s, 1H), 8.98 (s, 1H), 8.02 (d, J = 7.8 Hz, 1H), 
7.99 – 7.96 (m, 1H), 7.70 – 7.62 (m, 1H), 7.55 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.40 – 7.30 (m, 3H), 
7.17 (d, J = 2.2 Hz, 1H), 7.09 (d, J = 2.4 Hz, 1H), 7.05 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 7.02 – 6.94 (m, 
2H), 6.86 (d, J = 8.2 Hz, 1H), 6.38 (s, 1H), 4.60 (td, J = 7.6, 6.0 Hz, 1H), 4.29 – 4.19 (m, 1H), 3.58 (s, 
3H), 3.17 (dd, J = 14.6, 6.1 Hz, 1H), 3.06 (dd, J = 14.7, 7.5 Hz, 1H), 2.85 (dd, J = 13.9, 4.6 Hz, 1H), 
2.63 (dd, J = 14.0, 9.5 Hz, 1H), 1.28 (s, 9H). 
13C-NMR (101 MHz, 80 °C, DMSO-d6, ppm) δ = 171.6, 171.1, 154.6, 153.0, 138.9, 138.2, 135.9, 
134.2, 131.4, 129.2, 127.9, 126.8, 124.0, 123.5, 123.4, 123.2, 123.2, 122.1, 121.5, 120.5, 118.0, 117.6, 
115.4, 111.0, 109.0, 77.8, 55.5, 52.6, 51.2, 36.6, 27.7, 27.1. 
HRMS (ESI): m/z calc. for [M+Na; C34H35N3NaO6S]: 636.2144; found: 363.2144; m/z calc. for 
[M+H; C34H36N3O6S
+]: 614.2319; found: 614.2322; calc. for [M-H; C34H34N3O6S
-]: 612.2174; found: 
612.2177. 
IR (Diamond-ATR, neat): 𝜈 = 3327 (w), 3007 (w), 2977 (w), 2359 (w), 1731 (m), 1694 (m), 1660 (s), 
1610 (w), 1496 (s), 1456 (m), 1434 (m), 1366 (m), 1246 (m), 1215 (m), 1162 (s), 1111 (w), 1059 (w), 
1020 (w), 818 (w), 753 (vs), 706 (vw), 667 (w). 
M.p. 129.6 °C. 
C. EXPERIMENTAL PART    103 
Benzyl (S)-2-(((S)-5-amino-1-(((R)-1-(((S)-1-(tert-butoxy)-3-methyl-1-oxobutan-2-yl)amino)-3-(4-
hydroxy-3-(6-methoxypyridin-2-yl)phenyl)-1-oxopropan-2-yl)amino)-1,5-dioxopentan-2-
yl)carbamoyl)pyrrolidine-1-carboxylate (9a) 
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before iodotyrosine-
peptide 3d (247 mg, 0.30 mmol, 1.00 equiv) was added. The pyridylzinc pivalate solution 1g in 
THF/nhexane (3.13 mL, 0.24 M, 0.75 mmol, 2.50 equiv) was added dropwise over 1 h and the reaction 
mixture stirred at 25 °C for further 3 h. After quenching, extracting and evaporating, the crude product 
was pre-purified by flash column chromatography. After final preparative reversed-phase HPLC-
chromatography (MeCN/H2O), the modified tyrosine-peptide 9a was obtained as colorless solid 
(120 mg, 0.15 mmol, 50% yield). 
1H-NMR (400 MHz, 80 °C, DMSO-d6, ppm): δ = 12.55 (s, 1H), 7.94 – 7.86 (m, 2H), 7.83 (d, 
J = 8.2 Hz, 1H), 7.78 – 7.72 (m, 2H), 7.67 (d, J = 7.7 Hz, 1H), 7.33 (d, J = 4.9 Hz, 4H), 7.29 (t, J = 4.2 
Hz, 1H), 7.16 (dd, J = 8.3, 2.1 Hz, 1H), 6.81 (t, J = 8.1 Hz, 2H), 6.59 (s, 2H), 5.13 – 4.99 (m, 2H), 4.72 
– 4.63 (m, 1H), 4.27 – 4.18 (m, 2H), 4.07 (dd, J = 8.3, 5.8 Hz, 1H), 3.95 (s, 3H), 3.49 – 3.36 (m, 2H), 
3.07 – 2.99 (m, 2H), 2.84 (dd, J = 14.0, 9.0 Hz, 1H), 2.14 – 1.92 (m, 4H), 1.88 – 1.61 (m, 4H), 1.41 (s, 
9H), 0.87 – 0.78 (m, 6H). 
13C-NMR (101 MHz, 80 °C, DMSO-d6, ppm): δ = 173.3, 171.5, 170.6, 170.6, 169.8, 161.5, 156.2, 
154.2, 153.8, 140.4, 136.6, 131.6, 127.9, 127.7, 127.6, 127.2, 126.9, 119.0, 117.0, 112.7, 107.7, 80.3, 
65.7, 59.4, 57.7, 53.7, 53.3, 52.3, 46.4, 37.0, 37.0, 31.1, 29.7, 27.4, 27.3, 23.0, 18.3, 17.6. 
HRMS (ESI): m/z calc. for m/z calc. for [M+H; C42H55N6O10
+]: 803.3974; found: 803.3971; calc. for 
[M+2H; C42H56N6O10
2+]: 804.4047; found: 804.4010. 
IR (Diamond-ATR, neat): 𝜈 = 3285 (w), 2973 (w), 2359 (m), 2340 (m), 1732 (w), 1699 (m), 1652 (s), 
1638 (vs), 1540 (m), 1464 (m), 1419 (m), 1392 (w), 1358 (w), 1337 (w), 1286 (w), 1266 (m), 1210 (w), 
1160 (w), 668 (w). 
M.p. 175.7 °C. 
C. EXPERIMENTAL PART    104 
Benzyl (S)-2-(((S)-5-amino-1-(((R)-1-(((S)-1-(tert-butoxy)-3-methyl-1-oxobutan-2-yl)amino)-3-(6-
hydroxy-4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)-1-oxopropan-2-yl)amino)-1,5-dioxopentan-2-
yl)carbamoyl)pyrrolidine-1-carboxylate (9b) 
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before iodotyrosine-
peptide 3d (247 mg, 0.30 mmol, 1.00 equiv) was added. The arylzinc pivalate solution 1f in THF 
(1.09 mL, 0.69 M, 0.75 mmol, 2.50 equiv) was added dropwise over 1 h and the reaction mixture stirred 
at 25 °C for further 3 h. After quenching, extracting and evaporating, the crude product was pre-purified 
by flash column chromatography. After final preparative reversed-phase HPLC-chromatography 
(MeCN/H2O), the modified tyrosine-peptide 9b was obtained as colorless solid (202 mg, 0.24 mmol, 
80%). 
1H-NMR (400 MHz, 80 °C, DMSO-d6, ppm): δ = 9.24 (s, 1H), 7.91 (d, J = 7.8 Hz, 1H), 7.82 – 7.71 
(m, 4H), 7.74 – 7.67 (m, 2H), 7.40 – 7.24 (m, 5H), 7.19 (d, J = 2.2 Hz, 1H), 7.07 (dd, J = 8.3, 2.2 Hz, 
1H), 6.86 (d, J = 8.2 Hz, 1H), 6.62 (s, 2H), 5.13 – 5.01 (m, 2H), 4.67 (q, J = 7.9 Hz, 1H), 4.29 – 4.18 
(m, 2H), 4.06 (dd, J = 8.4, 5.8 Hz, 1H), 3.50 – 3.37 (m, 2H), 2.99 (dd, J = 13.9, 5.6 Hz, 1H), 2.81 (dd, 
J = 13.9, 8.7 Hz, 1H), 2.14 – 2.04 (m, 1H), 2.04 – 1.94 (m, 3H), 1.89 – 1.74 (m, 4H), 1.74 – 1.63 (m, 
1H), 1.41 (s, 9H), 0.81 (dd, J = 6.8, 5.8 Hz, 6H). 
13C-NMR (101 MHz, 80 °C, DMSO-d6, ppm): δ = 173.4, 171.5, 170.6, 170.6, 169.8, 153.8, 152.6, 
142.7, 136.7, 130.6, 129.7, 129.3, 128.1, 127.8, 127.2, 126.9, 126.6 (q, J = 31.9), 126.3 (q, J = 271.8), 
126.3, 125.5, 124.4, 124.3, 124.1 (q, J = 3.9), 115.8, 80.3, 65.6, 59.4, 57.6, 53.7, 52.3, 46.4, 36.9, 31.1, 
29.7, 27.5, 27.4, 23.2, 18.3, 17.6. 
19F-NMR (377 MHz, 80 °C, DMSO-d6): δ = –60.9. 
HRMS (ESI): m/z calc. for [M+Na; C43H52F3N5NaO9
+]: 862.3615; found: 862.3614; calc. for [M-H; 
C43H51F3N5O9
-]: 838.3644; found: 838.3667.  
IR (Diamond-ATR, neat): 𝜈 = 3294 (w), 2969 (w), 1657 (s), 1650 (s), 1618 (m), 1523 (m), 1508 (m), 
1424 (m), 1401 (m), 1358 (m), 1325 (vs), 1278 (m), 1215 (m), 1163 (s), 1122 (s), 1068 (m), 1017 (w), 
985 (vw), 845 (w), 755 (m), 697 (w). 
M.p. 180.2 °C. 
C. EXPERIMENTAL PART    105 
Benzyl (S)-2-(((S)-5-amino-1-(((R)-1-(((S)-1-(tert-butoxy)-3-methyl-1-oxobutan-2-yl)amino)-3-
(3'-cyano-6-hydroxy-[1,1'-biphenyl]-3-yl)-1-oxopropan-2-yl)amino)-1,5-dioxopentan-2-
yl)carbamoyl)pyrrolidine-1-carboxylate (9c) 
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before iodotyrosine-
peptide 3d (247 mg, 0.30 mmol, 1.00 equiv) was added. The arylzinc pivalate solution 1l in THF 
(1.70 mL, 0.44 M, 0.75 mmol, 2.50 equiv) was added dropwise over 1 h and the reaction mixture stirred 
at 25 °C for further 3 h. After quenching, extracting and evaporating, the crude product was pre-purified 
by flash column chromatography. After final preparative reversed-phase HPLC-chromatography 
(MeCN/H2O), the modified tyrosine-peptide 9c was obtained as colorless solid (215 mg, 0.27 mmol, 
89% yield). 
1H-NMR (400 MHz, 80 °C, DMSO-d6, ppm): δ = 9.31 (s, 1H), 7.96 (t, J = 1.8 Hz, 1H), 7.95 – 7.88 
(m, 2H), 7.78 (d, J = 8.3 Hz, 2H), 7.70 (dt, J = 7.7, 1.4 Hz, 1H), 7.59 (td, J = 7.8, 0.6 Hz, 1H), 7.38 – 
7.24 (m, 5H), 7.20 (d, J = 2.2 Hz, 1H), 7.06 (dd, J = 8.3, 2.2 Hz, 1H), 6.86 (d, J = 8.2 Hz, 1H), 6.81 – 
6.30 (m, 2H), 5.07 (s, 2H), 4.69 (q, J = 7.7 Hz, 1H), 4.23 (t, J = 7.3, 2H), 4.06 (dd, J = 8.4, 5.8 Hz, 1H), 
3.51 – 3.35 (m, 2H), 2.98 (dd, J = 13.9, 5.7 Hz, 1H), 2.81 (dd, J = 13.9, 8.7 Hz, 1H), 2.15 – 2.05 (m, 
1H), 2.04 – 1.92 (m, 3H), 1.89 – 1.74 (m, 4H), 1.70 (d, J = 8.1 Hz, 1H), 1.41 (s, 9H), 0.81 (dd, J = 7.7, 
6.8 Hz, 6H). 
13C-NMR (101 MHz, 80 °C, DMSO-d6, ppm): δ = 173.4, 171.5, 170.6, 170.6, 169.8, 153.8, 152.5, 
139.6, 136.7, 133.5, 132.0, 130.6, 129.8, 129.5, 128.7, 128.2, 127.9, 127.2, 126.9, 124.8, 118.5, 115.8, 
110.8, 80.3, 65.7, 59.4, 57.6, 53.6, 52.3, 46.4, 37.0, 36.9, 31.1, 29.7, 27.5, 27.4, 23.0, 18.3, 17.6. 
HRMS (ESI): m/z calc. for [M+Na; C43H52N6NaO9
+]: 819.3688; found: 819.3701; m/z calc. for [M+H; 
C43H53N6O9
+]: 797.3869; found 797.3880; m/z calc. for [M-H; C43H51F3N6O9
-]: 795.3723; found: 
795.3743.  
IR (Diamond-ATR, neat): 𝜈 = 3288 (w), 2968 (w), 2358 (w), 2228 (w), 1652 (vs), 1538 (m), 1511 (s), 
1447 (m), 1418 (m), 1395 (m), 1358 (m), 1310 (m), 1272 (m), 1258 (m), 1213 (m), 1145 (m), 693 (m). 
M.p. 129.0 °C. 
C. EXPERIMENTAL PART    106 
Methyl (8S,11S)-16-hydroxy-15-(6-methoxypyridin-2-yl)-8-methyl-6,9-dioxo-4-oxa-7,10-diaza-
1(1,3),3(1,2)-dibenzenacyclododecaphane-11-carboxylate (10a)  
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before iodotyrosine-
peptide 3e (162 mg, 0.30 mmol, 1.00 equiv) was added. The pyridylzinc pivalate solution 1g in 
THF/nhexane (3.13 mL, 0.24 M, 0.75 mmol, 2.50 equiv) was added dropwise over 1 h and the reaction 
mixture stirred at 25 °C for further 3 h. After quenching, extracting and evaporating, the crude product 
was pre-purified by flash column chromatography. After final preparative reversed-phase HPLC-
chromatography (MeCN/H2O), the modified tyrosine-peptide 10a was obtained as colorless solid 
(130 mg, 0.25 mmol, 82% yield). 
1H-NMR (400 MHz, DMSO-d6, ppm): δ = 13.69 (s, 1H), 8.17 (d, J = 8.4 Hz, 1H), 7.92 (t, J = 8.0 Hz, 
1H), 7.77 (d, J = 7.8 Hz, 1H), 7.72 (d, J = 2.1 Hz, 1H), 7.39 (dd, J = 7.5, 1.8 Hz, 1H), 7.26 (d, J = 8.8 Hz, 
1H), 7.22 (td, J = 7.9, 7.4, 1.8 Hz, 1H), 7.06 (d, J = 2.0 Hz, 1H), 7.03 (d, J = 8.1 Hz, 1H), 6.93 (t, J = 7.4 
Hz, 1H), 6.88 (d, J = 8.3 Hz, 1H), 4.70 (d, J = 14.3 Hz, 1H), 4.53 (d, J = 14.4 Hz, 1H), 4.51 – 4.46 (m, 
1H), 4.46 – 4.41 (m, 1H), 4.08 (d, J = 14.6 Hz, 1H), 3.97 (s, 3H), 3.89 (d, J = 14.7 Hz, 1H), 3.69 (s, 
3H), 3.04 (dd, J = 13.7, 3.3 Hz, 1H), 2.74 (dd, J = 13.6, 11.4 Hz, 1H), 1.02 (d, J = 6.9 Hz, 3H). 
13C-NMR (101 MHz, DMSO-d6, ppm): δ = 172.0, 171.0, 167.6, 161.5, 155.6, 155.0, 154.6, 141.3, 
132.8, 132.0, 128.4, 127.8, 127.7, 127.5, 125.4, 121.0, 118.1, 112.8, 111.4, 108.2, 66.7, 54.0, 53.9, 52.0, 
47.0, 35.7, 29.9, 16.4. 
HRMS (ESI): m/z calc. for [M+H, C28H30N3O7
+]: 520.2078. found: 520.2083  
IR (Diamond-ATR, neat): 𝜈 = 3295 (w), 3276 (w), 1730 (m), 1668 (m), 1650 (vs), 1594 (m), 1545 
(s), 1493 (m), 1465 (m), 1451 (s), 1433 (m), 1355 (w), 1302 (m), 1263 (s), 1243 (m), 1198 (s), 1176 
(m), 1121 (m), 1103 (m), 1054 (m), 1045 (w), 1034 (m), 999 (m), 923 (w), 828 (m), 810 (m), 745 (s), 
736 (s), 692 (m). 
M.p. 284.6 °C. 
C. EXPERIMENTAL PART    107 
Methyl (8S,11S)-16-hydroxy-8-methyl-6,9-dioxo-15-(pyridin-3-yl)-4-oxa-7,10-diaza-1(1,3),3(1,2)-
dibenzenacyclododecaphane-11-carboxylate (10b)  
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before iodotyrosine-
peptide 3e (162 mg, 0.30 mmol, 1.00 equiv) was added. The zinc pivalate solution 1d in THF (1.79 mL, 
0.42 M, 0.75 mmol, 2.50 equiv) was added dropwise over 1 h and the reaction mixture stirred at 25 °C 
for further 3 h. After quenching, extracting and evaporating, the crude product was pre-purified by flash 
column chromatography. After final preparative reversed-phase HPLC-chromatography (MeCN/H2O), 
the modified tyrosine-peptide 10b was obtained as colorless solid (78 mg, 0.16 mmol, 53% yield). 
1H-NMR (400 MHz, DMSO-d6, ppm): δ = 8.67 (dd, J = 2.3, 0.9 Hz, 1H), 8.50 (dd, J = 4.8, 1.7 Hz, 
1H), 8.06 (d, J = 8.7 Hz, 1H), 7.87 (ddd, J = 7.9, 2.3, 1.7 Hz, 1H), 7.43 (ddd, J = 7.9, 4.8, 0.9 Hz, 1H), 
7.34 (dd, J = 7.4, 1.8 Hz, 1H), 7.26 (ddd, J = 8.2, 7.4, 1.8 Hz, 1H), 7.09 (dd, J = 8.4, 1.1 Hz, 1H), 7.03 
(d, J = 9.0 Hz, 1H), 6.98 (d, J = 2.2 Hz, 1H), 6.95 (td, J = 7.4, 1.1 Hz, 1H), 6.82 (d, J = 2.2 Hz, 1H), 
4.75 (d, J = 14.2 Hz, 1H), 4.60 – 4.41 (m, 3H), 4.15 (d, J = 15.3 Hz, 1H), 3.86 (d, J = 15.3 Hz, 1H), 
3.66 (s, 3H), 3.01 (dd, J = 13.6, 3.6 Hz, 1H), 2.69 (dd, J = 13.6, 11.5 Hz, 1H), 1.01 (d, J = 7.0 Hz, 3H). 
13C-NMR (101 MHz, DMSO-d6, ppm): δ = 171.9, 171.0, 167.5, 155.6, 150.3, 149.7, 147.6, 136.5, 
134.6, 131.8, 130.4, 129.1, 128.9, 128.7, 127.8, 127.3, 126.5, 123.2, 121.0, 111.4, 66.5, 53.5, 52.0, 46.8, 
35.8, 30.6, 16.6. 
HRMS (ESI): m/z calc. for [M+H, C27H28N3O6
+]: 490.1973; found: 490.1977. 
IR (Diamond-ATR, neat): 𝜈 = 3370 (m), 3008 (w), 2930 (w), 1733 (m), 1668 (vs), 1537 (s), 1533 (s), 
1492 (m), 1454 (m), 1234 (s), 1217 (s), 1165 (m), 1117 (m), 752 (s). 
M.p. 145.0 °C. 
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Methyl (8S,11S)-16-hydroxy-8-methyl-6,9-dioxo-15-(pyridin-4-yl)-4-oxa-7,10-diaza-1(1,3),3(1,2)-
dibenzenacyclododecaphane-11-carboxylate (10c)  
 
According to TP5, Pd(OAc)2 (2.69 mg, 12.0 µmol, 4.00 mol%), SPhos (9.85 mg, 24.0 µmol, 
8.00 mol%) and freshly distilled THF (0.6 mL) were mixed and stirred for 10 min, before iodotyrosine-
peptide 3e (162 mg, 0.30 mmol, 1.00 equiv) was added. The zinc pivalate solution 1e in THF (3.26 mL, 
0.23 M, 0.75 mmol, 2.50 equiv) was added dropwise over 1 h and the reaction mixture stirred at 25 °C 
for further 3 h. After quenching, extracting and evaporating, the crude product was pre-purified by flash 
column chromatography. After final preparative reversed-phase HPLC-chromatography (MeCN/H2O), 
the modified tyrosine-peptide 10c was obtained as colorless solid (98 mg, 0.20 mmol, 67% yield). 
1H-NMR (400 MHz, DMSO-d6, ppm): δ = 8.66 (s, 1H), 8.59 (dd, J = 4.4, 1.6 Hz, 2H), 8.07 (d, 
J = 8.6 Hz, 1H), 7.51 (dd, J = 4.4, 1.6 Hz, 2H), 7.34 (dd, J = 7.5, 1.8 Hz, 1H), 7.26 (ddd, J = 8.2, 7.4, 
1.8 Hz, 1H), 7.11 – 7.05 (m, 2H), 7.02 (d, J = 2.2 Hz, 1H), 6.95 (td, J = 7.4, 1.1 Hz, 1H), 6.86 (d, J = 
2.2 Hz, 1H), 4.74 (d, J = 14.2 Hz, 1H), 4.57 – 4.40 (m, 3H), 4.15 (d, J = 15.3 Hz, 1H), 3.86 (d, J = 15.3 
Hz, 1H), f 3.01 (dd, J = 13.7, 3.5 Hz, 1H), 2.69 (dd, J = 13.6, 11.5 Hz, 1H), 1.01 (d, J = 6.9 Hz, 3H). 
13C-NMR (101 MHz, DMSO-d6, ppm): δ = 171.9, 171.0, 167.5, 155.6, 150.2, 149.3, 146.4, 131.8, 
131.1, 129.3, 129.1, 128.5, 127.8, 127.3, 127.1, 124.1, 121.0, 111.5, 66.6, 53.5, 52.0, 46.8, 35.7, 30.5, 
16.5. 
HRMS (ESI): m/z calc. for [M+H, C27H28N3O6
+]: 490.1973; found: 490.1976. 
IR (Diamond-ATR, neat): 𝜈 = 3280 (m), 3075 (w), 2950 (w), 2358 (w), 2340 (w), 1741 (m), 1644 
(vs), 1603 (m), 1544 (s), 1493 (m), 1471 (m), 1450 (m), 1410 (w), 1372 (w), 1326 (w), 1281 (m), 1243 
(s), 1213 (s), 1116 (m), 1054 (m), 1002 (w), 919 (w), 832 (w), 747 (s), 705 (w), 667 (w). 
M.p. 254.8 °C. 
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2.9 Negishi Cross-Coupling reactions of Iodophenylalanine containing Cyclopeptides 
with Pyridylzinc Pivalates 
(3S,6S,9R,12S,15S,20aR)-3-(2-iodobenzyl)-6,9,12,15-tetraisobutyl-8,11-
dimethyltetradecahydropyrrolo[1,2-a][1,4,7,10,13,16]hexaazacyclooctadecine-1,4,7,10,13,16-
hexaone (11) 
 
Cyclopeptide 11 was prepared by standard methods.127 
1H-NMR (599 MHz, CDCl3, ppm): δ = 7.80 (dd, J = 8.0, 1.3 Hz, 1H), 7.58 (d, J = 9.3 Hz, 1H), 7.29 
(dd, J = 7.7, 1.8 Hz, 1H), 7.24 (td, J = 7.5, 1.3 Hz, 1H), 7.04 (d, J = 9.3 Hz, 1H), 6.90 (td, J = 7.6, 
1.7 Hz, 1H), 6.23 (d, J = 9.7 Hz, 1H), 5.29 (dd, J = 11.7, 4.1 Hz, 1H), 5.13 (dt, J = 9.3, 7.2 Hz, 1H), 
4.92 – 4.88 (m, 1H), 4.88 – 4.83 (m, 2H), 4.05 (dd, J = 7.8, 4.8 Hz, 1H), 3.68 (ddd, J = 10.2, 7.5, 5.7 Hz, 
1H), 3.54 (dt, J = 10.3, 6.9 Hz, 1H), 3.48 (dd, J = 14.4, 4.8 Hz, 1H), 3.30 (dd, J = 14.4, 8.1 Hz, 1H), 
3.23 (s, 3H), 3.01 (s, 3H), 2.21 – 2.12 (m, 1H), 1.99 – 1.89 (m, 3H), 1.89 – 1.82 (m, 2H), 1.79 (dt, 
J = 13.2, 6.7 Hz, 1H), 1.71 (dt, J = 14.0, 7.1, 1H), 1.64 – 1.60 (m, 1H), 1.58 – 1.44 (m, 5H), 1.44 – 1.32 
(m, 2H), 1.00 (d, J = 6.6 Hz, 3H), 0.97 (d, J = 6.6 Hz, 3H), 0.95 – 0.90 (m, 15H), 0.87 (d, J = 6.5 Hz, 
3H). 
13C-NMR (151 MHz, CDCl3, ppm): δ = 174.1, 174.0, 171.3, 170.6, 170.0, 169.4, 140.4, 139.8, 130.7, 
128.9, 128.7, 101.9, 61.2, 55.0, 53.8, 52.8, 48.6, 47.9, 47.8, 42.3, 41.6, 40.7, 37.6, 36.3, 31.5, 30.8, 28.1, 
25.4, 25.4, 25.3, 25.0, 24.8, 23.7, 23.4, 23.0, 22.9, 22.9, 22.0, 21.3. 
HRMS (ESI): m/z calc. for [M+Na; C40H63IN6NaO6
+]: 873.3751; found: 873.3759; m/z calc. for 
[M+H; C40H64IN6O6
+]: 851.3927; found: 851.3943. 
IR (Diamond-ATR, neat): 𝜈 = 3302 (w), 2956 (m), 2933 (w), 2871 (w), 1626 (vs), 1516 (m), 1466 
(m), 1444 (m), 1386 (w), 1368 (w), 1340 (w), 1322 (w), 1294 (w), 1281 (w), 1238 (w), 1205 (w), 1171 
(w), 1128 (w), 1099 (w), 1011 (w), 921 (w), 730 (s). 
M.p. 190.4 °C. 
  
 
127 T. Vorherr, I. Lewis, J. Berghausen, S. Desrayaud, M. Schaefer, Int. J. Pept. Res. Ther. 2018, 24, 35. 
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(3S,6S,9R,12S,15S,20aR)-3-(3-iodobenzyl)-6,9,12,15-tetraisobutyl-8,11-
dimethyltetradecahydropyrrolo[1,2-a][1,4,7,10,13,16]hexaazacyclooctadecine-1,4,7,10,13,16-
hexaone (12) 
 
Cyclopeptide 12 was prepared by standard methods.128 
1H-NMR (599 MHz, CDCl3, ppm): δ = 7.56 (d, J = 8.0 Hz, 1H), 7.54 (s, 1H), 7.51 (d, J = 9.3 Hz, 1H), 
7.15 (d, J = 7.6 Hz, 1H), 7.07 (d, J = 9.4 Hz, 1H), 7.00 (t, J = 7.7 Hz, 1H), 6.14 (d, J = 9.7 Hz, 1H), 
5.28 (dd, J = 11.7, 4.1 Hz, 1H), 5.12 (dt, J = 9.4, 7.2 Hz, 1H), 4.90 (dt, J = 9.6, 7.1 Hz, 1H), 4.86 – 4.77 
(m, 2H), 4.03 (dd, J = 8.0, 4.6 Hz, 1H), 3.69 (ddd, J = 10.4, 7.5, 5.7 Hz, 1H), 3.56 (dt, J = 10.4, 7.0 Hz, 
1H), 3.29 (dd, J = 14.1, 6.7 Hz, 1H), 3.22 (s, 3H), 3.05 – 3.00 (m, 1H), 3.00 (s, 3H), 2.19 (dq, J = 12.1, 
7.2 Hz, 1H), 2.11 – 2.03 (m, 1H), 2.00 – 1.92 (m, 2H), 1.91 – 1.82 (m, 2H), 1.79 (dt, J = 13.4, 6.9 Hz, 
1H), 1.69 (dt, J = 13.9, 7.2 Hz, 1H), 1.62 – 1.46 (m, 5H), 1.46 – 1.33 (m, 3H), 1.00 (d, J = 6.6 Hz, 3H), 
0.97 (d, J = 6.6 Hz, 3H), 0.93 (td, J = 6.8, 3.5 Hz, 15H), 0.87 (d, J = 6.5 Hz, 3H). 
13C-NMR (151 MHz, CDCl3, ppm): δ = 174.2, 174.1, 171.4, 170.7, 170.0, 169.2, 139.4, 138.5, 136.3, 
130.4, 128.9, 94.8, 61.1, 55.1, 53.3, 52.9, 48.6, 47.9, 47.8, 42.4, 41.4, 38.7, 37.6, 36.5, 36.3, 31.5, 30.8, 
28.3, 25.5, 25.4, 25.3, 24.9, 24.8, 23.7, 23.4, 23.0, 23.0, 22.9, 22.0, 21.3. 
HRMS (ESI): m/z calc. for [M+Na; C40H63IN6NaO6
+]: 873.3751; found: 873.3755; m/z calc. for 
[M+H; C40H64IN6O6
+]: 851.3927; found: 851.3942. 
IR (Diamond-ATR, neat): 𝜈 = 3298 (w), 2953 (m), 2868 (w), 2359 (w), 2339 (w), 1625 (vs), 1508 
(m), 1466 (m), 1445 (m), 1419 (m), 1385 (m), 1366 (w), 1282 (w), 1202 (w), 1170 (w), 1127 (w), 1098 
(w), 1065 (w), 772 (w). 
M.p. 112.4 °C. 
 
128 T. Vorherr, I. Lewis, J. Berghausen, S. Desrayaud, M. Schaefer, Int. J. Pept. Res. Ther. 2018, 24, 35. 
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(3S,6S,9R,12S,15S,20aR)-3-(4-iodobenzyl)-6,9,12,15-tetraisobutyl-8,11-
dimethyltetradecahydropyrrolo[1,2-a][1,4,7,10,13,16]hexaazacyclooctadecine-1,4,7,10,13,16-
hexaone (13) 
 
Cyclopeptide 13 was prepared by standard methods.129 
1H-NMR (599 MHz, CDCl3, ppm): δ = 7.61 – 7.57 (m, 2H), 7.50 (d, J = 9.4 Hz, 1H), 7.07 (d, 
J = 9.5 Hz, 1H), 6.96 – 6.92 (m, 2H), 6.16 (d, J = 9.7 Hz, 1H), 5.28 (dd, J = 11.7, 4.1 Hz, 1H), 5.09 
(ddd, J = 9.4, 7.8, 6.7 Hz, 1H), 4.91 (dt, J = 9.6, 7.1 Hz, 1H), 4.85 – 4.78 (m, 2H), 4.02 (dd, J = 7.9, 4.6 
Hz, 1H), 3.70 (ddd, J = 10.4, 7.5, 5.6 Hz, 1H), 3.56 (dt, J = 10.4, 7.0 Hz, 1H), 3.28 (dd, J = 14.2, 6.7 
Hz, 1H), 3.23 (s, 3H), 3.02 (dd, J = 9.3, 5.1 Hz, 1H), 3.00 (s, 3H), 2.21 (dp, J = 12.3, 7.0 Hz, 1H), 2.09 
– 2.02 (m, 3H), 1.99 – 1.91 (m, 2H), 1.91 – 1.76 (m, 3H), 1.64 – 1.46 (m, 5H), 1.45 – 1.31 (m, 2H), 
1.01 (d, J = 6.6 Hz, 3H), 0.95 – 0.91 (m, 15H), 0.89 (d, J = 6.7 Hz, 3H), 0.87 (d, J = 6.5 Hz, 3H). 
13C-NMR (151 MHz, CDCl3, ppm): δ = 174.3, 174.1, 171.4, 170.9, 169.9, 169.3, 137.8, 136.5, 131.6, 
92.5, 61.1, 55.1, 53.3, 53.1, 48.5, 47.8, 47.8, 42.2, 41.3, 37.6, 36.6, 36.2, 31.5, 30.8, 28.3, 25.5, 25.4, 
25.3, 25.0, 24.6, 23.7, 23.3, 23.0, 23.0, 22.9, 22.8, 22.1, 21.2. 
HRMS (ESI): m/z calc. for [M+Na; C40H63IN6NaO6
+]: 873.3751; found: 873.3752; m/z calc. for 
[M+H; C40H64IN6O6
+]: 851.3927; found: 851.4205. 
IR (Diamond-ATR, neat): 𝜈 = 3521 (vw), 3316 (w), 2953 (w), 2869 (w), 2360 (w), 2339 (w), 1667 
(m), 1632 (vs), 1556 (w), 1516 (m), 1447 (m), 1402 (w), 1386 (w), 1367 (w), 1296 (w), 1263 (w), 1235 
(w), 1098 (w), 1006 (w), 806 (w), 761 (w). 
M.p. 134.5 °C. 
 
129 T. Vorherr, I. Lewis, J. Berghausen, S. Desrayaud, M. Schaefer, Int. J. Pept. Res. Ther. 2018, 24, 35. 
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(3S,6S,9R,12S,15S,20aR)-6,9,12,15-tetraisobutyl-8,11-dimethyl-3-(2-(pyridin-2-
yl)benzyl)tetradecahydropyrrolo[1,2-a][1,4,7,10,13,16]hexaazacyclooctadecine-1,4,7,10,13,16-
hexaone (14a) 
 
According to a modified version of TP8, Pd(OAc)2 (1.42 mg, 6.40 µmol, 8.00 mol%) and SPhos (5.26 
mg, 12.8 µmol, 16.00 mol%) were dissolved in freshly distilled THF (0.8 mL) and the catalyst mixture 
was stirred for 10 min. The ortho-iodophenylalanine cyclopeptide 11 (68.1 mg, 80.0 µmol, 1.0 equiv) 
was added and the mixture heated to 60 °C. Afterwards, the 2-pyridylzinc pivalate solution 1c in THF 
(0.46 mL, 0.52 M, 0.24 mmol, 3.00 equiv) was added dropwise over 1 h and the reaction stirred for 
further 23 h at this temperature. After quenching, extracting and evaporating, the crude product was 
flushed through a silica-plug with acetonitrile. Purification via preparative reversed-phase HPLC-
chromatography (MeCN/H2O) yielded the modified cyclopeptide 14a as colorless solid (24.4 mg, 
30.4 µmol, 38% yield). 
1H-NMR (400 MHz, CDCl3, ppm) δ = 10.64 (s, 1H), 8.77 (ddd, J = 5.0, 1.9, 0.9 Hz, 1H), 7.88 (s, 1H), 
7.76 (d, J = 9.5 Hz, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.48 (d, J = 7.5 Hz, 1H), 7.42 – 7.34 (m, 1H), 7.35 – 
7.27 (m, 2H), 7.04 (d, J = 9.3 Hz, 1H), 5.33 (dd, J = 11.7, 4.1 Hz, 1H), 5.04 (ddd, J = 9.6, 8.1, 6.3 Hz, 
1H), 4.86 (dt, J = 9.2, 6.8 Hz, 2H), 4.57 (s, 1H), 4.05 (t, J = 6.2 Hz, 1H), 3.56 (ddt, J = 22.1, 10.6, 5.5 
Hz, 2H), 3.33 (dd, J = 13.8, 4.7 Hz, 1H), 3.27 (s, 3H), 3.05 (s, 3H), 2.86 (t, J = 13.0 Hz, 1H), 2.36 (s, 
2H), 2.08 (p, J = 6.6, 5.8 Hz, 1H), 1.98 (ddd, J = 14.6, 10.5, 4.2 Hz, 1H), 1.85 (ddd, J = 14.8, 9.6, 5.5 
Hz, 2H), 1.79 – 1.50 (m, 9H), 1.49 – 1.32 (m, 2H), 1.00 (dd, J = 6.5, 5.7 Hz, 6H), 0.97 – 0.93 (m, 6H), 
0.93 (d, J = 2.1 Hz, 3H), 0.91 – 0.83 (m, 9H). 
13C-NMR (101 MHz, CDCl3, ppm) δ = 174.1, 174.1, 172.2, 170.9, 170.4, 169.8, 159.2, 147.8, 138.1, 
136.6, 130.7, 130.0, 129.5, 126.9, 125.2, 122.4, 61.0, 56.0, 55.1, 52.7, 48.8, 47.8, 47.7, 42.1, 41.4, 37.8, 
36.2, 33.9, 31.3, 30.9, 29.8, 28.5, 25.4, 25.3, 25.3, 25.1, 24.7, 23.8, 23.3, 23.2, 23.1, 23.0, 22.7, 22.2, 
21.3. 
HRMS (ESI): calcd. [M+H, C45H68O6N7]: 802.5226, found: 802.5212; calcd. [M-H, C45H66O6N7]: 
800.5080, found: 800.5086: calcd. [M, C45H67O6N7]: 801.5153, found: 801.5121. 
IR (ATR, cm-1) 𝜈 = 3494 (vw), 3304 (w), 2954 (m), 2869 (w), 2360 (vw), 1664 (m), 1627 (vs), 
1519 (m), 1470 (m), 1443 (m), 1386 (w), 1367 (w), 1265 (w), 1098 (w), 1024 (vw), 999 (vw), 758 (w). 
M.p. 115.4 °C. 
C. EXPERIMENTAL PART    113 
(3S,6S,9R,12S,15S,20aR)-6,9,12,15-tetraisobutyl-8,11-dimethyl-3-(2-(pyridin-3-
yl)benzyl)tetradecahydropyrrolo[1,2-a][1,4,7,10,13,16]hexaazacyclooctadecine-1,4,7,10,13,16-
hexaone (14b) 
 
According to TP8, Pd(OAc)2 (0.72 mg, 3.20 µmol, 4.00 mol%) and SPhos (2.63 mg, 6.40 µmol, 
8.00 mol%) were dissolved in freshly distilled THF (0.8 mL) and the catalyst mixture was stirred for 
10 min, before ortho-iodophenylalanine cyclopeptide 11 (68.1 mg, 80.0 µmol, 1.0 equiv) was inserted. 
Afterwards, the 3-pyridylzinc pivalate solution 1d in THF (0.48 mL, 0.42 M, 0.20 mmol, 2.50 equiv) 
was added dropwise over 1 h and the reaction mixture stirred for further 5 h. After quenching, extracting 
and evaporating, the crude product was flushed through a silica-plug with acetonitrile. Purification via 
preparative reversed-phase HPLC-chromatography (MeCN/H2O) yielded the modified cyclopeptide 
14b as colorless solid (39.8 mg, 49.6 µmol, 62% yield). 
1H-NMR (400 MHz, CDCl3, ppm) δ = 8.60 (d, J = 4.0 Hz, 1H), 8.55 (s, 1H), 7.65 (dt, J = 7.8, 1.8 Hz, 
1H), 7.45 (d, J = 9.4 Hz, 1H), 7.44 – 7.37 (m, 1H), 7.40 – 7.32 (m, 1H), 7.35 – 7.28 (m, 2H), 7.23 – 
7.17 (m, 1H), 7.04 (d, J = 9.5 Hz, 1H), 5.90 (d, J = 9.6 Hz, 1H), 5.27 (dd, J = 11.6, 4.0 Hz, 1H), 5.08 
(dt, J = 8.9, 7.2 Hz, 1H), 4.88 (dt, J = 9.3, 7.0 Hz, 1H), 4.79 (dd, J = 9.9, 5.5 Hz, 1H), 4.69 (s, 1H), 3.88 
– 3.83 (m, 1H), 3.66 (ddd, J = 11.4, 7.6, 5.1 Hz, 1H), 3.52 (dt, J = 11.2, 6.6 Hz, 1H), 3.38 (dd, J = 14.5, 
4.7 Hz, 1H), 3.19 (s, 3H), 3.14 (dd, J = 14.5, 7.6 Hz, 1H), 2.99 (s, 3H), 2.22 – 1.74 (m, 7H), 1.71 – 1.30 
(m, 9H), 1.00 (d, J = 6.6 Hz, 3H), 0.95 – 0.88 (m, 18H), 0.86 (d, J = 6.5 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm) δ = 174.0, 174.0, 171.1, 170.5, 169.8, 169.3, 149.8, 148.4, 138.7, 
137.2, 136.9, 134.8, 130.5, 130.4, 128.6, 127.1, 123.2, 60.9, 54.9, 53.5, 52.8, 48.3, 47.7 (2 C), 42.2, 
41.3, 37.5, 36.1, 33.3, 31.3, 30.6, 28.0, 25.3, 25.3, 25.2, 24.8, 24.6, 23.6, 23.2, 22.9, 22.8, 22.7, 22.7, 
21.9, 21.1. 
HRMS (ESI): calcd. [M+H, C45H68O6N7]: 802.5226, found: 802.5212; calcd. [M-H, C45H66O6N7]: 
800.5080, found: 800.5098. 
IR (ATR, cm-1) 𝜈 = 3511 (w), 3303 (w), 2955 (m), 2870 (w), 1629 (vs), 1517 (m), 1468 (m), 1448 (m), 
1386 (w), 1367 (w), 1100 (w), 1028 (vw), 1003 (vw), 760 (w), 718 (vw). 
M.p. 119.0 °C. 
C. EXPERIMENTAL PART    114 
(3S,6S,9R,12S,15S,20aR)-6,9,12,15-tetraisobutyl-8,11-dimethyl-3-(2-(pyridin-4-
yl)benzyl)tetradecahydropyrrolo[1,2-a][1,4,7,10,13,16]hexaazacyclooctadecine-1,4,7,10,13,16-
hexaone (14c) 
 
According to TP8, Pd(OAc)2 (0.72 mg, 3.20 µmol, 4.00 mol%) and SPhos (2.63 mg, 6.40 µmol, 
8.00 mol%) were dissolved in freshly distilled THF (0.8 mL) and the catalyst mixture was stirred for 
10 min, before ortho-iodophenylalanine cyclopeptide 11 (68.1 mg, 80.0 µmol, 1.0 equiv) was inserted. 
Afterwards, the 4-pyridylzinc pivalate solution 1e in THF (0.87 mL, 0.23 M, 0.20 mmol, 2.50 equiv) 
was added dropwise over 1 h and the reaction mixture stirred for further 5 h. After quenching, extracting 
and evaporating, the crude product was flushed through a silica-plug with acetonitrile. Purification via 
preparative reversed-phase HPLC-chromatography (MeCN/H2O) yielded the modified cyclopeptide 
14c as colorless solid (43.0 mg, 53.6 µmol, 67% yield). 
1H-NMR (599 MHz, CDCl3, ppm) δ = 8.67 (s, 2H), 7.40 (d, J = 9.2 Hz, 1H), 7.39 – 7.37 (m, 1H), 7.34 
– 7.27 (m, 4H), 7.19 – 7.16 (m, 1H), 7.06 (d, J = 9.4 Hz, 1H), 5.97 (d, J = 9.7, 1H), 5.27 (dd, J = 11.7 Hz, 
4.1, 1H), 5.07 (dt, J = 9.2, 7.1 Hz, 1H), 4.88 (dt, J = 9.5, 7.0 Hz, 1H), 4.79 (dd, J = 10.0, 5.4 Hz, 1H), 
4.68 (ddd, J = 9.9, 8.2, 4.6 Hz, 1H), 3.85 (dd, J = 7.7, 4.2 Hz, 1H), 3.68 – 3.63 (m, 1H), 3.52 (dt, 
J = 10.6, 7.0 Hz, 1H), 3.46 (dd, J = 14.6, 4.6 Hz, 1H), 3.18 (s, 3H), 3.06 (dd, J = 14.7, 8.2 Hz, 1H), 2.98 
(s, 3H), 2.20 – 2.11 (m, 1H), 1.94 (ddd, J = 14.7, 10.5, 4.2 Hz, 1H), 1.88 – 1.75 (m, 5H), 1.70 – 1.64 
(m, 1H), 1.61 – 1.46 (m, 5H), 1.45 – 1.31 (m, 3H), 1.00 (d, J = 6.6 Hz, 3H), 0.93 (ddd, J = 6.3, 4.8, 
2.8 Hz, 15H), 0.89 (d, J = 6.6 Hz, 3H), 0.87 (d, J = 6.5 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm)
 δ = 174.2, 171.3, 170.5, 170.0, 169.4, 149.8, 139.9, 134.4, 132.8, 
130.6, 130.0, 128.8, 127.3, 124.8, 124.7, 60.9, 55.1, 53.6, 53.0, 48.5, 47.8, 47.8, 42.3, 41.4, 37.6, 36.3, 
33.7, 31.5, 30.7, 29.8, 28.1, 25.4, 25.3, 25.0, 24.8, 23.7, 23.4, 23.0, 23.0, 22.9, 22.8, 22.0, 21.3. 
HRMS (ESI): calcd. [M+H, C45H68O6N7]: 802.5226, found: 802.5216; calcd. [M-H, C45H66O6N7]: 
800.5080, found: 800.5093.zzz 
IR (ATR, cm-1) 𝜈 = 3502 (w), 3296 (w), 2955 (m), 2927 (m), 2869 (w), 2360 (vw), 1631 (vs), 1516 
(m), 1448 (m), 1386 (w), 1367 (w), 1261 (w), 1098 (w), 802 (w), 763 (w). 
M.p. 137.9 °C 
C. EXPERIMENTAL PART    115 
(3S,6S,9R,12S,15S,20aR)-6,9,12,15-tetraisobutyl-8,11-dimethyl-3-(3-(pyridin-2-
yl)benzyl)tetradecahydropyrrolo[1,2-a][1,4,7,10,13,16]hexaazacyclooctadecine-1,4,7,10,13,16-
hexaone (15a) 
 
According to TP8, Pd(OAc)2 (0.72 mg, 3.20 µmol, 4.00 mol%) and SPhos (2.63 mg, 6.40 µmol, 
8.00 mol%) were dissolved in freshly distilled THF (0.8 mL) and the catalyst mixture was stirred for 
10 min, before meta-iodophenylalanine cyclopeptide 12 (68.1 mg, 80.0 µmol, 1.0 equiv) was inserted. 
Afterwards, the 2-pyridylzinc pivalate solution 1c in THF (0.39 mL, 0.52 M, 0.20 mmol, 2.50 equiv) 
was added dropwise over 1 h and the reaction mixture stirred for further 5 h. After quenching, extracting 
and evaporating, the crude product was flushed through a silica-plug with acetonitrile. Purification via 
preparative reversed-phase HPLC-chromatography (MeCN/H2O) yielded the modified cyclopeptide 
15a as colorless solid (46.2 mg, 57.6 µmol, 72% yield). 
1H-NMR (400 MHz, CDCl3, ppm) δ = 8.67 (d, J = 4.5 Hz, 1H), 7.87 (d, J = 7.9 Hz, 1H), 7.81 (s, 1H), 
7.78 – 7.70 (m, 2H), 7.54 (d, J = 9.4 Hz, 1H), 7.39 (t, J = 7.7 Hz, 1H), 7.26 – 7.21 (m, 2H), 7.04 (d, 
J = 9.4 Hz, 1H), 6.21 (d, J = 9.5 Hz, 1H), 5.29 (dd, J = 11.7, 4.1 Hz, 1H), 5.11 (dt, J = 9.4, 7.2 Hz, 1H), 
4.93 – 4.79 (m, 3H), 4.00 (dd, J = 7.9, 4.6 Hz, 1H), 3.68 (ddd, J = 10.4, 7.5, 5.7 Hz, 1H), 3.53 (dt, 
J = 10.3, 6.8 Hz, 1H), 3.43 (dd, J = 14.1, 6.9 Hz, 1H), 3.24 (s, 3H), 3.20 (dd, J = 14.3, 5.1 Hz, 1H), 3.01 
(s, 3H), 2.16 (dt, J = 11.9, 6.9 Hz, 1H), 2.07 – 1.72 (m, 6H), 1.68 – 1.31 (m, 9H), 1.01 (d, J = 6.6 Hz, 
3H), 0.92 (dd, J = 11.0, 6.3 Hz, 12H), 0.87 (d, J = 6.5 Hz, 3H), 0.84 (d, J = 6.5 Hz, 3H), 0.80 (d, 
J = 6.6 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm) δ = 174.2, 174.1, 171.2, 171.0, 170.0, 169.6, 157.4, 149.8, 139.9, 
137.4, 136.9, 130.2, 129.2, 128.1, 125.8, 122.3, 120.8, 61.1, 55.1, 53.5, 52.9, 48.6, 47.8, 47.8, 42.3, 
41.4, 37.7, 37.0, 36.3, 31.5, 30.8, 28.4, 25.4, 25.4, 25.3, 24.9, 24.7, 23.7, 23.4, 23.0, 22.9, 22.9, 22.8, 
22.1, 21.3. 
HRMS (ESI): calcd. [M+H, C45H68O6N7]: 802.5226, found: 802.5214; calcd. [M-H, C45H66O6N7]: 
800.5080, found: 800.5089. 
IR (ATR, cm-1) 𝜈 = 3509 (vw), 3303 (w), 2955 (m), 2930 (w), 2870 (w), 2359 (vw), 2341 (vw), 1629 
(vs), 1585 (w), 1518 (m), 1463 (m), 1446 (m), 1386 (w), 1099 (w), 769 (w), 753 (w), 668 (vw). 
M.p. 114.9 °C 
C. EXPERIMENTAL PART    116 
(3S,6S,9R,12S,15S,20aR)-6,9,12,15-tetraisobutyl-8,11-dimethyl-3-(3-(pyridin-3-
yl)benzyl)tetradecahydropyrrolo[1,2-a][1,4,7,10,13,16]hexaazacyclooctadecine-1,4,7,10,13,16-
hexaone (15b) 
 
According to TP8, Pd(OAc)2 (0.72 mg, 3.20 µmol, 4.00 mol%) and SPhos (2.63 mg, 6.40 µmol, 
8.00 mol%) were dissolved in freshly distilled THF (0.8 mL) and the catalyst mixture was stirred for 
10 min, before meta-iodophenylalanine cyclopeptide 12 (68.1 mg, 80.0 µmol, 1.0 equiv) was inserted. 
Afterwards, the 3-pyridylzinc pivalate solution 1d in THF (0.48 mL, 0.42 M, 0.20 mmol, 2.50 equiv) 
was added dropwise over 1 h and the reaction mixture stirred for further 5 h. After quenching, extracting 
and evaporating, the crude product was flushed through a silica-plug with acetonitrile. Purification via 
preparative reversed-phase HPLC-chromatography (MeCN/H2O) yielded the modified cyclopeptide 
15b as colorless solid (39.8 mg, 49.6 µmol, 62% yield). 
1H-NMR (400 MHz, CDCl3, ppm) δ = 8.90 (s, 1H), 8.63 (s, 1H), 8.03 (d, J = 7.7 Hz, 1H), 7.57 – 7.44 
(m, 4H), 7.41 (t, J = 7.7 Hz, 1H), 7.26 (d, J = 7.4 Hz, 1H), 7.07 (d, J = 9.3 Hz, 1H), 6.39 (d, J = 9.6 Hz, 
1H), 5.28 (dd, J = 11.6, 4.1 Hz, 1H), 5.10 (q, J = 7.7 Hz, 1H), 4.90 (d, J = 9.2 Hz, 2H), 4.82 (dd, J = 9.8, 
5.5 Hz, 1H), 4.05 (s, 1H), 3.69 (d, J = 5.9 Hz, 1H), 3.55 (t, J = 8.5 Hz, 1H), 3.42 (dd, J = 14.1, 6.8 Hz, 
1H), 3.23 (s, 3H), 3.22 – 3.16 (m, 1H), 3.00 (s, 3H), 2.23 – 2.11 (m, 1H), 2.06 – 1.71 (m, 6H), 1.68 – 
1.29 (m, 9H), 1.00 (d, J = 6.5 Hz, 3H), 0.92 (td, J = 6.3, 2.7 Hz, 12H), 0.87 (d, J = 6.5 Hz, 3H), 0.82 (d, 
J = 6.5 Hz, 3H), 0.79 (d, J = 6.6 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm) δ = 174.2, 174.1, 171.4, 170.9, 170.0, 169.4, 146.6, 146.4, 138.3, 
137.3, 136.4, 130.0, 129.6, 128.4, 125.9, 124.5, 61.1, 55.1, 53.4, 53.0, 48.6, 47.8 (2 C), 42.3, 41.4, 37.6, 
37.0, 36.3, 31.5, 30.8, 29.8, 28.3, 25.4, 25.4, 25.3, 24.9, 24.7, 23.7, 23.4, 23.0, 22.9, 22.9, 22.8, 22.0, 
21.3. 
HRMS (ESI): calcd. [M+H, C45H68O6N7]: 802.5226, found: 802.5213; calcd. [M-H, C45H66O6N7]: 
800.5080, found: 800.5094. 
IR (ATR, cm-1) 𝜈 = 3502 (w), 3301 (w), 2955 (m), 2870 (w), 2359 (vw), 1629 (vs), 1519 (m), 1467 
(m), 1447 (m), 1386 (w), 1367 (w), 1099 (w), 783 (vw), 712 (vw). 
M.p. 127.7 °C 
C. EXPERIMENTAL PART    117 
(3S,6S,9R,12S,15S,20aR)-6,9,12,15-tetraisobutyl-8,11-dimethyl-3-(3-(pyridin-4-
yl)benzyl)tetradecahydropyrrolo[1,2-a][1,4,7,10,13,16]hexaazacyclooctadecine-1,4,7,10,13,16-
hexaone (15c) 
 
According to TP8, Pd(OAc)2 (0.72 mg, 3.20 µmol, 4.00 mol%) and SPhos (2.63 mg, 6.40 µmol, 
8.00 mol%) were dissolved in freshly distilled THF (0.8 mL) and the catalyst mixture was stirred for 
10 min, before meta-iodophenylalanine cyclopeptide 12 (68.1 mg, 80.0 µmol, 1.0 equiv) was inserted. 
Afterwards, the 4-pyridylzinc pivalate solution 1e in THF (0.87 mL, 0.23 M, 0.20 mmol, 2.50 equiv) 
was added dropwise over 1 h and the reaction mixture stirred for further 5 h. After quenching, extracting 
and evaporating, the crude product was flushed through a silica-plug with acetonitrile. Purification via 
preparative reversed-phase HPLC-chromatography (MeCN/H2O) yielded the modified cyclopeptide 
15c as colorless solid (49.4 mg, 61.6 µmol, 77% yield). 
1H-NMR (400 MHz, CDCl3, ppm) δ = 8.71 (s, 2H), 7.78 (s, 2H), 7.59 (s, 1H), 7.57 (d, J = 7.8 Hz, 
1H), 7.49 (d, J = 9.8 Hz, 1H), 7.45 (t, J = 7.8 Hz, 1H), 7.34 (d, J = 7.6 Hz, 1H), 7.10 (d, J = 9.4 Hz, 
1H), 6.46 (d, J = 9.8 Hz, 1H), 5.28 (dd, J = 11.7, 4.1 Hz, 1H), 5.15 – 5.06 (m, 1H), 4.98 – 4.87 (m, 2H), 
4.81 (dd, J = 10.0, 5.4 Hz, 1H), 4.10 – 4.02 (m, 1H), 3.73 – 3.64 (m, 1H), 3.60 – 3.50 (m, 1H), 3.39 (dd, 
J = 14.2, 7.1 Hz, 1H), 3.26 (d, J = 5.3 Hz, 1H), 3.23 (s, 3H), 3.00 (s, 3H), 2.24 – 2.11 (m, 1H), 2.06 – 
1.72 (m, 6H), 1.69 – 1.31 (m, 9H), 1.01 (d, J = 6.5 Hz, 3H), 0.96 – 0.90 (m, 12H), 0.87 (d, J = 6.5 Hz, 
3H), 0.82 (d, J = 6.7 Hz, 3H), 0.80 (d, J = 7.9 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm) δ = 174.2, 174.1, 171.6, 170.7, 170.0, 169.3, 146.3 (2 C), 138.8, 
136.9, 131.8, 129.8, 128.6, 126.0, 122.9 (2 C), 61.1, 55.1, 53.4, 53.1, 48.6, 47.9, 47.8, 42.5, 41.4, 37.6, 
37.2, 36.3, 31.6, 30.8, 29.8, 28.1, 25.5 (2 C), 25.3, 25.0, 24.7, 23.7, 23.4, 23.0 (2 C), 22.9 (2 C), 22.0, 
21.3. 
HRMS (ESI): calcd. [M+H, C45H68O6N7]: 802.5226, found: 802.5213; calcd. [M-H, C45H66O6N7]: 
800.5080, found: 800.5087. 
IR (ATR, cm-1) 𝜈 =3302 (m), 2955 (m), 2930 (m), 2870 (w), 1688 (w), 1665 (m), 1657 (m), 1631 (vs), 
1513 (m), 1468 (m), 1461 (m), 1451 (m), 1445 (m), 1099 (w), 790 (vw). 
M.p. 135.3 °C 
C. EXPERIMENTAL PART    118 
(3S,6S,9R,12S,15S,20aR)-6,9,12,15-tetraisobutyl-8,11-dimethyl-3-(4-(pyridin-2-
yl)benzyl)tetradecahydropyrrolo[1,2-a][1,4,7,10,13,16]hexaazacyclooctadecine-1,4,7,10,13,16-
hexaone (16a) 
 
According to TP8, Pd(OAc)2 (0.72 mg, 3.20 µmol, 4.00 mol%) and SPhos (2.63 mg, 6.40 µmol, 
8.00 mol%) were dissolved in freshly distilled THF (0.8 mL) and the catalyst mixture was stirred for 
10 min, before para-iodophenylalanine cyclopeptide 13 (68.1 mg, 80.0 µmol, 1.0 equiv) was inserted. 
Afterwards, the 2-pyridylzinc pivalate solution 1c in THF (0.39 mL, 0.52 M, 0.20 mmol, 2.50 equiv) 
was added dropwise over 1 h and the reaction mixture stirred for further 5 h. After quenching, extracting 
and evaporating, the crude product was flushed through a silica-plug with acetonitrile. Purification via 
preparative reversed-phase HPLC-chromatography (MeCN/H2O) yielded the modified cyclopeptide 
16a as colorless solid (53.9 mg, 67.2 µmol, 84% yield). 
1H-NMR (400 MHz, CDCl3, ppm) δ = 8.68 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 7.91 (d, J = 8.2 Hz, 2H), 
7.75 (ddd, J = 8.0, 7.2, 1.8 Hz, 1H), 7.70 (dt, J = 8.0, 1.2 Hz, 1H), 7.57 (d, J = 9.3 Hz, 1H), 7.30 (d, 
J = 8.3 Hz, 2H), 7.22 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 7.06 (d, J = 9.4 Hz, 1H), 6.14 (d, J = 9.5 Hz, 1H), 
5.30 (dd, J = 11.7, 4.1 Hz, 1H), 5.17 – 5.08 (m, 1H), 4.94 – 4.85 (m, 2H), 4.82 (dd, J = 9.7, 5.7 Hz, 1H), 
4.00 (dd, J = 7.8, 4.7 Hz, 1H), 3.73 – 3.65 (m, 1H), 3.59 – 3.52 (m, 1H), 3.41 (dd, J = 14.1, 6.7 Hz, 1H), 
3.25 (s, 3H), 3.15 (dd, J = 14.1, 5.0 Hz, 1H), 3.01 (s, 3H), 2.25 – 2.15 (m, 1H), 2.09 – 1.75 (m, 6H), 
1.65 – 1.33 (m, 9H), 1.01 (d, J = 6.6 Hz, 3H), 0.98 – 0.90 (m, 15H), 0.88 (d, J = 2.4 Hz, 3H), 0.86 (d, 
J = 2.5 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm) δ = 174.2, 174.1, 171.2, 170.9, 169.9, 169.6, 157.2, 149.8, 138.3, 
137.8, 136.9, 130.0 (2 C), 127.3 (2 C), 122.2, 120.5, 61.1, 55.1, 53.4, 53.0, 48.6, 47.8, 47.8, 42.2, 41.4, 
37.7, 36.8, 36.3, 31.5, 30.8, 28.4, 25.5, 25.4, 25.3, 25.0, 24.6, 23.7, 23.4, 23.1, 23.0, 22.9, 22.8, 22.1, 
21.3. 
HRMS (ESI): calcd. [M+H, C45H68O6N7]: 802.5226, found: 802.5216; calcd. [M-H, C45H66O6N7]: 
800.5080, found: 800.5091. 
IR (ATR, cm-1) 𝜈 = 3498 (vw), 3303 (w), 2955 (m), 2930 (w), 2870 (w), 2359 (w), 1630 (vs), 1589 (w), 
1518 (m), 1467 (m), 1446 (m), 1386 (w), 1367 (w), 1098 (w), 776 (w), 668 (vw). 
M.p. 130.6°C 
C. EXPERIMENTAL PART    119 
(3S,6S,9R,12S,15S,20aR)-6,9,12,15-tetraisobutyl-8,11-dimethyl-3-(4-(pyridin-3-
yl)benzyl)tetradecahydropyrrolo[1,2-a][1,4,7,10,13,16]hexaazacyclooctadecine-1,4,7,10,13,16-
hexaone (16b) 
 
According to TP8, Pd(OAc)2 (0.72 mg, 3.20 µmol, 4.00 mol%) and SPhos (2.63 mg, 6.40 µmol, 
8.00 mol%) were dissolved in freshly distilled THF (0.8 mL) and the catalyst mixture was stirred for 
10 min, before para-iodophenylalanine cyclopeptide 13 (68.1 mg, 80.0 µmol, 1.0 equiv) was inserted. 
Afterwards, the 3-pyridylzinc pivalate solution 1d in THF (0.48 mL, 0.42 M, 0.20 mmol, 2.50 equiv) 
was added dropwise over 1 h and the reaction mixture stirred for further 5 h. After quenching, extracting 
and evaporating, the crude product was flushed through a silica-plug with acetonitrile. Purification via 
preparative reversed-phase HPLC-chromatography (MeCN/H2O) yielded the modified cyclopeptide 
16b as colorless solid (39.8 mg, 49.6 µmol, 62% yield). 
1H-NMR (400 MHz, CDCl3, ppm) δ = 8.83 (dd, J = 2.4, 0.9 Hz, 1H), 8.59 (dd, J = 4.8, 1.6 Hz, 1H), 
7.85 (ddd, J = 7.9, 2.4, 1.6 Hz, 1H), 7.52 (d, J = 10.0 Hz, 1H), 7.49 (d, J = 8.2 Hz, 2H), 7.37 (ddd, 
J = 7.9, 4.8, 0.9 Hz, 1H), 7.31 (d, J = 8.2 Hz, 2H), 7.09 (d, J = 9.5 Hz, 1H), 6.23 (d, J = 9.6 Hz, 1H), 
5.30 (dd, J = 11.6, 4.1 Hz, 1H), 5.20 – 5.09 (m, 1H), 4.95 – 4.87 (m, 2H), 4.82 (dd, J = 9.8, 5.5 Hz, 1H), 
4.05 (dd, J = 7.8, 4.6 Hz, 1H), 3.75 – 3.67 (m, 1H), 3.57 (dt, J = 10.4, 6.9 Hz, 1H), 3.42 (dd, J = 14.1, 
6.6 Hz, 1H), 3.25 (s, 3H), 3.13 (dd, J = 14.1, 4.9 Hz, 1H), 3.01 (s, 3H), 2.22 (dt, J = 11.8, 7.0 Hz, 1H), 
2.08 (dq, J = 11.0, 5.4 Hz, 1H), 2.01 – 1.75 (m, 6H), 1.65 – 1.33 (m, 8H), 1.01 (d, J = 6.6 Hz, 3H), 0.98 
– 0.92 (m, 12H), 0.92 (d, J = 3.1 Hz, 3H), 0.89 (d, J = 3.5 Hz, 3H), 0.88 (d, J = 3.4 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm) δ = 174.2, 174.2, 171.4, 170.8, 170.0, 169.5, 148.6, 148.4, 137.0, 
136.7, 136.4, 134.4, 130.4 (2 C), 127.5 (2 C), 123.7, 61.1, 55.1, 53.5, 53.1, 48.6, 47.9, 42.2, 41.4, 37.7, 
36.8, 36.3, 31.5, 30.8, 29.8, 28.3, 25.5, 25.4, 25.3, 25.0, 24.6, 23.7, 23.4, 23.1, 23.0, 22.9, 22.9, 22.1, 
21.3. 
HRMS (ESI): calcd. [M+H, C45H68O6N7]: 802.5226, found: 802.5215; calcd. [M-H, C45H66O6N7]: 
800.5080, found: 802.5090. 
IR (ATR, cm-1) 𝜈 = 3509 (w), 3303 (w), 2955 (m), 2930 (w), 2870 (w), 2361 (w), 2339 (w), 1630 (vs), 
1519 (m), 1469 (m), 1447 (m), 1367 (w), 1100 (w), 799 (w), 712 (vw). 
M.p. 140.6 °C 
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(3S,6S,9R,12S,15S,20aR)-6,9,12,15-tetraisobutyl-8,11-dimethyl-3-(4-(pyridin-4-
yl)benzyl)tetradecahydropyrrolo[1,2-a][1,4,7,10,13,16]hexaazacyclooctadecine-1,4,7,10,13,16-
hexaone (16c) 
 
According to TP8, Pd(OAc)2 (0.72 mg, 3.20 µmol, 4.00 mol%) and SPhos (2.63 mg, 6.40 µmol, 
8.00 mol%) were dissolved in freshly distilled THF (0.8 mL) and the catalyst mixture was stirred for 
10 min, before para-iodophenylalanine cyclopeptide 13 (68.1 mg, 80.0 µmol, 1.0 equiv) was inserted. 
Afterwards, the 4-pyridylzinc pivalate solution 1e in THF (0.87 mL, 0.23 M, 0.20 mmol, 2.50 equiv) 
was added dropwise over 1 h and the reaction mixture stirred for further 5 h. After quenching, extracting 
and evaporating, the crude product was flushed through a silica-plug with acetonitrile. Purification via 
preparative reversed-phase HPLC-chromatography (MeCN/H2O) yielded the modified cyclopeptide 
16c as colorless solid (51.3 mg, 64.0 µmol, 80% yield). 
1H-NMR (400 MHz, CDCl3, ppm) δ = 8.65 (d, J = 5.4 Hz, 1H), 7.55 (d, J = 8.1 Hz, 2H), 7.54 – 7.47 
(m, 3H), 7.32 (d, J = 7.9 Hz, 2H), 7.09 (d, J = 9.5 Hz, 1H), 6.27 (d, J = 9.7 Hz, 1H), 5.30 (dd, J = 11.7, 
4.1 Hz, 1H), 5.13 (q, J = 7.8 Hz, 1H), 4.96 – 4.86 (m, 2H), 4.82 (dd, J = 9.9, 5.5 Hz, 1H), 4.05 (dd, 
J = 7.0, 3.7 Hz, 1H), 3.69 (q, J = 8.2, 6.8 Hz, 1H), 3.56 (dt, J = 9.9, 6.6 Hz, 1H), 3.39 (dd, J = 14.1, 
6.7 Hz, 1H), 3.24 (s, 3H), 3.15 (dd, J = 14.1, 4.9 Hz, 1H), 3.00 (s, 3H), 2.16 (s, 6H), 2.13 – 1.74 (m, 
4H), 1.68 – 1.32 (m, 7H), 1.01 (d, J = 6.5 Hz, 3H), 0.94 (qd, J = 6.6, 4.1 Hz, 15H), 0.89 (d, J = 2.7 Hz, 
3H), 0.87 (d, J = 2.5 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm) δ = 174.1, 174.1, 171.3, 170.6, 169.9, 169.3, 150.0, 148.2, 138.2, 
136.7, 130.4, 127.2, 121.6, 60.9, 54.9, 53.3, 52.9, 48.4, 47.7, 42.1, 41.2, 37.5, 36.7, 36.1, 31.4, 30.6, 
29.7, 28.1, 25.3, 25.3, 25.2, 24.8, 24.5, 23.6, 23.2, 22.9, 22.8, 22.8, 22.7, 21.9, 21.1. 
HRMS (ESI): calcd. [M+H, C45H68O6N7]: 802.5226, found: 802.5211; calcd. [M-H, C45H66O6N7]: 
800.5080, found: 802.5089. 
IR (ATR, cm-1) 𝜈 = 3510 (w), 3297 (w), 3028 (vw), 2955 (m), 2870 (w), 2360 (w), 1630 (vs), 1600 
(w), 1519 (m), 1466 (w), 1447 (m), 1386 (w), 1367 (w), 1099 (w), 997 (vw), 804 (w). 
M.p. 141.5 °C 
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3 Pyrrole Protected 2-Aminoalkylzinc Reagents for the Enantioselective 
Synthesis of Amino Derivatives 
3.1 Typical Procedures (TP9–15) 
Typical procedure for the pyrrole protection of β-amino-alcohols (TP9): 130 
 
In a round-bottom flask equipped with a magnetic stirring bar, the corresponding amino-alcohol 
(1.00 equiv) and NaOAc⋅3H2O (1.00–2.40 equiv) were dissolved in a 1,2-dichloroethane/water mixture 
(1:1) and acidified with glacial acetic acid. 2,5-Dimethoxytetrahydrofuran (cis/trans mixture, 
1.00 equiv) was added and the two-phase mixture was refluxed at 90 °C under vigorous stirring for 1 h 
up to 16 h. The reaction was cooled to room temperature and the organic phase was separated. The 
aqueous phase was extracted three times with EtOAc and the combined organic phases were neutralized 
with sat. aq. NaHCO3 solution, washed with brine and dried over MgSO4. After evaporation of the 
solvent, the residue was purified by flash column chromatography (hexanes/EtOAc, addition of 
1% Et3N) and the corresponding N-pyrrolyl-alkyl alcohol was obtained. 
Typical procedure for the preparation of N-pyrrolyl-alkyl iodides (TP10): 131 
 
In a dry Schlenk flask or tube, PPh3 (1.05–1.20 equiv) and imidazole (1.05–1.20 equiv) were dissolved 
in dry DCM and cooled to 0 °C. Iodine (1.05–1.20 equiv) was added in three portions over a period of 
10 min. The corresponding N-pyrrolyl-alkylalcohol (1.00 equiv) dissolved in dry DCM was added 
dropwise to the reaction mixture at 0 °C over a period of 30 min. The mixture was stirred for 30 min at 
this temperature and was then allowed to warm to room temperature and stirred additionally for 1.5 h 
up to 3 h. The reaction was quenched with sat. aq. Na2S2O3 solution, the organic phase was separated 
and the aqueous phase extracted three times with DCM. The combined organic phases were dried over 
 
130 a) B. S. Gourlay, P. P. Molesworth, J. H. Ryan, J. A. Smith, Tetrahedron Lett. 2006, 47, 799; b) C. W. Jefford, 
de Villedon de Naide, Fabienne, K. Sienkiewicz, Tetrahedron: Asymmetry 1996, 7, 1069. 
131 a) V. Morozova, J. Skotnitzki, K. Moriya, K. Karaghiosoff, P. Knochel, Angew. Chem. Int. Ed. 2018, 57, 5516; 
b) G. L. Lange, C. Gottardo, Synth. Commun. 1990, 20, 1473; c) P. J. Garegg, B. Samuelsson, J. Chem. Soc., 
Perkin Trans. 1 1980, 2866; d) R. Appel, Angew. Chem. Int. Ed. 1975, 14, 801. 
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CaCl2 and the solvents evaporated. The crude product was purified via flash column chromatography 
(hexanes/EtOAc, darkness) and the corresponding N-pyrrolyl-alkyl iodide was obtained. 
Typical procedure for LiCl promoted oxidative zinc insertions (TP11): 
 
Two Schlenk tubes, equipped with a magnetic stirring bar, were dried using a heat gun at 630 °C under 
high vacuum and flushed with argon three times. In one tube, LiCl (1.0 equiv) was added and dried in 
vacuo at 470 °C. Zinc dust (1.5 equiv) was added and dried in vacuo at 350 °C. Under argon 
atmosphere, freshly distilled dry THF was added and the zinc dust was activated using 
1,2-dibromoethane (DBE, 5 mol%) and chlorotrimethylsilane (TMSCl, 5 mol%) and the solution was 
slightly heated until a gas formation started. The tube was placed in a water bath and the alkyl iodide 
was added dropwise or in small portions. After complete addition of the starting material, the water bath 
was removed. The reaction progress was monitored by quenching small aliquots with sat. aq. solution 
NH4Cl and gas chromatography analysis. After full conversion of the N-pyrrolyl-alkyliodide, the 
solution was passed through a syringe filter and the solution was transferred to the second dry Schlenk 
tube. The concentration of the corresponding N-pyrrolyl-alkylzinc iodide was determined by titration 
against iodine132 (approx. 30-40 mg) in dry THF (1.5 mL) under argon atmosphere. 
Typical procedure for palladium catalyzed cross-couplings (TP12): 
 
A Schlenk tube, equipped with a magnetic stirring bar, was dried using a heat gun at 630 °C under high 
vacuum and flushed with argon three times. Pd(OAc)2 (2.25 mg, 10.0 µmol, 2 mol%) and SPhos
133 
(8.21 mg, 20.0 µmol, 4 mol%) were dissolved in freshly distilled dry THF (1 mL) and stirred for 10 min. 
The corresponding aryl halide (0.50 mmol, 1.00 equiv) was added and to this mixture, the corresponding 
N-pyrrolyl-alkylzinc iodide in THF (0.60 mmol, 1.20 equiv) was added dropwise. The reaction was 
stirred upon full conversion of the electrophile and then quenched with sat. aq. NH4Cl solution (1 mL). 
The cross-coupling mixture was extracted three times with EtOAc, the combined organic phases dried 
 
132 A. Krasovskiy, P. Knochel, Synthesis 2006, 5, 890. 
133 T. E. Barder, S. D. Walker, J. R. Martinelli, S. L. Buchwald, J. Am. Chem. Soc. 2005, 127, 4685. 
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over MgSO4 and the solvent evaporated. After purification via flash column chromatography 
(hexanes/EtOAc) the corresponding cross-coupling product was obtained. 
Typical procedure for palladium catalyzed acylation reactions (TP13a): 134 
 
A Schlenk tube equipped, with a magnetic stirring bar, was dried using a heat gun at 630 °C under high 
vacuum and flushed with argon three times. Pd(PPh3)4 (23.1 mg, 20.0 µmol, 4 mol%) was dissolved in 
freshly distilled dry THF (1 mL) and the associated acid chloride (0.50 mmol, 1.00 equiv) was added. 
The corresponding N-pyrrolyl-alkylzinc iodide in THF (0.60 mmol, 1.20 equiv) was added dropwise 
and the mixture was stirred at room temperature or 50 °C 16 h. The reaction mixture was quenched with 
sat. aq. NH4Cl solution (1 mL) and extracted three times with EtOAc. The combined organic phases 
dried over MgSO4 and the solvent evaporated. Purification via flash column chromatography 
(hexanes/EtOAc) yielded the corresponding acylation product. 
Typical procedure for copper(I) iodide catalyzed acylation reactions (TP13b): 135 
 
A Schlenk tube, equipped with a magnetic stirring bar, was dried using a heat gun at 630 °C under high 
vacuum and flushed with argon three times. CuI (9.52 mg, 0.05 mmol, 10 mol%) was added to a freshly 
prepared solution of the corresponding N-pyrrolyl-alkylzinc iodide (0.60 mmol, 1.20 equiv) at 0 °C and 
the mixture stirred for 10 min. The associated acid chloride (0.50 mmol, 1.00 equiv) was added 
dropwise and the reaction was mixture stirred for 1 h at 0 °C. Cooling was removed and stirring was 
continued at room temperature for 16 h. The reaction mixture was quenched with sat. aq. NH4Cl, 
extracted three times with EtOAc and the combined organic layers dried over MgSO4. Evaporation of 
the solvent and flash column chromatography purification (hexanes/EtOAc) yielded the corresponding 
acylation product.  
 
134 a) D. Haas, D. Sustac-Roman, S. Schwarz, P. Knochel, Org. Lett. 2016, 18, 6380; b) R. D. Rieke, S.-H. Kim, 
Tetrahedron Lett. 2011, 52, 3094; c) E. Negishi, V. Bagheri, S. Chatterjee, F.-T. Luo, J. A. Miller, A.T. Stoll, 
Tetrahedron Lett. 1983, 24, 5181. 
135 a) H.-S. Jung, S.-H. Kim, Tetrahedron Lett. 2015, 56, 1004; b) E. Nakamura, I. Kuwajima, J. Am. Chem. Soc. 
1984, 106, 3368.  
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Typical procedure for stereoselective CBS-reduction (TP14): 136 
 
A Schlenk tube, equipped with a magnetic stirring bar, was dried using a heat gun at 630 °C under high 
vacuum and flushed with argon three times. The enantiopure CBS-catalyst ((R)- or (S)-2-methyl-CBS-
oxazaborolidine, 15 mol-%) was dissolved in freshly distilled dry THF and BH3⋅SMe2 (1.10 equiv) was 
added slowly at 0 °C. After 10 min of stirring at this temperature, a solution of the corresponding ketone 
(1.00 equiv) in dry THF was added dropwise to the reaction mixture. Cooling was removed and the 
reaction mixture was stirred at room temperature until full conversion of the ketone. The reaction was 
quenched by the slow addition of methanol and the solvents were removed under reduced pressure. The 
resulting residue was purified using flash column chromatography (hexane/EtOAc, addition of 
1% Et3N) to yield the desired enantioenriched alcohol. 
Typical procedure for the pyrrole deprotection reaction via ozonolysis (TP15): 137 
 
In a two-neck round bottom flask, the corresponding pyrrole derivative (1.0 equiv) was dissolved in a 
mixture of DCM and methanol (4:1) and cooled to –78 °C. Ozone was passed through the solution (flow 
approx. 2 L/min) until a blueish color was observed. Excess of ozone was removed by flushing with 
nitrogen for 10 min. Dimethyl sulfide (10.0 equiv) was added, cooling was removed, and the reaction 
mixture stirred for additional 6 h. After evaporation of all solvents, the residue was dissolved in KOH 
in EtOH (0.1 M) and stirred for 1 h. Ethanol was removed under reduced pressure and following 
purification of the crude product via flash column chromatography purification (hexanes/EtOAc, 
addition of 1% Et3N, KMnO4 stain) yielded the corresponding mono-formamide containing product. 
  
 
136 a) E. J. Corey, C. J. Helal, Angew. Chem. Int. Ed. 1998, 37, 1986; b) E. J. Corey, S. Shibata, R. K. Bakshi, J. 
Org. Chem. 1988, 53, 2861. 
137 a) E. Tokumaru, A. Tengeiji, T. Nakahara, I. Shiina, Chem. Lett. 2015, 44, 1768; b) C. Kashima, T. Maruyama, 
Y. Fujioka, K. Harada, J. Chem. Soc., Perkin Trans. 1 1989, 1041. 
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3.2 Precursor Syntheses 
2-Iodoethan-1-amine hydroiodide (pc1) 
 
The desired 2-iodoethan-1-amine hydroiodide was prepared as reported in the literature138: To a round 
bottle flask with 57% hydroiodic acid (44.89 g, 200 mmol, 2.00 equiv) 2-aminoethanol (6.11 g, 
100 mmol, 1.00 equiv) was added at 0 °C. The reaction mixture was heated to 170 °C for 4 h. During 
the reaction, 24 mL of water were removed with a Dean-Stark apparatus and a black solid was formed. 
The reaction mixture was cooled down to room temperature and the residue washed with Et2O several 
times. After recrystallization with Et2O/EtOH the pure product 2-iodoethan-1-amine hydroiodide pc1 
was obtained as colorless salt (20.8 g, 69.6 mmol, 70% yield). 
1H-NMR (400 MHz, DMSO-d6, ppm): δ = 7.86 (s, 3H), 3.30 – 3.25 (m, 2H), 3.24 – 3.17 (m, 2H). 
13C-NMR (101 MHz, DMSO-d6, ppm): δ = 41.4, -0.7. 
IR (Diamond-ATR, neat, cm-1): 𝜈 = 2995 (s), 1567 (m), 1552 (s), 1485 (s), 1468 (s), 1436 (s), 
1380 (m), 1315 (m), 1225 (m), 1207 (s), 1074 (m), 1058 (s), 1015 (s), 910 (s), 860 (vs), 785 (s). 
Methyl (S)-3-(4-methoxyphenyl)-2-(1H-pyrrol-1-yl)propanoate ((S)-pc3) 
 
According to a modified version of TP9, L-tyrosine (9.06 g, 50.0 mmol, 1.00 equiv) and NaOAc⋅3H2O 
(6.80 g, 50.0 mmol, 1.0 equiv) were dissolved in 1,2-dichloroethane (37.5 mL), water (37.5 mL) and 
glacial acetic acid (12.5 mL). 2,5-dimethoxytetrahydrofuran (6.60 g, 50.0 mmol, 1.00 equiv) was added 
and the resulting suspension was refluxed under vigorous stirring for 16 h at 90 °C. The organic phase 
was separated and the aqueous phase was extracted with ethyl acetate (3x150 mL). The combined 
organic layers were dried over MgSO4 and the solvent was removed in vacuo to obtain the crude (S)-3-
(4-hydroxyphenyl)-2-(1H-pyrrol-1-yl)propanoic acid ((S)-pc2). 
Without further purification, the crude product (S)-pc2 was dissolved in DMF (100 mL) and cooled 
with an ice-bath, before KOH (3.09 g, 55.0 mmol, 1.50 equiv) was added. Iodomethane (4.67 mL, 
75.0 mmol, 1.50 equiv) was added dropwise at 0 °C and the reaction mixture was then stirred for 1 h at 
ambient temperature. This step was repeated: After cooling down to 0 °C, another portion of KOH 
(3.09 g, 55.0 mmol, 1.50 equiv) and iodomethane (4.67 mL, 75.0 mmol, 1.50 equiv) were added. The 
resulting mixture was stirred for 24 h at room temperature. After aqueous workup and extraction with 
ethyl acetate (3x 150 mL), the combined organic layers were washed successively with a saturated LiCl 
 
138 Katchalski, E.; Ishai, D. B. J. Org. Chem. 1950, 15, 1067. 
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solution (100 mL) and brine (100 mL). The solvent was removed in vacuo and the crude product was 
purified by flash column chromatography to obtain (S)-pc3 as a colorless oil (7.56 g, 29.2 mmol, 
58% yield). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.95 – 6.89 (m, 2H), 6.79 – 6.75 (m, 2H), 6.72 (t, J = 2.2 Hz, 
2H), 6.15 (t, J = 2.2 Hz, 2H), 4.70 (dd, J = 8.8, 6.5 HZ, 1H), 3.76 (s, 3H), 3.70 (s, 3H), 3.36 (dd, 
J = 13.9, 6.5 Hz, 1H), 3.20 (dd, J = 13.9, 8.8 Hz, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 170.8, 158.7, 130.0, 128.4, 120.2, 114.1, 108.8, 63.9, 55.3, 
52.7, 38.8 
MS (EI, 70 eV, %): m/z = 259 (10), 192 (6); 122 (9), 121 (100), 91 (4), 77 (3). 
HRMS (EI, 70 eV): m/z calcd. for [C15H17NO3]: 259.1208; found 259.1200 ([M]
+).  
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2954 (w), 1741 (s), 1612 (m), 1513 (s), 1488 (m), 1464 (w), 
1439 (m), 1300 (m), 1283 (m), 1273 (m), 1245 (vs), 1198 (m), 1177 (s), 1164 (s), 1111 (m), 1091 (m), 
1072 (m), 1032 (s), 823 (m), 722 (vs). 
 
3.3 Preparation of β-N-Pyrrolyl-Alkyl Alcohols 
(R)-2-(1H-Pyrrol-1-yl)propan-1-ol ((R)-18b) 
 
Following TP9, the product was synthesized by refluxing a solution of D-alaninol (R)-17b (1.88 g, 
25.0 mmol, 1.00 equiv), NaOAc⋅3H2O (3.40 g, 25.0 mmol, 1.00 equiv) and 
2,5-dimethoxytetrahydrofuran (cis/trans mixture, 3.30 g, 25.0 mmol, 1.00 equiv) in 1,2-dichloroethane 
(37.5 mL), water (37.5 mL) and glacial acetic acid (12.5 mL) for 5 h. The crude product was purified 
by flash column to afford (R)-18b (2.47 g, 19.7 mmol, 79% yield) as a colorless solid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.75 (t, J = 2.1 Hz, 2H), 6.19 (t, J = 2.1 Hz, 2H), 4.17 (quint, 
J = 7.0, 4.6 Hz, 1H), 3.75 – 3.63 (m, 2H), 1.68 (br, 1H), 1.45 (d, J = 6.9 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 118.9, 108.4, 67.7, 57.2, 17.5. 
MS (EI, 70 eV, %): m/z = 125 (52), 94 (100), 93 (13), 78 (22), 68 (12). 
HRMS (EI, 70 eV): m/z calcd. for [C7H11NO]: 125.0841; found: 125.0836 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3392 (w), 2974 (w), 2936 (w), 2877 (w), 2360 (vw), 1548 
(vw), 1490 (m), 1454 (w), 1413 (w), 1387 (w), 1319 (w), 1275 (m), 1089 (m), 1049 (s), 984 (w), 953 
(w), 724 (vs). 
M.p. 50.3 °C. 
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(R)-3-Methyl-2-(1H-pyrrol-1-yl)butan-1-ol ((R)-18c) 
 
Following TP9, the product was synthesized by refluxing a solution of D-valinol (R)-17c (2.58 g, 
25.0 mmol, 1.00 equiv), NaOAc⋅3H2O (3.40 g, 25.0 mmol, 1.00 equiv) and 
2,5-dimethoxytetrahydrofuran (cis/trans mixture, 3.30 g, 25.0 mmol, 1.00 equiv) in 1,2-dichloroethane 
(37.5 mL), water (37.5 mL) and glacial acetic acid (12.5 mL) for 16 h. The crude product was purified 
by flash column chromatography to afford (R)-18c (3.21 g, 20.9 mmol, 84% yield) as a yellow liquid. 
1H-NMR (599 MHz, CDCl3, ppm): δ = 6.68 (t, J = 2.1 Hz, 2H), 6.17 (t, J = 2.2 Hz, 2H), 3.89 (dd, 
J = 11.9, 3.8 Hz, 1H), 3.81 (dd, J = 11.7, 8.7 Hz, 1H), 3.58 (td, J = 9.0, 3.8 Hz, 1H), 2.02 (dhept, J = 9.3, 
6.7 Hz, 1H), 1.58 (br, 1H), 1.01 (d, J = 6.8 Hz, 3H), 0.74 (d, J = 6.7 Hz, 3H). 
13C-NMR (151 MHz, CDCl3, ppm): δ = 119.8, 108.3, 68.8, 64.3, 30.8, 20.1, 19.6. 
MS (EI, 70 eV, %): m/z = 153 (37), 122 (100), 120 (10), 107 (12), 106 (12), 94 (18), 82 (31), 80 (38), 
68 (18), 67 (14), 44 (17). 
HRMS (EI, 70 eV): m/z calcd. for [C9H15NO]: 153.1154; found: 153.1147 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2961 (w), 2874 (w), 1489 (m), 1470 (w), 1413 (w), 1387 (w), 
1369 (w), 1275 (m), 1088 (m), 1062 (m), 1019 (m), 970 (w), 931 (w), 856 (vw), 824 (vw), 720 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +21.1. 
(S)-3-Phenyl-2-(1H-pyrrol-1-yl)propan-1-ol ((S)-18d) 
 
Following TP9, a solution of L-phenylalaninol (S)-17d (3.78 g, 25.0 mmol, 1.00 equiv), NaOAc⋅3H2O 
(3.40 g, 25.0 mmol, 1.00 equiv) and 2,5-dimethoxytetrahydrofuran (cis/trans mixture, 3.30 g, 
25.0 mmol, 1.00 equiv) in 1,2-dichloroethane (37.5 mL), distilled water (37.5 mL) and glacial acetic 
acid (12.5 mL) was heated under reflux for 16 h. Purification of the crude product by flash column 
chromatography afforded (S)-18d (4.27 g, 21.2 mmol, 85% yield) as a yellow oil. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.33 – 7.19 (m, 3H), 7.09 – 7.05 (m, 2H), 6.73 (t, J = 2.1 Hz, 
2H), 6.20 (t, J = 2.1 Hz, 2H), 4.22 (tt, J = 7.3, 5.9 Hz, 1H), 3.83 (d, J = 6.0 Hz, 2H), 3.14 – 3.04 (m, 
2H), 1.69 (br, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 137.7, 129.0, 128.6, 126.8, 119.3, 108.6, 65.4, 63.6, 38.7. 
MS (EI, 70 eV, %): m/z = 202 (14), 201 (90), 170 (39), 168 (16), 111 (11), 110 (100), 99 (12), 97 (21), 
91 (43), 85 (32), 83 (23), 82 (41), 77 (11), 71 (49), 70 (13), 67 (10), 65 (13), 56 (12), 57 (61), 55 (34), 
44 (17), 43 (43), 40 (28). 
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HRMS (EI, 70 eV): m/z calcd. for [C13H15NO]: 201.1154; found: 201.1150 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3456 (w), 3027 (w), 2939 (w), 2874 (vw), 1733 (vw), 1603 
(vw), 1547 (vw), 1489 (m), 1454 (w), 1412 (w), 1330 (w), 1272 (m), 1091 (m), 1063 (m), 1040 (m), 
1000 (w), 939 (w), 819 (vw), 722 (vs), 697 (vs). 
M.p.: 52.6 °C. 
(S)-2-Phenyl-2-(1H-pyrrol-1-yl)ethan-1-ol ((S)-18e) 
 
Following TP9, a solution of (S)-2-phenylglycinol (S)-17e (4.11 g, 30.0 mmol, 1.00 equiv), 
NaOAc⋅3H2O (4.08 g, 30.0 mmol, 1.00 equiv) and 2,5-dimethoxytetrahydrofuran (cis/trans mixture, 
3.97 g, 30.0 mmol, 1.00 equiv) in 1,2-dichloroethane (45 mL), distilled water (45 mL) and glacial acetic 
acid (15 mL) was heated under reflux for 16 h. Purification of the crude product by flash column 
chromatography afforded (S)-18e (5.17 g, 27.6 mmol, 92% yield) as a yellowish oil. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.38 – 7.27 (m, 3H), 7.18 – 7.14 (m, 2H), 6.82 (t, J = 2.2 Hz, 
2H), 6.24 (t, J = 2.1 Hz, 2H), 5.26 (dd, J = 8.3, 5.1 Hz, 1H), 4.27 – 4.12 (m, 3H), 1.87 (br, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 138.6, 129.0, 128.2, 126.7, 120.1, 108.9, 65.4, 65.0. 
MS (EI, 70 eV, %): m/z = 187 (14), 157 (12), 156 (100), 154 (11), 129 (14), 128 (12). 
HRMS (EI, 70 eV): m/z calcd. for [C12H13NO]: 187.0997; found: 187.0990 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3275 (m), 2953 (w), 2894 (w), 1491 (m), 1449 (s), 1408 (m), 
1326 (m), 1272 (s), 1201 (m), 1095 (m), 1081 (s), 1056 (s), 1029 (vs), 999 (s), 939 (m), 852 (w), 829 
(w), 748 (m), 722 (vs), 697 (vs). 
(R)-3-(1H-Indol-3-yl)-2-(1H-pyrrol-1-yl)propan-1-ol ((R)-18f) 
 
Following TP9, a solution of D-tryptophanol (R)-17f (3.81 mmol, 20.0 mmol, 1.00 equiv), 
NaOAc⋅3H2O (3.90 g, 28.7 mmol, 1.44 equiv) and 2,5-dimethoxytetrahydrofuran (cis/trans mixture, 
2.64 g, 20.0 mmol, 1.00 equiv) in 1,2-dichloroethane (40 mL), distilled water (40 mL) and glacial acetic 
acid (4.1 mL) was heated under reflux for 16 h. Purification of the crude product by flash column 
chromatography afforded (R)-18f (3.43 g 14.3 mmol, 71% yield) as a yellowish oil. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.94 (s, 1H), 7.57 (dt, J = 7.7, 1.0 Hz, 1H), 7.34 (dt, J = 8.1, 
0.9 Hz, 1H), 7.22 (ddd, J = 8.2, 7.0, 1.3 Hz, 1H), 7.15 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 6.76 (t, J = 2.0  Hz, 
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2H), 6.66 (d, J = 2.4 Hz, 1H), 6.21 (t, J = 2.1 Hz, 2H), 4.31 (dtd, J = 7.8, 6.6, 5.3 Hz, 1H), 3.85 (t, 
J = 5.9 Hz, 2H), 3.33 – 3.25 (m, 1H), 3.19 (ddd, J = 14.8, 7.8, 0.9 Hz, 1H), 1.66 (t, J = 6.3 Hz, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 136.1, 127.3, 122.6, 122.2, 119.6, 119.4, 118.5, 111.6, 111.3, 
108.5, 65.9, 62.5, 28.0. 
MS (EI, 70 eV, %): m/z = 241 (5), 240 (32), 173 (14), 131 (10), 130 (100). 
HRMS (EI, 70 eV): m/z calcd. for [C15H16N2O]: 240.1263; found: 240.1257 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3402 (m), 2942 (w), 1489 (m), 1456 (m), 1420 (m), 1336 
(m), 1271 (m), 1229 (m), 1091 (s), 1065 (m), 1011 (m), 938 (w), 821 (w), 724 (vs). 
 (S)-3-(4-Methoxyphenyl)-2-(1H-pyrrol-1-yl)propan-1-ol ((S)-18g) 
 
(S)-pc3 (5.78 g, 25.0 mmol, 1.00 equiv) was dissolved in ethanol (50 mL), the resulting solution cooled 
to 0 °C and NaBH4 (1.42 g, 37.5 mmol, 1.50 equiv) was added in small portions. The mixture was 
warmed to room temperature and stirred for 4 h, before all solvent were evaporated. The residue was 
suspended in EtOAc (150 mL), the remaining NaBH4 was quenched with sat. aq. NH4Cl and the organic 
phase separated. After washing with sat. aq. NaHCO3 solution and brine, the organic phase was dried 
over MgSO4, filtered and the solvents removed in vacuo. Purification by flash column chromatography 
yielded the alcohol (S)-18g as a viscous colorless liquid (4.01 g, 17.26 mmol, 69% yield).139 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.97 – 6.91 (m, 2H), 6.81 – 6.75 (m, 2H), 6.70 (t, J = 2.1 Hz, 
2H), 6.17 (t, J = 2.1 Hz, 2H), 4.15 (tt, J = 7.2, 5.9 Hz, 1H), 3.82 (d, J = 5.9 Hz, 2H), 3.77 (s, 3H), 3.02 
(s, 1H), 3.00 (d, J = 1.6 Hz, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 158.5, 130.0, 129.7, 119.3, 114.0, 108.6, 65.5, 63.8, 55.3, 
37.8. 
MS (EI, 70 eV, %): m/z = 231 (32), 200 (11), 198 (13), 164 (53), 121 (100), 110 (30), 91 (12), 82 (59). 
HRMS (EI, 70 eV): m/z calcd. for [C14H17O2N4]: 231.1259; found: 231.1253 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2836 (w), 1612 (m), 1584 (w), 1511 (s), 1490 (m), 1463 (m), 
1328 (w), 1300 (m), 1273 (m), 1243 (vs), 1178 (s), 1091 (m), 1066 (m), 1031 (s), 940 (w), 874 (w), 
831 (m), 816 (m), 766 (w), 722 (vs). 
  
 
139 J.-E. Joo, K.-Y. Lee, V.-T. Pham, Y.-S. Tian, W.-H. Ham, Org. Lett. 2007, 9, 3627. 
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(1S,2S)-2-(1H-Pyrrol-1-yl)cyclohexan-1-ol (S,S-18h) 
 
According to a modified version of TP9, (1S,2S)-2-aminocyclohexan-1-ol hydrochloride (S,S)-17h 
(6.07 g, 40.0 mmol, 1.00 equiv) and NaOAc⋅3H2O (10.9 g, 80 mmol, 2.00 equiv) were dissolved in a 
mixture of 1,2-dichloroethane (65 mL), water (65 mL) and glacial acetic acid (21 mL). Then, 
2,5-dimethoxytetrahydrofuran (cis/trans mixture, 5.29 g, 40.0 mmol, 1.00 equiv) was added and the 
two-phase mixture was stirred vigorously at 90 °C for 16 h. After aqueous workup and purification via 
flash column, (S,S)-18h was obtained as yellowish solid (5.45 g, 33.0 mmol, 83% yield, d.r. > 99.1). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.74 (t, J = 2.2 Hz, 2H), 6.17 (t, J = 2.2 Hz, 2H), 3.65 – 3.54 
(m, 2H), 2.15 – 1.98 (m, 3H), 1.88 – 1.79 (m, 2H), 1.77 – 1.64 (m, 1H), 1.46 – 1.30 (m, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 119.2, 108.4, 74.3, 65.8, 33.3, 32.4, 25.4, 24.4. 
MS (EI, 70 eV, %): m/z = 166 (10), 165 (100), 106 (22), 94 (21), 93 (10), 81 (15), 80 (20), 79 (11), 68 
(48), 67 (12). 
HRMS (EI, 70 eV): m/z calcd. for [C10H15NO]: 165.1154; found: 165.1148 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3466 (w), 2933 (m), 2858 (w), 1668 (vw), 1490 (m), 1450 
(m), 1414 (w), 1360 (w), 1274 (s), 1232 (w), 1134 (w), 1088 (s), 1062 (s), 1047 (m), 985 (w), 941 (m), 
867 (w), 848 (w), 718 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –2.7. 
M.p. 36.4 °C. 
(1R,2R)-2-(1H-Pyrrol-1-yl)cyclopentan-1-ol ((R,R)-18i) 
 
According to a modified version of TP9, (1R,2R)-2-aminocyclopentan-1-ol hydrochloride (R,R)-17i 
(2.75 mmol, 20.0 mmol, 1.00 equiv) and NaOAc⋅3H2O (6.53 g, 48.0 mmol, 2.40 equiv) were dissolved 
in a mixture of 1,2-dichloroethane (40 mL), water (40 mL) and glacial acetic acid (3 mL). Then, 2,5-
dimethoxytetrahydrofuran (cis/trans mixture, 2.64 g, 20.0 mmol, 1.00 equiv) was added and the two-
phase mixture was stirred vigorously at 90 °C for 16 h. After aqueous workup and purification via flash 
column, (R,R)-18i was obtained as colorless liquid (2.33 g, 15.4 mmol, 77% yield, d.r. >99:1). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.76 (t, J = 2.1 Hz, 2H), 6.18 (t, J = 2.2 Hz, 2H), 4.17 – 4.03 
(m, 2H), 2.43 (d, J = 2.4 Hz, 1H), 2.32 – 2.19 (m, 1H), 2.13 – 2.00 (m, 1H), 2.03 – 1.76 (m, 3H), 1.73 
– 1.57 (m, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 119.1, 108.2, 78.7, 67.5, 31.6, 29.9, 20.0. 
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MS (EI, 70 eV, %): m/z = 151 (100), 106 (56), 94 (74), 80 (58), 68 (100).  
HRMS (EI, 70 eV): m/z calcd. for [C9H13NO]: 151.0997; found: 151.0990 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3361 (w), 2962 (w), 2878 (w), 1666 (vw), 1491 (m), 1451 
(w), 1418 (w), 1280 (m), 1091 (m), 1064 (m), 1051 (m), 977 (w), 719 (vs). 
3.4 Preparation of β-N-Pyrrolyl-Alkyl Iodides 
1-(2-Iodoethyl)-1H-pyrrole (19a) 
 
According to a modified version of TP9, 2-iodoethan-1-amine hydroiodide (pc1, 5.98 g, 20.0 mmol, 
1.00 equiv) and NaOAc⋅3H2O (13.6 g, 100 mmol, 5.00 equiv) were dissolved in 10 mL glacial acetic 
acid. To the reaction mixture 2,5-dimethoxytetrahydrofuran (cis/trans mixture, 2.91 g, 20.0 mmol, 
1.00 equiv) was added and the mixture was refluxed at 90 °C for 1 h. The reaction was quenched with 
water and neutralized with saturated NaHCO3, extracted with ethyl acetate and the combined organic 
layers were washed with brine and dried over MgSO4. The crude product was purified by flash column 
chromatography to yield the alkyl iodide 19a as a yellowish liquid (3.12 g, 14.1 mmol, 71% yield).140 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.69 (t, J = 2.1, 2H), 6.19 (t, J = 2.1 Hz, 2H), 4.25 (t, J = 7.5 Hz, 
2H), 3.40 (t, J =7.5 Hz, 2H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 120.5, 108.9, 52.0, 3.4. 
MS (EI, 70 eV, %): m/z = 221 (100), 193 (35), 155 (18), 127 (14), 94 (44), 80 (20). 
HRMS (ESI): m/z calc. for [C6H8IN]: 220.9701; found: 220.9695 ([M]
+). 
IR (Diamond-ATR, neat, cm-1): 𝜈 = 3098 (vw), 2963 (vw), 2363 (vw), 1556 (w), 1495 (m), 1445 (w), 
1418 (w), 1350 (w), 1290 (m), 1276 (s), 1238 (m), 1172 (m), 1087 (s), 1064 (m), 964 (m), 834 (w), 717 
(vs). 
(R)-1-(1-Iodopropan-2-yl)-1H-pyrrole ((R)-19b) 
 
According to TP10, a solution of (R)-18b (2.47 g, 19.7 mmol, 1.00 equiv) in dry DCM (30 mL) was 
added dropwise to a 0 °C solution of PPh3 (6.20 g, 23.6 mmol, 1.20 equiv), imidazole (1.61 g, 
23.6 mmol, 1.20 equiv) and iodine (6.00 g, 23.6 mmol, 1.20 equiv) in dry DCM (33 mL) over a period 
of 30 min. The mixture was then allowed to warm to room temperature and stirred for an additional 
90 min. After quenching with Na2S2O3, extraction with DCM and purification via flash column 
 
140 Gracia, S.; Cazorla, C.; Métay, E.; Pellet-Rostaing, S.; Lemaire, M. J. Org. Chem. 2009, 74, 3160. 
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chromatography (R)-19b (4.23 g, 18.0 mmol, 91% yield, 99.7% ee) was obtained as a faint yellow 
liquid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.66 (t, J = 2.1 Hz, 2H), 6.18 (t, J = 2.1 Hz, 2H), 3.71 – 3.62 
(m, 2H), 3.51 – 3.43 (m, 1H), 2.18 – 2.04 (m, 1H), 1.03 (d, J = 6.7 Hz, 3H), 0.81 (d, J = 6.7 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 119.5, 108.0, 67.8, 34.4, 20.3, 19.4, 8.9. 
MS (EI, 70 eV, %): m/z = 263 (24), 220 (33), 193 (14), 122 (47), 94 (28), 93 (100). 
HRMS (EI, 70 eV): m/z calcd. for [C9H14NI]: 263.0171; found: 263.0164 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2961 (w), 2872 (w), 1545 (vw), 1487 (m), 1469 (w), 1419 
(w), 1387 (w), 1369 (w), 1293 (w), 1272 (m), 1190 (m), 1156 (w), 1087 (m), 1067 (m), 970 (w), 923 
(w), 856 (w), 717 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –49.6. 
(R)-1-(1-Iodo-3-methylbutan-2-yl)-1H-pyrrole ((R)-19c) 
 
According to TP10, a solution of (R)-18c (2.30 g, 15.0 mmol, 1.00 equiv) in dry dichloromethane 
(30 mL) was added dropwise to a 0 °C solution of PPh3 (4.33 g, 16.5 mmol, 1.10 equiv), imidazole 
(1.12 g, 16.5 mmol, 1.10 equiv) and iodine (4.19 g, 16.5 mmol, 1.10 equiv) in dry DCM (33 mL) over 
a period of 30 min. The mixture was then allowed to warm to room temperature and stirred for an 
additional 90 min. After quenching with sat. aq. Na2S2O3 solution, extraction with DCM and 
purification by flash column chromatography (R)-19c (3.46 g, 13.1 mmol, 88% yield, 99.5% ee) was 
obtained as a yellow oil. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.66 (t, J = 2.1 Hz, 2H), 6.18 (t, J = 2.1 Hz, 2H), 3.71 – 3.62 
(m, 2H), 3.51 – 3.43 (m, 1H), 2.18 – 2.04 (m, 1H), 1.03 (d, J = 6.7 Hz, 3H), 0.81 (d, J = 6.7 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 119.5, 108.0, 67.8, 34.4, 20.3, 19.4, 8.9. 
MS (EI, 70 eV, %): m/z = 263 (24), 220 (33), 193 (14), 122 (47), 94 (28), 93 (100). 
HRMS (EI, 70 eV): m/z calcd. for [C9H14NI]: 263.0171; found: 263.0164 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2961 (w), 2872 (w), 1545 (vw), 1487 (m), 1469 (w), 1419 
(w), 1387 (w), 1369 (w), 1293 (w), 1272 (m), 1190 (m), 1156 (w), 1087 (m), 1067 (m), 970 (w), 923 
(w), 856 (w), 717 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –34.0. 
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(S)-1-(1-Iodo-3-phenylpropan-2-yl)-1H-pyrrole ((S)-19d) 
 
Following TP10, (S)-18d (4.23 g, 21.0 mmol, 1.00 equiv) in dry DCM (40 mL) was added dropwise to 
a solution of triphenylphosphine (6.08 g, 23.2 mmol, 1.10 equiv), iodine (5.87 g, 23.1 mmol, 
1.10 equiv) and imidazole (1.58 g, 23.1 mmol, 1.10 equiv) in dry DCM (44 mL) at 0 °C over a period 
of 45 min. The mixture was stirred for another 30 min, allowed to warm to room temperature and stirred 
for an additional 90 min. Quenching with Na2S2O3, extraction with DCM and purification by flash 
column chromatography afforded (S)-19d (5.52 g, 17.7 mmol, 84% yield, 99.9% ee) as a yellow oil.  
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.26 – 7.16 (m, 3H), 7.02 – 6.97 (m, 2H), 6.61 (t, J = 2.1 Hz, 
2H), 6.14 (t, J = 2.2 Hz, 2H), 4.19 (tt, J = 7.7, 5.9 Hz, 1H), 3.51 (dd, J = 10.5, 5.5 Hz, 1H), 3.42 (dd, 
J = 10.5, 7.6 Hz, 1H), 3.22 (dd, J = 13.8, 6.3 Hz, 1H), 3.11 (dd, J = 13.7, 7.9 Hz, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 137.2, 129.0, 128.7, 127.1, 118.9, 108.5, 62.9, 42.1, 9.5. 
MS (EI, 70 eV, %): m/z = 311 (24), 220 (84), 117 (14), 115 (16), 93 (100), 91 (26). 
HRMS (EI, 70 eV): m/z calcd. for [C13H14NI]: 311.0171; found: 311.0163 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3061 (vw), 3025 (w), 2946 (vw), 1603 (vw), 1545 (vw), 1486 
(m), 1453 (w), 1414 (w), 1328 (w), 1273 (m), 1175 (m), 1089 (m), 1069 (m), 1030 (w), 964 (w), 917 
(w), 867 (vw), 821 (vw), 719 (vs), 697 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –1.5. 
(S)-1-(2-Iodo-1-phenylethyl)-1H-pyrrole ((S)-19e) 
 
Following TP10, (S)-18e (4.68 g, 25.0 mmol, 1.00 equiv) in dry DCM (40 mL) was added dropwise to 
a solution of triphenylphosphine (7.21 g, 27.5 mmol, 1.10 equiv), iodine (6.98 g, 27.5 mmol, 
1.10 equiv) and imidazole (1.87 g, 27.5 mmol, 1.10 equiv) in dry DCM (44 mL) at 0 °C over a period 
of 30 min. The mixture was stirred for another 30 min, allowed to warm to room temperature and stirred 
for an additional 3 h. Quenching with Na2S2O3, extraction with DCM and purification by flash column 
chromatography afforded (S)-19e (5.28 g, 17.8 mmol, 71% yield, 99.8% ee) as a yellow oil.  
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.40 – 7.32 (m, 3H), 7.23 – 7.17 (m, 2H), 6.78 (t, J = 2.1 Hz, 
2H), 6.25 (t, J = 2.1 Hz, 2H), 5.33 (dd, J = 9.5, 6.0 Hz, 1H), 3.86 (dd, J = 10.8, 6.1 Hz, 1H), 3.77 (dd, 
J =10.8, 9.5 Hz, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 139.6, 129.1, 128.5, 126.5, 119.6, 108.9, 65.2, 6.9. 
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MS (EI, 70 eV, %): m/z = 297 (45), 231 (31), 193 (59), 170 (39), 168 (31), 167 (14), 156 (25), 104 
(100), 103 (22), 78 (22), 77 (14). 
HRMS (EI, 70 eV): m/z calcd. for [C12H12NI]: 297.0014; found: 297.0005 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3059 (vw), 3028 (vw), 1485 (m), 1450 (m), 1423 (w), 1311 
(w), 1277 (m), 1175 (m), 1128 (w), 1089 (m), 1068 (m), 1022 (w), 961 (w), 913 (vw), 859 (w), 752 
(w), 718 (vs), 695 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +31.2. 
 
(R)-3-(3-Iodo-2-(1H-pyrrol-1-yl)propyl)-1H-indole ((R)-19f) 
 
Following TP10, (R)-18f (2.40 g, 10.0 mmol, 1.00 equiv) in dry DCM (20 mL) was added dropwise to 
a solution of PPh3 (2.75 g, 10.5 mmol, 1.05 equiv), imidazole (715 mg, 10.5 mmol, 1.05 equiv) and 
iodine (2.67 g, 10.5 mmol, 1.05 equiv) in dry DCM (21 mL) at 0 °C over a period of 30 min. The 
mixture was stirred for another 30 min, allowed to warm to room temperature and stirred for an 
additional 2h. Quenching with Na2S2O3, extraction with DCM and purification by flash column 
chromatography afforded (R)-19f as a yellowish oil (2.96 g, 8.45 mmol, 84% yield, 99.5% ee) 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.91 (s, 1H), 7.59 (dd, J = 7.8, 1.1 Hz, 1H), 7.37 (dt, 
J = 8.1 Hz, 0.9, 1H), 7.29 – 7.20 (m, 1H), 7.18 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 6.72 (t, J = 2.1 Hz, 2H), 
6.69 (d, J = 2.4 Hz, 1H), 6.21 (t, J = 2.2 Hz, 2H), 4.37 – 4.28 (m, 1H), 3.59 (dd, J = 10.4, 5.4 Hz, 1H), 
3.49 (dd, J = 10.4, 7.4 Hz, 1H), 3.47 (dd, J = 14.7, 6.5 Hz, 1H), 3.28 (ddd, J = 14.7, 7.7, 0.9 Hz, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 136.0, 127.1, 122.9, 122.3, 119.8, 119.0, 118.4, 111.4, 111.1, 
108.3, 61.5, 31.6, 10.4. 
MS (EI, 70 eV, %): m/z = 350 (5), 156 (2), 131 (10), 130 (100), 128 (3), 93 (3), 77 (2). 
HRMS (EI, 70 eV): m/z calcd. for [C15H15IN2]: 350.0280; found: 350.0267 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3409 (m), 1487 (m), 1456 (m), 1419 (m), 1336 (m), 1272 
(m), 1228 (m), 1177 (m), 1090 (s), 1066 (m), 1010 (m), 918 (w), 809 (w), 721 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +5.7. 
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(S)-1-(1-Iodo-3-(4-methoxyphenyl)propan-2-yl)-1H-pyrrole ((S)-19g) 
 
Following TP10, (S)-18g (3.47 g, 15.0 mmol, 1.00 equiv) in dry DCM (30 mL) was added dropwise to 
a solution of PPh3 (4.72 g, 18.0 mmol, 1.05 equiv), imidazole (1.23 g, 18.0 mmol, 1.05 equiv) and 
iodine (4.57 g, 18.0 mmol, 1.05 equiv) in dry DCM (36 mL) at 0 °C over a period of 30 min. The 
mixture was stirred for another 30 min, allowed to warm to room temperature and stirred for an 
additional 2 h. Quenching with Na2S2O3, extraction with DCM and purification by flash column 
chromatography afforded (S)-19g as a colorless oil (4.86 g, 14.3 mmol, 95% yield, 92.0% ee) 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.94 – 6.89 (m, 2H), 6.82 – 6.76 (m, 2H), 6.63 (t, J = 2.1 Hz, 
2H), 6.16 (t, J = 2.1 Hz, 2H), 4.16 (tt, J = 7.7 Hz, 6.1, 1H), 3.78 (s, 3H), 3.53 (dd, J = 10.5, 5.5 Hz, 1H), 
3.43 (dd, J = 10.5, 7.7 Hz, 1H), 3.17 (dd, J = 13.9, 6.3 Hz, 1H), 3.07 (dd, J = 13.9, 7.8 Hz, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 158.6, 130.0, 129.1, 118.9, 114.1, 108.4, 63.0, 55.3, 41.2, 9.6. 
MS (EI, 70 eV, %): m/z = 341 (20), 147 (9), 121 (100), 93 (16), 77 (10). 
HRMS (EI, 70 eV): m/z calcd. for [C14H16INO]: 341.0277; found: 341.0271 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 1611 (m), 1511 (s), 1487 (m), 1463 (m), 1440 (m), 1301 (m), 
1273 (m), 1244 (vs),1177 (s), 1090 (m), 1069 (m), 1032 (s), 963 (w), 934 (w), 817 (m), 810 (m), 
719 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –4.4. 
1-((1S,2R)-2-Iodocyclohexyl)-1H-pyrrole (S,R-19h) 
 
Based on a modified version of TP10, PPh3 (4.93 g, 18.8 mmol, 1.20 equiv), imidazole (1.28 g, 
18.8 mmol, 1.20 equiv) and iodine (4.77 g, 18.8 g, 1.20 equiv) were dissolved in DCM (30 mL) at 0 °C 
and stirred for 15 min. A solution of (S,S)-18h (2.60 g, 15.7 mmol, 1.00 equiv) in DCM (38 mL) was 
added dropwise to the reaction mixture over 30 min. Afterwards, cooling was removed and the reaction 
heated up to 50 °C for 30 h. After quenching with NaS2O3-solution, aqueous workup and purification 
via flash column chromatography, (S,R)-19h  was obtained as a colorless oil (3.30 g, 12.0 mmol, 
76% yield, 99.8% ee). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.74 (t, J = 2.2 Hz, 2H), 6.18 (t, J = 2.1 Hz, 2H), 4.90 (tq, 
J = 3.1, 1.5 Hz, 1H), 3.26 (dt, J = 11.7, 3.3 Hz, 1H), 2.30 – 2.21 (m, 1H), 2.21 – 2.09 (m, 1H), 2.04 – 
1.87 (m, 2H), 1.82 (tt, J = 12.7, 3.4 Hz, 1H), 1.70 – 1.61 (m, 1H), 1.58 – 1.43 (m, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 118.5, 108.0, 60.5, 44.4, 35.2, 28.1, 25.4, 21.8. 
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MS (EI, 70 eV, %): m/z = 275 (49), 193 (129), 148 (100), 127 (12), 118 (24), 106 (16), 81 (76), 80 
(38), 79 (66), 77 (15), 68 (63), 67 (29).  
HRMS (EI, 70 eV): m/z calcd. for [C10H14IN]: 275.0171; found: 275.0164 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2936 (m), 2860 (w), 1488 (m), 1445 (w), 1297 (m), 1279 
(m), 1256 (m), 1162 (m), 1093 (m), 1055 (w), 998 (m), 956 (m), 834 (w), 714 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –59.4. 
1-((1R,2S)-2-Iodocyclopentyl)-1H-pyrrole ((R,S)-19i) 
 
According to a modified version of TP10, PPh3 (4.32 g, 16.5 mmol, 1.10 equiv) and imidazole (1.12 g, 
16.5 mmol, 1.10 equiv) were dissolved in dry DCM (20 mL). Iodine (4.19 g, 16.5 mmol, 1.10 equiv) 
was added in small portions at 0 °C, followed by the addition of (R,R)-18i (2.27 g, 15.0 mmol, 
1.00 equiv) in dry DCM (20 mL) over a period of 30 min. The resulting reaction mixture further stirred 
for 30 min at room temperature and refluxed at 50 °C for 16 h. The reaction mixture was quenched with 
sat. aq. Na2S2O3 (75 mL) and diluted with water (75 mL). After extraction with DCM (3x150 mL), the 
combined organic phases were dried over MgSO4 and the solvent evaporated. Purification by flash 
column chromatography afforded the title (R,S)-19i compound as white solid (1.67 g, 6.64 mmol, 
43% yield, 98.1% ee, d.r. >99:1). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.75 (t, J = 2.2 Hz, 2H), 6.19 (t, J = 2.2 Hz, 2H), 4.63 (td, 
J = 5.0, 3.5 Hz, 1H), 3.83 (ddd, J = 9.4, 7.4, 4.9 Hz, 1H), 2.55 – 2.44 (m, 1H), 2.44 – 2.28 (m, 2H), 2.25 
– 2.06 (m, 2H), 1.89 – 1.75 (m, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 119.8, 108.1, 63.7, 37.4, 36.0, 27.9, 21.1. 
MS (EI, 70 eV, %): m/z = 261 (100), 192 (51), 134 (92), 127 (81), 106 (51), 68 (76). 
HRMS (EI, 70 eV): m/z calcd. for [C9H12IN]: 261.0014; found: 261.0010 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2959 (m), 2915 (w), 2855 (w), 1492 (m), 1443 (w), 1362 (w), 
1337 (m), 1296 (w), 1280 (m), 1261 (s), 1199 (w), 1174 (m), 1100 (s), 1063 (s), 1018 (s), 976 (m), 922 
(w), 870 (w), 796 (vs), 727 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +97.5. 
M.p. 77.4 °C. 
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3.5 Preparation of Organozinc Reagents from Chiral β-N-Pyrrolyl-Alkyl Iodides 
(2-(1H-Pyrrol-1-yl)ethyl)zinc(II) iodide (20a) 
 
According to TP11, LiCl (424 mg, 10.0 mmol, 1.00 equiv) and zinc dust (981 mg, 15.0 mmol, 
1.50 equiv) were dried and suspended in freshly distilled dry THF (15 mL). After activation with DBE 
and TMSCl, the suspension was cooled with a water-bath and 19a (2.21 g, 10.0 mmol, 1.00 equiv) was 
added dropwise. After 10 min, the reaction mixture was passed through a syringe filter and a 0.58 M 
yellow solution of the title compound 20a was obtained (16.0 mL, 9.28 mmol, 93% yield).  
(R)-(2-(1H-Pyrrol-1-yl)propyl)zinc(II) iodide ((R)-20b) 
 
According to TP11, LiCl (255 mg, 6.00 mmol, 1.00 equiv) and zinc powder (588 mg, 9.00 mmol, 
1.50 equiv) were dried. Dry THF (9.0 mL) was added and the zinc powder was activated using DBE 
and TMSCl. (R)-19b (1.41 g, 6.00 mmol, 1.00 equiv) was added dropwise and the reaction mixture was 
stirred for 20 min. After syringe-filtration (R)-20b was obtained as a 503 mM yellow solution in THF 
(9.10 mL, 4.58 mmol, 76% yield). 
(R)-(3-Methyl-2-(1H-pyrrol-1-yl)butyl)zinc(II) iodide ((R)-20c) 
 
According to TP11, LiCl (170 mg, 4.00 mmol, 1.00 equiv) and zinc powder (392 mg, 6.00 mmol, 
1.50 equiv) were dried. Freshly distilled THF (6.0 mL) was added and the zinc powder was activated 
using DBE and TMSCl. (R)-19c (1.05 g,4.00 mmol, 1.00 equiv) was added dropwise and the reaction 
mixture was stirred for 10 min. After syringe-filtration, (R)-20c was obtained as a 0.52 M yellow 
solution in THF (6.10 mL, 3.18 mmol, 80% yield). 
(S)-(3-Phenyl-2-(1H-pyrrol-1-yl)propyl)zinc(II) iodide ((S)-20d) 
 
Following TP11, LiCl (340 mg, 8.02 mmol, 1.00 equiv) and zinc dust (785 mg, 12.0 mmol, 1.50 equiv) 
were dried, suspended in dry THF (12 mL) and activated with DBE and TMSCl. (S)-19d (2.49 g, 
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8.00 mmol, 1.00 equiv) was added dropwise. After 10 min, the suspension was filtered with a syringe 
filter and a 0.50 M yellow solution of (S)-20d in THF (13.0 mL, 6.52 mmol, 82% yield) was obtained. 
(S)-(2-Phenyl-2-(1H-pyrrol-1-yl)ethyl)zinc(II) iodide ((S)-20e) 
 
Following TP11, LiCl (255 mg, 6.00 mmol, 1.00 equiv) and zinc dust (589 mg, 9.00 mmol, 
1.50 equiv) were dried, suspended in dry THF (9 mL) and activated with DBE and TMSCl. (S)-19e 
(1.78 g, 6.00 mmol, 1.00 equiv) was added dropwise. After 90 min, the suspension was filtered with a 
syringe filter and a 0.45 M yellow solution of (S)-20e in THF (9.50 mL, 4.28 mmol, 71% yield) was 
obtained. 
(R)-(3-(1H-Indol-3-yl)-2-(1H-pyrrol-1-yl)propyl)zinc(II) iodide ((R)-20f) 
 
Following TP11, LiCl (314 mg, 7.40 mmol, 1.00 equiv) and zinc dust (726 mg, 11.1 mmol, 
1.50 equiv) were dried, suspended in dry THF (15 mL) and activated with DBE and TMSCl. (R)-19f 
(2.60 g, 7.40 mmol, 1.00 equiv) was added dropwise. After 30 min, the suspension was filtered with a 
syringe filter and a 0.42 M solution of (R)-20f in THF (16.0 mL, 6.78 mmol, 91% yield) was obtained. 
(S)-(3-(4-Methoxyphenyl)-2-(1H-pyrrol-1-yl)propyl)zinc(II) iodide ((S)-20g) 
 
Following TP11, LiCl (254 mg, 6.00 mmol, 1.00 equiv) and zinc dust (588 mg, 9.00 mmol, 
1.50 equiv) were dried, suspended in dry THF (12 mL) and activated with DBE and TMSCl. (S)-19g 
(2.44 g, 6.00 mmol, 1.00 equiv) was added dropwise. After 15 min, the suspension was filtered with a 
syringe filter and a 0.47 M solution of (S)-20g in THF (12.0 mL, 5.64 mmol, 95% yield) was obtained. 
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(S)-(2-(1H-Pyrrol-1-yl)cyclohexyl)zinc(II) iodide ((S)-20h) 
 
According to TP11, LiCl (140 mg, 3.30 mmol, 1.00 equiv) and zinc powder (324 mg, 4.95 mmol, 
1.50 equiv) were dried. Freshly distilled THF (6.6 mL) was added and the zinc powder was activated 
using DBE and TMSCl. (S,R)-19h (908 mg, 3.30 mmol, 1.00 equiv) was added dropwise and the 
reaction mixture was stirred for 10 min. After syringe-filtration, (S)-20h was obtained as a 0.39 M 
yellow solution (6.6 mL, 2.60 mmol, 79% yield). 
(R)-(2-(1H-Pyrrol-1-yl)cyclopentyl)zinc(II) iodide (R-20i) 
 
According to TP11, LiCl (212 mg, 5.00 mmol, 1.00 equiv) and zinc powder (490 mg, 7.50 mmol, 
1.50 equiv) were dried. Freshly distilled THF (10 mL) was added and the zinc powder was activated 
using DBE and TMSCl. (R,S)-19i (1.31 g, 5.00 mmol, 1.00 equiv) was added dropwise and the reaction 
mixture was stirred for 10 min. After syringe-filtration, (R)-20i was obtained as a 0.48 M clear solution 
(10.0 mL, 4.78 mmol, 96% yield). 
 
3.6 Transition-Metal-Catalyzed Reactions using β-N-Pyrrolyl-Alkylzinc Reagents 
2-(2-(1H-Pyrrol-1-yl)ethyl)aniline (21a) 
 
According to TP12 a freshly prepared solution of 20a (1.03 mL, 0.58 M, 0.60 mmol, 1.20 equiv) was 
added dropwise to a solution of 2-bromoaniline (86.0 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 (2.25 mg, 
10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL) and stirred for 16 h. 
The reaction mixture was quenched with sat. aq. NH4Cl solution and extracted with EtOAc. The crude 
product was purified by flash column chromatography to afford 21a (91 mg, 0.49 mmol, 98% yield) as 
a brownish liquid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.12 (t, J = 8.0 Hz, 1H), 6.65 (t, J = 2.0 Hz, 2H), 6.62 (dd, 
J = 8.0, 0.8 Hz, 1H), 6.09 (d, J = 7.6 Hz, 2H), 6.47 (t, J = 2.0 Hz,1H), 6.16 (t, J = 2.0 Hz,1H), 4.11 (t, 
J = 7.6 Hz, 2H), 3.55 (br, 2H), 2.99 (t, J = 7.6 Hz, 2H). 
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13C-NMR (101 MHz, CDCl3, ppm): δ = 145.9, 139.7, 129.5, 120.5, 119.2, 115.7, 113.7, 107.9, 51.0, 
38.3. 
MS (EI, 70 eV, %): m/z = 186 (100), 185 (26), 184 (13), 119 (49), 106 (9), 80 (61). 
HRMS (EI, 70 eV): m/z calcd. for [C12H14N2]: 186.1157; found: 186.1145 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3436 (w), 3356 (w), 2925 (w), 2870 (w), 1618 (s), 1604 (s), 
1589 (m), 1495 (s), 1459 (m), 1279 (s), 1168 (m), 1088 (s), 1066 (m), 865 (w), 780 (m), 722 (vs), 
691 (s). 
1-(4-Methoxyphenethyl)-1H-pyrrole (21b) 
 
According to TP12, a freshly prepared solution of 20a (1.03 mL, 0.58 M, 0.60 mmol, 1.20 equiv) was 
added dropwise to a solution of 4-iodoanisole (117 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 (2.25 mg, 
10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL). The resulting 
reaction mixture was stirred for 16 h and quenched with sat. aq. NH4Cl solution. Extraction with EtOAc 
and purification by flash column chromatography afforded 21b (96.0 mg, 0.48 mmol, 95% yield) as a 
colorless solid. 
In a large-scale attempt, the same procedure was carried out using 1.17 g (5.00 mmol, 1.00 equiv) of 
ethyl 4-iodoanisole and a freshly prepared solution of 20a (10.3 mL, 0.58 M, 6.00 mmol, 1.20 equiv) 
with catalytic amounts of Pd(OAc)2 (23.0 mg, 0.10 mmol, 2 mol%) and SPhos (82.0 mg, 0.20 mmol, 
4 mol%), yielding 908 mg (4.51 mmol, 90% yield) of 21b. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.05 – 6.98 (m, 2H), 6.87 – 6.81 (m, 2H), 6.61 (t, J = 2.1 Hz, 
2H), 6.14 (t, J = 1.9, 2H), 4.08 (dd, J = 8.0, 6.8 Hz, 2H), 3.81 (s, 3H), 3.01 (t, J = 7.4 Hz, 2H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 158.4, 130.6, 129.8, 120.6, 114.0, 108.0, 55.4, 51.5, 37.6. 
MS (EI, 70 eV, %): m/z = 201 (13), 134 (33), 122 (10), 121 (100), 91 (12), 80 (23). 
HRMS (EI, 70 eV): m/z calcd. for [C13H15NO]: 201.1154; found: 201.1143 ([M
+]). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2929 (w), 2360 (w), 1704 (w), 1613 (m), 1513 (vs), 1500 
(m), 1458 (w), 1282 (m), 1247 (s), 1179 (m), 1089 (w), 1035 (m), 824 (w), 724 (s). 
M.p. 40.6 °C. 
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Ethyl 4-(2-(1H-pyrrol-1-yl)ethyl)benzoate (21c) 
 
Following TP12, ethyl 4-iodobenzoate (138 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 (2.25 mg, 
10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) were dissolved in dry THF (1 mL). A 
freshly prepared solution of 20a (1.03 mL, 0.58 M, 0.60 mmol, 1.20 equiv) was added dropwise and 
the reaction mixture was stirred for 16 h. After quenching and extraction, the crude product was purified 
by flash column chromatography to afford 21c (118 mg, 0.49 mmol, 97% yield) as a yellow oil. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.99 – 7.92 (m, 2H), 7.16 – 7.11 (m, 2H), 6.57 (t, J = 2.1 Hz, 
2H), 6.12 (t, J = 2.1 Hz, 2H), 4.37 (q, J = 7.1 Hz, 2H), 4.13 (t, J = 7.2 Hz, 2H), 3.10 (t, J = 7.2 Hz, 2H), 
1.40 (t, J = 7.2 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 166.6, 143.8, 129.9, 129.0, 128.8, 120.6, 108.3, 61.0, 50.8, 
38.5, 14.5. 
MS (EI, 70 eV, %): m/z = 243 (46), 198 (10), 131 (13), 80 (100). 
HRMS (EI, 70 eV): m/z calcd. for [C15H17NO2]: 243.1259; found: 243.1245 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2981 (w), 2930 (w), 1713 (s), 1612 (w), 1500 (w), 1416 (w), 
1366 (w), 1310 (w), 1276 (vs), 1180 (w), 1105 (m), 1070 (w), 1022 (w), 852 (vw), 767 (w), 726 (m), 
706 (w). 
1-(4-Fluoro-3-methylphenethyl)-1H-pyrrole (21d) 
 
According to TP12, a freshly prepared solution of 20a (1.03 mL, 0.58 M, 0.60 mmol, 1.20 equiv) was 
added dropwise to a solution of 2-fluoro-5-iodotoulene (118 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 
(2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL). The 
reaction mixture was stirred for 16 h and afterwards quenched with sat. aq. NH4Cl solution and extracted 
with EtOAc. The crude product was purified by flash column chromatography to afford 21d (84.0 mg, 
0.41 mmol, 83% yield) as a colorless liquid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.98 – 6.87 (m, 3H), 6.64 (t, J = 1.6 Hz, 2H), 6.19 (t, J = 1.6 
Hz, 2H), 4.12 (t, J = 7.2 Hz, 2H), 3.03 (t, J = 7.2 Hz, 2H), 2.30 (s, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 160.2 (d, J = 244.4 Hz), 133.7 (d, J = 4.0 Hz), 131.6 (d, J = 
5.1 Hz), 127.2 (d, J = 7.1 Hz), 124.7 (d, J = 17.2 Hz), 120.4, 114.9 (d, J = 23.2 Hz), 108.0, 51.2 (d, J = 
1.0 Hz), 37.5, 14.4 (d, J = 4.0 Hz). 
19F-NMR (377 MHz, CDCl3, ppm): δ = –120.8. 
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MS (EI, 70 eV, %): m/z = 203 (10), 136 (16), 123 (23), 80 (100), 78 (14). 
HRMS (EI, 70 eV): m/z calcd. for [C13H14FN]: 203.1110; found: 203.1097 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2926 (w), 2871 (vw), 1498 (s), 1440 (w), 1359 (w), 1283 
(m), 1248 (m), 1210 (m), 1119 (m), 1088 (m), 1069 (w), 969 (w), 817 (m), 758 (w), 718 (vs). 
3-(2-(1H-Pyrrol-1-yl)ethyl)benzonitrile (21e) 
 
According to TP12, 3-iodobenzonitrile (115 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 (2.25 mg, 
10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) were dissolved in dry THF (1 mL). A 
freshly prepared solution of 20a (1.03 mL, 0.58 M, 0.60 mmol, 1.20 equiv) was added dropwise and 
the reaction mixture stirred for 16 h. The reaction mixture was quenched with sat. aq. NH4Cl solution 
and extracted with EtOAc. The crude product was purified by flash column chromatography to afford 
21e as a brownish liquid (83 mg, 0.43 mmol, 85% yield). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.54 (dt, J = 7.6, 1.2 Hz, 1H), 7.38 (t, J = 7.6 Hz, 1H), 7.33 (t, 
J = 1.6 Hz, 1H), 7.54 (dt, J = 7.6, 1.6 Hz, 1H), 6.55 (t, J = 2.0 Hz, 2H), 6.14 (t, J = 2.0 Hz, 2H), 4.13 (t, 
J = 7.0 Hz, 2H), 3.09 (t, J = 7.0 Hz, 2H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 139.8, 133.2, 132.2, 130.4, 129.3, 120.4, 118.7, 112.5, 108.4, 
50.5, 37.7. 
MS (EI, 70 eV, %): m/z = 196 (9), 116 (15), 89 (16), 80 (100), 78 (15). 
HRMS (EI, 70 eV): m/z calcd. for [C13H12N2]: 196.1000; found: 196.0990 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2923 (m), 2853 (w), 2228 (w), 1498 (m), 1460 (w), 1441 (w), 
1361 (w), 1281 (m), 1088 (m), 1068 (m), 1023 (w), 969 (w), 916 (w), 796 (m), 722 (vs), 687 (s). 
2-(2-(1H-Pyrrol-1-yl)ethyl)-5-(trifluoromethyl)pyridine (21f) 
 
According to TP12, a freshly prepared solution of 20a (1.03 mL, 0.58 M, 0.60 mmol, 1.20 equiv) was 
added dropwise to a solution of 2-chloro-5-trifluoromethylpyridine (91.0 mg, 0.50 mmol, 1.00 equiv), 
Pd(OAc)2 (2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL). 
The reaction mixture was stirred for 16 h and afterwards quenched with sat. aq. NH4Cl solution and 
extracted with EtOAc. The crude product was purified by flash column chromatography to afford 21f 
(99.0 mg, 0.41 mmol, 82% yield) as a colorless solid. 
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1H-NMR (400 MHz, CDCl3, ppm): δ = 8.87 (s, 1H), 7.80 (dd, J = 8.0, 2.0 Hz, 1H), 7.07 (d, J = 8.0 Hz, 
1H), 6.59 (t, J = 2.0 Hz, 2H), 6.12 (t, J = 2.0 Hz, 2H), 4.37 (t, J = 7.0 Hz, 2H), 3.32 (t, J = 7.0 Hz, 2H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 162.3 (q, J = 1.0 Hz), 146.3 (q, J = 4.0 Hz), 133.6 (q, 
J = 4.0 Hz), 124.8 (q, J = 33.0 Hz), 123.5 (q, J = 273.7 Hz), 123.3, 120.4, 108.3, 48.6, 40.3. 
19F-NMR (377 MHz, CDCl3, ppm): δ = –62.3 
MS (EI, 70 eV, %): m/z = 240 (6), 174 (35), 161 (22), 147 (13), 80 (100), 78 (16), 67 (8). 
HRMS (EI, 70 eV): m/z calcd. for [C12H11F3N2]: 240.0874; found: 240.0862 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2931 (w), 1605 (m), 1573 (m), 1498 (w), 1395 (w), 1326 (s), 
1282 (m), 1167 (m), 1119 (vs), 1079 (s), 1067 (s), 1031 (w), 1015 (m), 968 (w), 944 (w), 863 (m), 843 
(m), 722 (vs). 
M.p. 38.5 °C. 
Ethyl 2-(2-(1H-pyrrol-1-yl)ethyl)nicotinate (21g) 
 
According to TP12, a freshly prepared solution of 20a (1.03 mL, 0.58 M, 0.60 mmol, 1.20 equiv) was 
added dropwise to a solution of 2-chloronicotinate (93.0 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 
(2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL). The 
reaction mixture was stirred for 16 h and afterwards quenched with sat. aq. NH4Cl solution and extracted 
with EtOAc. The crude product was purified by flash column chromatography to afford 21g (116 mg, 
0.48 mmol, 95% yield) as a yellowish solid. 
In a large-scale attempt, the same procedure was carried out using 427 mg (2.30 mmol, 1.00 equiv) of 
ethyl 2-chloronicotinate and a freshly prepared solution of 20a (4.76 mL, 0.58 M, 2.76 mmol, 
1.20 equiv) with catalytic amounts of Pd(OAc)2 (11.0 mg, 46.0 µmol, 2 mol%) and SPhos (38.0 mg, 
92.0 µmol, 4 mol%), affording 512 mg (2.10 mmol, 90% yield) of 21g. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.68 (dd, J = 4.8, 1.8 Hz, 1H), 8.21 (dd, J = 7.9, 1.8 Hz, 1H), 
7.26 (dd, J = 8.0, 4.8 Hz, 1H), 6.70 (t, J = 2.1 Hz, 2H), 6.11 (t, J = 2.1 Hz, 2H), 4.38 (q, J = 7.1 Hz, 
2H), 4.35 – 4.29 (m, 2H), 3.69 – 3.63 (m, 2H), 1.40 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 166.2, 159.4, 151.9, 138.8, 126.3, 121.6, 120.7, 108.0, 61.7, 
49.1, 39.2, 14.4. 
MS (EI, 70 eV, %): m/z = 245 (15), 244 (100), 215 (61), 199 (21), 197 (27), 178 (77), 171 (57), 170 
(10, 169 (26), 165 (11), 150 (46), 148 (11), 132 (16), 104 (10), 93 (20), 80 (49), 78 (10). 
HRMS (EI, 70 eV): m/z calcd. for [C14H16N2O2]: 244.1212; found: 244.1204 ([M
+]). 
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FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3092 (w), 2988 (w), 1715 (vs), 1572 (m), 1501 (w), 1444 
(m), 1361 (w), 1282 (m), 1262 (s), 1245 (s), 1235 (s), 1137 (s), 1085 (vs), 1057 (s), 1020 (m), 967 (m), 
866 (w), 829 (w), 780 (m), 734 (vs), 707 (s). 
M.p. 57.1 °C. 
5-(2-(1H-Pyrrol-1-yl)ethyl)-1H-indole (21h) 
 
According to TP12, a freshly prepared solution of 20a (1.03 mL, 0.58 M, 0.60 mmol, 1.20 equiv) was 
added dropwise to a solution of 5-bromoindole (98.0 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 (2.25 mg, 
10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL). The reaction mixture 
was stirred for 16 h and afterwards quenched with sat. aq. NH4Cl solution and extracted with EtOAc. 
The crude product was purified by flash column chromatography to afford 21h (95 mg, 0.45 mmol, 
90% yield) as a brownish solid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.00 (s, 1H), 7.49 (s, 1H), 7.34 (d, J = 8.3 Hz, 1H), 7.19 (t, 
J = 2.8 Hz, 1H), 7.02 (dq, J = 8.3, 1.7 Hz, 1H), 6.80 – 6.70 (m, 2H), 6.58 (q, J = 2.7 Hz, 1H), 6.33 – 
6.13 (m, 2H), 4.25 – 4.17 (m, 1H), 3.45 – 2.87 (m, 2H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 134.7, 129.8, 128.2, 124.7, 123.0, 120.7, 120.4, 111.1, 107.9, 
102.3, 52.0, 38.6. 
MS (EI, 70 eV, %): m/z = 210 (5), 143 (14), 131 (10), 130 (100), 128 (9), 115 (8), 103 (8), 80 (16). 
HRMS (EI, 70 eV): m/z calcd. for [C14H14N2]: 210.1157; found: 210.1146 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3423 (w), 3096 (vw), 2924 (w), 1498 (w), 1472 (w), 1457 
(w), 1412 (w), 1336 (w), 1279 (m), 1085 (m), 1063 (m), 965 (w), 892 (w), 819 (w), 800 (m), 762 (m), 
720 (vs), 698 (m). 
M.p. 88.6 °C. 
1-(4-Methoxyphenyl)-3-(1H-pyrrol-1-yl)propan-1-one (21i) 
 
According to TP13a, 4-methoxybenzoyl chloride (85.3 mg, 0.50 mmol, 1.00 equiv) and a freshly 
prepared solution of 20a (1.03 mL, 0.58 M, 0.60 mmol, 1.20 equiv) with catalytic amount of Pd(PPh3)4 
(23.0 mg, 20.0 μmol, 4 mol%) were used. The reaction mixture was stirred at 50 °C for 16 h and 
afterwards quenched with sat. aq. NH4Cl solution. The crude product was extracted with EtOAc and 
purified by flash column chromatography. 21i (113 mg, 0.44 mmol, 87% yield) was obtained as an 
orange oil. 
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1H-NMR (400 MHz, CDCl3, ppm): δ = 7.92 (d, J = 9.2 Hz, 2H), 6.95 (d, J = 9.2 Hz, 2H), 6.73 (t, 
J = 2.2 Hz, 2H), 6.16 (t, J = 2.2 Hz, 2H), 4.38 (t, J = 7.2 Hz, 2H), 3.89 (s, 3H), 3.41 (t, J = 7.2 Hz, 2H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 195.9, 163.7, 130.3, 129.6, 120.7, 113.8, 108.3, 55.5, 44.4, 
40.2. 
MS (EI, 70 eV, %): m/z = 229 (24), 212 (15), 211 (100), 210 (25), 196 (72), 180 (21), 168 (26), 167 
(49), 135 (71), 94 (84), 77 (18). 
HRMS (EI, 70 eV): m/z calcd. for [C14H15NO2]: 229.1103; found: 229.1098 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2933 (w), 2839 (vw), 1671 (s), 1598 (vs), 1574 (m), 1509 
(m), 1419 (m), 1371 (m), 1313 (m), 1255 (s), 1213 (s), 1167 (vs), 1089 (m), 1025 (s), 982 (m), 834 (s), 
722 (vs). 
1-(3-Chlorophenyl)-3-(1H-pyrrol-1-yl)propan-1-one (21j) 
 
According to TP13a, 3-chlorobenzoyl chloride (87.5 mg, 0.50 mmol, 1.00 equiv) and a freshly prepared 
solution of 20a (1.03 mL, 0.58 M, 0.60 mmol, 1.20 equiv) with catalytic amount of Pd(PPh3)4 (23.0 mg, 
20.0 μmol, 4 mol%) were used. The mixture was stirred at 50 °C for 16 h and afterwards quenched with 
sat. aq. NH4Cl solution. The crude product was extracted with EtOAc and purified by flash column 
chromatography. 21j (96 mg, 0.41 mmol, 82% yield) was obtained as an orange oil. 
In a large-scale attempt according to a modified version of TP13b, the reaction was carried out using 
1.75 g (10.0 mmol, 1.00 equiv) of 3-chlorobenzoyl chloride and a freshly prepared solution of 20a 
(19.0 mL, 0.58 M, 11.0 mmol, 1.10 equiv) with catalytic amounts of CuI (190 mg, 1.00 mmol, 
10 mol%) at 0 °C up to 25 °C. After quenching, extraction and flash column chromatography 
purification, 1.76 g (7.53 mmol, 75% yield) of 21j was obtained. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.91 (t, J = 2.0 Hz, 1H), 7.80 (dt, J = 7.6, 1.2 Hz, 1H), 7.57 
(ddd, J = 8.0, 2.0, 1.2 Hz, 1H), 7.42 (t, J = 8.0 Hz, 1H), 6.73 (t, J = 2.0 Hz, 2H), 6.17 (t, J = 2.0 Hz, 
2H), 4.39 (t, J = 6.8 Hz, 2H), 3.43 (t, J = 6.8 Hz, 2H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 196.4, 138.0, 135.2, 133.5, 130.2, 128.3, 126.2, 120.8, 108.7, 
44.2, 40.8. 
MS (EI, 70 eV, %): m/z = 233 (11), 180 (3), 139 (16), 111 (27), 94 (100), 80 (32), 67 (12), 53 (11). 
HRMS (EI, 70 eV): m/z calcd. for [C13H12ClNO]: 233.0607; found: 233.0602 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3098 (vw), 3065 (vw), 2919 (w), 2850 (vw), 1684 (s), 1570 
(m), 1498 (m), 1423 (m), 1370 (m), 1282 (m), 1203 (s), 1088 (m), 1071 (m), 997 (w), 896 (w), 776 (m), 
722 (vs), 695 (m), 677 (s). 
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3-(1H-Pyrrol-1-yl)-1-(thiophen-2-yl)propan-1-one (21k) 
 
According to TP13a, 2-thiophenecarbonyl chloride (73.3 mg, 0.50 mmol, 1.00 equiv) and a freshly 
prepared solution of 20a (1.03 mL, 0.58 M, 0.60 mmol, 1.20 equiv) with catalytic amount of Pd(PPh3)4 
(23.0 mg, 20.0 μmol, 4 mol%) were used. The mixture was stirred at 50 °C for 16 h and afterwards 
quenched with sat. aq. NH4Cl solution. The crude product was extracted with EtOAc and purified by 
flash column chromatography. 21k (75 mg, 0.37 mmol, 73% yield) was obtained as a colorless solid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.66 (s, 1H), 7.65 (q, J = 1.1 Hz, 1H), 7.14 – 7.09 (m, 1H), 
6.70 (t, J = 2.1 Hz, 2H), 6.14 (t, J = 2.1 Hz, 2H), 4.36 (t, J = 6.9 Hz, 2H), 3.37 (t, J = 6.9 Hz, 2H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 190.4, 143.8, 134.3, 132.3, 128.4, 120.8, 108.6, 44.4, 41.4. 
MS (EI, 70 eV, %): m/z = 205 (37), 186 (56), 154 (16), 111 (55), 94 (100), 80 (16). 
HRMS (EI, 70 eV): m/z calcd. for [C11H11NOS]: 205.0561; found: 205.0556 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3104 (vw), 3075 (w), 2954 (w), 2905 (w), 1661 (s), 1498 
(m), 1438 (w), 1414 (s), 1395 (m), 1364 (m), 1278 (m), 1238 (s), 1219 (m), 1088 (m), 1059 (m), 1040 
(m), 961 (w), 928 (m), 894 (m), 841 (m), 825 (m), 732 (s), 709 (vs). 
M.p. 60.1 °C. 
1-Cyclopropyl-3-(1H-pyrrol-1-yl)propan-1-one (21l) 
 
According to TP13a, cyclopropanecarbonyl chloride (52.3 mg, 0.50 mmol, 1.00 equiv) and a freshly 
prepared solution of 20a (1.03 mL, 0.58 M, 0.60 mmol, 1.20 equiv) with catalytic amount of Pd(PPh3)4 
(23.0 mg, 20.0 μmol, 4 mol%) were used. The mixture was stirred at 50 °C for 16 h and afterwards 
quenched with sat. aq. NH4Cl solution. The crude product was extracted with EtOAc and purified by 
flash column chromatography. 21l (69 mg, 0.42 mmol, 83% yield) was obtained as an orange liquid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.65 (t, J = 2.1 Hz, 2H), 6.13 (t, J = 2.1 Hz, 2H), 4.20 (t, 
J = 6.8 Hz, 2H), 3.02 (t, J = 6.8 Hz, 2H), 1.87 (tt, J = 7.8 Hz, 4.6, 1H), 1.09 – 1.00 (m, 2H), 0.89 (dt, 
J = 7.9, 3.4 Hz, 2H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 208.3, 120.7, 108.4, 45.0, 44.1, 21.1, 11.2. 
MS (EI, 70 eV, %): m/z = 163 (39), 145 (15), 130 (12), 117 (10), 106 (28), 94 (100), 93 (13), 80 (34). 
HRMS (EI, 70 eV): m/z calcd. for [C10H13NO]: 163.0997; found: 163.0991 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3098 (vw), 3008 (vw), 2932 (vw), 1694 (s), 1552 (vw), 1499 
(m), 1444 (w), 1389 (m), 1282 (m), 1194 (w), 1085 (s), 1067 (m), 1014 (m), 903 (w), 875 (w), 818 (w), 
721 (vs). 
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 (R)-1-(1-(4-Methoxyphenyl)propan-2-yl)-1H-pyrrole ((R)-22a) 
 
Following TP12, a freshly prepared solution of (R)-20b (1.52 mL, 394 mM, 0.60 mol, 1.20 equiv) was 
added dropwise to a solution of 4-iodoanisole (117 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 (2.25 mg, 
10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL). The reaction mixture 
was stirred for 16 h and afterwards quenched with sat. aq. NH4Cl solution and extracted with EtOAc. 
The crude product was purified by flash column chromatography to obtain (R)-22a (89.0 mg, 
0.41 mmol, 83% yield, >95% ee) as a brown liquid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.91 – 6.88 (m, 2H), 6.82 – 6.78 (m, 2H), 6.66 (t, J = 2.0 Hz, 
2H), 6.14 (t, J = 2.0 Hz, 2H), 4.22 (sextet, J = 6.8 Hz, 1H), 3.80 (s, 3H), 3.01 (dd, J = 13.6, 7.2 Hz, 1H), 
2.89 (dd, J = 13.6, 6.8 Hz, 1H), 1.48 (d, J = 6.8 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 158.2, 130.3, 130.0, 118.5, 113.7, 107.5, 57.1, 55.2, 44.2, 
21.2. 
MS (EI, 70 eV, %): m/z = 215 (17), 148 (11), 121 (19), 94 (100), 78 (9). 
HRMS (EI, 70 eV): m/z calcd. for [C14H17NO]: 215.1310; found: 215.1306 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2971 (w), 2933 (w), 2834 (w), 1611 (m), 1511 (s), 1489 (m), 
1454 (w), 1301 (m), 1269 (m), 1244 (vs), 1178 (m), 1090 (m), 1034 (m), 955 (w), 815 (m), 721 (vs).     
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): -94.6. 
(R)-1-(1-(4-Fluorophenyl)propan-2-yl)-1H-pyrrole ((R)-22b) 
 
Following TP12, a freshly prepared solution of (R)-20b (1.52 mL, 394 mM, 0.60 mmol, 1.20 equiv) 
was added dropwise to a solution of 4-fluoroiodobenzene (111 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 
(2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL). The 
reaction mixture was stirred for 16 h and afterwards quenched with sat. aq. NH4Cl solution and extracted 
with EtOAc. The crude product was purified by flash column chromatography to obtain (R)-22b 
(87.0 mg, 0.43 mmol, 86% yield, 98.5% ee) as a brown liquid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.96 – 6.88 (m, 4H), 6.63 (t, J = 2.0 Hz, 2H), 6.13 (t, J = 2.0 Hz, 
2H), 4.22 (sextet, J = 6.8 Hz, 1H), 3.01 (dd, J = 13.6, 7.6 Hz, 1H), 2.93 (dd, J = 13.6, 6.4 Hz, 1H), 1.51 
(d, J = 6.8 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 161.7 (d, J = 245.4 Hz), 133.8 (d, J = 3.0 Hz), 130.4 (d, 
J = 8.1 Hz), 118.5, 115.1 (d, J = 21.2 Hz), 107.7, 56.9, 44.2, 21.2. 
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MS (EI, 70 eV, %): m/z = 203 (13), 109 (10), 94 (100), 78 (11). 
HRMS (EI, 70 eV): m/z calcd. for [C13H14FN]: 203.1110; found: 203.1104 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2975 (w), 2933 (w), 1603 (w), 1509 (vs), 1489 (m), 1452 
(w), 1414 (w), 1378 (w), 1320 (w), 1269 (m), 1221 (s), 1158 (w), 1092 (m), 955 (w), 821 (m), 722 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –96.5. 
(R)-1-(4-(2-(1H-Pyrrol-1-yl)propyl)phenyl)ethan-1-one ((R)-22c) 
 
Following TP12, a freshly prepared solution of (R)-20b (1.52 mL, 394 mM, 0.60 mmol, 1.20 equiv) 
was added dropwise to a solution of 4-iodoacetophenone (123 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 
(2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL). The 
reaction mixture was stirred for 16 h and afterwards quenched with sat. aq. NH4Cl solution and extracted 
with EtOAc. The crude product was purified by flash column chromatography to obtain (R)-22c 
(103 mg, 0.45 mmol, 91% yield, 99.0% ee) as a brown liquid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.84 (d, J = 5.2 Hz, 2H), 7.04 (d, J = 5.2 Hz, 2H), 6.62 (t, 
J = 1.2 Hz, 2H), 6.13 (t, J = 1.2 Hz, 2H), 4.29 (sextet, J = 4.4 Hz, 1H), 3.10 (dd, J = 9.2, 5.2 Hz, 1H), 
3.02 (dd, J = 9.2, 4.4 Hz, 1H), 2.59 (s, 3H), 1.53 (d, J = 4.4 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 197.8, 143.8, 135.6, 129.2, 128.4, 118.5, 107.8, 56.6, 45.0, 
26.5, 21.5. 
MS (EI, 70 eV, %): m/z = 227 (5), 94 (100), 78 (8). 
HRMS (EI, 70 eV): m/z calcd. for [C15H17NO]: 227.1310; found: 227.1306 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2974 (w), 2932 (w), 1679 (vs), 1606 (m), 1489 (m), 1413 
(m), 1358 (m), 1267 (vs), 1183 (w), 1091 (w), 1018 (w), 956 (m), 847 (w), 814 (w), 724 (s), 695 (w). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –137.2. 
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Ethyl (R)-4-(2-(1H-pyrrol-1-yl)propyl)benzoate ((R)-22d) 
 
Following TP12, a freshly prepared solution of (R)-20b (1.38 mL, 0.44 M, 0.60 mmol, 1.20 equiv) was 
added dropwise to a solution of ethyl 4-iodobenzoate (138 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 
(2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL). The 
reaction mixture was stirred for 16 h and afterwards quenched with sat. aq. NH4Cl solution and extracted 
with EtOAc. Flash column chromatography purification of the crude product afforded (R)-22d (128 mg, 
0.49 mmol, 99% yield, 99.0% ee) as an orange liquid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.97 – 7.86 (m, 2H), 7.07 – 6.95 (m, 2H), 6.61 (t, J = 2.2, 2H), 
6.11 (t, J = 2.1, 2H), 4.36 (q, J = 7.1, 2H), 4.26 (h, J = 6.8, 1H), 3.08 (dd, J = 13.4, 7.7, 1H), 3.00 (dd, 
J = 13.5, 6.2, 1H), 1.50 (d, J = 6.8, 3H), 1.39 (t, J = 7.1, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 166.6, 143.5, 129.7, 129.1, 128.9, 118.6, 107.9, 61.0, 56.7, 
45.2, 21.5, 14.4. 
MS (EI, 70 eV, %): m/z = 257 (6), 94 (100), 78 (7). 
HRMS (EI, 70 eV): m/z calcd. for [C16H19NO2]: 257.1416; found: 257.1412 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2977 (w), 2934 (w), 1711 (s), 1611 (w), 1489 (w), 1415 (w), 
1367 (w), 1310 (w), 1271 (vs), 1178 (m), 1102 (s), 1021 (m), 954 (w), 761 (m), 719 (s), 706 (s). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): −104.9. 
(R)-1-(4-Fluorophenyl)-3-(1H-pyrrol-1-yl)butan-1-one ((R)-22e) 
 
According to TP13b, catalytic amounts of CuI (9.52 mg, 0.05 mmol, 10 mol%) were added at 0 °C to 
a freshly prepared solution of (R)-20b (1.38 mL, 0.44 M, 0.60 mmol, 1.20 equiv). After dropwise 
addition of 4-fluorobenzoyl chloride (79 mg, 0.50 mmol, 1.00 equiv) the reaction mixture was stirred 
for 1 h at 0 °C, warmed to room temperature and stirred for 16 h. The reaction mixture was quenched 
with sat. aq. NH4Cl solution and extracted with EtOAc. Flash column chromatography purification of 
the crude product afforded (R)-22e (84 mg, 0.36 mmol, 73% yield, 99.7% ee) as a yellow liquid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.96 – 7.90 (m, 2H), 7.16 – 7.10 (m, 2H), 6.78 (t, J = 2.0 Hz, 
2H), 6.16 (t, J = 2.0 Hz, 2H), 4.85 (sextet, J = 6.8 Hz, 1H), 3.46 (dd, J = 16.8, 6.0 Hz, 1H), 3,28 (dd, 
J = 16.8, 7.2 Hz, 1H), 1.60 (d, J = 6.8 Hz, 3H). 
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13C-NMR (101 MHz, CDCl3, ppm): δ = 195.7, 165.9 (d, J = 256.5 Hz), 133.1 (d, J = 3.0 Hz), 130.6 
(d, J = 9.1 Hz), 118.5, 115.8 (d, J = 22.2 Hz), 108.1, 51.2, 47.0, 21.9. 
19F-NMR (376 MHz, CDCl3, ppm): δ = -104.6. 
MS (EI, 70 eV, %): m/z = 231 (12), 211 (20), 198 (16), 123 (100), 108 (77), 94 (32), 75 (12). 
HRMS (EI, 70 eV): m/z calcd. for [C14H14FNO]: 231.1059; found: 231.1053 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3101 (vw), 3066 (vw), 2977 (w), 2935 (vw), 1684 (vs), 1597 
(vs), 1506 (m), 1411 (m), 1361 (m), 1322 (w), 1275 (m), 1228 (s), 1203 (m), 1157 (s), 1089 (m), 996 
(w), 955 (w), 835 (s), 726 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): −22.3. 
(R)-1-(4-Chlorophenyl)-3-(1H-pyrrol-1-yl)butan-1-one ((R)-22f) 
 
According to TP13b, catalytic amounts of CuI (9.52 mg, 0.05 mmol, 10 mol%) were added at 0 °C to 
a freshly prepared solution of (R)-20b (1.38 mL, 0.44 M, 0.60 mmol, 1.20 equiv). After dropwise 
addition of 4-chlorobenzoyl chloride (88 mg, 0.50 mmol, 1.00 equiv) the mixture was stirred for 1 h at 
0 °C, warmed to room temperature and then stirred for 16 h. The reaction mixture was quenched with 
sat. aq. NH4Cl solution and extracted with EtOAc. Flash column chromatography purification of the 
crude product afforded (R)-22f (83 mg, 0.34 mmol, 67% yield, 99.5% ee) as a yellow liquid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.85 – 7.82 (m, 2H), 7.45 – 7.42 (m, 2H), 6.77 (t, J = 2.0 Hz, 
2H), 6.16 (t, J = 2.0 Hz, 2H), 4.85 (sextet, J = 6.8 Hz, 1H), 3.46 (dd, J = 16.8, 5.6 Hz, 1H), 3,28 (dd, 
J = 16.8, 7.2 Hz, 1H), 1.60 (d, J = 6.8 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 196.1, 139.9, 135.0, 129.4, 129.0, 118.5, 108.1, 51.1, 47.0, 
21.9. 
MS (EI, 70 eV, %): m/z = 247 (9), 231 (19), 229 (62), 227 (100), 214 (63), 191 (64), 139 (59), 108 
(55), 94 (22). 
HRMS (EI, 70 eV): m/z calcd. for [C14H14ClNO]: 247.0764; found: 247.0759 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2976 (w), 2934 (vw), 1685 (vs), 1588 (s), 1489 (m), 1400 (m), 
1361 (m), 1321 (w), 1289 (m), 1274 (m), 1212 (m), 1203 (m), 1090 (vs), 995 (m), 955 (w), 819 (m), 
725 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): −9.5. 
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(R)-1-(2-Bromophenyl)-3-(1H-pyrrol-1-yl)butan-1-one ((R)-22g) 
 
According to TP13b, catalytic amounts of CuI (9.52 mg, 0.05 mmol, 10 mol%) were added at 0 °C to 
a freshly prepared solution of (R)-20b (1.38 mL, 0.44 M, 0.60 mmol, 1.20 equiv). After dropwise 
addition of 2-bromobenzoyl chloride (110 mg, 0.50 mmol, 1.00 equiv) the reaction mixture was stirred 
for 1 h at 0 °C, warmed to room temperature and then stirred for 16 h. The reaction mixture was 
quenched with sat. aq. NH4Cl solution and extracted with EtOAc. Flash column chromatography 
purification of the crude product afforded (R)-22g (115 mg, 0.39 mmol, 79% yield, 99.6% ee) as a 
yellow liquid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.57 (dd, J = 7.2, 2.0 Hz, 1H), 7.32 – 7.24 (m, 2H), 7.11 (dd, 
J = 7.2, 2.0 Hz, 1H), 6.70 (t, J = 2.0 Hz, 2H), 6.11 (t, J = 2.0 Hz, 2H), 4.78 (sextet, J = 6.8 Hz, 1H), 
3.41 (dd, J = 17.2, 6.8 Hz, 1H), 3,27 (dd, J = 17.2, 6.8 Hz, 1H), 1.56 (d, J = 6.8 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 201.4, 141.3, 133.6, 131.8, 128.4, 127.5, 118.6, 118.4, 108.1, 
51.3, 51.0, 21.9. 
MS (EI, 70 eV, %): m/z = 291 (1), 212 (66), 191 (100), 182 (92), 170 (27), 165 (59), 145 (33), 108 
(42), 94 (36). 
HRMS (EI, 70 eV): m/z calcd. for [C14H14BrNO]: 291.0259; found: 291.0258 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3097 (vw), 3064 (vw), 2975 (w), 2934 (vw), 1696 (m), 1586 
(w), 1489 (m), 1427 (m), 1357 (w), 1315 (w), 1290 (m), 1274 (m), 1200 (w), 1088 (m), 1056 (m), 1025 
(m), 994 (m), 954 (m), 756 (m), 719 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): −21.5. 
(R)-3-(1H-Pyrrol-1-yl)-1-(thiophen-2-yl)butan-1-one ((R)-22h) 
 
According to TP13b, catalytic amounts of CuI (9.52 mg, 0.05 mmol, 10 mol%) were added at 0 °C to 
a freshly prepared solution of (R)-20b (1.38 mL, 0.44 M, 0.60 mmol, 1.20 equiv). After dropwise 
addition of 2-thiophenecarbonyl chloride (73.0 mg, 0.5 mmol, 1.00 equiv), the mixture was stirred for 
1 h at 0 °C, warmed to room temperature and then stirred for 16 h. The reaction mixture was quenched 
with sat. aq. NH4Cl solution and extracted with EtOAc. Flash column chromatography purification of 
the crude product afforded (R)-22h (65 mg, 0.30 mmol, 59% yield, 99.5% ee) as a yellowish solid. 
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1H-NMR (400 MHz, CDCl3, ppm): δ = 7.66 (dd, J = 4.8, 1.2 Hz, 1H), 7.65 (dd, J = 3.8, 1.2 Hz, 1H), 
7.12 (dd, J = 4.8, 3.8 Hz, 1H), 6.78 (t, J = 2.0 Hz, 2H), 6.15 (t, J = 2.0 Hz, 2H), 4.83 (sextet, J = 6.8 Hz, 
1H), 3.41 (dd, J = 16.0, 6.0 Hz, 1H), 3,25 (dd, J = 16.0, 7.2 Hz, 1H), 1.60 (d, J = 6.8 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 190.2, 144.2, 134.3, 132.3, 128.3, 118.7, 108.2, 51.5, 48.0, 
21.9. 
MS (EI, 70 eV, %): m/z = 219 (26), 210 (100), 199 (89), 186 (92), 111 (86), 108 (78), 94 (29). 
HRMS (EI, 70 eV): m/z calcd. for [C12H13NOS]: 219.0718; found: 219.0712 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3097 (vw), 2976 (w), 2933 (vw), 1656 (s), 1517 (w), 1489 
(w), 1414 (s), 1360 (w), 1318 (w), 1274 (m), 1234 (w), 1222 (w), 1089 (m), 1060 (m), 946 (w), 857 
(w), 721 (vs). 
M.p.: 44.5 °C. 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): −34.0. 
(S)-3-(3-Methyl-2-(1H-pyrrol-1-yl)butyl)aniline ((S)-23a) 
 
According to TP12, a freshly prepared solution of (R)-20c (1.15 mL, 0.52 M, 0.60 mol, 1.20 equiv) 
was added dropwise to a solution of 3-bromoaniline (86.0 mg, 0.50 mol, 1.00 equiv), Pd(OAc)2 
(2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL) and the 
resulting mixture was stirred for 16 h. After aqueous workup, extraction and flash column 
chromatography purification, (S)-23a (106 mg, 0.46 mmol, 93% yield, 99.8% ee) was obtained as a 
yellow oil. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.99 (t, J = 7.7 Hz, 1H), 6.57 (t, J = 2.1 Hz, 2H), 6.49 (ddd, 
J = 7.9, 2.4, 1.0 Hz, 1H), 6.38 (dt, J = 7.5, 1.3 Hz, 1H), 6.19 (t, J = 2.0 Hz, 1H), 6.08 (t, J = 2.1 Hz, 
2H), 3.66 (ddd, J = 9.7, 7.7, 4.5 Hz, 1H), 3.51 (br, 2H), 3.06 (dd, J = 13.8, 4.5 Hz, 1H), 2.89 (dd, 
J = 13.8, 9.7 Hz, 1H), 2.03 (dhept, J = 13.4, 6.8 Hz, 1H), 1.04 (d, J = 6.7 Hz, 3H), 0.79 (d, J = 6.8 Hz, 
3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 146.4, 140.3, 129.2, 119.9, 119.2, 115.7, 113.2, 107.2, 68.5, 
40.0, 33.6, 20.7, 18.9. 
MS (EI, 70 eV, %): m/z = 228 (32), 183 (12), 122 (100), 107 (10), 106 (11), 80 (20). 
HRMS (EI, 70 eV): m/z calcd. for [C15H20N2]: 228.1626; found: 228.1620 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3362 (w), 2958 (w), 2925 (w), 2871 (w), 1604 (m), 1590 (m), 
1489 (m), 1461 (m), 1411 (w), 1386 (w), 1368 (w), 1290 (m), 1272 (m), 1168 (w), 1086 (m), 1067 (m), 
995 (w), 929 (w), 867 (w), 779 (m), 720 (vs), 696 (s). 
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[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –101.2. 
(S)-1-(1-(4-Methoxyphenyl)-3-methylbutan-2-yl)-1H-pyrrole ((S)-23b) 
 
According to TP12, a freshly prepared solution of (R)-20c (1.15 mL, 0.52 M, 0.60 mol, 1.20 equiv) 
was added dropwise to a solution of 4-iodoanisole (117 mg, 0.50 mol, 1.00 equiv), Pd(OAc)2 (2.25 mg, 
10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL) and the resulting 
mixture was stirred for 16 h. After aqueous workup, extraction and flash column chromatography 
purification, (S)-23b (109 mg, 0.45 mmol, 89% yield, 99.4% ee) was obtained as colorless oil. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.84 – 6.79 (m, 2H), 6.76 – 6.70 (m, 2H), 6.55 (t, J = 2.1 Hz, 
2H), 6.08 (t, J = 2.1 Hz, 2H), 3.75 (s, 3H), 3.62 (ddd, J = 10.1, 7.9, 4.2 Hz, 1H), 3.11 (dd, J = 14.0, 
4.2 Hz, 1H), 2.92 (dd, J = 14.0, 10.1 Hz, 1H), 2.04 (dhept, J = 13.3, 6.8 Hz, 1H), 1.07 (d, J = 6.7 Hz, 
3H), 0.80 (d, J = 6.7 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 158.1, 131.1, 129.7, 119.8, 113.7, 107.3, 68.9, 55.2, 39.1, 
33.7, 20.7, 19.1. 
MS (EI, 70 eV, %): m/z = 243 (10), 122 (100), 121 (18), 80 (20). 
HRMS (EI, 70 eV): m/z calcd. for [C16H21NO]: 243.1623; found: 243.1617 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2957 (w), 1612 (w), 1511 (s), 1488 (m), 1465 (m), 1412 (w), 
1386 (w), 1368 (w), 1300 (m), 1274 (m), 1243 (s), 1177 (m), 1086 (m), 1068 (w), 1034 (m), 912 (w), 
820 (m), 718 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –124.1. 
(S)-4-(3-Methyl-2-(1H-pyrrol-1-yl)butyl)benzaldehyde ((S)-23c) 
 
According to TP12, a freshly prepared solution of (R)-20c (1.15 mL, 0.52 M, 0.60 mol, 1.20 equiv) 
was added dropwise to a solution of 4-bromobenzaldehyd (92.5 mg, 0.50 mol, 1.00 equiv), Pd(OAc)2 
(2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL) and the 
resulting mixture was stirred for 16 h. After aqueous workup, extraction and flash column 
chromatography purification, (S)-23b (112 mg, 0.46 mmol, 92% yield, 99.6% ee) was obtained as an 
orange oil. 
C. EXPERIMENTAL PART    154 
1H-NMR (599 MHz, CDCl3, ppm): δ = 9.92 (s, 1H), 7.78 – 7.61 (m, 2H), 7.11 – 6.98 (m, 2H), 6.50 
(t, J = 2.1, 2H), 6.05 (t, J = 2.2, 2H), 3.65 (ddd, J = 10.9, 8.3, 3.8, 1H), 3.24 (dd, J = 13.8, 3.7, 1H), 3.02 
(dd, J = 13.8, 10.8, 1H), 2.13 – 2.03 (m, 1H), 1.11 (s, 2H), 0.80 (d, J = 6.7, 3H). 
13C-NMR (151 MHz, CDCl3, ppm): δ = 192.1, 146.4, 134.9, 129.9, 129.4, 119.6, 107.7, 68.5, 40.4, 
34.2, 20.6, 19.3.z 
MS (EI, 70 eV, %): m/z = 241 (8), 122 (100), 91 (17), 80 (19). 
HRMS (EI, 70 eV): m/z calcd. for [C16H19NO]: 241.1467; found: 241.1458 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2961 (w), 2925 (w), 1698 (s), 1605 (s), 1576 (w), 1488 (m), 
1469 (w), 1386 (w), 1306 (w), 1274 (m), 1259 (m), 1214 (m), 1168 (m), 1086 (m), 1068 (m), 928 (w), 
845 (w), 816 (m), 779 (m), 719 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –180.5. 
Ethyl (S)-4-(3-methyl-2-(1H-pyrrol-1-yl)butyl)benzoate ((S)-23d) 
 
According to TP12, a freshly prepared solution of (R)-20c (1.15 mL, 0.52 M, 0.60 mol, 1.20 equiv) 
was added dropwise to a solution of ethyl 4-iodobenzoate (138 mg, 0.50 mol, 1.00 equiv), Pd(OAc)2 
(2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL) and the 
resulting mixture was stirred for 16 h. After aqueous workup, extraction and flash column 
chromatography purification, (S)-23d (126 mg, 0.44 mmol, 88% yield, 99.7% ee) was obtained as 
colorless oil. 
1H-NMR (599 MHz, CDCl3, ppm): δ = 7.87 – 7.84 (m, 2H), 6.98 – 6.92 (m, 2H), 6.51 (t, J = 2.1 Hz, 
2H), 6.05 (t, J = 2.1 Hz, 2H), 4.33 (q, J = 7.1 Hz, 2H), 3.64 (ddd, J = 10.6, 8.2, 3.9 Hz, 1H), 3.21 (dd, 
J = 13.8, 3.9 Hz, 1H), 3.00 (dd, J = 13.8, 10.6 Hz, 1H), 2.06 (dhept, J = 8.2, 6.7 Hz, 1H), 1.36 (t, 
J = 7.1 Hz, 3H), 1.09 (d, J = 6.7 Hz, 3H), 0.80 (d, J = 6.7 Hz, 3H). 
13C-NMR (151 MHz, CDCl3, ppm): δ = 166.7, 144.4, 129.6, 128.8, 128.7, 119.7, 107.6, 68.5, 60.9, 
40.2, 34.1, 20.6, 19.2, 14.4. 
MS (EI, 70 eV, %): m/z = 285 (4), 122 (100), 80 (16). 
HRMS (EI, 70 eV): m/z calcd. for [C16H23NO2]: 285.1729; found: 285.1721 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2960 (w), 2873 (w), 1711 (s), 1611 (w), 1488 (w), 1469 (w), 
1444 (w), 1416 (w), 1388 (w), 1367 (m), 1271 (vs), 1179 (m), 1100 (s), 1088 (m), 1069 (m), 1021 (m), 
929 (w), 873 (w), 764 (m), 720 (s), 704 (s). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –136.1. 
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(S)-4-(3-Methyl-2-(1H-pyrrol-1-yl)butyl)benzonitrile ((S)-23e) 
 
According to TP12, a freshly prepared solution of (R)-20c (1.15 mL, 0.52 M, 0.60 mol, 1.20 equiv) 
was added dropwise to a solution of 4-iodobenzonitrile (115 mg, 0.50 mol, 1.00 equiv), Pd(OAc)2 
(2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL) and the 
resulting mixture was stirred for 16 h. After aqueous workup, extraction and flash column 
chromatography purification, (S)-23e (111 mg, 0.47 mmol, 93% yield, 99.6% ee) was obtained as a 
yellowish oil. 
1H-NMR (599 MHz, CDCl3, ppm): δ = 7.46 – 7.41 (m, 2H), 6.98 – 6.93 (m, 2H), 6.48 (t, J = 2.1 Hz, 
2H), 6.05 (t, J = 2.2 Hz, 2H), 3.59 (ddd, J = 11.0, 8.4, 3.6 Hz, 1H), 3.20 (dd, J = 13.9, 3.6 Hz, 1H), 2.99 
(dd, J = 13.9, 10.9 Hz, 1H), 2.08 (dhept, J = 8.5, 6.7 Hz, 1H), 1.10 (d, J = 6.7 Hz, 3H), 0.79 (d, 
J = 6.8 Hz, 3H). 
13C-NMR (151 MHz, CDCl3, ppm): δ = 144.6, 132.1, 129.5, 119.5, 119.0, 110.4, 107.9, 68.4, 40.4, 
34.2, 20.5, 19.3. 
MS (EI, 70 eV, %): m/z = 238 (10), 195 (17), 193 (13), 122 (100), 116 (27), 80 (21). 
HRMS (EI, 70 eV): m/z calcd. for [C16H18N2]: 238.1470; found: 238.1463 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2961 (w), 2226 (m), 1607 (w), 1505 (w), 1488 (m), 1470 
(w), 1414 (w), 1387 (w), 1369 (w), 1300 (w), 1274 (m), 1259 (m), 1177 (w), 1087 (m), 1068 (m), 1022 
(w), 928 (w), 821 (m), 721 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –185.4. 
(S)-1-(4-Methoxyphenyl)-4-methyl-3-(1H-pyrrol-1-yl)pentan-1-one ((S)-23f) 
 
According to TP13a, 3-methoxybenzoyl chloride (85.3 mg, 0.50 mmol, 1.00 equiv) and a freshly 
prepared solution of (R)-20c (1.15 mL, 0.52 M, 0.60 mol, 1.20 equiv) with catalytic amount of 
Pd(PPh3)4 (23.0 mg, 20.0 μmol, 4 mol%) were used. The reaction mixture was stirred at 50 °C for 16 h 
and quenched with sat. aq. NH4Cl solution. The crude product was extracted with EtOAc and purified 
by flash column chromatography. (S)-23f (116 mg, 0.43 mmol, 85% yield, 99.8% ee) was obtained as 
a yellowish solid. 
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1H-NMR (400 MHz, CDCl3, ppm): δ = 7.89 – 7.84 (m, 2H), 6.93 – 6.87 (m, 2H), 6.68 (t, J = 2.1 Hz, 
2H), 6.07 (t, J = 2.1 Hz, 2H), 4.39 (td, J = 8.0, 5.0 Hz, 1H), 3.86 (s, 3H), 3.47 (dd, J = 16.7, 7.9 Hz, 
1H), 3.33 (dd, J = 16.7, 5.1 Hz, 1H), 2.13 – 1.98 (m, 1H), 1.00 (d, J = 6.7 Hz, 3H), 0.78 (d, J = 6.7 Hz, 
3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 195.8, 163.6, 119.7, 113.7, 107.5, 77.3, 77.0, 76.7, 61.7, 55.4, 
42.2, 34.1, 20.2, 19.0. 
MS (EI, 70 eV, %): m/z = 271 (5), 253 (27), 238 (25), 210 (100), 167 (21), 135 (93), 77 (9). 
HRMS (EI, 70 eV): m/z calcd. for [C17H21NO2]: 271.1572; found: 271.1564 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2963 (m), 2937 (w), 2360 (w), 2340 (w), 1675 (m), 1600 
(vs), 1575 (m), 1510 (m), 1489 (m), 1465 (w), 1419 (m), 1359 (w), 1306 (w), 1259 (vs), 1218 (w), 1170 
(s), 1088 (w), 1029 (m), 834 (m), 725 (m). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +1.1. 
M.p. 50.5 °C. 
(S)-1-(4-Chlorophenyl)-4-methyl-3-(1H-pyrrol-1-yl)pentan-1-one ((S)-23g) 
 
According to TP13b, a freshly prepared solution of (R)-20c (1.15 mL, 0.52 M, 0.60 mol, 1.20 equiv) 
was mixed with catalytic amounts of CuI (9.52 mg, 0.05 mmol, 10 mol%) at 0 °C. 3-Chlorobenzoyl 
chloride (87.5 mg, 0.50 mmol, 1.00 equiv) was added and the mixture stirred for 1 h at 0 °C before 
warming to room temperature. The reaction mixture was stirred for 16 h and quenched with sat. aq. 
NH4Cl solution. The crude product was extracted with EtOAc and purified by flash column 
chromatography to obtain (S)-23g (110 mg, 0.40 mmol, 80% yield, 99.7% ee) as an orange oil. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.84 – 7.76 (m, 2H), 7.49 – 7.34 (m, 2H), 6.66 (t, J = 2.1 Hz, 
2H), 6.07 (t, J = 2.1 Hz, 2H), 4.35 (td, J = 8.3, 4.7 Hz, 1H), 3.49 (dd, J = 16.8, 8.2 Hz, 1H), 3.33 (dd, 
J = 16.8, 4.7 Hz, 1H), 2.18 – 1.99 (m, 1H), 1.01 (d, J = 6.7 Hz, 3H), 0.78 (d, J = 6.7 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 196.5, 139.9, 135.3, 129.5, 129.1, 119.8, 107.8, 61.9, 42.7, 
34.3, 20.3, 19.2. 
MS (EI, 70 eV, %): m/z = 275 (6), 257 (27), 242 (35), 214 (73), 141 (35), 139 (100), 111 (7), 94 (8). 
HRMS (EI, 70 eV): m/z calcd. for [C16H18ClNO]: 275.1077; found: 275.1067 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2963 (w), 2874 (w), 1686 (s), 1589 (m), 1488 (m), 1400 (m), 
1358 (w), 1274 (m), 1212 (m), 1176 (w), 1089 (s), 1012 (w), 930 (w), 828 (m), 783 (w), 723 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –6.7. 
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(S)-1-(4-Fluorophenyl)-4-methyl-3-(1H-pyrrol-1-yl)pentan-1-one ((S)-23h) 
 
According to TP13b, a freshly prepared solution of (R)-20c (1.15 mL, 0.52 M, 0.60 mol, 1.20 equiv) 
was mixed with catalytic amounts of CuI (9.52 mg, 0.05 mmol, 10 mol%) at 0 °C. 4-Fluorobenzoyl 
chloride (79.3 mg, 0.50 mmol, 1.00 equiv) was added and the mixture stirred for 1 h at 0 °C before 
warming to room temperature. The reaction mixture was stirred for 16 h and quenched with sat. aq. 
NH4Cl solution. The crude product was extracted with EtOAc and purified by flash column 
chromatography to obtain (S)-23h (91 mg, 0.35 mmol, 70% yield, 99.4% ee) as a colorless liquid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.97 – 7.77 (m, 2H), 7.16 – 7.05 (m, 2H), 6.67 (t, J = 2.1 Hz, 
2H), 6.07 (t, J = 2.1 Hz, 2H), 4.36 (td, J = 8.3, 4.8 Hz, 1H), 3.50 (dd, J = 16.8, 8.2 Hz, 1H), 3.33 (dd, 
J = 16.8, 4.8 Hz, 1H), 2.16 – 2.00 (m, 1H), 1.01 (d, J = 6.7 Hz, 3H), 0.79 (d, J = 6.7 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 196.0, 165.9 (d, J = 255.1), 133.4 (d, J = 3.0), 130.8 (d, 
J = 9.4), 119.8, 115.8 (d, J = 21.9), 107.8, 61.9, 42.6, 34.3, 20.3, 19.2. 
19F-NMR (377 MHz, CDCl3, ppm): δ = –104.9. 
MS (EI, 70 eV, %): m/z = 259 (6), 241 (38), 239 (12), 226 (47), 199 (14), 198 (100), 170 (13), 136 
(15), 123 (66). 
HRMS (EI, 70 eV): m/z calcd. for [C16H18FNO]: 259.1372; found: 259.1363 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2963 (m), 2874 (w), 1684 (s), 1596 (s), 1506 (m), 1489 (m), 
1471 (w), 1411 (m), 1388 (w), 1359 (m), 1298 (m), 1274 (s), 1235 (s), 1156 (s), 1088 (m), 1069 (w), 
994 (w), 930 (w), 838 (s), 818 (w), 724 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –22.3. 
(S)-1-(Furan-2-yl)-4-methyl-3-(1H-pyrrol-1-yl)pentan-1-one ((S)-23i) 
 
According to TP13a, 2-furoyl chloride (65.3 mg, 0.50 mmol, 1.00 equiv) and a freshly prepared solution 
of (R)-20c (1.15 mL, 0.52 M, 0.60 mol, 1.20 equiv) with catalytic amount of Pd(PPh3)4 (23.0 mg, 
20.0 μmol, 4 mol%) were used. The reaction mixture was stirred at 50 °C for 16 h and quenched with 
sat. aq. NH4Cl solution. The crude product was extracted with EtOAc and purified by flash column 
chromatography to obtain (S)-23i (83 mg, 0.36 mmol, 72% yield, 99.9% ee) as a pale yellow solid. 
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1H-NMR (400 MHz, CDCl3, ppm): δ = 7.55 (dd, J = 1.7, 0.8 Hz, 1H), 7.12 (dd, J = 3.6, 0.8 Hz, 1H), 
6.66 (t, J = 2.1 Hz, 2H), 6.49 (dd, J = 3.6, 1.7 Hz, 1H), 6.06 (t, J = 2.1 Hz, 2H), 4.33 (td, J = 8.5 Hz, 
4.9, 1H), 3.40 (dd, J = 16.3, 8.7 Hz, 1H), 3.22 (dd, J = 16.3, 4.9 Hz, 1H), 2.18 – 1.95 (m, 1H), 1.00 (d, 
J = 6.7 Hz, 3H), 0.78 (d, J = 6.7 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 186.6, 152.8, 146.6, 119.8, 117.4, 112.5, 107.7, 61.7, 42.5, 
34.3, 20.2, 19.1. 
MS (EI, 70 eV, %): m/z = 231 (11), 213 (54), 198 (51), 170 (100), 167 (15), 136 (11), 115 (11), 95 
(43). 
HRMS (EI, 70 eV): m/z calcd. for [C14H17NO2]: 231.1259; found: 231.1252 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3123 (w), 3094 (w), 2965 (w), 2880 (w), 1645 (vs), 1490 
(w), 1465 (s), 1416 (w), 1397 (m), 1290 (w), 1274 (w), 1164 (w), 1098 (w), 1063 (w), 998 (w), 914 
(w), 775 (m), 733 (m). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –4.9. 
M.p. 90.5 °C. 
Ethyl (S)-7-methyl-4-oxo-6-(1H-pyrrol-1-yl)octanoate ((S)-23j) 
 
According to TP13a, ethyl 4-chloro-4-oxobutyrate (82.3 mg, 0.50 mmol, 1.00 equiv) and a freshly 
prepared solution of (R)-20c (1.15 mL, 0.52 M, 0.60 mol, 1.20 equiv) with catalytic amount of 
Pd(PPh3)4 (23.0 mg, 20.0 μmol, 4 mol%) were used. The reaction mixture was stirred at 50 °C for 16 h 
and quenched with sat. aq. NH4Cl solution. The crude product was extracted with EtOAc and purified 
by flash column chromatography to obtain (S)-23j (88 mg, 0.33 mmol, 66% yield, 99.5% ee) as an 
orange liquid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.62 (t, J = 2.2 Hz, 2H), 6.09 (t, J = 2.1 Hz, 2H), 4.15 – 4.05 
(m, 3H), 2.98 (dd, J = 16.1, 9.1 Hz, 1H), 2.88 (dd, J = 16.1, 4.7 Hz, 1H), 2.73 – 2.62 (m, 1H), 2.58 – 
2.48 (m, 1H), 2.45 – 2.30 (m, 2H), 2.04 – 1.89 (m, 1H), 1.22 (t, J = 7.1 Hz, 3H), 0.95 (d, J = 6.7 Hz, 
3H), 0.73 (d, J = 6.7 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 206.9, 172.8, 119.7, 107.9, 62.1, 60.8, 46.8, 37.9, 34.2, 28.0, 
20.1, 19.1, 14.3.206.7, 172.6, 119.5, 107.7, 61.9, 60.6, 46.7, 37.8, 34.0, 27.9, 20.0, 19.0, 14.1. 
MS (EI, 70 eV, %): m/z = 265 (1), 247 (32), 186 (22), 174 (88), 159 (43), 144 (42), 130 (100), 101 
(53). 
HRMS (EI, 70 eV): m/z calcd. for [C15H23NO3]: 265.1678; found: 265.1670 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2964 (m), 2934 (w), 2875 (w), 1731 (vs), 1719 (vs), 1489 
(m), 1470 (w), 1413 (m), 1371 (m), 1349 (w), 1275 (m), 1195 (m), 1089 (m), 1035 (w), 726 (s). 
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[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –71.1. 
(S)-1-(1-(4-Methoxyphenyl)-3-phenylpropan-2-yl)-1H-pyrrole ((S)-24a) 
 
According to TP12, a freshly prepared solution of (S)-20d (1.30 mL, 0.47 M, 0.60 mol, 1.20 equiv) 
was added dropwise to a solution of 4-iodoanisole (118 mg, 0.50 mol, 1.00 equiv), Pd(OAc)2 (2.25 mg, 
10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL). The mixture was 
stirred for 16 h and quenched with sat. aq. NH4Cl solution. The crude product was extracted with EtOAc 
and purified by flash column chromatography to afford (S)-24a (123 mg, 0.42 mmol, 84% yield, 
98.8% ee) as a yellow oil. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.27 – 7.16 (m, 3H), 6.99 – 6.94 (m, 2H), 6.88 – 6.83 (m, 2H), 
6.80 – 6.75 (m, 2H), 6.55 (t, J = 2.1 Hz, 2H), 6.08 (t, J = 2.1 Hz, 2H), 4.18 (tt, J = 7.8, 6.3 Hz, 1H), 3.77 
(s, 3H), 3.13 – 2.98 (m, 4H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 158.4, 138.4, 130.4, 130.0, 129.0, 128.5, 126.6, 119.1, 113.9, 
107.8, 64.0, 55.3, 42.6, 41.8. 
MS (EI, 70 eV, %): m/z = 291 (9), 200 (42), 198 (18), 171 (13), 170 (100), 168 (64), 153 (11), 121 
(18), 91 (41). 
HRMS (EI, 70 eV): m/z calcd. for [C20H21NO]: 291.1623; found: 291.1617 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3027 (w), 2929 (w), 1611 (w), 1583 (w), 1511 (s), 1488 (m), 
1454 (m), 1441 (w), 1411 (w), 1301 (m), 1243 (vs), 1177 (m), 1109 (w), 1089 (m), 1070 (m), 1032 (s), 
910 (w), 823 (m), 719 (vs), 698 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +7.8. 
(S)-4-(3-Phenyl-2-(1H-pyrrol-1-yl)propyl)benzaldehyde ((S)-24b) 
 
According to TP12, a solution of (S)-20d (1.30 mL, 0.47 M, 0.60 mmol, 1.20 equiv) was added 
dropwise to a solution of 4-bromo benzaldehyde (82.5 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 (2.25 mg, 
10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL) and the resulting 
reaction mixture stirred for 16 h. After quenching with sat. aq. NH4Cl solution and extraction with 
EtOAc, the crude product was purified by flash column chromatography to afford (S)-24b (133 mg, 
0.46 mmol, 91% yield, 99.8% ee) as a dark-orange oil. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 9.89 (s, 1H), 7.69 – 7.64 (m, 2H), 7.24 – 7.13 (m, 3H), 7.00 
(d, J = 8.1 Hz, 2H), 6.98 – 6.94 (m, 2H), 6.47 (t, J = 2.1 Hz, 2H), 6.01 (t, J = 2.1 Hz, 2H), 4.19 (tt, 
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J = 7.8, 6.6 Hz, 1H), 3.13 (dd, J = 13.8, 8.0 Hz, 1H), 3.09 (d, J = 7.1 Hz, 2H), 3.03 (dd, J = 13.7, 6.4 Hz, 
1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 192.1, 145.6, 137.9, 135.1, 130.0, 129.6, 129.0, 128.7, 126.9, 
119.0, 108.2, 63.5, 43.0, 42.7. 
MS (EI, 70 eV, %): m/z = 289 (10), 198 (68), 196 (20), 171 (13), 170 (100), 168 (57), 167 (12), 153 
(12), 119 (10), 91 (40). 
HRMS (EI, 70 eV): m/z calcd. for [C20H19NO]: 289.1467; found: 289.1462 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3027 (w), 2922 (w), 2850 (vw), 2736 (vw), 1694 (s), 1605 
(s), 1576 (m), 1488 (m), 1454 (w), 1306 (m), 1267 (m), 1213 (m), 1169 (m), 1089 (m), 1070 (m), 930 
(w), 853 (w), 821 (m), 775 (m), 720 (vs), 698 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +49.9. 
Ethyl (S)-4-(3-phenyl-2-(1H-pyrrol-1-yl)propyl)benzoate ((S)-24c) 
 
According to TP12, a solution of (S)-20d (1.30 mL, 0.47 M, 0.60 mmol, 1.20 equiv) was added 
dropwise to a solution of ethyl 4-iodobenzoate (140 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 (2.25 mg, 
10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL) and the resulting 
reaction mixture stirred for 16 h. After quenching with sat. aq. NH4Cl solution and extraction with 
EtOAc, the crude product was purified by flash column chromatography to afford (S)-24c (162 mg, 
0.49 mmol, 96% yield, 99.9% ee) as a yellow oil. 
In a large-scale attempt, the same procedure was carried out using 552 mg (2.00 mmol, 1.00 equiv) of 
ethyl 4-iodobenzoate and a freshly prepared solution of (S)-20d (4.80 mL, 0.50 M, 2.40 mmol, 
1.20 equiv) with catalytic amounts of Pd(OAc)2 (9.00 mg, 40.0 µmol, 2 mol%) and SPhos (33.0 mg, 
80.3 µmol, 4 mol%), resulting in a yield of 632 mg (S)-24c (1.90 mmol, 95% yield). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.94 (d, J = 8.3 Hz, 2H), 7.33 – 7.22 (m, 3H), 7.06 – 7.00 (m, 
4H), 6.57 (t, J = 2.1 Hz, 2H), 6.11 (t, J = 2.1 Hz, 2H), 4.39 (q, J = 7.1 Hz, 2H), 4.28 (quint, J = 7.1 Hz, 
1H), 3.23 – 3.07 (m, 4H), 1.42 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 166.6, 143.5, 138.0, 129.7, 128.9, 128.9, 128.9, 128.5, 126.7, 
119.0, 108.0, 63.4, 60.9, 42.8, 42.5, 14.4. 
MS (EI, 70 eV, %): m/z = 333 (6), 242 (40), 171 (13), 170 (100), 168 (61), 167 (14), 163 (12), 91 (30). 
HRMS (EI, 70 eV): m/z calcd. for [C22H23NO2]: 333.1729; found: 333.1721 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2979 (w), 2928 (w), 1710 (s), 1610 (w), 1575 (vw), 1488 
(m), 1454 (w), 1415 (w), 1366 (w), 1311 (w), 1271 (vs), 1178 (m), 1101 (s), 1070 (m), 1021 (m), 932 
(w), 850 (w), 752 (m), 720 (s), 698 (vs). 
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[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +32.4. 
(S)-4-(3-Phenyl-2-(1H-pyrrol-1-yl)propyl)benzonitrile ((S)-24d) 
 
According to TP12, the product was synthesized from 4-iodobenzonitrile (458 mg, 2.00 mmol, 
1.00 equiv) and a freshly prepared solution of (S)-20d (4.80 mL, 0.50 M, 2.40 mmol, 1.20 equiv) in the 
presence of Pd(OAc)2 (2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%). The 
mixture was stirred at room temperature for 16 h and quenched sat. aq. NH4Cl solution. Extraction of 
crude product with EtOAc and flash column chromatography purification afforded (S)-24d (540 mg, 
1.89 mmol, 94% yield, 98.8% ee) as a brown oil. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.52 – 7.46 (m, 2H), 7.32 – 7.22 (m, 4H), 7.07 – 7.02 (m, 2H), 
7.00 – 6.95 (m, 2H), 6.53 (t, J = 2.1 Hz, 2H), 6.09 (t, J = 2.1 Hz, 2H), 4.22 (tt, J = 7.8, 6.5 Hz, 1H), 3.22 
(dd, J = 13.7, 7.9 Hz, 1H), 3.15 – 3.06 (m, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 143.8, 137.8, 132.2, 129.7, 129.0, 128.7, 126.9, 119.0, 119.0, 
110.6, 108.3, 63.4, 43.0, 42.6. 
MS (EI, 70 eV, %): m/z = 286 (11), 196 (14), 195 (100), 193 (32), 171 (11), 170 (84), 168 (43), 167 
(10), 116 (44), 91 (24). 
HRMS (EI, 70 eV): m/z calcd. for [C20H18N2]: 286.1470; found: 286.1465 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3062 (vw), 3028 (vw), 2924 (w), 2226 (m), 1733 (vw), 1606 
(w), 1488 (m), 1454 (w), 1414 (w), 1267 (m), 1178 (w), 1089 (m), 1070 (m), 931 (w), 846 (w), 826 
(m), 755 (m), 721 (vs), 698 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +44.3. 
(S)-1-(4-Methoxyphenyl)-4-phenyl-3-(1H-pyrrol-1-yl)butan-1-one ((S)-24e) 
 
Following TP13a, the product was synthesized from 4-methoxybenzoyl chloride (85 mg, 0.50 mmol, 
1.00 equiv) and freshly prepared solution of (S)-20d (1.40 mL, 0.42 M, 0.60 mmol, 1.20 equiv) with 
catalytic amount of Pd(PPh3)4 (23 mg, 20.0 μmol, 4 mol%). The reaction mixture was stirred at 50 °C 
for 16 h and quenched sat. aq. NH4Cl solution. Extraction of the crude product with EtOAc and flash 
column chromatography purification afforded (S)-24e (154 mg, 0.48 mmol, 86% yield, 99.9% ee) as a 
white solid. 
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1H-NMR (400 MHz, CDCl3, ppm): δ = 7.95 (d, J = 8.8 Hz, 2H), 7.31 – 7.26 (m, 3H), 7.08 (d, 
J = 7.2 Hz, 2H), 6.98 (d, J = 8.8 Hz, 2H), 6.73 (td, J = 2.0, 1.2 Hz, 2H), 6.16 (td, J = 2.0, 1.6 Hz, 2H), 
4.95 (quint, J = 6.8 Hz, 1H), 3.92 (s, 3H), 3.55 (dd, J = 16.8, 6.4 Hz, 1H), 3.43 (dd, J = 16.8, 7.0 Hz, 
1H), 3.22 (dd, J = 13.6, 5.6 Hz, 1H), 3.15 (dd, J = 13.6, 8.4 Hz, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 195.5, 163.6, 137.8, 126.6, 119.0, 113.7, 107.8, 77.3, 77.0, 
76.7, 57.3, 55.4, 43.8, 42.8. 
MS (EI, 70 eV, %): m/z = 319 (1), 298 (15), 210 (50), 184 (8), 167 (9), 135 (100), 91 (5), 77 (8). 
HRMS (EI, 70 eV): m/z calcd. for [C21H21NO2]: 319.1572; found: 319.1565 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3027 (w), 2934 (w), 1674 (s), 1600 (vs), 1575 (m), 1510 (m), 
1490 (m), 1419 (m), 1360 (w), 1259 (s), 1218 (m), 1171 (s), 1090 (m), 1029 (m), 990 (w), 834 (w), 725 
(m), 701 (m). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –31.2. 
M.p.: 90.1 °C. 
(S)-1-(3-Chlorophenyl)-4-phenyl-3-(1H-pyrrol-1-yl)butan-1-one ((S)-24f) 
 
According to TP13a, 3-chlorobenzoyl chloride (88 mg, 0.50 mmol, 1.00 equiv) and a freshly prepared 
solution of (S)-20d (1.40 mL, 0.42 M, 0.60 mmol, 1.20 equiv) with catalytic amount of Pd(PPh3)4 
(23.0 mg, 20.0 μmol, 4 mol%) were used. The reaction mixture was stirred at 50 °C for 16 h and 
quenched sat. aq. NH4Cl solution. Extraction of the crude product with EtOAc and flash column 
chromatography purification afforded (S)-24f (138 mg, 0.43 mmol, 85% yield, 99.9% ee) as a white 
solid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.86 (s, 1H), 7.76 (d, J = 7.6 Hz, 1H), 7.56 (d, J = 8.0 Hz, 1H), 
7.41 (t, J = 8.0 Hz, 1H), 7.29 – 7.23 (m, 3H), 7.05 (d, J = 7.6 Hz, 2H), 6.69 (td, J = 2.0, 1.6 Hz, 2H), 
6.12 (td, J = 2.0, 1.6 Hz, 2H), 4.90 (quint, J = 6.8 Hz, 1H), 3.53 (dd, J = 17.2, 6.4 Hz, 1H), 3.43 (dd, 
J = 17.2, 6.4 Hz, 1H), 3.15 (d, J = 7.2 Hz, 2H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 196.0, 138.3, 137.7, 135.1, 133.4, 130.1, 129.1, 128.6, 128.2, 
126.9, 126.2, 119.2, 108.3, 57.3, 44.4, 42.9. 
MS (EI, 70 eV, %): m/z = 323 (1), 302 (16), 267 (18), 214 (100), 139 (83), 111 (9), 91 (6). 
HRMS (EI, 70 eV): m/z calcd. for [C20H18ClNO]: 323.1077; found: 323.1071 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3063 (w), 3028 (w), 2918 (w), 2360 (s), 2340 (m), 1688 (vs), 
1571 (m), 1489 (m), 1420 (m), 1360 (m), 1276 (m), 1256 (m), 1212 (m), 1090 (m), 724 (vs), 700 (s). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –22.5. 
M.p.: 66.5 °C. 
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(R)-1-(3-Chlorophenyl)-4-phenyl-3-(1H-pyrrol-1-yl)butan-1-one ((R)-24f) 
 
To obtain the (R)-enantiomer, the reaction was repeated using the (R)-zinc species starting from the D-
phenylalaninol. The procedure for preparation of the starting materials was done in the same way as for 
the L-phenylalaninol (18d–20d). 
According to TP13a, 3-chlorobenzoyl chloride (88 mg, 0.50 mmol, 1.00 equiv) and a freshly prepared 
solution of (R)-20d (1.53 mL, 0.39 M, 0.60 mmol, 1.20 equiv) with catalytic amount of Pd(PPh3)4 
(23.0 mg, 20.0 μmol, 4 mol%) were used. The reaction mixture was stirred at 50 °C for 16 h and 
quenched sat. aq. NH4Cl solution. Extraction of the crude product and flash column chromatography 
purification afforded (R)-24f (133 mg, 0.41 mmol, 82% yield, 99.9% ee) as a white solid. 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +20.9. 
(S)-1-(Furan-2-yl)-4-phenyl-3-(1H-pyrrol-1-yl)butan-1-one ((S)-24g) 
 
Following TP13a, 2-furoyl chloride (65.0 mg, 0.50 mmol, 1.00 equiv), a freshly prepared solution of 
(S)-20d (1.40 mL, 0.42 M, 0.60 mmol, 1.20 equiv) and catalytic amount of Pd(PPh3)4 (23.0 mg, 
20.0 μmol, 4 mol%) were used. The reaction mixture was stirred at 50 °C for 16 h and quenched sat. 
aq. NH4Cl solution. Extraction of the crude product with EtOAc and flash column chromatography 
purification afforded (S)-24g (118 mg, 0.42 mmol, 84% yield, 99.8% ee) as a white solid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.56 (dd, J = 1.6, 0.7 Hz, 1H), 7.26 – 7.19 (m, 3H), 7.14 (d, 
J = 3.6 Hz, 1H), 7.04 – 6.99 (m, 2H), 6.65 (t, J = 2.1 Hz, 2H), 6.51 (dd, J = 3.6, 1.7 Hz, 1H), 6.08 (t, 
J = 2.1 Hz, 2H), 4.85 (pent, J = 7.0 Hz, 1H), 3.42 (dd, J = 16.5, 7.1 Hz, 1H), 3.25 (dd, J = 16.5, 6.6 Hz, 
1H), 3.12 (d, J = 7.1 Hz, 2H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 186.1, 152.6, 146.7, 137.7, 129.1, 128.5, 126.8, 119.2, 117.5, 
112.5, 108.1, 57.2, 44.1, 42.9. 
MS (EI, 70 eV, %): m/z = 279 (4), 188 (23), 170 (29), 115 (9), 95 (100), 91 (8). 
HRMS (EI, 70 eV): m/z calcd. for [C18H17NO2]: 279.1259; found: 279.1253 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3124 (w), 3095 (w), 3024 (vw), 1650 (vs), 1561 (w), 1492 
(w), 1465 (m), 1397 (m), 1288 (w), 1279 (m), 1162 (w), 1057 (w), 1031 (w), 1002 (w), 917 (w), 774 
(m), 737 (m), 697 (m). 
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[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –37.5. 
M.p.: 120.5 °C. 
Ethyl (S)-4-oxo-7-phenyl-6-(1H-pyrrol-1-yl)heptanoate ((S)-24h) 
 
Following TP13a, ethyl 4-chloro-4-oxobutyrate (82 mg, 0.50 mmol, 1.00 equiv), a freshly prepared 
solution of (S)-20d (1.40 mL, 0.42 M, 0.60 mmol, 1.20 equiv) and catalytic amount of Pd(PPh3)4 
(23.0 mg, 20.0 μmol, 4 mol%) were used. The reaction mixture was stirred at 50 °C for 16 h and 
quenched sat. aq. NH4Cl solution. Extraction of the crude product with EtOAc and flash column 
chromatography purification afforded (S)-24h (110 mg, 0.35 mmol, 70% yield, 99.9% ee) as a brownish 
liquid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.21 (dddt, J = 6.9, 5.2, 3.5, 1.8 Hz, 3H), 7.01 – 6.90 (m, 3H), 
6.59 (t, J = 2.1 Hz, 2H), 6.08 (t, J = 2.1 Hz, 2H), 4.66 (p, J = 7.1 Hz, 1H), 4.11 (q, J = 7.1 Hz, 2H), 3.03 
(d, J = 7.1 Hz, 2H), 3.02 (dd, J = 16.5, 7.4 Hz, 1H), 2.89 (dd, J = 16.6, 6.3 Hz, 1H), 2.71 – 2.39 (m, 
4H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 206.3, 172.7, 137.6, 129.1, 128.5, 126.8, 119.1, 108.2, 60.8, 
57.3, 48.3, 42.9, 37.9, 27.9, 14.3. 
MS (EI, 70 eV, %): m/z = 311 (1), 295 (15), 222 (18), 204 (29), 176 (20), 130 (100), 101 (54), 91 (20). 
HRMS (EI, 70 eV): m/z calcd. for [C19H23NO3]: 313.1678; found: 313.1622 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2980 (w), 2926 (w), 1718 (vs), 1490 (m), 1412 (m), 1371 
(m), 1350 (m), 1270 (m), 1196 (m), 1092 (m), 1030 (w), 749 (w), 726 (s), 701 (m). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –16.3. 
(R)-3-(2-Phenyl-2-(1H-pyrrol-1-yl)ethyl)aniline ((R)-25a) 
 
According to TP12, 3-Bromoaniline (86 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 (2.25 mg, 10.0 µmol, 
2 mol%), SPhos (8.21 mg, 20.0 µmol, 4 mol%) and a freshly prepared solution of (S)-20e (1.33 mL, 
0.45 M, 0.60 mmol, 1.20 equiv) were used. The mixture was stirred at room temperature for 16 h and 
quenched sat. aq. NH4Cl solution. Extraction of the crude product with EtOAc and flash column 
chromatography purification afforded Purification of the crude product by flash column 
chromatography afforded (R)-25a (98 mg, 0.38 mmol, 75% yield, 99.8% ee) as a light orange solid. 
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1H-NMR (400 MHz, CDCl3, ppm): δ = 7.35 – 7.24 (m, 3H), 7.20 – 7.15 (m, 2H), 7.02 (t, J = 7.7 Hz, 
1H), 6.75 (t, J = 2.1 Hz, 2H), 6.53 (ddd, J = 7.9, 2.4, 1.0 Hz, 1H), 6.45 (d, J = 6.9 Hz, 1H), 6.30 (t, 
J = 2.0 Hz, 1H), 6.16 (t, J = 2.1 Hz, 2H), 5.28 (dd, J = 8.5, 6.5 Hz, 1H), 3.55 (br, 2H), 3.47 (dd, J = 13.8, 
8.6 Hz, 1H), 3.34 (dd, J = 13.8, 6.5 Hz, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 146.5, 141.8, 139.2, 129.4, 128.7, 127.7, 126.7, 119.9, 119.4, 
115.9, 113.5, 108.1, 64.8, 42.3. 
MS (EI, 70 eV, %): m/z = 262 (3), 157 (12), 156 (100), 129 (13), 128 (10). 
HRMS (EI, 70 eV): m/z calcd. for [C18H18N2]: 262.1470; found: 262.1464 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3396 (w), 3313 (w), 3214 (w), 3126 (w), 3023 (w), 1630 (m), 
1586 (m), 1486 (m), 1454 (m), 1407 (m), 1322 (w), 1283 (m), 1268 (s), 1164 (w), 1090 (s), 1039 (w), 
1025 (w), 981 (w), 949 (w), 906 (w), 870 (w), 775 (m), 727 (s), 693 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –24.2. 
M.p.: 81.3 °C. 
(R)-1-(2-(4-Methoxyphenyl)-1-phenylethyl)-1H-pyrrole ((R)-25b) 
 
Following TP12, 4-iodoanisole (118 mg, 0.50 mmol, 1.00 equiv) and a freshly prepared solution of 
(S)-20e (1.33 mL, 0.45 M, 0.60 mmol, 1.20 equiv) were used as starting materials with catalytic 
amounts of Pd(OAc)2 (2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%). Stirring 
the reaction mixture for 16 h followed by quenching, extraction and purification of the crude product 
by flash column chromatography afforded (R)-25b (105 mg, 0.38 mmol, 75% yield, 99.7% ee) as a 
faint yellow liquid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.32 – 7.22 (m, 4H), 7.18 – 7.13 (m, 2H), 6.92 – 6.86 (m, 2H), 
6.77 – 6.73 (m, 2H), 6.72 (t, J = 2.1 Hz, 2H), 6.14 (t, J = 2.1 Hz, 2H), 5.21 (dd, J = 8.6, 6.6 Hz, 1H), 
3.76 (s, 3H), 3.48 (dd, J = 13.9, 8.6 Hz, 1H), 3.35 (dd, J = 13.8, 6.6 Hz, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 158.4, 141.7, 130.1, 130.0, 128.7, 127.8, 126.8, 119.8, 113.9, 
108.2, 65.3, 55.3, 41.4. 
MS (EI, 70 eV, %): m/z = 277 (2), 157 (12), 156 (100), 129 (12), 121 (9). 
HRMS (EI, 70 eV): m/z calcd. for [C19H19NO]: 277.1467; found: 277.1460 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3029 (vw), 2930 (w), 2834 (vw), 1611 (w), 1584 (w), 1511 
(s), 1487 (m), 1451 (m), 1408 (w), 1301 (w), 1244 (s), 1178 (m), 1088 (m), 1031 (m), 972 (w), 910 (w), 
820 (m), 756 (m), 720 (vs), 697 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –17.3. 
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(R)-4-(2-Phenyl-2-(1H-pyrrol-1-yl)ethyl)benzaldehyde ((R)-25c) 
 
According to TP12, 4-bromobenzaldehyde (93.0 mg, 0.50 mmol, 1.00 equiv) and a freshly prepared 
solution of (S)-20e (1.33 mL, 0.45 M, 0.60 mmol, 1.20 equiv) were used as starting materials with 
catalytic amounts of Pd(OAc)2 (2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) 
present. The reaction mixture was stirred at room temperature for 16 h and quenched sat. aq. NH4Cl 
solution. Extraction of the crude product with EtOAc and flash column chromatography purification 
afforded (R)-25c (116 mg, 0.42 mmol, 84% yield, 99.4% ee) as a yellow solid. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 9.95 (s, 1H), 7.74 (d, J = 8.2 Hz, 2H), 7.36 – 7.27 (m, 3H), 
7.21 – 7.12 (m, 4H), 6.70 (t, J = 2.1 Hz, 2H), 6.14 (t, J = 2.1 Hz, 2H), 5.29 (dd, J = 9.0, 6.4 Hz, 1H), 
3.62 (dd, J = 13.7, 9.0 Hz, 1H), 3.51 (dd, J = 13.7, 6.3 Hz, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 192.0, 145.2, 141.0, 135.1, 130.0, 129.7, 128.9, 128.1, 126.6, 
119.7, 108.5, 64.5, 42.4. 
MS (EI, 70 eV, %): m/z = 275 (1), 157 (12), 156 (100), 129 (11). 
HRMS (EI, 70 eV): m/z calcd. for [C19H17NO]: 275.1310; found: 275.1305 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2923 (w), 1686 (s), 1602 (s), 1576 (m), 1488 (m), 1451 (m), 
1398 (w), 1345 (w), 1308 (m), 1266 (m), 1216 (m), 1201 (m), 1165 (m), 1093 (m), 1078 (m), 1026 (w), 
977 (m), 863 (m), 832 (m), 808 (m), 747 (m), 725 (vs), 696 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +1.0. 
M.p.: 67.0 °C. 
Ethyl (R)-4-(2-phenyl-2-(1H-pyrrol-1-yl)ethyl)benzoate ((R)-25d) 
 
Following TP12, ethyl 4-iodobenzoate (140 mg, 0.50 mmol, 1.00 equiv), a freshly prepared solution of 
(S)-20e (1.33 mL, 0.45 M, 0.60 mmol, 1.20 equiv) as well as Pd(OAc)2 (2.25 mg, 10.0 µmol, 2 mol%) 
and SPhos (8.21 mg, 20.0 µmol, 4 mol%). The reaction mixture was stirred at room temperature for 
16 h and quenched sat. aq. NH4Cl solution. Extraction of the crude product with EtOAc and flash 
column chromatography purification afforded (R)-25d (149 mg, 0.47 mmol, 92% yield, 99.9% ee) as a 
yellow oil. 
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1H-NMR (400 MHz, CDCl3, ppm): δ = 7.93 – 7.86 (m, 2H), 7.35 – 7.22 (m, 3H), 7.20 – 7.13 (m, 2H), 
7.06 (d, J = 8.6 Hz, 1H), 6.70 (t, J = 2.2 Hz, 2H), 6.13 (t, J = 2.1 Hz, 2H), 5.27 (dd, J = 8.9, 6.4 Hz, 
1H), 4.35 (q, J = 7.1 Hz, 2H), 3.58 (dd, J = 13.7, 8.9 Hz, 1H), 3.47 (dd, J = 13.7, 6.4 Hz, 1H), 1.37 (t, 
J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 166.6, 143.2, 141.1, 129.8, 129.1, 129.1, 128.8, 128.0, 126.7, 
119.7, 108.4, 64.6, 61.0, 42.2, 14.4. 
MS (EI, 70 eV, %): m/z = 319 (1), 178 (8), 157 (12), 156 (100), 129 (9). 
HRMS (EI, 70 eV): m/z calcd. for [C21H21NO2]: 319.1572; found: 319.1564 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3030 (vw), 2980 (w), 2931 (vw), 1709 (s), 1611 (w), 1487 
(m), 1451 (w), 1416 (w), 1366 (w), 1311 (w), 1272 (vs), 1179 (m), 1102 (s), 1021 (m), 974 (w), 926 
(w), 872 (w), 841 (w), 754 (m), 722 (vs), 697 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –7.7. 
(R)-4-(2-Phenyl-2-(1H-pyrrol-1-yl)ethyl)benzonitrile ((R)-25e) 
 
According to TP12, 4-iodobenzonitrile (115 mg, 0.50 mmol, 1.00 equiv), a freshly prepared solution 
of (S)-20e (1.33 mL, 0.45 M, 0.60 mmol, 1.20 equiv) as well as Pd(OAc)2 (2.25 mg, 10.0 µmol, 
2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%). The reaction mixture was stirred at room 
temperature for 16 h and quenched sat. aq. NH4Cl solution. Extraction of the crude product with EtOAc 
and flash column chromatography purification afforded (R)-25e (130 mg, 0.48 mmol, 95% yield, 
99.7% ee) as a yellow oil. 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.53 – 7.47 (m, 2H), 7.37 – 7.26 (m, 3H), 7.21 – 7.16 (m, 2H), 
7.10 – 7.05 (m, 2H), 6.68 (t, J = 2.1 Hz, 2H), 6.14 (t, J = 2.1 Hz, 2H), 5.24 (dd, J = 9.2, 6.1 Hz, 1H), 
3.59 (dd, J = 13.8, 9.2 Hz, 1H), 3.48 (dd, J = 13.8, 6.1 Hz, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 143.5, 140.7, 132.3, 129.8, 128.9, 128.2, 126.6, 119.7, 118.9, 
110.8, 108.7, 64.4, 42.3. 
MS (EI, 70 eV, %): m/z = 272 (1), 157 (12), 156 (100), 129 (12). 
HRMS (EI, 70 eV): m/z calcd. for [C19H16N2]: 272.1313; found: 272.1310 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3030 (vw), 2923 (w), 2853 (vw), 2226 (m), 1607 (w), 1486 
(m), 1451 (w), 1415 (w), 1265 (m), 1178 (w), 1089 (m), 1071 (m), 1021 (w), 973 (vw), 911 (w), 821 
(m), 753 (m), 722 (vs), 698 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +8.3. 
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(R)-1-(3-Bromophenyl)-3-phenyl-3-(1H-pyrrol-1-yl)propan-1-one ((R)-25f) 
 
According to TP13b, a freshly prepared solution of (S)-20e (1.33 mL, 0.45 M, 0.60 mmol, 1.20 equiv) 
was mixed with catalytic amounts of CuI (9.52 mg, 0.05 mmol, 10 mol%) at 0 °C. 3-Bromobenzoyl 
chloride (109 mg, 0.50 mmol, 1.00 equiv) was added and the mixture stirred for 1 h at 0 °C before 
warming to room temperature. The reaction mixture was stirred at room temperature for 16 h and 
quenched sat. aq. NH4Cl solution. Extraction of the crude product with EtOAc and flash column 
chromatography purification afforded a white solid (R)-25f (142 mg, 0.40 mmol, 80% yield, 99.8% ee). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.05 (t, J = 1.8 Hz, 1H), 7.85 (ddd, J = 7.8, 1.7, 1.1 Hz, 1H), 
7.70 (ddd, J = 7.9, 2.0, 1.0 Hz, 1H), 7.38 – 7.24 (m, 4H), 7.23 – 7.19 (m, 2H), 6.76 (t, J = 2.2 Hz, 2H), 
6.16 (t, J = 2.1 Hz, 2H), 5.95 (t, J = 6.9 Hz, 1H), 3.91 (dd, J = 17.3, 7.6 Hz, 1H), 3.74 (dd, J = 17.3, 
6.4 Hz, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 195.1, 141.0, 138.3, 136.5, 131.3, 130.5, 129.0, 128.1, 126.7, 
126.5, 123.2, 119.9, 108.7, 58.4, 44.9. 
MS (EI, 70 eV, %): m/z = 353 (2), 337 (36), 336 (14), 335 (38), 334 (14), 256 (22), 254 (38), 185 (85), 
183 (86), 180 (16), 171 (12), 170 (100), 157 (17), 155 (17), 127 (13), 103 (16), 76 (15). 
HRMS (EI, 70 eV): m/z calcd. for [C19H16BrNO]: 353.0415; found: 353.0409 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3095 (vw), 3063 (vw), 3028 (vw), 2922 (w), 1681 (s), 1567 
(w), 1488 (m), 1450 (m), 1423 (m), 1368 (w), 1305 (m), 1260 (m), 1203 (m), 1097 (m), 1069 (m), 995 
(m), 887 (m), 823 (w), 791 (m), 770 (m), 730 (s), 697 (vs), 671 (s). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –8.2. 
M.p.: 118.4 °C. 
(S)-3-(3-(4-Fluorophenyl)-2-(1H-pyrrol-1-yl)propyl)-1H-indole ((S)-26a) 
 
According to TP12, 1-bromo-4-fluorobenzene (88.0 mg, 0.50 mmol, 1.00 equiv) and a freshly prepared 
solution of (R)-20f (1.43 mL, 0.42 M, 0.60 mmol, 1.20 equiv) were used as starting materials with 
catalytic amounts of Pd(OAc)2 (2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol% 
present. The reaction mixture was stirred at room temperature for 16 h and quenched sat. aq. NH4Cl 
solution. Extraction of the crude product with EtOAc and flash column chromatography purification 
afforded (S)-26a as brownish highly viscous gel (109 mg, 0.34 mmol, 68% yield, 99.4% ee). 
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1H-NMR (400 MHz, CDCl3, ppm): δ = 7.90 (s, 1H), 7.46 (dd, J = 7.9, 1.1 Hz, 1H), 7.35 (dt, J = 8.1, 
1.0 Hz, 1H), 7.23 – 7.18 (m, 1H), 7.16 – 7.11 (m, 1H), 6.93 – 6.84 (m, 4H), 6.60 – 6.57 (m, 3H), 6.09 
(t, J = 2.1 Hz, 2H), 4.27 (tt, J = 8.3, 6.0 Hz, 1H), 3.29 (dd, J = 14.8, 6.1 Hz, 1H), 3.23 (dd, J = 14.9, 
8.2 Hz, 1H), 3.12 (dd, J = 13.1, 5.0 Hz, 1H), 3.07 (dd, J = 13.1, 7.7 Hz, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 161.7 (d, J = 244.3 Hz), 136.1, 134.2 (d, J = 3.2 Hz), 130.4 
(d, J = 7.9 Hz), 127.3, 122.7, 122.1, 119.6, 119.1, 118.4, 115.2 (d, J = 21.1 Hz), 112.1, 111.3, 107.8, 
62.8, 42.2, 32.0. 
19F-NMR (377 MHz, CDCl3, ppm): δ = –116.6. 
MS (EI, 70 eV, %): m/z = 318 (10), 209 (12), 188 (16), 186 (13), 131 (10), 130 (100), 109 (15). 
HRMS (EI, 70 eV): m/z calcd. for [C21H19FN2]: 318.1532; found: 318.1520 ([M]). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3412 (w), 2920 (w), 2852 (w), 1602 (w), 1508 (s), 1490 (m), 
1456 (m), 1418 (w), 1356 (w), 1336 (w), 1266 (w), 1220 (s), 1158 (m), 1090 (m), 1070 (w), 1012 (w), 
924 (w), 910 (w), 822 (m), 724 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +19.7.  
(S)-1-(4-(3-(1H-Indol-3-yl)-2-(1H-pyrrol-1-yl)propyl)phenyl)ethan-1-one ((S)-26b) 
 
According to TP12, 1-(4-iodophenyl)ethan-1-one (123 mg, 0.50 mmol, 1.00 equiv) and a freshly 
prepared solution of (R)-20f (1.43 mL, 0.42 M, 0.60 mmol, 1.20 equiv) were used as starting materials 
with catalytic amounts of Pd(OAc)2 (2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 
4 mol%) present. The reaction mixture was stirred at room temperature for 16 h and quenched sat. aq. 
NH4Cl solution. Extraction of the crude product with EtOAc and flash column chromatography 
purification afforded (S)-26b as a highly viscous colorless gel (168 mg, 0.49 mmol, 98% yield, 
99.4% ee). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.00 (s, 1H), 7.83 – 7.77 (m, 2H), 7.48 (d, J = 7.9 Hz, 1H), 
7.38 – 7.31 (m, 1H), 7.21 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 7.13 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 7.03 – 
6.99 (m, 2H), 6.60 (d, J = 2.4 Hz, 1H), 6.59 (t, J = 2.1 Hz, 2H), 6.09 (t, J = 2.1 Hz, 2H), 4.40 – 4.30 (m, 
1H), 3.34 – 3.24 (m, 2H), 3.23 – 3.13 (m, 2H), 2.56 (s, 3H).  
13C-NMR (101 MHz, CDCl3, ppm): δ = 198.0, 144.2, 136.1, 135.6, 129.2, 128.6, 127.3, 122.7, 122.1, 
119.6, 119.1, 118.4, 111.9, 111.4, 107.9, 62.4, 42.9, 32.3, 26.7. 
MS (EI, 70 eV, %): m/z = 343 (6), 342 (25), 242 (18), 209 (12), 131 (11), 130 (100), 43 (16). 
HRMS (EI, 70 eV): m/z calcd. for [C23H22N2O]: 342.1732; found: 342.1727 ([M]
+). 
C. EXPERIMENTAL PART    170 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3378 (w), 3006 (w), 2920 (vw), 1674 (s), 1606 (m), 1572 
(w), 1488 (w), 1456 (m), 1414 (m), 1358 (m), 1268 (s), 1216 (m), 1184 (m), 1090 (m), 1070 (m), 1010 
(w), 958 (w), 926 (w), 846 (w), 818 (w), 740 (vs), 722 (vs), 666 (m). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –11.2. 
Ethyl (S)-4-(3-(1H-indol-3-yl)-2-(1H-pyrrol-1-yl)propyl)benzoate ((S)-26c) 
 
According to TP12, ethyl 4-iodobenzoate (138 mg, 0.50 mmol, 1.00 equiv) and a freshly prepared 
solution of (R)-20f (1.43 mL, 0.42 M, 0.60 mmol, 1.20 equiv) were used as starting materials with 
catalytic amounts of Pd(OAc)2 (2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) 
present. The reaction mixture was stirred at room temperature for 16 h and quenched sat. aq. NH4Cl 
solution. Extraction of the crude product with EtOAc and flash column chromatography purification 
afforded (S)-26c as a brownish highly viscous gel (180 mg, 0.48 mmol, 97% yield, 99.0% ee). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.96 (s, 1H), 7.91 – 7.85 (m, 2H), 7.47 (dt, J = 7.9, 1.0 Hz, 
1H), 7.35 (dt, J = 8.1, 1.0 Hz, 1H), 7.20 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.13 (ddd, J = 8.0, 7.1, 1.1 Hz, 
1H), 7.03 – 6.95 (m, 2H), 6.59 (d, J = 2.3 Hz, 1H), 6.58 (t, J = 2.2 Hz, 2H), 6.08 (t, J = 2.1 Hz, 2H), 
4.35 (q, J = 7.1 Hz, 2H), 4.44 – 4.29 (m, 1H), 3.33 – 3.22 (m, 2H), 3.22 – 3.11 (m, 2H), 1.38 (t, J = 7.1 
Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 166.6, 143.7, 136.0, 129.6, 128.9, 128.7, 127.2, 122.6, 122.0, 
119.5, 119.0, 118.3, 111.8, 111.2, 107.8, 62.3, 60.9, 42.8, 32.0, 14.3. 
MS (EI, 70 eV, %): 373 (8), 372 (26), 242 (30), 209 (17), 163 (6), 130 (100), 43 (17). 
HRMS (EI, 70 eV): m/z calcd. for [C24H24N2O2]: 372.1838; found: 372.1833 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3386 (w), 2984 (w), 2930 (w), 1704 (s), 1610 (w), 1490 (w), 
1456 (m), 1416 (m), 1368 (w), 1312 (m), 1274 (vs), 1228 (m), 1180 (m), 1104 (s), 1090 (s), 1070 (m), 
1020 (m), 928 (w), 852 (w), 740 (vs), 722 (vs), 666 (w). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –9.4. 
(S)-3-(3-(1H-Indol-3-yl)-2-(1H-pyrrol-1-yl)propyl)benzonitrile ((S)-26d) 
 
According to TP12, 3-iodobenzonitrile (115 mg, 0.50 mmol, 1.00 equiv) and a freshly prepared 
solution of (R)-20f (1.43 mL, 0.42 M, 0.60 mmol, 1.20 equiv) were used as starting materials with 
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catalytic amounts of Pd(OAc)2 (2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) 
present. The reaction mixture was stirred at room temperature for 16 h and quenched sat. aq. NH4Cl 
solution. Extraction of the crude product with EtOAc and flash column chromatography purification 
afforded (S)-26d as yellowish highly viscous gel (150 mg, 0.46 mmol, 92% yield, 99.1% ee). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.99 (s, 1H), 7.51 (dd, J = 7.8, 1.2 Hz, 1H), 7.45 (dt, J = 7.8, 
1.4 Hz, 1H), 7.40 – 7.34 (m, 1H), 7.29 – 7.19 (m, 2H), 7.18 – 7.12 (m, 2H), 7.04 (dt, J = 7.8, 1.5 Hz, 
1H), 6.66 (d, J = 2.4 Hz, 1H), 6.56 (t, J = 2.1 Hz, 2H), 6.10 (t, J = 2.1 Hz, 2H), 4.35 – 4.23 (m, 1H), 
3.30 (d, J = 7.2 Hz, 2H), 3.16 (dd, J = 13.9, 4.8 Hz, 1H), 3.09 (dd, J = 13.9, 9.4 Hz, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 139.9, 136.1, 133.5, 132.5, 130.4, 129.1, 127.2, 122.7, 122.3, 
119.7, 119.0, 119.0, 118.3, 112.3, 111.7, 111.4, 108.2, 62.3, 42.4, 32.2. 
MS (EI, 70 eV, %): 326 (5), 325 (20), 131 (10), 130 (100), 61 (7), 43 (30). 
HRMS (EI, 70 eV): m/z calcd. for [C22H19N3]: 325.1579; found: 325.1574 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3408 (m), 2950 (w), 2922 (w), 2230 (m), 1488 (m), 1458 
(m), 1422 (w), 1356 (w), 1336 (w), 1266 (w), 1230 (w), 1090 (m), 1070 (w), 1010 (w), 938 (w), 910 
(w), 798 (w), 728 (vs), 692 (m). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –3.6. 
(S)-3-(3-(3-Nitrophenyl)-2-(1H-pyrrol-1-yl)propyl)-1H-indole ((S)-26e) 
 
According to TP12, 1-iodo-3-nitrobenzene (138 mg, 0.50 mmol, 1.00 equiv) and a freshly prepared 
solution of (R)-20f (1.43 mL, 0.42 M, 0.60 mmol, 1.20 equiv) were used as starting materials with 
catalytic amounts of Pd(OAc)2 (2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) 
present. The reaction mixture was stirred at room temperature for 16 h and quenched sat. aq. NH4Cl 
solution. Extraction of the crude product with EtOAc and flash column chromatography purification 
afforded (S)-26e as a yellow highly viscous gel (157 mg, 0.45 mmol, 91%, 99.1% ee). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.02 (ddd, J = 8.2, 2.3, 1.1 Hz, 1H), 7.97 (s, 1H), 7.78 (t, J = 
2.0 Hz, 1H), 7.52 (dq, J = 7.9, 0.9 Hz, 1H), 7.36 (dt, J = 8.1, 1.0 Hz, 1H), 7.31 (t, J = 7.9 Hz, 1H), 7.22 
(ddd, J = 8.2, 7.0, 1.3 Hz, 1H), 7.15 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 7.10 (dt, J = 7.7, 1.4 Hz, 1H), 6.68 
(d, J = 2.4 Hz, 1H), 6.58 (t, J = 2.1 Hz, 2H), 6.10 (t, J = 2.1 Hz, 2H), 4.40 – 4.29 (m, 1H), 3.35 – 3.30 
(m, 2H), 3.24 (dd, J = 13.9, 4.8 Hz, 1H), 3.17 (dd, J = 13.9, 9.5 Hz, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 148.2, 140.4, 136.1, 135.2, 129.2, 127.3, 123.9, 122.8, 122.3, 
121.8, 119.7, 119.0, 118.4, 111.8, 111.4, 108.3, 62.3, 42.5, 32.3. 
MS (EI, 70 eV, %): 345 (8), 185 (10), 130 (62), 70 (10), 61 (17), 45 (15), 43 (100). 
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HRMS (EI, 70 eV): m/z calcd. for [C19H18N4]: 345.1477; found: 345.1472 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3412 (w), 2924 (vw), 1524 (s), 1488 (m), 1456 (m), 1422 
(w), 1350 (s), 1266 (w), 1090 (m), 1070 (m), 1010 (w), 928 (w), 816 (w), 804 (w), 724 (vs), 692 (m). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +13.2. 
(R)-3-(3-(Pyrazin-2-yl)-2-(1H-pyrrol-1-yl)propyl)-1H-indole ((R)-26f) 
 
According to TP12, 2-iodopyrazine (103 mg, 0.50 mmol, 1.00 equiv) and a freshly prepared solution 
of (R)-20f (1.43 mL, 0.42 M, 0.60 mmol, 1.20 equiv) were used as starting materials with catalytic 
amounts of Pd(OAc)2 (2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) present. 
The reaction mixture was stirred at room temperature for 16 h and quenched sat. aq. NH4Cl solution. 
Extraction of the crude product with EtOAc and flash column chromatography purification afforded 
(R)-26f as an orange highly viscous gel (148 mg, 0.49 mmol, 98% yield, 99.3% ee). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.45 (dd, J = 2.6, 1.5 Hz, 1H), 8.35 (d, J = 2.6 Hz, 1H), 8.06 
(d, J = 1.5 Hz, 1H), 8.03 (s, 1H), 7.52 (dd, J = 7.9, 1.2 Hz, 1H), 7.32 (dt, J = 8.1, 1.0 Hz, 1H), 7.19 (ddd, 
J = 8.2, 7.0, 1.3 Hz, 1H), 7.13 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 6.64 (d, J = 2.4 Hz, 1H), 6.58 (t, J = 2.1 Hz, 
2H), 6.06 (t, J = 2.1 Hz, 2H), 4.71 (dtd, J = 8.9, 7.2, 5.5 Hz, 1H), 3.41 – 3.24 (m, 4H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 154.2, 145.1, 144.1, 142.7, 136.1, 127.4, 122.8, 122.1, 119.6, 
119.0, 118.5, 111.8, 111.3, 108.2, 60.6, 42.3, 32.3. 
MS (EI, 70 eV, %): 302 (1), 235 (20), 208 (17), 207 (19), 172 (14), 131 (10), 130 (100), 128 (11), 94 
(11). 
HRMS (EI, 70 eV): m/z calcd. for [C19H18N4]: 302.1531; found: 302.1522 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3406 (w), 3224 (w), 3056 (w), 2924 (w), 1488 (w), 1456 (m), 
1404 (m), 1356 (w), 1336 (w), 1268 (w), 1228 (w), 1132 (w), 1090 (m), 1058 (m), 1018 (m), 926 (w), 
826 (w), 738 (vs), 722 (vs), 666 (w). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –6.7. 
(S)-1-(1-(3,5-Dimethylphenyl)-3-(4-methoxyphenyl)propan-2-yl)-1H-pyrrole ((S)-27a) 
 
According to TP12, 1-iodo-3,5-dimethylbenzene (116 mg, 0.50 mmol, 1.00 equiv) and a freshly 
prepared solution of (S)-20g (1.28 mL, 0.47 M, 0.60 mmol, 1.20 equiv) were used as starting materials 
with catalytic amounts of Pd(OAc)2 (2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 
C. EXPERIMENTAL PART    173 
4 mol% present. The reaction mixture was stirred at room temperature for 16 h and quenched sat. aq. 
NH4Cl solution. Extraction of the crude product with EtOAc and flash column chromatography 
purification afforded (S)-27a a colorless liquid (152 mg, 0.48 mmol, 95% yield, 92.5% ee) 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.88 – 6.83 (m, 3H), 6.80 – 6.75 (m, 2H), 6.61 (s, 2H), 6.58 
(t, J = 2.1 Hz, 2H), 6.10 (t, J = 2.1 Hz, 2H), 4.18 (p, J = 7.1 Hz, 1H), 3.78 (s, 3H), 3.10 – 2.94 (m, 4H), 
2.27 (s, 6H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 158.3, 138.2, 137.9, 130.5, 130.0, 128.2, 126.9, 119.1, 113.8, 
107.6, 63.9, 55.3, 42.5, 41.5, 21.4. 
MS (EI, 70 eV, %): m/z = 319 (3), 198 (100), 183 (11), 169 (14), 131 (10), 119 (25). 
HRMS (EI, 70 eV): m/z calcd. for [C22H25NO]: 319.1936; found: 319.1928 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3009 (w), 2916 (w), 2835 (w), 1608 (m), 1511 (vs), 1488 
(m), 1464 (m), 1441 (m), 1245 (vs), 1178 (m), 1089 (m), 1034 (s), 840 (m), 719 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –16.6. 
Methyl (S)-2-(3-(4-methoxyphenyl)-2-(1H-pyrrol-1-yl)propyl)benzoate ((S)-27b) 
 
According to TP12, methyl 2-iodobenzoate (131 mg, 0.50 mmol, 1.00 equiv) and a freshly prepared 
solution of (S)-20g (1.28 mL, 0.47 M, 0.60 mmol, 1.20 equiv) were used as starting materials with 
catalytic amounts of Pd(OAc)2 (2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) 
present. The reaction mixture was stirred at room temperature for 16 h and quenched sat. aq. NH4Cl 
solution. Extraction of the crude product with EtOAc and flash column chromatography purification 
afforded (S)-27b a colorless liquid (168 mg, 0.48 mmol, 96% yield, 92.5% ee). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.92 – 7.85 (m, 1H), 7.31 – 7.19 (m, 2H), 6.92 – 6.85 (m, 2H), 
6.82 (dd, J = 7.4, 1.7 Hz, 1H), 6.77 – 6.70 (m, 2H), 6.48 (t, J = 2.1 Hz, 2H), 6.00 (t, J = 2.1 Hz, 2H), 
4.28 (dddd, J = 10.0, 8.4, 6.0, 4.5 Hz, 1H), 3.84 (s, 3H), 3.74 (s, 3H), 3.65 (dd, J = 13.2, 4.4 Hz, 1H), 
3.22 (dd, J = 13.2, 9.5 Hz, 1H), 3.15 – 3.04 (m, 2H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 168.0, 158.2, 140.3, 132.0, 131.6, 130.9, 130.6, 130.0, 129.4, 
126.7, 119.2, 113.7, 107.5, 64.0, 55.3, 52.1, 42.0, 41.5. 
MS (EI, 70 eV, %): m/z = 349 (2), 228 (50), 197 (14), 196 (100), 168 (17), 167 (10). 
HRMS (EI, 70 eV): m/z calcd. for [C22H23NO3] 349.1678; found: 349.1670 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2951 (w), 1715 (s), 1612 (w), 1512 (s), 1488 (m), 1434 (m), 
1294 (m), 1244 (vs), 1178 (m), 1132 (m), 1082 (s), 1034 (m), 963 (w), 819 (m), 748 (m), 720 (s). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +25.8. 
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(S)-3-(3-(4-Methoxyphenyl)-2-(1H-pyrrol-1-yl)propyl)benzonitrile ((S)-27c) 
 
According to TP4, 3-iodobenzonitrile (115 mg, 0.50 mmol, 1.00 equiv) and a freshly prepared solution 
of (S)-20g (1.28 mL, 0.47 M, 0.60 mmol, 1.20 equiv) were used as starting materials with catalytic 
amounts of Pd(OAc)2 (2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol% present. 
The reaction mixture was stirred at room temperature for 16 h and quenched sat. aq. NH4Cl solution. 
Extraction of the crude product with EtOAc and flash column chromatography purification afforded 
(S)-27c a colorless liquid (147 mg, 0.47 mmol, 93% yield, 92.0% ee). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.45 (dt, J = 7.8, 1.4 Hz, 1H), 7.26 (t, J = 7.7 Hz, 1H), 7.13 (t, 
J = 1.8 Hz, 1H), 7.03 (dt, J = 8.0, 1.4 Hz, 1H), 6.95 – 6.90 (m, 2H), 6.82 – 6.77 (m, 2H), 6.50 (t, 
J = 2.1 Hz, 2H), 6.07 (t, J = 2.1 Hz, 2H), 4.12 (dddd, J = 8.9, 7.8, 6.6, 5.4 Hz, 1H), 3.78 (s, 3H), 3.17 – 
2.97 (m, 4H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 158.5, 139.7, 133.4, 132.5, 130.4, 130.0, 129.8, 129.2, 118.9, 
118.9, 114.0, 112.4, 108.3, 77.5, 77.2, 76.8, 63.6, 55.3, 42.0, 41.9. 
MS (EI, 70 eV, %): m/z = 316 (15), 249 (13), 200 (48), 198 (11), 196 (14), 195 (100), 193 (32), 121 
(36), 116 (24). 
HRMS (EI, 70 eV): m/z calcd. for [C21H20N2O]: 316.1576; found: 316.1567 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2935 (w), 2228 (m), 1612 (m), 1583 (w), 1512 (vs), 1487 
(m), 1442 (w), 1301 (m), 1244 (vs), 1178 (m), 1090 (m), 1071 (m), 1033 (m), 939 (w), 920 (w), 819 
(m), 797 (m), 722 (vs), 691 (s). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +7.3. 
(S)-1-(4-Fluorophenyl)-4-(4-methoxyphenyl)-3-(1H-pyrrol-1-yl)butan-1-one ((S)-27d) 
 
According to TP13a, a solution of (S)-20g (1.28 mL, 0.47 M, 0.60 mmol, 1.20 equiv) was added 
dropwise to a solution of 4-fluorobenzoyl chloride (79.3 mg, 0.50 mmol, 1.00 equiv) and Pd(PPh3)4 
(23.1 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL) and stirred for 16 h. After quenching with sat. aq. 
NH4Cl and extraction with EtOAc, the crude product was purified by flash column chromatography to 
afford the title compound (S)-27d as a colorless solid (131 mg, 0.39 mmol, 78% yield, 92.3% ee). 
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1H-NMR (400 MHz, CDCl3, ppm): δ = 7.95 – 7.85 (m, 2H), 7.16 – 7.06 (m, 2H), 6.95 – 6.86 (m, 2H), 
6.82 – 6.72 (m, 2H), 6.65 (t, J = 2.2 Hz, 2H), 6.09 (t, J = 2.1 Hz, 2H), 4.81 (dq, J = 7.7, 6.4 Hz, 1H), 
3.76 (s, 3H), 3.48 (dd, J = 17.0, 6.5 Hz, 1H), 3.35 (dd, J = 17.0, 6.6 Hz, 1H), 3.12 – 2.98 (m, 2H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 195.7, 166.0 (d, J = 255.4 Hz), 158.5, 133.2 (d, J = 3.0 Hz), 
130.8 (d, J = 9.3 Hz), 130.2, 129.7, 119.2, 115.9 (d, J = 22.0 Hz), 113.9, 108.1, 57.5, 55.3, 44.1, 42.0. 
19F-NMR (377 MHz, CDCl3, ppm): δ = –105.9. 
MS (EI, 70 eV, %): m/z = 337 (2), 199 (13), 123 (100), 121 (15). 
HRMS (EI, 70 eV): m/z calcd. for [C21H20O2NF] 337.1478; found: 337.1473 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 1679 (s), 1594 (m), 1510 (m), 1490 (m), 1461 (m), 1371 (m), 
1327 (m), 1300 (m), 1278 (m), 1247 (s), 1177 (m), 1159 (m), 1101 (m), 1073 (m), 1053 (w), 1029 (m), 
998 (m), 939 (w), 846 (m), 822 (s), 813 (s), 714 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –28.1. 
M.p. 81.3 °C. 
(S)-1-(3-Chlorophenyl)-4-(4-methoxyphenyl)-3-(1H-pyrrol-1-yl)butan-1-one ((S)-27e) 
 
According to TP13b, CuI (9.52 mg, 0.05 mmol, 10 mol%) was added to a freshly prepared solution of 
(S)-20g (1.28 mL, 0.47 M, 0.60 mmol, 1.20 equiv) at 0 °C and the mixture stirred for 10 min before 
3-chlorobenzoyl chloride (87.5 mg, 0.50 mmol, 1.00 equiv) was added dropwise. The reaction mixture 
stirred for 1 h at 0 °C and stirring was continued afterwards at room temperature for 16 h. After 
quenching with sat. aq. NH4Cl and extraction with EtOAc, the crude product was purified by flash 
column chromatography and the title compound (S)-27e was obtained as white solid (148 mg, 
0.41 mmol, 84% yield, 92.8% ee). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.83 (t, J = 1.9 Hz, 1H), 7.73 (dt, J = 7.8, 1.4 Hz, 1H), 7.53 
(ddd, J = 8.0, 2.1, 1.0 Hz, 1H), 7.38 (t, J = 7.9 Hz, 1H), 6.96 – 6.87 (m, 2H), 6.81 – 6.71 (m, 2H), 6.66 
(t, J = 2.1 Hz, 2H), 6.09 (t, J = 2.1 Hz, 2H), 4.81 (p, J = 6.8 Hz, 1H), 3.77 (s, 3H), 3.48 (dd, J = 17.1, 
6.6 Hz, 1H), 3.35 (dd, J = 17.2, 6.5 Hz, 1H), 3.06 (d, J = 7.1 Hz, 2H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 196.1, 158.5, 138.2, 135.1, 133.4, 130.2, 130.1, 129.6, 128.2, 
126.2, 119.2, 114.0, 108.2, 57.4, 55.3, 44.3, 42.0. 
MS (EI, 70 eV, %): m/z = 353 (2), 199 (19), 141 (34), 139 (100), 121 (25). 
HRMS (EI, 70 eV): m/z calcd. for [C21H20ClNO2] 353.1183; found: 353.1177 ([M]
+).  
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 1673 (m), 1611 (m), 1513 (s), 1490 (m), 1419 (m), 1360 (w), 
1276 (m), 1252 (s), 1210 (m), 1175 (m), 1093 (m), 1032 (m), 830 (m), 811 (m), 786 (s), 740 (m), 715 
(vs), 691 (m), 674 (m). 
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[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –22.4. 
M.p. 86.6 °C. 
(S)-1-(2-Bromophenyl)-4-(4-methoxyphenyl)-3-(1H-pyrrol-1-yl)butan-1-one ((S)-27f) 
 
According to TP13b, CuI (9.52 mg, 0.05 mmol, 10 mol%) was added to a freshly prepared solution of 
(S)-20g (1.28 mL, 0.47 M, 0.60 mmol, 1.20 equiv) at 0 °C and the mixture stirred for 10 min before 2-
bromobenzoyl chloride (110 mg, 0.50 mmol, 1.00 equiv) was added dropwise. The reaction mixture 
stirred for 1 h at 0 °C and stirring was continued afterwards at room temperature for 16 h. After 
quenching with sat. aq. NH4Cl and extraction with EtOAc, the crude product was purified by flash 
column chromatography and the title compound (S)-27f was obtained as colorless liquid (149 mg, 
0.37 mmol, 75% yield, 92.1% ee). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.61 – 7.52 (m, 1H), 7.35 – 7.22 (m, 2H), 7.10 – 7.01 (m, 1H), 
6.94 – 6.85 (m, 2H), 6.81 – 6.73 (m, 2H), 6.58 (t, J = 2.1 Hz, 2H), 6.06 (t, J = 2.1 Hz, 2H), 4.73 (p, 
J = 7.3 Hz, 1H), 3.77 (s, 3H), 3.47 (dd, J = 17.0, 7.6 Hz, 1H), 3.37 (dd, J = 17.0, 6.3 Hz, 1H), 3.11 – 
2.97 (m, 2H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 201.6, 158.5, 141.4, 133.7, 131.9, 130.2, 129.6, 128.6, 127.6, 
119.3, 118.5, 114.0, 108.2, 57.9, 55.3, 48.5, 42.1. 
MS (EI, 70 eV, %): m/z = 397 (1), 185 (98), 183 (100), 121 (21). 
HRMS (EI, 70 eV): m/z calcd. for [C21H20BrNO2] 397.0677; found: 397.0671 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2935 (w), 1697 (m), 1612 (m), 1586 (w), 1511 (s), 1489 (m), 
1465 (m), 1427 (m), 1357 (w), 1244 (vs), 1178 (m), 1110 (w), 1090 (m), 1068 (m), 1030 (s), 990 (m), 
923 (w), 820 (m), 755 (m), 721 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –22.1. 
(3-((1R,2S)-2-(1H-Pyrrol-1-yl)cyclohexyl)aniline ((R,S)-28a) 
 
According to TP12, a solution of (S)-20h (1.54 mL, 0.39 M, 0.60 mmol, 1.20 equiv) was added 
dropwise to a solution of 2-bromoaniline (86.0 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 (2.25 mg, 
10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL) and stirred for 16 h. 
After quenching with sat. aq. NH4Cl and extraction with EtOAc, the crude product was purified by flash 
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column chromatography to afford the title compound (R,S)-28a as a yellow solid (111 mg, 0.46 mmol, 
92% yield, 99.7% ee, dr > 99:1). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.97 (t, J = 7.8 Hz, 1H), 6.49 (t, J = 2.2 Hz, 2H), 6.48 – 6.43 
(m, 3H), 6.31 (t, J = 2.0 Hz, 1H), 5.95 (t, J = 2.1 Hz, 2H), 3.87 (td, J = 11.5, 3.9 Hz, 1H), 3.32 (s, 2H), 
2.80 – 2.63 (m, 1H), 2.24 – 2.14 (m, 1H), 2.05 – 1.94 (m, 2H), 1.93 – 1.81 (m, 2H), 1.72 – 1.60 (m, 
1H), 1.58 – 1.39 (m, 2H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 146.2, 144.6, 129.1, 119.0, 117.4, 114.3, 113.4, 107.0, 63.8, 
51.8, 34.9, 34.1, 26.1. 
MS (EI, 70 eV, %): m/z = 241 (16), 240 (100), 239 (19), 173 (41), 158 (34), 144 (27), 134 (41), 132 
(15), 130 (18), 121 (10), 120 (25), 119 (17), 118 (11), 107 (30), 106 (39), 81 (13), 79 (10). 
HRMS (EI, 70 eV): m/z calcd. for [C16H20N2]: 240.1626; found: 240.1622 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3359 (w), 2929 (s), 2855 (m), 1686 (w), 1607 (s), 1591 (m), 
1490 (s), 1460 (m), 1447 (m), 1408 (w), 1272 (s), 1168 (w), 1090 (m), 1066 (m), 932 (w), 861 (w), 780 
(m), 721 (vs), 698 (s). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +98.4. 
M.p. 88.5 °C. 
1-((1S,2R)-2-(4-Methoxyphenyl)cyclohexyl)-1H-pyrrole ((S,R)-28b) 
 
According to TP12, a solution of (S)-20h (1.54 mL, 0.39 M, 0.60 mmol, 1.20 equiv) was added 
dropwise to a solution of 4-iodoanisole (117 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 (2.25 mg, 
10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL) and stirred for 16 h. 
After quenching with sat. aq. NH4Cl and extraction with EtOAc, the crude product was purified by flash 
column chromatography to afford the title compound (S,R)-28b as colorless oil (107 mg, 0.42 mmol, 
84% yield, 99.5% ee, dr > 99:1). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 6.96 – 6.89 (m, 2H), 6.75 – 6.68 (m, 2H), 6.46 (t, J = 2.1 Hz, 
2H), 5.94 (t, J = 2.1 Hz, 2H), 3.83 (td, J = 11.5, 3.9 Hz, 1H), 3.73 (s, 3H), 2.76 (td, J = 11.6, 3.5 Hz, 
1H), 2.19 (dtd, J = 12.8, 4.0, 2.1 Hz, 1H), 2.04 – 1.94 (m, 2H), 1.94 – 1.82 (m, 2H), 1.74 – 1.60 (m, 
1H), 1.60 – 1.39 (m, 2H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 158.0, 135.5, 127.9, 118.9, 113.6, 107.0, 64.3, 55.2, 51.0, 
35.0, 34.3, 26.2, 26.2. 
MS (EI, 70 eV, %): m/z =  256 (13), 255 (75), 254 (16), 189 (14), 188 (100), 173 (14), 160 (13), 159 
(21), 147 (16), 134 (81), 121 (95), 120 (36), 115 (14), 106 (18), 91 (24), 82 (16), 81 (21), 80 (17).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
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HRMS (EI, 70 eV): m/z calcd. for [C17H21NO]: 255.1623; found: 255.1619 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2929 (m), 2855 (w), 1611 (w), 1512 (s), 1489 (m), 1461 (w), 
1446 (m), 1286 (m), 1272 (m), 1247 (s), 1178 (m), 1089 (m), 1066 (w), 1034 (m), 997 (w), 959 (w), 
822 (s), 716 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +122.7. 
1-((1S,2R)-2-(3-(Trifluoromethyl)phenyl)cyclohexyl)-1H-pyrrole ((S,R)-28c) 
 
According to a modified version of TP12, a solution of (S)-20h (4.31 mL, 0.39 M, 1.68 mmol, 
1.20 equiv) was added dropwise to a solution of 3-iodobenzotrifluoride (381 mg, 1.40 mmol, 
1.00 equiv), Pd(OAc)2 (6.29 mg, 28.0 µmol, 2 mol%) and SPhos (23.0 mg, 56.0 µmol, 4 mol%) in dry 
THF (3 mL) and stirred for 16 h. After quenching with sat. aq. NH4Cl and extraction with EtOAc, the 
crude product was purified by flash column chromatography to afford the title compound (S,R)-28c as 
a white solid (398 mg, 1.36 mmol, 97% yield, 99.9% ee, dr > 99:1). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.38 (ddt, J = 7.7, 1.8, 1.0 Hz, 1H), 7.28 – 7.22 (m, 2H), 7.13 
(dtd, J = 7.7, 1.3, 0.7 Hz, 1H), 6.42 (t, J = 2.1 Hz, 2H), 5.92 (t, J = 2.1 Hz, 2H), 3.86 (td, J = 11.4, 
3.9 Hz, 1H), 2.88 (ddd, J = 12.1, 10.9, 3.5 Hz, 1H), 2.27 – 2.18 (m, 1H), 2.06 – 1.98 (m, 2H), 1.97 – 
1.86 (m, 2H), 1.73 (dtd, J = 13.8, 12.4, 3.7 Hz, 1H), 1.63 – 1.42 (m, 2H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 144.3, 130.6 (q, J = 1.4 Hz), 130.5 (q, J = 31.9 Hz), 128.6, 
124.3 (q, J = 272.3 Hz), 123.7 (q, J = 3.8 Hz), 123.4 (q, J = 3.9 Hz), 118.8, 107.6, 64.1, 51.9, 34.8, 33.7, 
26.1, 26.1. 
19F NMR (376 MHz, CDCl3, ppm): δ = -62.6. 
MS (EI, 70 eV, %): m/z = 294 (19), 192 (100), 292 (25), 211 (14), 185 (11), 29 (), 134 (51), 120 (36), 
106 (32), 81 (15), 80 (15), 68 (16). 
HRMS (EI, 70 eV): m/z calcd. for [C17H18F3N]: 293.1391; found: 293.1383 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2942 (w), 2861 (vw), 2358 (vw), 1489 (w), 1449 (w), 1329 
(s), 1270 (w), 1195 (w), 1158 (s), 1119 (s), 1090 (s), 1074 (s), 961 (w), 916 (w), 804 (m), 722 (vs), 702 
(s), 666 (w). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +45.6. 
M.p. 80.9 °C. 
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4-((1R,2S)-2-(1H-Pyrrol-1-yl)cyclohexyl)benzonitrile ((R,S)-28d) 
 
According to TP12, a solution of (S)-20h (1.54 mL, 0.39 M, 0.60 mmol, 1.20 equiv) was added 
dropwise to a solution of 4-iodobenzonitrile (115 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 (2.25 mg, 
10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL) and stirred for 16 h. 
After quenching with sat. aq. NH4Cl and extraction with EtOAc, the crude product was purified by flash 
column chromatography to afford the title compound (R,S)-28d as a yellowish solid (120 mg, 
0.48 mmol, 96% yield, 99.8% ee, dr > 99:1). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.48 – 7.40 (m, 2H), 7.15 – 7.07 (m, 2H), 6.42 (t, J = 2.1 Hz, 
2H), 5.91 (t, J = 2.1, 2H), 3.85 (td, J = 11.5, 3.9, 1H), 2.88 (td, J = 11.6, 3.5 Hz, 1H), 2.27 – 2.17 (m, 
1H), 2.06 – 1.84 (m, 4H), 1.68 (qd, J = 12.6, 3.4 Hz, 1H), 1.60 – 1.41 (m, 2H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 148.9, 132.1, 127.9, 119.1, 118.7, 110.4, 107.6, 63.8, 52.2, 
34.7, 33.6, 26.0, 25.9. 
MS (EI, 70 eV, %): m/z = 251 (19), 250 (100), 249 (36), 183 (14), 169 (18), 168 (25), 154 (14), 142 
(17), 140 (18), 134 (62), 121 (17), 120 (51), 116 (42), 115 (17), 106 (52), 93 (15), 89 (13), 81 (27), 80 
(25), 79 (17), 68 (26), 67 (11). 
HRMS (EI, 70 eV): m/z calcd. for [C17H18N2]: 250.1470; found: 250.1467 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2932 (m), 2857 (w), 2225 (m), 1700 (vw), 1608 (m), 1504 
(w), 1489 (m), 1448 (w), 1415 (w), 1300 (w), 1272 (m), 1090 (m), 1066 (w), 959 (w), 911 (vw), 826 
(m), 720 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +158.9. 
M.p. 94.8 °C. 
(1S,2S)-2-(1H-Pyrrol-1-yl)cyclohexyl)(4-fluorophenyl)methanone ((S,S)-28e) 
 
According to TP13a, a solution of (S)-20h (1.54 mL, 0.39 M, 0.60 mmol, 1.20 equiv) was added 
dropwise to a solution of 4-fluorobenzoyl chloride (79.3 mg, 0.50 mmol, 1.00 equiv) and Pd(PPh3)4 
(23.1 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL) and stirred for 16 h. After quenching with sat. aq. 
NH4Cl and extraction with EtOAc, the crude product was purified by flash column chromatography to 
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afford the title compound (S,S)-28e as a colorless solid (128 mg, 0.47 mmol, 94% yield, 99.8% ee, 
dr > 99:1). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.80 – 7.73 (m, 2H), 7.06 – 6.99 (m, 2H), 6.65 (t, J = 2.1 Hz, 
2H), 5.95 (t, J = 2.1 Hz, 2H), 4.36 (ddd, J = 12.2, 10.6, 4.0 Hz, 1H), 3.68 (ddd, J = 11.9, 10.6, 3.6 Hz, 
1H), 2.25 – 2.16 (m, 1H), 2.03 – 1.94 (m, 2H), 1.94 – 1.82 (m, 2H), 1.65 – 1.49 (m, 2H), 1.49 – 1.36 
(m, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 200.7, 165.84 (d, J = 254.9 Hz), 133.09 (d, J = 3.0 Hz), 
130.64 (d, J = 9.3 Hz), 119.1, 115.68 (d, J = 21.9 Hz), 107.8, 59.5, 52.2, 33.7, 30.7, 25.5, 25.3. 
19F NMR (376 MHz, CDCl3, ppm): δ = -105.3. 
MS (EI, 70 eV, %): m/z = 123 (50), 148 (100), 149 (10), 175 (31), 271 (28). 
HRMS (EI, 70 eV): m/z calcd. for [C17H18FNO]: 271.1372; found: 271.1366 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2934 (m), 2858 (w), 1674 (s), 1597 (s), 1506 (m), 1488 (m), 
1410 (m), 1377 (w), 1300 (m), 1273 (m), 1234 (s), 1214 (s), 1156 (s), 1090 (m), 1060 (m), 984 (m), 
947 (m), 838 (s), 746 (m), 716 (vs), 685 (m). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +45.6. 
M.p. 63.2 °C. 
1-((1R,2S)-2-(4-Methoxyphenyl)cyclopentyl)-1H-pyrrole ((R,S)-29a) 
 
According to TP12, a solution of (R)-20i (1.25 mL, 0.48 M, 0.60 mmol, 1.20 equiv) was added 
dropwise to a solution of 4-iodoanisole (117 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 (2.25 mg, 
10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL) and stirred for 16 h. 
After quenching with sat. aq. NH4Cl and extraction with EtOAc, the crude product was purified by flash 
column chromatography to afford the title compound (R,S)-29a as yellowish solid (95 mg, 0.39 mmol, 
79% yield, 99.2% ee, dr > 99:1). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.05 – 6.97 (m, 2H), 6.87 – 6.78 (m, 2H), 6.65 (t, J = 2.2 Hz, 
2H), 6.12 (t, J = 2.2 Hz, 2H), 4.26 (q, J = 8.7 Hz, 1H), 3.79 (s, 3H), 3.19 (td, J = 9.8 Hz, 8.0, 1H), 2.45 
– 2.31 (m, 1H), 2.25 (ddt, J = 12.5, 8.0, 4.2 Hz, 1H), 2.19 – 2.05 (m, 1H), 2.07 – 1.83 (m, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 158.3, 134.7, 128.1, 119.0, 114.0, 107.8, 77.5, 77.2, 76.8, 
67.8, 55.3, 52.5, 33.3, 32.7, 22.8. 
MS (EI, 70 eV, %): m/z = 241 (5), 159 (10), 174 (100), 143 (19), 121 (10), 106 (6), 91 (5). 
HRMS (EI, 70 eV): m/z calcd. for [C16H19NO]: 241.1467; found: 241.1462 ([M]
+). 
C. EXPERIMENTAL PART    181 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2955 (w), 2907 (w), 2876 (w), 1612 (w), 1581 (w), 1514 (s), 
1492 (m), 1461 (m), 1421 (w), 1324 (w), 1305 (w), 1278 (s), 1234 (s), 1176 (m), 1108 (w), 1088 (m), 
1070 (m), 1026 (s), 982 (w), 825 (s), 722 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –165.1. 
M.p. 55.6 °C. 
1-((1R,2S)-2-(3-Chlorophenyl)cyclopentyl)-1H-pyrrole ((R,S)-29b) 
 
According to TP12, a solution of (R)-20i (1.25 mL, 0.48 M, 0.60 mmol, 1.20 equiv) was added 
dropwise to a solution of 1-chloro-3-iodobenzene (119 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 
(2.25 mg, 10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL) and stirred 
for 16 h. After quenching with sat. aq. NH4Cl and extraction with EtOAc, the crude product was purified 
by flash column chromatography to afford the title compound (R,S)-29b as yellowish oil (114 mg, 
0.46 mmol, 93% yield, 99.6% ee, dr > 99:1). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.22 – 7.12 (m, 2H), 7.09 (qd, J = 1.6, 1.0 Hz, 1H), 6.95 – 6.86 
(m, 1H), 6.62 (t, J = 2.2 Hz, 2H), 6.12 (t, J = 2.2 Hz, 2H), 4.28 (dt, J = 9.6, 8.5 Hz, 1H), 3.20 (td, J = 9.8, 
8.0 Hz, 1H), 2.38 (dtd, J = 13.2, 8.0, 5.4 Hz, 1H), 2.33 – 2.20 (m, 1H), 2.19 – 2.04 (m, 1H), 2.07 – 1.82 
(m, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 144.9, 134.4, 129.9, 127.1, 126.9, 125.7, 119.0, 108.1, 67.6, 
53.1, 33.4, 32.6, 22.9. 
MS (EI, 70 eV, %): m/z = 245 (49), 178 (30), 143 (100), 106 (26), 68 (39). 
HRMS (EI, 70 eV): m/z calcd. for [C15H16ClN]: 245.0971; found: 245.0966 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2961 (w), 2874 (w), 1596 (w), 1571 (w), 1489 (m), 1477 (m), 
1452 (w), 1415 (w), 1325 (w), 1279 (m), 1090 (m), 1067 (m), 978 (w), 782 (m), 718 (vs), 691 (s). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –183.0. 
Methyl 2-((1S,2R)-2-(1H-pyrrol-1-yl)cyclopentyl)benzoate ((S,R)-29c) 
 
According to TP12, a solution of (R)-20i (1.25 mL, 0.48 M, 0.60 mmol, 1.20 equiv) was added 
dropwise to a solution of methyl 2-iodobenzoate (131 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 (2.25 mg, 
10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL) and stirred 16 h. 
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After quenching with sat. aq. NH4Cl and extraction with EtOAc, the crude product was purified by flash 
column chromatography to afford the title compound (S,R)-29c as a white solid (115 mg, 0.43 mmol, 
85%, 99.9% ee, d.r. = 98:2). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.71 (d, J = 7.8 Hz, 1H), 7.52 – 7.44 (m, 2H), 7.28 – 7.19 (m, 
1H), 6.59 (t, J = 2.2 Hz, 2H), 6.04 (t, J = 2.2 Hz, 2H), 4.47 (q, J = 8.6 Hz, 1H), 4.32 (q, J = 9.3 Hz, 1H), 
3.80 (s, 3H), 2.45 – 2.31 (m, 2H), 2.16 – 1.88 (m, 3H), 1.86 – 1.74 (m, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 168.4, 144.0, 132.1, 131.1, 130.3, 126.7, 126.2, 119.1, 107.7, 
67.2, 52.2, 47.8, 33.7, 33.6, 22.8. 
MS (EI, 70 eV, %): m/z = 269 (23), 210 (100), 201 (53), 170 (58), 169 (35), 153 (38). 
HRMS (EI, 70 eV): m/z calcd. for [C17H19NO2]: 269.1416; found: 269.1408 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2965 (w), 2948 (w), 2872 (w), 1703 (vs), 1574 (w), 1493 (w), 
1430 (m), 1296 (m), 1279 (m), 1237 (vs), 1184 (m), 1128 (m), 1099 (m), 1076 (s), 980 (w), 966 (w), 
834 (w), 817 (w), 753 (m), 731 (vs), 709 (s). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –17.2. 
M.p. 105.5 °C. 
Ethyl 4-((1S,2R)-2-(1H-pyrrol-1-yl)cyclopentyl)benzoate ((S,R)-29d) 
 
According to TP12, a solution of (R)-20i (1.25 mL, 0.48 M, 0.60 mmol, 1.20 equiv) was added 
dropwise to a solution of ethyl 4-iodobenzoate (138 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 (2.25 mg, 
10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL) and stirred for 16 h. 
After quenching with sat. aq. NH4Cl and extraction with EtOAc, the crude product was purified by flash 
column chromatography to afford the title compound (S,R)-29d as colorless liquid (119 mg, 0.42 mmol, 
84% yield, 99.3% ee, dr > 99:1). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.94 (d, J = 8.2 Hz, 2H), 7.13 (d, J = 8.2 Hz, 2H), 6.60 (t, 
J = 2.1 Hz, 2H), 6.09 (t, J = 2.1 Hz, 2H), 4.36 (q, J = 7.1 Hz, 2H), 4.30 (q, J = 8.8 Hz, 1H), 3.27 (td, 
J = 9.7, 8.1 Hz, 1H), 2.39 (dtd, J = 13.0, 7.9, 5.4 Hz, 1H), 2.28 (ddt, J = 12.0, 8.5, 4.7 Hz, 1H), 2.19 – 
2.07 (m, 1H), 2.07 – 1.86 (m, 3H), 1.38 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 166.6, 148.1, 129.9, 128.9, 127.2, 119.0, 108.1, 77.5, 77.2, 
76.8, 67.7, 61.0, 53.5, 33.4, 32.5, 22.9, 14.5. 
MS (EI, 70 eV, %): m/z = 283 (38), 216 (70), 187 (42), 143 (100), 128 (38), 120 (44), 115 (45), 106 
(55), 94 (37), 68 (20). 
HRMS (EI, 70 eV): m/z calcd. for [C18H21NO2]: 283.1572; found: 283.1566 ([M]
+). 
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FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2962 (w), 2876 (w), 1711 (s), 1610 (m), 1490 (m), 1451 (w), 
1417 (w), 1367 (w), 1271 (vs), 1181 (m), 1102 (s), 1067 (m), 1020 (m), 978 (w), 852 (w), 770 (m), 
720 (s), 705 (s). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –250.6. 
3-((1S,2R)-2-(1H-Pyrrol-1-yl)cyclopentyl)benzonitrile ((S,R)-29e) 
 
According to TP12, a solution of (R)-20i (1.25 mL, 0.48 M, 0.60 mmol, 1.20 equiv) was added 
dropwise to a solution of 3-iodobenzonitrile (115 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 (2.25 mg, 
10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL) and stirred for 16 h. 
After quenching with sat. aq. NH4Cl and extraction with EtOAc, the crude product was purified by flash 
column chromatography to afford the title compound (S,R)-29e as a white solid (107 mg, 0.45 mmol, 
91% yield, 99.8% ee, dr > 99:1). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.48 (dt, J = 7.7 Hz, 1.4, 1H), 7.38 – 7.29 (m, 2H), 7.21 (dt, 
J = 8.0, 1.6 Hz, 1H), 6.59 (t, J = 2.1 Hz, 2H), 6.11 (t, J = 2.1 Hz, 2H), 4.24 (q, J = 8.7 Hz, 1H), 3.24 
(td, J = 10.1, 7.9 Hz, 1H), 2.45 – 2.34 (m, 1H), 2.33 – 2.23 (m, 1H), 2.20 – 1.82 (m, 4H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 144.1, 131.9, 130.6, 130.4, 129.4, 119.0, 118.9, 112.6, 108.4, 
67.6, 52.9, 33.2, 32.0, 22.7. 
MS (EI, 70 eV, %): m/z = 236 (83), 168 (100), 120 (37), 106 (42), 94 (30), 68 (42). 
HRMS (EI, 70 eV): m/z calcd. for [C15H16N2]: 236.1313; found: 236.1308 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2960 (w), 2944 (w), 2873 (w), 2227 (w), 1581 (w), 1492 (m), 
1471 (w), 1435 (w), 1408 (w), 1332 (w), 1278 (m), 1098 (m), 1064 (w), 978 (w), 915 (w), 900 (w), 832 
(w), 797 (m), 728 (vs), 694 (s). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –199.9. 
M.p. 57.7 °C. 
1-((1R,2S)-2-(3-Nitrophenyl)cyclopentyl)-1H-pyrrole ((R,S)-29f) 
 
According to TP12, a solution of (R)-20i (1.25 mL, 0.48 M, 0.60 mmol, 1.20 equiv) was added 
dropwise to a solution of 1-iodo-3-nitrobenzene (125 mg, 0.50 mmol, 1.00 equiv), Pd(OAc)2 (2.25 mg, 
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10.0 µmol, 2 mol%) and SPhos (8.21 mg, 20.0 µmol, 4 mol%) in dry THF (1 mL) and stirred for 16 h. 
After quenching with sat. aq. NH4Cl and extraction with EtOAc, the crude product was purified by flash 
column chromatography to afford the title compound (R,S)-29f as a yellowish solid (96 mg, 0.37 mmol, 
75% yield, 99.6% ee, dr > 99:1). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 8.05 (ddd, J = 8.1, 2.3, 1.1 Hz, 1H), 8.00 (t, J = 2.0 Hz, 1H), 
7.39 (t, J = 7.9 Hz, 1H), 7.26 (dt, J = 7.7, 1.4 Hz, 1H), 6.61 (t, J = 2.2 Hz, 2H), 6.11 (t, J = 2.2 Hz, 2H), 
4.29 (q, J = 8.8 Hz, 1H), 3.33 (td, J = 9.9, 7.9 Hz, 1H), 2.48 – 2.36 (m, 1H), 2.32 (ddt, J = 11.9, 8.1, 
4.4 Hz, 1H), 2.16 (ddd, J = 13.3, 8.4, 5.8 Hz, 1H), 2.11 – 1.90 (m, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 148.5, 144.7, 134.0, 129.5, 121.9, 121.7, 118.9, 108.4, 67.7, 
53.0, 33.2, 32.2, 22.6. 
MS (EI, 70 eV, %): m/z = 256 (100), 239 (44), 128 (39), 120 (61), 115 (71), 106 (85), 94 (67), 68 (69). 
HRMS (EI, 70 eV): m/z calcd. for [C15H16N2O2]: 256.1212; found: 256.1206 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 2952 (w), 2873 (vw), 1528 (m), 1511 (w), 1492 (w), 1346 
(m), 1279 (m), 1094 (m), 1069 (w), 896 (vw), 860 (w), 831 (w), 806 (w), 733 (vs), 682 (m). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –162.8. 
M.p. 55.8 °C. 
 
3.7 Selective CBS-Reduction of Pyrrole-containing Ketones 
(1S,3R)-1-(3-Chlorophenyl)-4-phenyl-3-(1H-pyrrol-1-yl)butan-1-ol ((S,R)-30a) 
 
According to TP14, (R)-2-methyl-CBS-oxazaborolidine (41.6 mg, 0.15 mmol, 15 mol%) was dissolved 
in freshly distilled THF (3 mL) and the resulting solution was cooled down to 0 °C. BH3⋅SMe2 (83.6 mg, 
1.10 mmol, 1.10 equiv) was added dropwise and the mixture stirred for 15 min. (R)-24f (323 mg, 
1.00 mmol, 1.00 equiv) was dissolved in freshly distilled THF (3 mL) and added to the reaction mixture 
via syringe-pump over a period of 1 h at 0 °C. After complete addition, stirring was continued for 1h at 
0 °C and for 2 h at room temperature. The reaction was quenched with methanol, the solvents were 
removed in vacuo and the crude product was purified by flash column chromatography to yield 
(S,R)-30a as a colorless oil (310 mg, 0.95 mmol, 95% yield, 99.9% ee, d.r. = 99:1). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.26 – 7.18 (m, 6H), 7.11 – 7.07 (m, 1H), 6.98 (d, J = 1.9 Hz, 
1H), 6.98 – 6.95 (m, 1H), 6.68 (t, J = 2.1 Hz, 2H), 6.16 (t, J = 2.1 Hz, 2H), 4.49 (dddd, J = 10.5, 8.4, 
6.0, 4.2 Hz, 1H), 4.19 (dd, J = 9.6, 3.3 Hz, 1H), 3.08 (dd, J = 13.7, 8.4 Hz, 1H), 2.97 (dd, J = 13.7, 6.1 
Hz, 1H), 2.15 – 2.00 (m, 2H), 1.79 (s, 1H). 
C. EXPERIMENTAL PART    185 
13C-NMR (101 MHz, CDCl3, ppm): δ = 146.8, 138.1, 134.5, 129.9, 129.0, 128.5, 127.8, 126.7, 125.8, 
123.7, 119.2, 108.2, 70.1, 58.6, 45.3, 43.6. 
MS (EI, 70 eV, %): m/z = 325 (8), 171 (100), 141 (28), 139 (44), 113 (11), 111 (13), 104 (25), 94 (92), 
93 (13), 91 (24), 77 (36), 68 (14). 
HRMS (EI, 70 eV): m/z calcd. for [C20H20ClNO]: 325.1233; found: 325.1231. 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3437 (w, br), 3028 (w), 2920 (w), 1598 (w), 1574 (w), 1489 
(m), 1477 (w), 1454 (w), 1432 (w), 1416 (m), 1333 (w), 1270 (m), 1202 (w), 1089 (m), 1068 (m), 1057 
(m), 1030 (w), 957 (w), 787 (m), 754 (m), 725 (s), 699 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +33.8. 
(1R,3S)-1-(3-Chlorophenyl)-4-phenyl-3-(1H-pyrrol-1-yl)butan-1-ol ((R,S)-30b) 
 
According to TP14, (S)-2-methyl-CBS-oxazaborolidine (20.8 mg, 0.08 mmol, 15 mol%) was dissolved 
in freshly distilled THF (1.5 mL) and the resulting solution was cooled down to 0 °C. BH3⋅SMe2 
(41.7 mg, 0.55 mmol, 1.10 equiv) was added dropwise and the mixture stirred for 15 min. (S)-24f 
(162 mg, 0.50 mmol, 1.00 equiv) was dissolved in freshly distilled THF (1.5 mL) and added to the 
reaction mixture via syringe-pump over a period of 1 h at 0 °C. After complete addition, stirring was 
continued for 1h at 0 °C and for 2 h at room temperature. The reaction was quenched with methanol, 
the solvents were removed in vacuo and the crude product was purified by flash column 
chromatography to yield (S,R)-30b as a colorless oil (153 mg, 0.47 mmol, 94% yield, 99.7% ee, 
d.r. = 99:1). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –43.4. 
(1R,3R)-1-(3-Chlorophenyl)-4-phenyl-3-(1H-pyrrol-1-yl)butan-1-ol ((R,R)-30c) 
 
According to TP14, (S)-2-methyl-CBS-oxazaborolidine (20.8 mg, 0.08 mmol, 15 mol%) was dissolved 
in freshly distilled THF (1.5 mL) and the resulting solution was cooled down to 0 °C. BH3⋅SMe2 
(41.7 mg, 0.55 mmol, 1.10 equiv) was added dropwise and the mixture stirred for 15 min. (R)-24f 
(162 mg, 0.50 mmol, 1.00 equiv) was dissolved in freshly distilled THF (1.5 mL) and added to the 
reaction mixture via syringe-pump over a period of 1 h at 0 °C. After complete addition, stirring was 
continued for 1h at 0 °C and for 2 h at room temperature. The reaction was quenched with methanol, 
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the solvents were removed in vacuo and the crude product was purified by flash column 
chromatography to yield (R,R)-30c as a colorless oil (150 mg, 0.46 mmol, 92% yield, 99.4% ee, 
d.r. = 99:1). 
1H-NMR (400 MHz, CDCl3, ppm): δ = 7.28 – 7.26 (m, 2H), 7.24 (s, 1H), 7.22 – 7.20 (m, 1H), 7.20 – 
7.18 (m, 2H), 7.10 – 7.06 (m, 1H), 6.91 – 6.86 (m, 2H), 6.59 (t, J = 2.1 Hz, 2H), 6.15 (t, J = 2.1 Hz, 
2H), 4.46 (td, J = 7.0, 2.1 Hz, 1H), 3.96 – 3.85 (m, 1H), 3.07 – 2.95 (m, 2H), 2.41 (ddd, J = 14.2, 9.9, 
6.6 Hz, 1H), 2.16 (ddd, J = 14.1, 7.3, 4.7 Hz, 1H), 1.74 (s, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): δ = 145.6, 137.7, 134.7, 130.0, 129.0, 128.5, 128.3, 126.8, 126.6, 
124.7, 119.0, 108.5, 71.9, 59.2, 44.3, 43.6. 
MS (EI, 70 eV, %): m/z = 325 (7), 234 (13), 172 (11), 171 (91), 141 (25), 139 (39), 111 (11), 104 (19), 
94 (100), 93 (11), 91 (22), 77 (34), 68 (12). 
HRMS (EI, 70 eV): m/z calcd. for [C20H20ClNO]: 325.1233; found: 325.1226 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3389 (w, br), 3062 (vw), 3028 (vw), 2948 (w), 2923 (w), 
1597 (w), 1574 (w), 1489 (m), 1433 (w), 1328 (w), 1271 (m), 1201 (w), 1089 (m), 1064 (m), 1028 (w), 
886 (w), 788 (m), 751 (m), 722 (s), 697 (vs). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +34.9. 
(1R,3S)-1-(3-Chlorophenyl)-4-phenyl-3-(1H-pyrrol-1-yl)butan-1-ol ((S,S)-30d) 
 
According to TP14, (R)-2-methyl-CBS-oxazaborolidine (20.8 mg, 0.08 mmol, 15 mol%) was dissolved 
in freshly distilled THF (1.5 mL) and the resulting solution was cooled down to 0 °C. BH3⋅SMe2 
(41.7 mg, 0.55 mmol, 1.10 equiv) was added dropwise and the mixture stirred for 15 min. (S)-24f 
(162 mg, 0.50 mmol, 1.00 equiv) was dissolved in freshly distilled THF (1.5 mL) and added to the 
reaction mixture via syringe-pump over a period of 1 h at 0 °C. After complete addition, stirring was 
continued for 1h at 0 °C and for 2 h at room temperature. The reaction was quenched with methanol, 
the solvents were removed in vacuo and the crude product was purified by flash column 
chromatography to yield (S,S)-30d as a colorless oil (160 mg, 0.49 mmol, 98% yield, 99.4% ee, 
d.r. = 99:1). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –41.6. 
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3.8 Deprotection of Pyrrole-Derivatives using Ozonolysis 
General remark: All deprotected products contain a mono-formamides moiety as a mixture of the cis 
and the trans conformation.141 The NMR values stated are for the major conformer. 
Ethyl 4-(2-formamidoethyl)benzoate (31a) 
 
According to TP15, 21c (243 mg, 1.00 mmol, 1.00 equiv) was dissolved in 8 mL DCM and 2 mL 
methanol and cooled to –78 °C. Ozone was passed through for 5 min followed by nitrogen for 10 min. 
Dimethyl sulfide (621 mg, 10.0 mmol, 10.0 equiv) was added and the reaction mixture stirred for 6 h 
at room temperature. After evaporation of the solvents, the residue was stirred for 1 h in 10 mL KOH 
in ethanol (0.1 M) and afterwards ethanol removed under reduced pressure. The crude product was 
purified by via flash column chromatography purification and the title compound 31a (158 mg, 
0.71 mmol, 71% yield) was obtained as a white solid. 
1H-NMR (400 MHz, DMSO-d6, ppm): major conformer δ = 8.14 – 8.02 (m, 1H), 7.97 (d, J = 1.7 Hz, 
1H), 7.91 – 7.84 (m, 2H), 7.42 – 7.32 (m, 2H), 4.29 (q, J = 7.1 Hz, 2H), 3.35 (q, J = 6.9 Hz, 3H), 2.80 
(t, J = 7.2 Hz, 2H), 1.31 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, DMSO-d6, ppm): major conformer δ = 165.7, 161.1, 145.1, 129.2, 129.1, 127.9, 
60.6, 38.3, 35.0, 14.2. 
MS (EI, 70 eV, %): m/z = 221 (5), 177 (13), 176 (100), 164 (23), 148 (49), 136 (37), 135 (21), 132 
(13), 131 (90), 118 (21), 107 (15), 103 (15), 91 (32), 90 (31), 89 (20), 77 (18), 58 (18). 
HRMS (ESI): m/z calcd. for [M+H, C12H16NO3
+]: 222.1125; found: 222.1124. 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3236 (w), 3055 (w), 2982 (w), 1705 (s), 1685 (w), 1655 (s), 
1610 (m), 1541 (m), 1440 (m), 1382 (m), 1364 (m), 1278 (vs), 1241 (s), 1177 (s), 1121 (s), 1105 (s), 
1045 (m), 1026 (m), 851 (m), 782 (s), 765 (m), 704 (s). 
M.p. 65.5 °C. 
Ethyl (S)-4-(2-formamido-3-phenylpropyl)benzoate ((S)-31b) 
 
According to TP15, (S)-24c (334 mg, 1.00 mmol, 1.00 equiv) was dissolved in 8 mL DCM and 2 mL 
methanol and cooled to –78 °C. Ozone was passed through for 5 min followed by nitrogen for 10 min. 
Dimethyl sulfide (621 mg, 10.0 mmol, 10.0 equiv) was added and the reaction mixture stirred for 6 h 
 
141 M. J. Deetz, J. E. Fahey, B. D. Smith, J. Phys. Org. Chem. 2001, 14, 463. 
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at room temperature. After evaporation of the solvents, the residue was stirred for 1 h in 10 mL KOH 
in ethanol (0.1 M) and afterwards ethanol removed under reduced pressure. The crude product was 
purified by via flash column chromatography purification and the title compound (S)-31b (230 mg, 
0.74 mmol, 74% yield, 99.5% ee) was obtained as a colorless solid. 
1H-NMR (400 MHz, CDCl3, ppm): major conformer δ = 8.06 – 7.95 (m, 3H), 7.38 – 7.13 (m, 7H), 
5.49 (d, J = 7.4 Hz, 1H), 4.58 (sext, J = 7.3 Hz, 1H), 4.38 (q, J = 7.1 Hz, 2H), 3.04 – 2.73 (m, 4H), 1.40 
(t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3, ppm): major conformer δ = 166.6, 160.8, 143.2, 137.4, 129.9, 129.5, 
129.4, 129.4, 128.7, 126.9, 61.0, 50.3, 40.1, 14.4. 
MS (EI, 70 eV, %): m/z = 311 (1), 267 (17), 266 (100), 221 (16), 220 (32), 193 (38), 192 (33), 174 
(35), 164 (24), 148 (61), 120 (89), 119 (12), 103 (20), 91 (52), 77 (12). 
HRMS (EI, 70 eV): m/z calcd. for [C19H21NO3]: 311.1521; found: 311.1520 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3272 (w), 3029 (w), 2981 (w), 2928 (w), 2856 (vw), 1712 
(s), 1659 (s), 1610 (m), 1496 (w), 1444 (w), 1416 (w), 1386 (m), 1366 (m), 1311 (w), 1273 (vs), 1178 
(m), 1103 (s), 1021 (m), 911 (w), 853 (w), 759 (m), 732 (m), 699 (s). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –1.6. 
M.p. 127.8 °C. 
(S)-N-(1-(4-Cyanophenyl)-3-phenylpropan-2-yl)formamide ((S)-31c) 
 
According to TP15, (S)-24d (286 mg, 1.00 mmol, 1.00 equiv) was dissolved in 8 mL DCM and 2 mL 
methanol and cooled to –78 °C. Ozone was passed through for 5 min followed by nitrogen for 10 min. 
Dimethyl sulfide (621 mg, 10.0 mmol, 10.0 equiv) was added and the reaction mixture stirred for 6 h 
at room temperature. After evaporation of the solvents, the residue was stirred for 1 h in 10 mL KOH 
in ethanol (0.1 M) and afterwards ethanol removed under reduced pressure. The crude product was 
purified by via flash column chromatography purification and the title compound (S)-31c (172 mg, 
0.74 mmol, 65% yield, 99.9% ee) was obtained as a colorless solid. 
1H-NMR (400 MHz, CDCl3, ppm): major conformer δ = 8.02 (s, 1H), 7.65 – 7.55 (m, 2H), 7.35 – 
7.22 (m, 5H), 7.23 – 7.13 (m, 2H), 5.52 (d, J = 6.4 Hz, 1H), 4.56 (sext, J = 7.6 Hz, 1H), 3.05 – 2.72 (m, 
4H). 
13C-NMR (101 MHz, CDCl3, ppm): major conformer δ = 160.8, 143.7, 137.1, 132.4, 130.2, 129.3, 
128.8, 127.0, 118.9, 110.6, 50.2, 40.3, 40.2. 
MS (EI, 70 eV, %): m/z = 264 (1), 220 (16), 219 (100), 218 (15), 173 (42), 148 (32), 145 (69), 128 
(29), 120 (62), 117 (11), 116 (19), 103 (17), 91 (50), 89 (14), 77 (15), 65 (15). 
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HRMS (EI, 70 eV): m/z calcd. for [C17H16N2O]: 264.1263; found: 264.1260 ([M]
+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3265 (w), 3029 (w), 2923 (w), 2857 (w), 2226 (m), 1661 
(vs), 1607 (m), 1540 (m), 1506 (m), 1496 (m), 1454 (m), 1387 (m), 1252 (w), 734 (w), 701 (m). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): +1.2. 
M.p. 137.6 °C. 
 (S)-N-(1-(3,5-Dimethylphenyl)-3-(4-methoxyphenyl)propan-2-yl)formamide ((S)-31d) 
 
According to TP15, (S)-27a (160 mg, 0.50 mmol, 1.00 equiv) was dissolved in 4 mL DCM and 1 mL 
methanol and cooled to –78 °C. Ozone was passed through for 5 min followed by nitrogen for 10 min. 
Dimethyl sulfide (311 mg, 5.00 mmol, 10.0 equiv) was added and the reaction mixture stirred for 6 h 
at room temperature. After evaporation of the solvents, the residue was stirred for 1 h in 5 mL KOH in 
ethanol (0.1 M) and afterwards ethanol removed under reduced pressure. The crude product was 
purified by via flash column chromatography purification and the title compound (S)-31d (92 mg, 
0.31 mmol, 62% yield, 92.0% ee) was obtained as a white solid. 
1H-NMR (400 MHz, CDCl3, ppm): major conformer δ = 8.04 (d, J = 1.7 Hz, 1H), 7.16 – 7.09 (m, 
2H), 6.89 – 6.70 (m, 5H), 5.37 (d, J = 8.4 Hz, 1H), 4.47 (dt, J = 8.2, 6.6 Hz, 1H), 3.79 (s, 3H), 2.93 – 
2.58 (m, 4H), 2.29 (s, 6H). 
13C-NMR (101 MHz, CDCl3, ppm): major conformer δ = 160.8, 158.4, 138.1, 137.6, 130.4, 129.7, 
128.4, 127.2, 114.0, 55.3, 50.5, 39.7, 38.9, 21.4. 
MS (EI, 70 eV, %): m/z = 298 (1), 252 (100), 237 (49), 150 (10), 148 (47), 144 (11), 131 (27), 121 
(29), 118 (12), 91 (17). 
HRMS (EI, 70 eV): m/z calcd. for [M+H, C19H24NO2
+]: 298.1802; found: 298.1801 ([M+H]+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3296 (m), 2951 (w), 2917 (w), 2860 (w), 1659 (vs), 1608 
(m), 1539 (m), 1511 (s), 1441 (m), 1385 (m), 1260 (m), 1240 (s), 1176 (m), 1109 (w), 1039 (s), 848 
(m), 835 (m), 822 (m), 810 (m), 745 (m), 701 (s). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –1.1. 
M.p. 91.3 °C. 
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N-((1S,2R)-2-(3-(Trifluoromethyl)phenyl)cyclohexyl)formamide ((S,R)-31e) 
 
According to TP15, (S,R)-28c (147 mg, 0.50 mmol, 1.00 equiv) was dissolved in 4 mL DCM and 1 mL 
methanol and cooled to –78 °C. Ozone was passed through for 5 min followed by nitrogen for 10 min. 
Dimethyl sulfide (311 mg, 5.00 mmol, 10.0 equiv) was added and the reaction mixture stirred for 6 h 
at room temperature. After evaporation of the solvents, the residue was stirred for 1 h in 5 mL KOH in 
ethanol (0.1 M) and afterwards ethanol removed under reduced pressure. The crude product was 
purified by via flash column chromatography purification and the title compound (S,R)-31e (100 mg, 
0.37 mmol 74% yield, 99.8% ee, dr > 99:1) was obtained as a white solid. 
1H-NMR (400 MHz, DMSO-d6, ppm): δ = 7.83 (d, J = 9.2, 1H), 7.69 (dd, J = 1.9, 0.7, 1H), 7.58 – 
7.47 (m, 4H), 3.99 (qd, J = 11.1, 4.0, 1H), 2.62 (td, J = 11.9, 3.6, 1H), 1.92 – 1.84 (m, 1H), 1.83 – 1.67 
(m, 3H), 1.62 – 1.21 (m, 4H). 
13C-NMR (101 MHz, DMSO-d6, ppm): δ = 159.71, 145.61, 131.60, 128.96, 128.68 (q, J = 31.2), 
124.38 (q, J = 272.3), 124.27 (q, J = 4.0), 122.83 (q, J = 3.9), 49.56, 48.79, 34.22, 33.45, 25.57, 24.81. 
19F NMR (376 MHz, DMSO-d6, ppm): δ = –60.9. 
MS (EI, 70 eV, %): m/z = 272 (1), 227 (14), 226 (100), 211 (37), 206 (13), 172 (10), 159 (10), 129 
(14). 
HRMS (EI, 70 eV): m/z calcd. for [C14H17F3NO]
+: 272.1257; found: 272.1255 ([M+H]+). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3251 (w), 3037 (w), 2936 (m), 2860 (m), 1678 (m), 1651 (s), 
1543 (m), 1449 (m), 1384 (m), 1318 (s), 1233 (m), 1160 (s), 1114 (s), 1072 (s), 894 (m), 800 (s), 701 
(s), 663 (m). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –15.2. 
M.p. 89.3 °C  
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N-((1R,2S)-2-(3-Nitrophenyl)cyclopentyl)formamide ((R,S)-31f) 
 
According to TP15, (R,S)-29f (128 mg, 0.50 mmol, 1.00 equiv) was dissolved in 4 mL DCM and 1 mL 
methanol and cooled to –78 °C. Ozone was passed through for 5 min followed by nitrogen for 10 min. 
Dimethyl sulfide (311 mg, 5.00 mmol, 10.0 equiv) was added and the reaction mixture stirred for 6 h 
at room temperature. After evaporation of the solvents, the residue was stirred for 1 h in 5 mL KOH in 
ethanol (0.1 M) and afterwards ethanol removed under reduced pressure. The crude product was 
purified by via flash column chromatography purification and the title compound (R,S)-31f (82.0 mg, 
0.35 mmol 71% yield, 99.3% ee, dr > 99:1) was obtained as a white solid. 
1H-NMR (400 MHz, CDCl3, ppm): major conformer δ = 8.12 – 8.01 (m, 2H), 8.04 (d, J = 1.2 Hz, 
1H), 7.62 (dt, J = 7.7, 1.4 Hz, 1H), 7.48 (q, J = 7.8 Hz, 1H), 5.87 (d, J = 8.1 Hz, 1H), 4.42 (p, J = 8.6 
Hz, 1H), 2.99 (td, J = 9.8, 8.0 Hz, 1H), 2.36 – 2.13 (m, 2H), 1.98 – 1.53 (m, 4H). 
13C-NMR (101 MHz, CDCl3, ppm): major is conformer δ = 161.1, 148.4, 144.6, 133.5, 129.7, 122.7, 
121.9, 56.0, 51.9, 32.9, 32.6, 22.4. 
MS (EI, 70 eV, %): m/z = 235.1 (1), 189 (68), 172 (100), 142 (27), 128 (19), 115 (37), 107 (44), 77 (14). 
HRMS (EI, 70 eV): m/z calcd. for[C12H15N2O3]
+: 235.1077; found: 235.1076 ([M+H]+).  
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3295 (w), 2948 (w), 2869 (w), 1650 (s), 1526 (vs), 1389 (m), 
1345 (s), 1095 (w), 890 (w), 811 (w), 735 (m), 689 (m). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –56.6. 
M.p. 110.7 °C. 
N-((2R,4S)-4-(3-Chlorophenyl)-4-hydroxy-1-phenylbutan-2-yl)formamide ((R,S)-31g) 
 
According to TP15, (S,R)-30a (244 mg, 0.75 mmol, 1.00 equiv) was dissolved in 12.5 mL DCM and 
2.5 mL methanol and cooled to –78 °C. Ozone was passed through for 3 min followed by nitrogen for 
5 min. Dimethyl sulfide (466 mg, 7.50 mmol, 10.0 equiv) was added and the reaction mixture stirred 
for 6 h at room temperature. After evaporation of the solvents, the residue was stirred for 1 h in 8 mL 
KOH in ethanol (0.1 M) and afterwards ethanol removed under reduced pressure. The crude product 
was purified by via flash column chromatography purification and the title compound (R,S)-31g 
(173 mg, 0.57 mmol 76% yield, 99% ee, dr = 99:1) was obtained as a white solid. 
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1H-NMR (400 MHz, CDCl3, ppm): major conformer δ = 8.15 (d, J = 1.9 Hz, 1H), 7.33 (t, J = 1.7 Hz, 
1H), 7.30 (dt, J = 8.1, 1.8 Hz, 2H), 7.27 – 7.23 (m, 2H), 7.23 – 7.19 (m, 2H), 7.19 – 7.14 (m, 3H), 5.87 
(d, J = 8.9 Hz, 1H), 4.64 (dd, J = 11.0, 2.5 Hz, 1H), 4.29 (s, 1H), 2.92 (dd, J = 14.1, 6.2 Hz, 1H), 2.82 
(dd, J = 14.1, 7.5 Hz, 1H), 1.87 (ddd, J = 14.0, 11.0, 2.8 Hz, 1H), 1.64 (ddd, J = 13.9, 10.8, 2.6 Hz, 1H). 
13C-NMR (101 MHz, CDCl3, ppm): major is conformer δ = 162.4, 146.0, 136.9, 134.4, 129.8, 129.2, 
128.9, 127.5, 127.1, 126.0, 123.8, 69.4, 46.6, 44.9, 40.8. 
MS (EI, 70 eV, %): m/z = 194 (19), 151 (14), 149 (35), 145 (13), 139 (19), 138 (18), 127 (13), 125 
(33), 103 (38), 92 (12), 91 (100), 77 (25), 65 (20). 
HRMS (ESI): m/z calcd. for [M+H; C17H19ClNO2
+]: 304.1099; found: 304.1101 ([M+H]+); calcd. for 
[M-H; C17H17ClNO2
-]: 302.0953; found: 302.0954 ([M-H]-). 
FT-IR (Diamond-ATR, neat, cm-1): 𝜈 = 3290 (m, br), 3063 (w), 3029 (w), 2917 (w), 1662 (vs), 1599 
(m), 1574 (m), 1541 (m), 1497 (m), 1477 (w), 1454 (m), 1433 (m), 1385 (m), 1079 (w), 787 (m), 700 (s). 
[𝜶]D
𝟐𝟎 (CHCl3, °⋅mL⋅dm–1⋅g–1): –51.8. 
M.p. 110.7 °C. 
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Single Crystal Structure of 1-((1R,2S)-2-iodocyclopentyl)-1H-pyrrole ((R,S)-19i) 
 
Molecular structure of compound (R,S)-19i in the crystal; thermal ellipsoids are drawn at 50% 
probability level.  
Details for X-ray data collection and structure refinement for compound (R,S)-19i. 
(R,S)-19i 
Empirical formula C9H12IN ρcalcd. [g cm
-3] 1.892 
Formula mass 261.10 μ [mm-1] 3.430 
T[K] 123(2) F(000) 504 
Crystal size [mm] 0.20 × 0.15 × 0.03 Θ range [°] 3.10 – 25.24 
Crystal description colorless platelet Index ranges -9 ≤ h ≤ 9 
Crystal system orthorhombic  -14 ≤ k ≤ 14 
Space group P212121  -18 ≤ l ≤ 18 
a [Ǻ] 6.7058(2) Reflns. collected 18366 
b [Ǻ] 10.4137(3) Reflns. obsd. 2608 
c [Ǻ] 13.1287(3) Reflns. unique 2792 (Rint = 0.0444) 
α [°] 90.0 R1, wR2 (2σ data) 0.0246, 0.0534 
β [°] 90.0 R1, wR2 (all data) 0.0284, 0.0548 
γ [°] 90.0 GOOF on F2 1.065 
V [Ǻ3] 916.81(4) Peak/hole [e Ǻ-3] 0.892 / -0.506 
Z 4 ρcalcd. [g cm
-3] 1.892 
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Single Crystal Structure of Methyl 2-((1S,2R)-2-(1H-pyrrol-1-yl)cyclopentyl)benzoate ((S,R)-
29c) 
 
Molecular structure of compound (S,R)-29c in the crystal; thermal ellipsoids are drawn at 50% 
probability level.  
(S,R)-29c 
Empirical formula C17H19NO2 ρcalcd. [g cm
-3] 1.280 
Formula mass 269.33 μ [mm-1] 0.084 
T[K] 123(2) F(000) 576 
Crystal size [mm] 0.20 × 0.10 × 0.02 Θ range [°] 2.46 – 25.24 
Crystal description colorless block Index ranges -10 ≤ h ≤ 10 
Crystal system orthorhombic  -7 ≤ k ≤ 11 
Space group P212121  -19 ≤ l ≤ 19 
a [Ǻ] 8.9810(8) Reflns. collected 9514 
b [Ǻ] 9.6691(6) Reflns. obsd. 1723 
c [Ǻ] 16.0885(12) Reflns. unique 2647 (Rint = 0.0878) 
α [°] 90.0 R1, wR2 (2σ data) 0.0581, 0.0802 
β [°] 90.0 R1, wR2 (all data) 0.1090, 0.0952 
γ [°] 90.0 GOOF on F2 1.005 
V [Ǻ3] 1397.10(18) Peak/hole [e Ǻ-3] 0.203 / -0.199 
Z 
 
 
 
4 ρcalcd. [g cm
-3] 1.280 
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Mosher-Ester Analysis of (R,S)-30d using 1H-NMR spectroscopy 
The analysis of the absolute configuration has been performed as reported in the literature142: 
 
 
  
 
According to the ∆𝛿 shifts of both 1H-NMR spectra, configuration 2 fits. The 
∆𝛿 values for L1 protons are positive, therefore the L1 residue must stand back. 
On the other hand, the ∆𝛿 values for the L2 protons are negative, therefore the 
L2 chain must stand in front. In conclusion the alcohol has an absolute (S) 
configuration as draw here:  
 
142 a) T. R. Hoye, C. S. Jeffrey, F. Shao, Nat. Protoc. 2007, 2, 2451; b) J. M. Seco, E. Quiñoá, R. Riguera, Chem. 
Rev. 2004, 104, 17. 
For L1: 
∆𝛿 (𝐻1)𝑆−𝑅 = 7.174 − 7.026 = 0.148 > 0 
∆𝛿 (𝐻2)𝑆−𝑅 = 7.080 − 6.975 = 0.105 > 0 
For L2: 
∆𝛿 (𝐻3)𝑆−𝑅 = 2.498 − 2.562 = −0.064 < 0 
∆𝛿 (𝐻4)𝑆−𝑅 = 2.246 − 2.304 = −0.058 <  0 
∆𝛿𝑆−𝑅 = 𝛿𝑆− 𝛿𝑅 
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Single Crystal Structure of N-((1S,2R)-2-(3-(trifluoromethyl)phenyl)cyclohexyl)formamide 
((S,R)-31e) 
 
Molecular structure of compound (S,R)-31e in the crystal; thermal ellipsoids are drawn at 50% 
probability level. The fluorine atoms of both CF3 groups are disordered. Splitting of the positions of the 
fluorine atoms did not result in a significant decrease of the R-values.  
(S,R)-31e 
Empirical formula C14H16F3NO Z 4 
Formula mass 271.28 ρcalcd. [g cm
-3] 1.310 
T[K] 123(2) μ [mm-1] 0.110 
Crystal size [mm] 0.40 × 0.40 × 0.30 F(000) 568 
Crystal description colorless block Θ range [°] 2.10 – 25.24 
Crystal system monoclinic Index ranges -10 ≤ h ≤ 12 
Space group P21  -10 ≤ k ≤ 10 
a [Ǻ] 9.9214(8)  -19 ≤ l ≤ 17 
b [Ǻ] 8.8541(5) Reflns. collected 9015 
c [Ǻ] 16.0010(11) Reflns. obsd. 3721 
α [°] 90.0 Reflns. unique 5163 
(Rint = 0.0330) β [°] 101.894(8) R1, wR2 (2σ data) 0.0626, 0.1 58 
γ [°] 90.0 R1, wR2 (all data) 0.0923, 0.1555 
V [Ǻ3] 1375.43(17) GOOF on F2 1.026 
  Peak/hole [e Ǻ-3] 0.392 / -0.262 
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Single Crystal Structure of N-((2R,4S)-4-(3-chlorophenyl)-4-hydroxy-1-phenylbutan-2-
yl)formamide ((R,S)-31g) 
 
Molecular structure of compound (R,S)-31g in the crystal; thermal ellipsoids are drawn at 50% 
probability level.  
 
Hydrogen bonding in the crystal structure of compound (R,S)-31g; thermal ellipsoids are drawn at 50% 
probability level. Symmetry codes: -0.5+x, 1.5-y, -z; 0.5+x, 1.5-y, -z. 
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(R,S)-31g 
Empirical formula C17H18ClNO2 Z 4 
Formula mass 303.77 ρcalcd. [g cm
-3] 1.303 
T[K] 123(2) μ [mm-1] 0.250 
Crystal size [mm] 0.40 × 0.05 × 0.05 F(000) 640 
Crystal description colorless rod Θ range [°] 2.24 – 25.24 
Crystal system orthorhombic Index ranges -6 ≤ h ≤ 7 
Space group P212121  -17 ≤ k ≤ 13 
a [Ǻ] 6.0177(5)  -22 ≤ l ≤ 18 
b [Ǻ] 14.1572(17) Reflns. collected 8907 
c [Ǻ] 18.1767(18) Reflns. obsd. 2304 
α [°] 90.0 Reflns. unique 3174 (Rint = 0.0616) 
β [°] 90.0 R1, wR2 (2σ data) 0.0482, 0.0455 
γ [°] 90.0 R1, wR2 (all data) 0.0775, 0.0527 
V [Ǻ3] 1548.5(3) GOOF on F2 0.918 
 
